US8133710B2	NNP	O
-	:	O
Oligoadenylate	NN	O
synthetase	NN	O
(	(	O
OAS	NNP	O
)	)	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS	NNP	O
REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/601,440	CD	O
,	,	O
filed	VBN	O
on	IN	O
Nov.	NNP	O
17	CD	O
,	,	O
2006	CD	O
,	,	O
now	RB	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
7,732,177	CD	O
titled	VBN	O
“	JJ	O
OLIGOADENYLATE	NNP	O
SYNTHETASE	NNP	O
(	(	O
OAS	NNP	O
)	)	O
”	NN	O
,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Applications	NNP	O
Nos	NNP	O
.	.	O
60/739,159	CD	O
,	,	O
filed	VBD	O
Nov.	NNP	O
23	CD	O
,	,	O
2005	CD	O
,	,	O
and	CC	O
60/752,668	CD	O
,	,	O
filed	VBN	O
Dec.	NNP	O
21	CD	O
,	,	O
2005	CD	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
This	DT	O
application	NN	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S	NNP	O
.	.	O
Provisional	JJ	O
Applications	NNP	O
Nos	NNP	O
.	.	O
60/739,159	CD	O
,	,	O
filed	VBD	O
Nov.	NNP	O
23	CD	O
,	,	O
2005	CD	O
,	,	O
and	CC	O
60/752,668	CD	O
,	,	O
filed	VBN	O
Dec.	NNP	O
21	CD	O
,	,	O
2005	CD	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
1	CD	O
.	.	O
Field	NN	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
novel	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
virus	NN	O
infections	NNS	O
and	CC	O
cancer	NN	O
in	IN	O
mammals	NNS	O
.	.	O
2	CD	O
.	.	O
Description	NN	O
of	IN	O
the	DT	O
Related	NNP	O
Art	NNP	O
Oligoadenylate	NNP	O
synthetase	NN	O
(	(	O
OAS	NNP	O
)	)	O
proteins	NNS	O
are	VBP	O
interferon-induced	JJ	O
proteins	NNS	O
characterized	VBN	O
by	IN	O
their	PRP$	O
capacity	NN	O
to	TO	O
catalyze	VB	O
the	DT	O
synthesis	NN	O
of	IN	O
2-prime	JJ	O
,	,	O
5-prime	JJ	O
oligomers	NNS	O
of	IN	O
adenosine	NN	O
(	(	O
2-5As	JJ	O
)	)	O
.	.	O
Hovanessian	JJ	B
et	NN	I
al.	NN	I
,	,	I
EMBO	NNP	I
6:1273-1280	CD	I
(	(	I
1987	CD	I
)	)	I
found	VBD	O
that	IN	O
interferon-treated	JJ	O
human	JJ	O
cells	NNS	O
contain	VBP	O
several	JJ	O
OASs	NNP	O
corresponding	VBG	O
to	TO	O
proteins	NNS	O
of	IN	O
40	CD	O
(	(	O
OAS1	NNP	O
)	)	O
,	,	O
46	CD	O
(	(	O
OAS1	NNP	O
)	)	O
,	,	O
69	CD	O
(	(	O
OAS2	NNP	O
)	)	O
,	,	O
and	CC	O
100	CD	O
(	(	O
OAS3	NNP	O
)	)	O
kD	NN	O
.	.	O
Marie	NNP	B
et	CC	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
160:580-587	CD	I
(	(	I
1989	CD	I
)	)	I
generated	VBD	O
highly	RB	O
specific	JJ	O
polyclonal	JJ	O
antibodies	NNS	O
against	IN	O
p69	NN	O
,	,	O
the	DT	O
69-kD	JJ	O
OAS2	NNP	O
.	.	O
By	IN	O
screening	VBG	O
an	DT	O
interferon-treated	JJ	O
human	NN	O
cell	NN	O
expression	NN	O
library	NN	O
with	IN	O
the	DT	O
anti-p69	JJ	O
antibodies	NNS	O
,	,	O
Marie	NNP	B
and	CC	I
Hovanessian	NNP	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
267:9933-9939	CD	I
(	(	I
1992	CD	I
)	)	I
isolated	VBD	O
a	DT	O
partial	JJ	O
OAS2	NNP	O
cDNA	NN	O
.	.	O
They	PRP	O
screened	VBD	O
additional	JJ	O
libraries	NNS	O
with	IN	O
the	DT	O
partial	JJ	O
cDNA	NN	O
and	CC	O
recovered	VBD	O
cDNAs	NNS	O
encoding	VBG	O
two	CD	O
OAS2	NNP	O
isoforms	NNS	O
.	.	O
The	DT	O
smaller	JJR	O
isoform	NN	O
is	VBZ	O
encoded	VBN	O
by	IN	O
two	CD	O
mRNAs	NNS	O
that	WDT	O
differ	VBP	O
in	IN	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
3-prime	JJ	O
untranslated	JJ	O
region	NN	O
.	.	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
revealed	VBD	O
that	IN	O
OAS2	NNP	O
is	VBZ	O
expressed	VBN	O
as	IN	O
four	CD	O
interferon-induced	JJ	O
mRNAs	NN	O
in	IN	O
human	JJ	O
cells	NNS	O
.	.	O
The	DT	O
predicted	JJ	O
OAS2	NNP	O
proteins	NNS	O
have	VBP	O
a	DT	O
common	JJ	O
683-amino	JJ	O
acid	NN	O
sequence	NN	O
and	CC	O
different	JJ	O
3-prime	JJ	O
termini	NN	O
.	.	O
According	VBG	O
to	TO	O
SDS-PAGE	NN	O
of	IN	O
in	IN	O
vitro	JJ	O
transcription/translation	NN	O
products	NNS	O
,	,	O
two	CD	O
isoforms	NNS	O
have	VBP	O
molecular	JJ	O
masses	NNS	O
of	IN	O
69	CD	O
and	CC	O
71	CD	O
kD	NN	O
.	.	O
Both	DT	O
isoforms	NNS	O
exhibited	VBD	O
OAS	NNP	O
activity	NN	O
in	IN	O
vitro	NN	O
.	.	O
Sequence	NN	O
analysis	NN	O
indicated	VBD	O
that	IN	O
OAS2	NNP	O
contains	VBZ	O
two	CD	O
OAS1-homologous	JJ	O
domains	NNS	O
separated	VBN	O
by	IN	O
a	DT	O
proline-rich	JJ	O
putative	JJ	O
linker	NN	O
region	NN	O
.	.	O
The	DT	O
N-	NNP	O
and	CC	O
C-terminal	JJ	O
domains	NNS	O
are	VBP	O
41	CD	O
%	NN	O
and	CC	O
53	CD	O
%	NN	O
identical	JJ	O
to	TO	O
OAS1	NNP	O
,	,	O
respectively	RB	O
.	.	O
Likewise	RB	O
,	,	O
OAS3	NNP	O
contains	VBZ	O
three	CD	O
tandem	JJ	O
units	NNS	O
of	IN	O
the	DT	O
OAS1-homologous	JJ	O
domains	NNS	O
.	.	O
By	IN	O
fluorescence	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
and	CC	O
by	IN	O
inclusion	NN	O
within	IN	O
mapped	JJ	O
clones	NNS	O
,	,	O
Hovanian	JJ	B
et	NN	I
al.	NN	I
,	,	I
Genomics	NNP	I
52:267-277	CD	I
(	(	I
1998	CD	I
)	)	I
determined	VBD	O
that	IN	O
the	DT	O
OAS1	NNP	O
,	,	O
OAS2	NNP	O
,	,	O
and	CC	O
OAS3	NNP	O
genes	NNS	O
are	VBP	O
clustered	VBN	O
with	IN	O
a	DT	O
130-kb	JJ	O
region	NN	O
on	IN	O
12q24.2	CD	O
.	.	O
2-5As	JJ	O
bind	NN	O
to	TO	O
and	CC	O
activate	VB	O
RNase	NNP	O
I	PRP	O
,	,	O
which	WDT	O
degrades	VBZ	O
viral	JJ	O
and	CC	O
cellular	JJ	O
RNAs	NNP	O
,	,	O
leading	VBG	O
to	TO	O
inhibition	NN	O
of	IN	O
cellular	JJ	O
protein	NN	O
synthesis	NN	O
and	CC	O
impairment	NN	O
of	IN	O
viral	JJ	O
replication	NN	O
.	.	O
A	DT	O
fourth	JJ	O
human	JJ	O
OAS	NNP	O
gene	NN	O
,	,	O
referred	VBD	O
to	TO	O
as	IN	O
OASL	NNP	O
,	,	O
differs	NNS	O
from	IN	O
OAS1	NNP	O
,	,	O
OAS2	NNP	O
and	CC	O
OAS3	NNP	O
in	IN	O
that	DT	O
OASL	NNP	O
lacks	VBZ	O
enzyme	JJ	O
activity	NN	O
.	.	O
The	DT	O
OASL	NNP	O
gene	NN	O
encodes	VBZ	O
a	DT	O
two-domain	JJ	O
protein	NN	O
composed	VBD	O
of	IN	O
an	DT	O
OAS	NNP	O
unit	NN	O
fused	VBD	O
to	TO	O
a	DT	O
164	CD	O
amino	NN	O
acid	JJ	O
C-terminal	JJ	O
domain	NN	O
that	WDT	O
is	VBZ	O
homologous	JJ	O
to	TO	O
a	DT	O
tandem	JJ	O
repeat	NN	O
of	IN	O
ubiquitin	NN	O
.	.	O
(	(	O
Eskildsen	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nuc	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
31:3166-3173	CD	I
,	,	I
2003	CD	I
;	:	O
Kakuta	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Interferon	NNP	I
&	CC	I
Cytokine	NNP	I
Res	NNP	I
.	.	I
22:981-993	CD	I
,	,	I
2002	CD	I
.	.	O
)	)	O
The	DT	O
present	JJ	O
invention	NN	O
fulfills	NNS	O
needs	VBZ	O
in	IN	O
the	DT	O
art	NN	O
by	IN	O
providing	VBG	O
engineering	NN	O
and	CC	O
modification	NN	O
of	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
proteins	NNS	O
to	TO	O
improve	VB	O
their	PRP$	O
drug	NN	O
properties	NNS	O
.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
novel	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
composed	VBN	O
of	IN	O
engineered	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
oligoadenylate	NN	O
synthetases	NNS	O
.	.	O
These	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
include	VBP	O
mutant	JJ	O
forms	NNS	O
designed	VBN	O
to	TO	O
have	VB	O
enhanced	VBN	O
cell	NN	O
permeability	NN	O
,	,	O
reduced	VBD	O
oxidative	JJ	O
potential	NN	O
,	,	O
enhanced	JJ	O
antiviral	JJ	O
activity	NN	O
,	,	O
enhanced	VBD	O
enzymatic	JJ	O
activity	NN	O
,	,	O
or	CC	O
absent	JJ	O
enzymatic	JJ	O
activity	NN	O
.	.	O
These	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
further	RBR	O
embody	NN	O
oligoadenylate	JJ	O
synthetases	NNS	O
chemically	RB	O
modified	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	NNS	O
to	TO	O
any	DT	O
possible	JJ	O
combination	NN	O
of	IN	O
mutant	JJ	O
forms	NNS	O
or	CC	O
chemical	JJ	O
modifications	NNS	O
in	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
no	DT	O
enzymatic	JJ	O
activity	NN	O
,	,	O
but	CC	O
that	IN	O
retain	VBP	O
their	PRP$	O
antiviral	JJ	O
activity	NN	O
,	,	O
described	VBN	O
as	IN	O
Class	NN	O
I	PRP	O
modifications	NNS	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
These	DT	O
forms	NNS	O
have	VBP	O
one	CD	O
or	CC	O
two	CD	O
mutations	NNS	O
of	IN	O
aspartic	JJ	O
acid	NN	O
to	TO	O
alanine	VB	O
in	IN	O
the	DT	O
magnesium	NN	O
binding	VBG	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
,	,	O
rendering	VBG	O
the	DT	O
resulting	VBG	O
OAS	NNP	O
forms	NNS	O
enzymatically	RB	O
inactive	JJ	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
2	CD	O
.	.	O
These	DT	O
Class	NNP	O
I	PRP	O
enzymatically	RB	O
inactive	JJ	O
OAS	NNP	O
polypeptides	NNS	O
retain	VBP	O
antiviral	JJ	O
activity	NN	O
,	,	O
demonstrated	VBD	O
using	VBG	O
an	DT	O
encephalomyocarditis	NN	O
virus	NN	O
replication	NN	O
assay	RB	O
,	,	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
reduced	VBN	O
oxidative	JJ	O
potential	NN	O
,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
II	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
These	DT	O
forms	NNS	O
have	VBP	O
one	CD	O
or	CC	O
more	JJR	O
cysteine	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
deleted	VBD	O
or	CC	O
replaced	VBN	O
with	IN	O
an	DT	O
alternative	JJ	O
residue	NN	O
of	IN	O
the	DT	O
form	NN	O
:	:	O
alanine	NN	O
,	,	O
serine	NN	O
,	,	O
threonine	NN	O
,	,	O
methionine	NN	O
,	,	O
or	CC	O
glycine	NN	O
.	.	O
Deletion	NN	O
or	CC	O
modification	NN	O
of	IN	O
these	DT	O
residues	NNS	O
reduces	VBZ	O
the	DT	O
oxidative	JJ	O
potential	NN	O
of	IN	O
the	DT	O
resulting	JJ	O
polypeptide	JJ	O
drug	NN	O
product	NN	O
,	,	O
thereby	RB	O
improving	VBG	O
manufacturability	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
serum	JJ	O
stability	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O
Manufacturability	NNP	O
is	VBZ	O
improved	VBN	O
by	IN	O
obviating	VBG	O
the	DT	O
need	NN	O
for	IN	O
a	DT	O
reducing	NN	O
environment	NN	O
during	IN	O
drug	NN	O
manufacture	NN	O
while	IN	O
reducing	VBG	O
the	DT	O
propensity	NN	O
of	IN	O
drug	NN	O
aggregation	NN	O
during	IN	O
manufacture	NN	O
,	,	O
transport	NN	O
,	,	O
and	CC	O
drug	NN	O
delivery	NN	O
.	.	O
Class	NN	O
II	NNP	O
modifications	NNS	O
also	RB	O
improve	VBP	O
stability	NN	O
of	IN	O
the	DT	O
drug	NN	O
in	IN	O
excipients	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
in	IN	O
man	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
mutant	VB	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
enhanced	VBN	O
cell	NN	O
permeability	NN	O
,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
III	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Cell	NNP	O
permeability	NN	O
is	VBZ	O
enhanced	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
histidine	NN	O
,	,	O
arginine	NN	O
,	,	O
and	CC	O
lysine	NN	O
,	,	O
to	TO	O
the	DT	O
amino	NN	O
terminus	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Addition	NN	O
of	IN	O
basic	JJ	O
or	CC	O
positively-charged	JJ	O
amino	NN	O
acids	NNS	O
increases	VBZ	O
cell	NN	O
permeability	NN	O
through	IN	O
an	DT	O
absorptive	JJ	O
endocytic	JJ	O
process	NN	O
,	,	O
thereby	RB	O
increasing	VBG	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
(	(	O
compare	JJ	O
FIG	NNP	O
.	.	O
3	LS	O
with	IN	O
FIG	NNP	O
.	.	O
4	CD	O
)	)	O
.	.	O
Enhancement	NN	O
of	IN	O
absorptive	JJ	O
endocytosis	NN	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
through	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acids	NNS	O
results	NNS	O
in	IN	O
the	DT	O
significant	JJ	O
accumulation	NN	O
of	IN	O
active	JJ	O
drug	NN	O
in	IN	O
intracellular	NN	O
,	,	O
detergent	NN	O
insoluble	JJ	O
stores	NNS	O
(	(	O
FIG	NNP	O
.	.	O
5	CD	O
)	)	O
thereby	RB	O
enhancing	VBG	O
in	IN	O
vivo	JJ	O
therapeutic	JJ	O
effect	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
chemical	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
to	TO	O
contain	VB	O
a	DT	O
polyethylene	NN	O
glycol	NN	O
moiety	NN	O
,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Chemical	NNP	O
modification	NN	O
of	IN	O
cysteine	NN	O
residues	NNS	O
results	NNS	O
in	IN	O
retention	NN	O
of	IN	O
full	JJ	O
enzyme	NN	O
activity	NN	O
(	(	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
)	)	O
,	,	O
improved	VBN	O
in	IN	O
vitro	JJ	O
bulk	JJ	O
drug	NN	O
product	NN	O
stability	NN	O
,	,	O
enhanced	VBD	O
serum	JJ	O
elimination	NN	O
half	NN	O
life	NN	O
,	,	O
reduced	VBN	O
in	IN	O
vivo	JJ	O
drug	NN	O
immunogenicity	NN	O
,	,	O
and	CC	O
reduced	VBN	O
in	IN	O
vivo	NN	O
proteolytic	JJ	O
cleavage	NN	O
of	IN	O
the	DT	O
drug	NN	O
polypeptide	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
additional	JJ	O
mutant	NN	O
oligoadenylate	NN	O
synthetase	NN	O
forms	NNS	O
having	VBG	O
significant	JJ	O
anti-viral	JJ	O
or	CC	O
anti-cancer	JJ	O
activity	NN	O
,	,	O
described	VBN	O
as	IN	O
Class	NNP	O
V	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Class	NN	O
V	NNP	O
polypeptides	NNS	O
are	VBP	O
additional	JJ	O
mutant	JJ	O
OAS	NNP	O
forms	NNS	O
resulting	VBG	O
from	IN	O
a	DT	O
mixture	NN	O
of	IN	O
developmental	NN	O
and	CC	O
optimizing	VBG	O
considerations	NNS	O
including	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
:	:	O
manufacturing	NN	O
tests	NNS	O
in	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
recombinant	JJ	O
vector	NN	O
development	NN	O
,	,	O
and	CC	O
comparison	NN	O
with	IN	O
other	JJ	O
identified	JJ	O
forms	NNS	O
of	IN	O
OAS	NNP	O
proteins	NNS	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	NNS	O
to	TO	O
any	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
or	CC	O
pharmaceutical	JJ	O
composition	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
modified	JJ	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
to	TO	O
treat	VB	O
or	CC	O
prevention	VB	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer	NN	O
in	IN	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
or	CC	O
any	DT	O
combination	NN	O
of	IN	O
the	DT	O
modifications	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
to	TO	O
enhance	VB	O
cellular	JJ	O
growth	NN	O
in	IN	O
a	DT	O
tissue	NN	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
lung	NN	O
or	CC	O
liver	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
further	RBR	O
relates	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
or	CC	O
pharmaceutical	JJ	O
composition	NN	O
for	IN	O
the	DT	O
prevention	NN	O
or	CC	O
treatment	NN	O
of	IN	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer	NN	O
in	IN	O
a	DT	O
mammal	NN	O
or	CC	O
to	TO	O
promote	VB	O
cellular	JJ	O
or	CC	O
tissue	JJ	O
growth	NN	O
or	CC	O
proliferation	NN	O
in	IN	O
a	DT	O
mammal	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
the	DT	O
modified	JJ	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
gene	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
manufacture	VB	O
a	DT	O
drug	NN	O
product	NN	O
using	VBG	O
recombinant	JJ	O
DNA	NNP	O
technologies	NNS	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
expression	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
effected	VBN	O
in	IN	O
mammalian	JJ	O
,	,	O
insect	JJ	O
,	,	O
plant	NN	O
,	,	O
bacterial	JJ	O
,	,	O
or	CC	O
fungal	JJ	O
cells	NNS	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
compound	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
inhibiting	VBG	O
infection	NN	O
by	IN	O
a	DT	O
virus	NN	O
,	,	O
preferably	RB	O
a	DT	O
flavivirus	NN	O
,	,	O
most	RBS	O
preferably	RB	O
hepatitis	VBP	O
C	NNP	O
virus	NN	O
,	,	O
wherein	VBP	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polypeptide	NN	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polynucleotide	NN	O
,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
encoding	VBG	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
combination	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
described	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
within	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
molecule	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
therapeutic	JJ	O
compound	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
treating	VBG	O
cancer	NN	O
,	,	O
preferably	RB	O
prostate	JJ	O
cancer	NN	O
,	,	O
wherein	VBP	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polypeptide	NN	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
compound	NN	O
is	VBZ	O
a	DT	O
polynucleotide	NN	O
,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
encoding	VBG	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
compositions	NNS	O
are	VBP	O
provided	VBN	O
that	IN	O
comprise	NN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
in	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
prepare	VB	O
a	DT	O
medicament	NN	O
for	IN	O
preventing	VBG	O
or	CC	O
inhibiting	VBG	O
hepatitis	NN	O
C	NNP	O
or	CC	O
respiratory	JJ	O
syncytial	JJ	O
virus	NN	O
infection	NN	O
.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
preventing	VBG	O
or	CC	O
curing	VBG	O
infection	NN	O
by	IN	O
a	DT	O
flavivirus	NN	O
or	CC	O
any	DT	O
other	JJ	O
virus	NN	O
in	IN	O
a	DT	O
human	JJ	O
subject	NN	O
susceptible	NN	O
to	TO	O
the	DT	O
infection	NN	O
by	IN	O
administering	VBG	O
one	CD	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Other	JJ	O
embodiments	NNS	O
involve	VBP	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
mammal	NN	O
.	.	O
The	DT	O
invention	NN	O
embodies	NNS	O
also	RB	O
treatments	NNS	O
for	IN	O
infection	NN	O
with	IN	O
the	DT	O
human	JJ	O
immunodeficiency	NN	O
virus	NN	O
(	(	O
HIV	NNP	O
)	)	O
.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
cancer	NN	O
,	,	O
such	JJ	O
as	IN	O
prostate	JJ	O
cancer	NN	O
or	CC	O
breast	NN	O
cancer	NN	O
by	IN	O
administration	NN	O
of	IN	O
polypeptides	NNS	O
disclosed	VBN	O
herein	NN	O
.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
promoting	VBG	O
cellular	JJ	O
or	CC	O
tissue	NN	O
growth	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides	NNS	O
,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
reducing	VBG	O
inflammation	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides	NNS	O
,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
still	RB	O
further	RB	O
relates	VBZ	O
to	TO	O
a	DT	O
method	NN	O
of	IN	O
promoting	VBG	O
immune	JJ	O
suppression	NN	O
by	IN	O
administration	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
disclosed	VBD	O
herein	NN	O
or	CC	O
polynucleotides	NNS	O
,	,	O
such	JJ	O
as	IN	O
DNA	NN	O
or	CC	O
RNA	NNP	O
,	,	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Also	RB	O
provided	VBN	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
as	IN	O
a	DT	O
component	NN	O
of	IN	O
a	DT	O
therapeutic	JJ	O
composition	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
gene	NN	O
therapy	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
any	DT	O
method	NN	O
of	IN	O
preparing	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
or	CC	O
the	DT	O
genes	NNS	O
encoding	VBG	O
said	VBD	O
polypeptides	NNS	O
,	,	O
including	VBG	O
the	DT	O
use	NN	O
any	DT	O
recombinant	JJ	O
DNA	NN	O
methodologies	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
site	NN	O
directed	VBN	O
mutagenesis	NN	O
,	,	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
,	,	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
chemical	NN	O
synthesis	NN	O
to	TO	O
prepare	VB	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
or	CC	O
their	PRP$	O
encoding	JJ	O
genes	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
chemical	JJ	O
cross-linking	JJ	O
targets	NNS	O
the	DT	O
reactive	JJ	O
sulfhydryl	NN	O
species	NNS	O
of	IN	O
the	DT	O
cysteine	NN	O
residues	NNS	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
cross-linking	JJ	O
targets	NNS	O
a	DT	O
single	JJ	O
solvent-exposed	JJ	O
cysteine	NN	O
residue	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
chemical	JJ	O
cross-linking	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
is	VBZ	O
mediated	VBN	O
through	IN	O
the	DT	O
amino-terminal	JJ	O
primary	NN	O
or	CC	O
secondary	JJ	O
amines	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
chemical	JJ	O
cross-linking	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
is	VBZ	O
mediated	VBN	O
through	IN	O
any	DT	O
carboxyl	JJ	O
group	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
cross-linking	NN	O
is	VBZ	O
achieved	VBN	O
by	IN	O
conjugation	NN	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
any	DT	O
lysine	NN	O
or	CC	O
arginine	NN	O
amino	NN	O
acid	VBP	O
residue	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
multiple	JJ	O
sites	NNS	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
conjugation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
therapeutic	JJ	O
product	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
treating	VBG	O
virus	JJ	O
infection	NN	O
or	CC	O
cancer	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
promoting	VBG	O
cellular	JJ	O
or	CC	O
tissue	NN	O
growth	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
administering	VBG	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
treating	VBG	O
inflammation	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
forms	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
that	WDT	O
are	VBP	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
for	IN	O
use	NN	O
in	IN	O
promoting	VBG	O
suppression	NN	O
of	IN	O
the	DT	O
immune	JJ	O
system	NN	O
of	IN	O
a	DT	O
mammal	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
most	RBS	O
particularly	RB	O
those	DT	O
described	VBN	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
whereby	JJR	O
cross-linking	NN	O
is	VBZ	O
achieved	VBN	O
using	VBG	O
a	DT	O
maleimide	NN	O
,	,	O
ortho-pyridyldisulfide	JJ	O
,	,	O
vinylsulfone	NN	O
,	,	O
or	CC	O
thiol	JJ	O
functional	JJ	O
group	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
single	JJ	O
chain	NN	O
,	,	O
multiple	NN	O
chain	NN	O
,	,	O
multi-arm	NN	O
,	,	O
branched	VBN	O
,	,	O
or	CC	O
forked	VBD	O
polyethylene	JJ	O
glycols	NNS	O
of	IN	O
any	DT	O
molecular	JJ	O
weight	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
may	MD	O
contain	VB	O
radioactive	JJ	O
or	CC	O
fluorescent	JJ	O
moieties	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
methods	NNS	O
of	IN	O
chemically	RB	O
cross-linking	JJ	O
polyethylene	NN	O
glycol	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
using	VBG	O
succinimidyl	JJ	O
alpha-methylbutanoate	JJ	O
,	,	O
succinimidyl	JJ	O
propionate	NN	O
,	,	O
N-hydroxysuccinimide	NNP	O
,	,	O
ester	NN	O
,	,	O
aldehyde	NN	O
,	,	O
ortho-pyridylthioester	JJ	O
,	,	O
or	CC	O
amine	JJ	O
functional	JJ	O
groups	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
increasing	VBG	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
a	DT	O
drug	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
increasing	VBG	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
a	DT	O
drug	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
five	CD	O
or	CC	O
more	JJR	O
consecutive	JJ	O
amino	NN	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
delivering	VBG	O
a	DT	O
drug	NN	O
into	IN	O
a	DT	O
cell	NN	O
by	IN	O
conjugation	NN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
or	CC	O
five	CD	O
or	CC	O
more	JJR	O
consecutive	JJ	O
amino	NN	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
conjugation	NN	O
may	MD	O
be	VB	O
affected	VBN	O
using	VBG	O
chemical	JJ	O
methods	NNS	O
and	CC	O
may	MD	O
be	VB	O
through	IN	O
covalent	NN	O
or	CC	O
non-covalent	JJ	O
interaction	NN	O
.	.	O
In	IN	O
a	DT	O
still	RB	O
further	JJ	O
embodiment	NN	O
,	,	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
joined	VBN	O
with	IN	O
other	JJ	O
nucleic	JJ	O
acids	NNS	O
in	IN	O
order	NN	O
to	TO	O
make	VB	O
heterologous	JJ	O
polypeptides	NNS	O
with	IN	O
increased	VBN	O
cell	NN	O
permeability	NN	O
,	,	O
said	VBD	O
increased	VBN	O
permeability	NN	O
being	VBG	O
derived	VBN	O
from	IN	O
five	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
FIGURES	NNP	O
FIG	NNP	O
.	.	O
1	CD	O
is	VBZ	O
a	DT	O
Table	JJ	O
describing	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
their	PRP$	O
defining	JJ	O
mutations	NNS	O
or	CC	O
modifications	NNS	O
relative	VBP	O
to	TO	O
a	DT	O
reference	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
.	.	O
FIG	NNP	O
.	.	O
2	CD	O
is	VBZ	O
a	DT	O
comparison	NN	O
of	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
mutant	NN	O
polypeptide	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
versus	VBZ	O
a	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
polypeptide	NN	O
variant	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
.	.	O
Lane	NNP	O
1	CD	O
:	:	O
50	CD	O
ng	NN	O
of	IN	O
the	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
variant	NN	O
.	.	O
Lane	NNP	O
2	CD	O
:	:	O
1	CD	O
g	NN	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
Variant	NNP	O
.	.	O
Lane	NNP	O
3	CD	O
:	:	O
blank	JJ	O
reaction	NN	O
containing	VBG	O
no	DT	O
protein	NN	O
.	.	O
Oligoadenylate	NNP	O
synthetase	NN	O
activity	NN	O
is	VBZ	O
measured	VBN	O
according	VBG	O
to	TO	O
a	DT	O
standard	JJ	O
reaction	NN	O
involving	VBG	O
the	DT	O
incorporation	NN	O
of	IN	O
32P-labeled	JJ	O
adenosine	NN	O
triphosphate	NN	O
into	IN	O
2′-5′	JJ	O
oligoadenylate	NN	O
species	NNS	O
that	WDT	O
migrate	VBP	O
more	RBR	O
rapidly	RB	O
on	IN	O
polyethylenimine	NN	O
treated	VBN	O
thin	JJ	O
layer	NN	O
chromatography	NN	O
plates	VBZ	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
specification	NN	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
demonstrates	VBZ	O
inhibition	NN	O
of	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
in	IN	O
Huh7	NNP	O
cells	NNS	O
by	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
mutant	NN	O
polypeptide	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:4	NNP	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
and	CC	O
a	DT	O
reference	NN	O
Class	NNP	O
III	NNP	O
modified	VBD	O
polypeptide	JJ	O
variant	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
.	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
pretreated	VBN	O
for	IN	O
8	CD	O
hours	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
a	DT	O
Class	NNP	O
I-Class	NNP	O
III	NNP	O
combination	NN	O
polypeptide	NN	O
,	,	O
a	DT	O
Class	NN	O
III	NNP	O
reference	NN	O
polypeptides	NNS	O
,	,	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
drug	NN	O
vehicle	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
mock-infected	JJ	O
with	IN	O
medium	NN	O
or	CC	O
with	IN	O
50	CD	O
or	CC	O
250	CD	O
plaque	JJ	O
forming	VBG	O
units	NNS	O
(	(	O
pfu	NN	O
)	)	O
of	IN	O
encephalomyocarditis	NN	O
virus	NN	O
for	IN	O
18	CD	O
hours	NNS	O
.	.	O
Cell	NNP	O
viability	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
18	CD	O
hours	NNS	O
was	VBD	O
measured	VBN	O
by	IN	O
incubation	NN	O
of	IN	O
the	DT	O
cells	NNS	O
with	IN	O
a	DT	O
tetrazolium	NN	O
compound	NN	O
(	(	O
3-	JJ	O
(	(	O
4,5-dimethylthiazol-2-yl	JJ	O
)	)	O
-5-	NN	O
(	(	O
3-carboxymethoxyphenyl	JJ	O
)	)	O
-2-	NN	O
(	(	O
4-sulfophenyl	JJ	O
)	)	O
-2H-tetrazolium	NN	O
,	,	O
inner	JJ	O
salt	NN	O
;	:	O
MTS	NNP	O
)	)	O
followed	VBN	O
by	IN	O
the	DT	O
spectroscopic	JJ	O
measurement	NN	O
of	IN	O
absorbance	NN	O
at	IN	O
492	CD	O
nm	JJ	O
indicating	VBG	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan	VB	O
.	.	O
Higher	JJR	O
optical	JJ	O
densities	NNS	O
represent	VBP	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
live	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
assay	NN	O
.	.	O
Both	DT	O
the	DT	O
Class	NNP	O
I-III	NNP	O
combination	NN	O
polypeptide	NN	O
and	CC	O
the	DT	O
Class	NNP	O
III	NNP	O
reference	NN	O
polypeptide	NN	O
inhibit	NN	O
virus-induced	JJ	O
cell	NN	O
death	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
OAS	NNP	O
drugs	NNS	O
have	VBP	O
antiviral	JJ	O
activity	NN	O
independent	JJ	O
of	IN	O
enzymatic	JJ	O
activity	NN	O
.	.	O
FIG	NNP	O
.	.	O
4	CD	O
shows	NNS	O
inhibition	NN	O
of	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
in	IN	O
Huh7	NNP	O
by	IN	O
a	DT	O
Class	NN	O
V	NNP	O
modified	VBD	O
polypeptide	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:3	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
as	IN	O
described	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
pretreated	VBN	O
for	IN	O
8	CD	O
hours	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
protein	NN	O
vehicle	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
mock-infected	JJ	O
with	IN	O
medium	NN	O
or	CC	O
with	IN	O
250	CD	O
or	CC	O
500	CD	O
plaque	JJ	O
forming	VBG	O
units	NNS	O
(	(	O
pfu	NN	O
)	)	O
of	IN	O
encephalomyocarditis	NN	O
virus	NN	O
for	IN	O
18	CD	O
hours	NNS	O
.	.	O
Cell	NNP	O
viability	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
MTS	NNP	O
assay	NN	O
by	IN	O
the	DT	O
change	NN	O
in	IN	O
absorbance	NN	O
at	IN	O
492	CD	O
nm	JJ	O
indicating	VBG	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan	VB	O
.	.	O
Class	NN	O
III	NNP	O
polypeptide	NN	O
drugs	NNS	O
have	VBP	O
increased	VBN	O
cell	NN	O
permeability	NN	O
and	CC	O
therefore	RB	O
increased	VBD	O
antiviral	JJ	O
activity	NN	O
(	(	O
see	VB	O
FIG	NNP	O
.	.	O
3	LS	O
)	)	O
compared	VBN	O
with	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
Class	NNP	O
V	NNP	O
polypeptide	NN	O
of	IN	O
the	DT	O
present	JJ	O
figure	NN	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
shows	NNS	O
increase	NN	O
in	IN	O
cell-associated	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
after	IN	O
treatment	NN	O
with	IN	O
a	DT	O
Class	NN	O
III	NNP	O
polypeptide	NN	O
variant	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
.	.	O
Huh7	NNP	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
6	CD	O
M	NNP	O
of	IN	O
the	DT	O
polypeptide	NN	O
for	IN	O
the	DT	O
indicated	JJ	O
period	NN	O
of	IN	O
time	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
extensively	RB	O
trypsinized	VBN	O
to	TO	O
remove	VB	O
extracellular	JJ	O
protein	NN	O
and	CC	O
then	RB	O
lysed	VBD	O
with	IN	O
assay	JJ	O
buffer	NN	O
containing	VBG	O
0.1	CD	O
%	NN	O
NP40	NNP	O
.	.	O
Detergent	NNP	O
soluble	JJ	O
and	CC	O
detergent	JJ	O
resistant	JJ	O
fractions	NNS	O
were	VBD	O
assayed	VBN	O
for	IN	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
specification	NN	O
.	.	O
The	DT	O
fold-increase	NN	O
in	IN	O
cell-associated	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
is	VBZ	O
graphed	VBN	O
relative	JJ	O
to	TO	O
untreated	JJ	O
cells	NNS	O
.	.	O
As	IN	O
demonstrated	VBN	O
in	IN	O
the	DT	O
figure	NN	O
,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
penetrate	VB	O
cells	NNS	O
and	CC	O
enter	VB	O
both	DT	O
the	DT	O
cytoplasm	NN	O
and	CC	O
detergent	NN	O
resistant	JJ	O
membrane	NN	O
components	NNS	O
.	.	O
This	DT	O
property	NN	O
of	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
enhanced	VBN	O
in	IN	O
polypeptides	NNS	O
with	IN	O
Class	NNP	O
III	NNP	O
modifications	NNS	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
figure	NN	O
.	.	O
FIG	NNP	O
.	.	O
6A	CD	O
.	.	O
Coomassie	NNP	O
stained	VBD	O
12	CD	O
%	NN	O
polyacrylamide	JJ	O
gel	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
conjugated	VBD	O
to	TO	O
a	DT	O
20	CD	O
kilodalton	NN	O
,	,	O
single	JJ	O
chain	NN	O
,	,	O
maleimide	RB	O
conjugated	VBD	O
polyethylene	JJ	O
glycol	NN	O
(	(	O
mPEG-MAL	JJ	O
20	CD	O
kDa	NN	O
)	)	O
.	.	O
Lane	NNP	O
1	CD	O
,	,	O
MW	NNP	O
standards	NNS	O
;	:	O
lane	VBZ	O
2	CD	O
,	,	O
unmodified	JJ	O
polypeptide	NN	O
,	,	O
lanes	VBZ	O
3-7	CD	O
,	,	O
polypeptide	RB	O
reacted	VBD	O
with	IN	O
mPEG-MAL	JJ	O
20	CD	O
kDa	NN	O
at	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
0.5:1	CD	O
,	,	O
1:1	CD	O
,	,	O
2:1	CD	O
,	,	O
5:1	CD	O
,	,	O
and	CC	O
10:1	CD	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
well	RB	O
conjugated	VBN	O
through	IN	O
cysteine	NN	O
residues	NNS	O
to	TO	O
polyethylene	VB	O
glycols	NNS	O
.	.	O
FIG	NNP	O
.	.	O
6B	CD	O
.	.	O
Coomassie	NNP	O
stained	VBD	O
12	CD	O
%	NN	O
polyacrylamide	JJ	O
gel	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
conjugated	VBD	O
to	TO	O
a	DT	O
40	CD	O
kilodalton	NN	O
,	,	O
branched	VBD	O
chain	NN	O
,	,	O
maleimide	RB	O
conjugated	VBD	O
polyethylene	JJ	O
glycol	NN	O
(	(	O
mPEG2-MAL	JJ	O
40	CD	O
kDa	NN	O
)	)	O
.	.	O
Lane	NNP	O
1	CD	O
,	,	O
MW	NNP	O
standards	NNS	O
,	,	O
lane	NN	O
2	CD	O
,	,	O
unmodified	JJ	O
polypeptide	NN	O
,	,	O
lanes	VBZ	O
3-7	CD	O
,	,	O
polypeptide	RB	O
reacted	VBD	O
with	IN	O
mPEG2-MAL	JJ	O
40	CD	O
kDa	NN	O
at	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
0.5:1	CD	O
,	,	O
1:1	CD	O
,	,	O
2:1	CD	O
,	,	O
5:1	CD	O
,	,	O
and	CC	O
10:1	CD	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
well	RB	O
conjugated	VBN	O
to	TO	O
polyethylene	VB	O
glycols	NNS	O
through	IN	O
reactive	JJ	O
cysteines	NNS	O
.	.	O
FIG	NNP	O
.	.	O
6C	CD	O
.	.	O
Oligoadenylate	NNP	O
synthetase	NN	O
activity	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
7	CD	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
and	CC	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
conjugated	VBD	O
to	TO	O
mPEG2-MAL	JJ	O
20	CD	O
kDa	NN	O
or	CC	O
branched	VBN	O
mPEG2-MAL	JJ	O
40	CD	O
kDa	NN	O
.	.	O
Lane	NNP	O
1	CD	O
,	,	O
unmodified	JJ	O
polypeptide	NN	O
.	.	O
Lanes	NNS	O
2-6	CD	O
,	,	O
PEG2-MAL	JJ	O
20	CD	O
kDa-conjugated	JJ	O
polypeptides	NNS	O
reacted	VBD	O
at	IN	O
0.5:1	CD	O
,	,	O
1:1	CD	O
,	,	O
2:1	CD	O
,	,	O
5:1	CD	O
,	,	O
and	CC	O
10:1	CD	O
molar	JJ	O
ratios	NNS	O
,	,	O
respectively	RB	O
.	.	O
Lanes	NNS	O
7-11	CD	O
,	,	O
mPEG-MAL	JJ	O
20	CD	O
kDa-conjugated	JJ	O
polypeptides	NNS	O
reacted	VBD	O
at	IN	O
0.5:1	CD	O
,	,	O
1:1	CD	O
,	,	O
2:1	CD	O
,	,	O
5:1	CD	O
,	,	O
and	CC	O
10:1	CD	O
molar	JJ	O
ratios	NNS	O
,	,	O
respectively	RB	O
.	.	O
As	IN	O
can	MD	O
be	VB	O
seen	VBN	O
from	IN	O
the	DT	O
figure	NN	O
,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
retain	VBP	O
full	JJ	O
enzymatic	JJ	O
activity	NN	O
when	WRB	O
conjugated	VBN	O
to	TO	O
polyethylene	VB	O
glycol	NN	O
at	IN	O
reactive	JJ	O
cysteines	NNS	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
shows	VBZ	O
the	DT	O
polynucleotide	JJ	O
sequences	NNS	O
of	IN	O
SEQUENCE	NNP	O
2	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
;	:	O
SEQUENCE	$	O
3	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
;	:	O
and	CC	O
SEQUENCE	$	O
4	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Introduction	NNP	O
and	CC	O
Definitions	NNP	O
We	PRP	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
mutations	NNS	O
in	IN	O
the	DT	O
OAS	NNP	O
genes	NNS	O
confer	VBP	O
resistance	NN	O
to	TO	O
virus	VB	O
infection	NN	O
.	.	O
(	(	O
U.S.	NNP	O
Patent	NNP	O
Application	NNP	O
Ser	NNP	O
.	.	O
Nos	NNP	O
.	.	O
60/513,888	CD	O
,	,	O
filed	VBN	O
Oct.	NNP	O
23	CD	O
,	,	O
2003	CD	O
;	:	O
60/542,373	CD	O
,	,	O
filed	VBD	O
Feb.	NNP	O
6	CD	O
,	,	O
2004	CD	O
;	:	O
60/554,758	CD	O
,	,	O
filed	VBN	O
Mar	NNP	O
.	.	O
19	CD	O
,	,	O
2004	CD	O
;	:	O
60/560,524	CD	O
,	,	O
filed	VBN	O
Apr	NNP	O
.	.	O
8	CD	O
,	,	O
2004	CD	O
;	:	O
60/578,323	CD	O
,	,	O
filed	VBN	O
Jun	NNP	O
.	.	O
8	CD	O
,	,	O
2004	CD	O
;	:	O
60/605,243	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
26	CD	O
,	,	O
2004	CD	O
;	:	O
10/972,135	CD	O
,	,	O
filed	VBN	O
Oct.	NNP	O
22	CD	O
,	,	O
2004	CD	O
;	:	O
60/677,680	CD	O
,	,	O
filed	VBD	O
May	NNP	O
4	CD	O
,	,	O
2005	CD	O
;	:	O
and	CC	O
60/710,704	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
23	CD	O
,	,	O
2004	CD	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
.	.	O
)	)	O
Several	JJ	O
novel	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
OAS	NNP	O
1	CD	O
,	,	O
OAS2	NNP	O
,	,	O
and	CC	O
OAS3	NNP	O
genes	NNS	O
have	VBP	O
been	VBN	O
cloned	VBN	O
by	IN	O
us	PRP	O
,	,	O
and	CC	O
we	PRP	O
have	VBP	O
developed	VBN	O
pharmaceutical	JJ	O
compositions	NNS	O
derived	VBN	O
from	IN	O
these	DT	O
and	CC	O
other	JJ	O
novel	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
forms	NNS	O
.	.	O
We	PRP	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
antiviral	JJ	O
in	IN	O
vitro	NN	O
and	CC	O
cause	NN	O
growth	NN	O
arrest	NN	O
in	IN	O
cancer	NN	O
cell	NN	O
lines	NNS	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
promote	VBP	O
cellular	JJ	O
growth	NN	O
in	IN	O
certain	JJ	O
cell	NN	O
lines	NNS	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
a	DT	O
mitogenic	JJ	O
effect	NN	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
enter	VB	O
a	DT	O
cell	NN	O
and	CC	O
remain	VBP	O
enzymatically	RB	O
active	JJ	O
in	IN	O
intracellular	JJ	O
stores	NNS	O
for	IN	O
several	JJ	O
days	NNS	O
or	CC	O
more	JJR	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
the	DT	O
cell-penetrating	JJ	O
property	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
enhanced	VBN	O
through	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
including	VBG	O
arginine	NN	O
,	,	O
lysine	NN	O
,	,	O
and	CC	O
histidine	NN	O
(	(	O
described	VBN	O
as	IN	O
Class	NNP	O
III	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
)	)	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
broad	JJ	O
antiviral	JJ	O
activity	NN	O
.	.	O
We	PRP	O
have	VBP	O
further	RB	O
demonstrated	VBN	O
that	IN	O
these	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
derivatized	VBN	O
with	IN	O
polyethylene	NN	O
glycol	NN	O
and	CC	O
retain	VB	O
their	PRP$	O
enzymatic	JJ	O
activity	NN	O
.	.	O
We	PRP	O
show	VBP	O
that	IN	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
reducing	VBG	O
agents	NNS	O
and	CC	O
we	PRP	O
propose	VBP	O
several	JJ	O
modifications	NNS	O
to	TO	O
provide	VB	O
more	JJR	O
oxidation	NN	O
resistant	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
protein	NN	O
.	.	O
We	PRP	O
demonstrate	VBP	O
that	IN	O
bulk	NN	O
quantities	NNS	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
manufactured	VBN	O
using	VBG	O
recombinant	JJ	O
DNA	NNP	O
technologies	NNS	O
by	IN	O
expression	NN	O
in	IN	O
Escherichia	NNP	O
coli	NN	O
.	.	O
We	PRP	O
further	VBP	O
demonstrate	VB	O
that	IN	O
these	DT	O
manufactured	VBD	O
pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
to	TO	O
mammals	NNS	O
and	CC	O
produce	VBP	O
no	DT	O
observable	JJ	O
toxic	NN	O
effects	NNS	O
.	.	O
We	PRP	O
further	VBP	O
demonstrate	VB	O
that	IN	O
these	DT	O
manufactured	VBD	O
pharmaceutical	JJ	O
compositions	NNS	O
have	VBP	O
good	JJ	O
biodistribution	NN	O
and	CC	O
pharmacokinetic	JJ	O
properties	NNS	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
mammal	JJ	O
by	IN	O
injection	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
describes	VBZ	O
mutant	JJ	O
or	CC	O
modified	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptides	NNS	O
that	WDT	O
efficiently	RB	O
enter	VBP	O
mammalian	JJ	O
cells	NNS	O
and	CC	O
enhance	VB	O
the	DT	O
performance	NN	O
of	IN	O
the	DT	O
OAS-RNAse	NNP	O
L	NNP	O
pathway	NN	O
.	.	O
These	DT	O
novel	JJ	O
polypeptide	NN	O
compositions	NNS	O
are	VBP	O
antiviral	JJ	O
in	IN	O
in	IN	O
vitro	NN	O
cell	NN	O
culture	NN	O
models	NNS	O
.	.	O
They	PRP	O
also	RB	O
cause	VBP	O
certain	JJ	O
transformed	VBN	O
cell	NN	O
lines	NNS	O
to	TO	O
undergo	VB	O
growth	NN	O
arrest	NN	O
and	CC	O
promote	NN	O
cellular	JJ	O
growth	NN	O
in	IN	O
other	JJ	O
cell	NN	O
lines	NNS	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
five	CD	O
classes	NNS	O
of	IN	O
modified	JJ	O
oligoadenylate	JJ	O
synthetase	NN	O
proteins	NNS	O
,	,	O
including	VBG	O
:	:	O
Class	NN	O
I	PRP	O
,	,	O
enzymatically	RB	O
inactive	JJ	O
antiviral	JJ	O
forms	NNS	O
;	:	O
Class	NNP	O
II	NNP	O
,	,	O
oxidation	NN	O
resistant	JJ	O
forms	NNS	O
;	:	O
Class	NNP	O
III	NNP	O
,	,	O
enhanced	VBD	O
cell	NN	O
permeable	JJ	O
forms	NNS	O
;	:	O
Class	NNP	O
IV	NNP	O
,	,	O
polyethylene	NN	O
glycol	NN	O
conjugated	VBD	O
forms	NNS	O
;	:	O
and	CC	O
Class	NNP	O
V	NNP	O
,	,	O
mixed	JJ	O
developmental	NN	O
and	CC	O
optimization	NN	O
forms	NNS	O
.	.	O
The	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
manufacture	NN	O
and	CC	O
use	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
virus	NN	O
infection	NN	O
,	,	O
inflammation	NN	O
,	,	O
and	CC	O
neoplastic	JJ	O
disease	NN	O
and	CC	O
to	TO	O
promote	VB	O
cellular	JJ	O
growth	NN	O
and	CC	O
regeneration	NN	O
in	IN	O
mammals	NNS	O
.	.	O
In	IN	O
reference	NN	O
to	TO	O
the	DT	O
detailed	JJ	O
description	NN	O
,	,	O
the	DT	O
following	JJ	O
definitions	NNS	O
are	VBP	O
used	VBN	O
:	:	O
A	DT	O
:	:	O
adenine	NN	O
;	:	O
C	NNP	O
:	:	O
cytosine	NN	O
;	:	O
G	NNP	O
:	:	O
guanine	NN	O
;	:	O
T	NNP	O
:	:	O
thymine	NN	O
(	(	O
in	IN	O
DNA	NNP	O
)	)	O
;	:	O
and	CC	O
U	NNP	O
:	:	O
uracil	NN	O
(	(	O
in	IN	O
RNA	NNP	O
)	)	O
Allele	NNP	O
:	:	O
A	DT	O
variant	NN	O
of	IN	O
DNA	NNP	O
sequence	NN	O
of	IN	O
a	DT	O
specific	JJ	O
gene	NN	O
.	.	O
In	IN	O
diploid	JJ	O
cells	NNS	O
a	DT	O
maximum	NN	O
of	IN	O
two	CD	O
alleles	NNS	O
will	MD	O
be	VB	O
present	JJ	O
,	,	O
each	DT	O
in	IN	O
the	DT	O
same	JJ	O
relative	JJ	O
position	NN	O
or	CC	O
locus	NN	O
on	IN	O
homologous	JJ	O
chromosomes	NNS	O
of	IN	O
the	DT	O
chromosome	NN	O
set	NN	O
.	.	O
When	WRB	O
alleles	NNS	O
at	IN	O
any	DT	O
one	CD	O
locus	NN	O
are	VBP	O
identical	JJ	O
the	DT	O
individual	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
homozygous	JJ	O
for	IN	O
that	DT	O
locus	NN	O
,	,	O
and	CC	O
when	WRB	O
they	PRP	O
differ	VBP	O
the	DT	O
individual	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
heterozygous	JJ	O
for	IN	O
that	DT	O
locus	NN	O
.	.	O
Since	IN	O
different	JJ	O
alleles	NNS	O
of	IN	O
any	DT	O
one	CD	O
gene	NN	O
may	MD	O
vary	VB	O
by	IN	O
only	RB	O
a	DT	O
single	JJ	O
base	NN	O
,	,	O
the	DT	O
possible	JJ	O
number	NN	O
of	IN	O
alleles	NNS	O
for	IN	O
any	DT	O
one	CD	O
gene	NN	O
is	VBZ	O
very	RB	O
large	JJ	O
.	.	O
When	WRB	O
alleles	NNS	O
differ	VBP	O
,	,	O
one	CD	O
is	VBZ	O
often	RB	O
dominant	JJ	O
to	TO	O
the	DT	O
other	JJ	O
,	,	O
which	WDT	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
recessive	JJ	O
.	.	O
Dominance	NN	O
is	VBZ	O
a	DT	O
property	NN	O
of	IN	O
the	DT	O
phenotype	NN	O
and	CC	O
does	VBZ	O
not	RB	O
imply	VB	O
inactivation	NN	O
of	IN	O
the	DT	O
recessive	JJ	O
allele	NN	O
by	IN	O
the	DT	O
dominant	JJ	O
.	.	O
In	IN	O
numerous	JJ	O
examples	NNS	O
the	DT	O
normally	RB	O
functioning	JJ	O
(	(	O
wild-type	JJ	O
)	)	O
allele	NN	O
is	VBZ	O
dominant	JJ	O
to	TO	O
all	DT	O
mutant	JJ	O
alleles	NNS	O
of	IN	O
more	JJR	O
or	CC	O
less	RBR	O
defective	JJ	O
function	NN	O
.	.	O
In	IN	O
such	JJ	O
cases	NNS	O
the	DT	O
general	JJ	O
explanation	NN	O
is	VBZ	O
that	IN	O
one	CD	O
functional	JJ	O
allele	VBZ	O
out	IN	O
of	IN	O
two	CD	O
is	VBZ	O
sufficient	JJ	O
to	TO	O
produce	VB	O
enough	JJ	O
active	JJ	O
gene	NN	O
product	NN	O
to	TO	O
support	VB	O
normal	JJ	O
development	NN	O
of	IN	O
the	DT	O
organism	NN	O
(	(	O
i.e.	FW	O
,	,	O
there	EX	O
is	VBZ	O
normally	RB	O
a	DT	O
two-fold	JJ	O
safety	NN	O
margin	NN	O
in	IN	O
quantity	NN	O
of	IN	O
gene	NN	O
product	NN	O
)	)	O
.	.	O
Haplotype	NN	O
:	:	O
One	CD	O
of	IN	O
many	JJ	O
possible	JJ	O
pluralities	NNS	O
of	IN	O
Alleles	NNP	O
,	,	O
serially	RB	O
ordered	VBN	O
by	IN	O
chromosomal	JJ	O
localization	NN	O
and	CC	O
representing	VBG	O
that	DT	O
set	NN	O
of	IN	O
Alleles	NNP	O
carried	VBN	O
by	IN	O
one	CD	O
particular	JJ	O
homologous	JJ	O
chromosome	NN	O
of	IN	O
the	DT	O
chromosome	NN	O
set	NN	O
.	.	O
Nucleotide	NN	O
:	:	O
A	DT	O
monomeric	JJ	O
unit	NN	O
of	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
consisting	NN	O
of	IN	O
a	DT	O
sugar	NN	O
moiety	NN	O
(	(	O
pentose	JJ	O
)	)	O
,	,	O
a	DT	O
phosphate	NN	O
,	,	O
and	CC	O
a	DT	O
nitrogenous	JJ	O
heterocyclic	JJ	O
base	NN	O
.	.	O
The	DT	O
base	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
sugar	NN	O
moiety	NN	O
via	IN	O
the	DT	O
glycosidic	JJ	O
carbon	NN	O
(	(	O
1′	CD	O
carbon	NN	O
of	IN	O
the	DT	O
pentose	NN	O
)	)	O
and	CC	O
that	DT	O
combination	NN	O
of	IN	O
base	NN	O
and	CC	O
sugar	NN	O
is	VBZ	O
a	DT	O
nucleoside	NN	O
.	.	O
When	WRB	O
the	DT	O
nucleoside	NN	O
contains	VBZ	O
a	DT	O
phosphate	NN	O
group	NN	O
bonded	VBD	O
to	TO	O
the	DT	O
3′	CD	O
or	CC	O
5′	CD	O
position	NN	O
of	IN	O
the	DT	O
pentose	NN	O
it	PRP	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
nucleotide	NN	O
.	.	O
A	DT	O
sequence	NN	O
of	IN	O
operatively	RB	O
linked	VBN	O
nucleotides	NNS	O
is	VBZ	O
typically	RB	O
referred	VBN	O
to	TO	O
herein	VB	O
as	IN	O
a	DT	O
“	JJ	O
base	NN	O
sequence	NN	O
”	NN	O
or	CC	O
“	JJ	O
nucleotide	JJ	O
sequence	NN	O
”	NN	O
,	,	O
and	CC	O
their	PRP$	O
grammatical	JJ	O
equivalents	NNS	O
,	,	O
and	CC	O
is	VBZ	O
represented	VBN	O
herein	NN	O
by	IN	O
a	DT	O
formula	NN	O
whose	WP$	O
left	VBD	O
to	TO	O
right	JJ	O
orientation	NN	O
is	VBZ	O
in	IN	O
the	DT	O
conventional	JJ	O
direction	NN	O
of	IN	O
5′-terminus	JJ	O
to	TO	O
3′-terminus	CD	O
.	.	O
Base	NNP	O
Pair	NNP	O
(	(	O
bp	NN	O
)	)	O
:	:	O
A	DT	O
partnership	NN	O
of	IN	O
adenine	NN	O
(	(	O
A	DT	O
)	)	O
with	IN	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
or	CC	O
of	IN	O
cytosine	NN	O
(	(	O
C	NNP	O
)	)	O
with	IN	O
guanine	NN	O
(	(	O
G	NNP	O
)	)	O
in	IN	O
a	DT	O
double	JJ	O
stranded	JJ	O
DNA	NN	O
molecule	NN	O
.	.	O
In	IN	O
RNA	NNP	O
,	,	O
uracil	NN	O
(	(	O
U	NNP	O
)	)	O
is	VBZ	O
substituted	VBN	O
for	IN	O
thymine	NN	O
.	.	O
When	WRB	O
referring	VBG	O
to	TO	O
RNA	NNP	O
herein	NN	O
,	,	O
the	DT	O
symbol	NN	O
T	NNP	O
may	MD	O
be	VB	O
used	VBN	O
interchangeably	RB	O
with	IN	O
U	NNP	O
to	TO	O
represent	VB	O
uracil	NN	O
at	IN	O
a	DT	O
particular	JJ	O
position	NN	O
in	IN	O
the	DT	O
RNA	NNP	O
molecule	NN	O
.	.	O
Nucleic	JJ	O
Acid	NNP	O
:	:	O
A	DT	O
polymer	NN	O
of	IN	O
nucleotides	NNS	O
,	,	O
either	CC	O
single	JJ	O
or	CC	O
double	JJ	O
stranded	VBN	O
.	.	O
Polynucleotide	NN	O
:	:	O
A	DT	O
polymer	NN	O
of	IN	O
single	JJ	O
or	CC	O
double	JJ	O
stranded	JJ	O
nucleotides	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
“	NNP	O
polynucleotide	NN	O
”	NNP	O
and	CC	O
its	PRP$	O
grammatical	JJ	O
equivalents	NNS	O
will	MD	O
include	VB	O
the	DT	O
full	JJ	O
range	NN	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
.	.	O
A	DT	O
polynucleotide	NN	O
will	MD	O
typically	RB	O
refer	VB	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprised	VBN	O
of	IN	O
a	DT	O
linear	JJ	O
strand	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
deoxyribonucleotides	NNS	O
and/or	VBP	O
ribonucleotides	NNS	O
.	.	O
The	DT	O
exact	JJ	O
size	NN	O
will	MD	O
depend	VB	O
on	IN	O
many	JJ	O
factors	NNS	O
,	,	O
which	WDT	O
in	IN	O
turn	NN	O
depends	NNS	O
on	IN	O
the	DT	O
ultimate	JJ	O
conditions	NNS	O
of	IN	O
use	NN	O
,	,	O
as	IN	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
primers	NNS	O
,	,	O
probes	NNS	O
,	,	O
RNA/DNA	NNP	O
segments	NNS	O
,	,	O
oligonucleotides	NNS	O
or	CC	O
“	VB	O
oligos	JJ	O
”	NNP	O
(	(	O
relatively	RB	O
short	JJ	O
polynucleotides	NNS	O
)	)	O
,	,	O
genes	NNS	O
,	,	O
vectors	NNS	O
,	,	O
plasmids	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Gene	NNP	O
:	:	O
A	DT	O
nucleic	JJ	O
acid	NN	O
whose	WP$	O
nucleotide	JJ	O
sequence	NN	O
codes	NNS	O
for	IN	O
an	DT	O
RNA	NNP	O
or	CC	O
polypeptide	NN	O
.	.	O
A	DT	O
gene	NN	O
can	MD	O
be	VB	O
either	CC	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
.	.	O
Duplex	NNP	O
DNA	NN	O
:	:	O
A	DT	O
double-stranded	JJ	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
comprising	VBG	O
two	CD	O
strands	NNS	O
of	IN	O
substantially	RB	O
complementary	JJ	O
polynucleotides	NNS	O
held	VBD	O
together	RB	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
hydrogen	JJ	O
bonds	NNS	O
between	IN	O
each	DT	O
of	IN	O
the	DT	O
complementary	JJ	O
bases	NNS	O
present	VBP	O
in	IN	O
a	DT	O
base	JJ	O
pair	NN	O
of	IN	O
the	DT	O
duplex	NN	O
.	.	O
Because	IN	O
the	DT	O
nucleotides	NNS	O
that	WDT	O
form	VBP	O
a	DT	O
base	NN	O
pair	NN	O
can	MD	O
be	VB	O
either	CC	O
a	DT	O
ribonucleotide	JJ	O
base	NN	O
or	CC	O
a	DT	O
deoxyribonucleotide	JJ	O
base	NN	O
,	,	O
the	DT	O
phrase	NN	O
“	NNP	O
duplex	NN	O
DNA	NNP	O
”	NNP	O
refers	NNS	O
to	TO	O
either	VB	O
a	DT	O
DNA-DNA	JJ	O
duplex	JJ	O
comprising	VBG	O
two	CD	O
DNA	NNP	O
strands	NNS	O
(	(	O
ds	VB	O
DNA	NNP	O
)	)	O
,	,	O
or	CC	O
an	DT	O
RNA-DNA	JJ	O
duplex	NN	O
comprising	VBG	O
one	CD	O
DNA	NN	O
and	CC	O
one	CD	O
RNA	NNP	O
strand	NN	O
.	.	O
Complementary	JJ	O
Bases	NNP	O
Nucleotides	NNP	O
that	IN	O
normally	RB	O
pair	VB	O
up	RP	O
when	WRB	O
DNA	NN	O
or	CC	O
RNA	NNP	O
adopts	VBZ	O
a	DT	O
double	JJ	O
stranded	JJ	O
configuration	NN	O
.	.	O
Complementary	NNP	O
Nucleotide	NNP	O
Sequence	NNP	O
:	:	O
A	DT	O
sequence	NN	O
of	IN	O
nucleotides	NNS	O
in	IN	O
a	DT	O
single-stranded	JJ	O
molecule	NN	O
of	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
that	WDT	O
is	VBZ	O
sufficiently	RB	O
complementary	JJ	O
to	TO	O
that	DT	O
on	IN	O
another	DT	O
single	JJ	O
strand	NN	O
to	TO	O
specifically	RB	O
hybridize	VB	O
to	TO	O
it	PRP	O
with	IN	O
consequent	JJ	O
hydrogen	NN	O
bonding	NN	O
.	.	O
Conserved	VBN	O
:	:	O
A	DT	O
nucleotide	JJ	O
sequence	NN	O
is	VBZ	O
conserved	VBN	O
with	IN	O
respect	NN	O
to	TO	O
a	DT	O
preselected	VBN	O
(	(	O
reference	NN	O
)	)	O
sequence	NN	O
if	IN	O
it	PRP	O
non-randomly	RB	O
hybridizes	VBZ	O
to	TO	O
an	DT	O
exact	JJ	O
complement	NN	O
of	IN	O
the	DT	O
preselected	JJ	O
sequence	NN	O
.	.	O
Hybridization	NN	O
:	:	O
The	DT	O
pairing	NN	O
of	IN	O
substantially	RB	O
complementary	JJ	O
nucleotide	NN	O
sequences	NNS	O
(	(	O
strands	NNS	O
of	IN	O
nucleic	JJ	O
acid	NN	O
)	)	O
to	TO	O
form	VB	O
a	DT	O
duplex	NN	O
or	CC	O
heteroduplex	NN	O
by	IN	O
the	DT	O
establishment	NN	O
of	IN	O
hydrogen	NN	O
bonds	NNS	O
between	IN	O
complementary	JJ	O
base	NN	O
pairs	NN	O
.	.	O
It	PRP	O
is	VBZ	O
a	DT	O
specific	JJ	O
,	,	O
i.e	JJ	O
.	.	O
non-random	NN	O
,	,	O
interaction	NN	O
between	IN	O
two	CD	O
complementary	JJ	O
polynucleotides	NNS	O
that	WDT	O
can	MD	O
be	VB	O
competitively	RB	O
inhibited	VBN	O
.	.	O
Nucleotide	NNP	O
Analog	NNP	O
:	:	O
A	DT	O
purine	NN	O
or	CC	O
pyrimidine	VB	O
nucleotide	IN	O
that	DT	O
differs	NNS	O
structurally	RB	O
from	IN	O
A	NNP	O
,	,	O
T	NNP	O
,	,	O
G	NNP	O
,	,	O
C	NNP	O
,	,	O
or	CC	O
U	NNP	O
,	,	O
but	CC	O
is	VBZ	O
sufficiently	RB	O
similar	JJ	O
to	TO	O
substitute	VB	O
for	IN	O
the	DT	O
normal	JJ	O
nucleotide	NN	O
in	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
.	.	O
DNA	NN	O
Homolog	NNP	O
:	:	O
A	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
a	DT	O
preselected	VBN	O
conserved	JJ	O
nucleotide	JJ	O
sequence	NN	O
and	CC	O
a	DT	O
sequence	NN	O
coding	NN	O
for	IN	O
a	DT	O
receptor	NN	O
capable	JJ	O
of	IN	O
binding	VBG	O
a	DT	O
preselected	JJ	O
ligand	NN	O
.	.	O
Upstream	NN	O
:	:	O
In	IN	O
the	DT	O
direction	NN	O
opposite	NN	O
to	TO	O
the	DT	O
direction	NN	O
of	IN	O
DNA	NNP	O
transcription	NN	O
,	,	O
and	CC	O
therefore	RB	O
going	VBG	O
from	IN	O
5′	CD	O
to	TO	O
3′	CD	O
on	IN	O
the	DT	O
non-coding	JJ	O
strand	NN	O
,	,	O
or	CC	O
3′	CD	O
to	TO	O
5′	CD	O
on	IN	O
the	DT	O
mRNA	NN	O
.	.	O
Downstream	NN	O
:	:	O
Further	RB	O
along	IN	O
a	DT	O
DNA	NN	O
sequence	NN	O
in	IN	O
the	DT	O
direction	NN	O
of	IN	O
sequence	NN	O
transcription	NN	O
or	CC	O
read	VB	O
out	RP	O
,	,	O
that	WDT	O
is	VBZ	O
traveling	VBG	O
in	IN	O
a	DT	O
3′-	JJ	O
to	TO	O
5′-direction	JJ	O
along	IN	O
the	DT	O
non-coding	JJ	O
strand	NN	O
of	IN	O
the	DT	O
DNA	NN	O
or	CC	O
5′-	JJ	O
to	TO	O
3′-direction	JJ	O
along	IN	O
the	DT	O
RNA	NNP	O
transcript	NN	O
.	.	O
Stop	NNP	O
Codon	NNP	O
:	:	O
Any	NN	O
of	IN	O
three	CD	O
codons	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
code	VB	O
for	IN	O
an	DT	O
amino	NN	O
acid	NN	O
,	,	O
but	CC	O
instead	RB	O
cause	VB	O
termination	NN	O
of	IN	O
protein	JJ	O
synthesis	NN	O
.	.	O
They	PRP	O
are	VBP	O
UAG	NNP	O
,	,	O
UAA	NNP	O
and	CC	O
UGA	NNP	O
and	CC	O
are	VBP	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
nonsense	NN	O
or	CC	O
termination	NN	O
codon	NN	O
.	.	O
Reading	VBG	O
Frame	NN	O
:	:	O
Particular	JJ	O
sequence	NN	O
of	IN	O
contiguous	JJ	O
nucleotide	JJ	O
triplets	NNS	O
(	(	O
codons	NNS	O
)	)	O
employed	VBN	O
in	IN	O
translation	NN	O
.	.	O
The	DT	O
reading	NN	O
frame	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
.	.	O
Intron	NN	O
:	:	O
Also	RB	O
referred	VBD	O
to	TO	O
as	IN	O
an	DT	O
intervening	NN	O
sequence	NN	O
,	,	O
a	DT	O
noncoding	JJ	O
sequence	NN	O
of	IN	O
DNA	NN	O
that	WDT	O
is	VBZ	O
initially	RB	O
copied	VBN	O
into	IN	O
RNA	NNP	O
but	CC	O
is	VBZ	O
cut	VBN	O
out	IN	O
of	IN	O
the	DT	O
final	JJ	O
RNA	NNP	O
transcript	NN	O
.	.	O
Protein	NNP	O
or	CC	O
polypeptide	NN	O
:	:	O
The	DT	O
term	NN	O
“	NNP	O
protein	NN	O
”	NN	O
or	CC	O
“	JJ	O
polypeptide	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polymer	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
and	CC	O
does	VBZ	O
not	RB	O
refer	VB	O
to	TO	O
a	DT	O
specific	JJ	O
length	NN	O
of	IN	O
the	DT	O
product	NN	O
.	.	O
Peptides	NNS	O
,	,	O
oligopeptides	NNS	O
,	,	O
polypeptides	NNS	O
,	,	O
proteins	NNS	O
,	,	O
and	CC	O
polyproteins	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
fragments	NNS	O
of	IN	O
these	DT	O
,	,	O
are	VBP	O
included	VBN	O
within	IN	O
this	DT	O
definition	NN	O
.	.	O
The	DT	O
term	NN	O
may	MD	O
include	VB	O
post	NN	O
expression	NN	O
modifications	NNS	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
glycosylations	NNS	O
,	,	O
acetylations	NNS	O
,	,	O
phosphorylations	NNS	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Included	VBN	O
within	IN	O
the	DT	O
definition	NN	O
are	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
proteins	VBZ	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
analogs	NNS	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
(	(	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
unnatural	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
proteins	VBZ	O
with	IN	O
substituted	JJ	O
linkages	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
modifications	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
both	DT	O
naturally	RB	O
occurring	VBG	O
and	CC	O
non-naturally	RB	O
occurring	NN	O
.	.	O
Unless	IN	O
otherwise	RB	O
indicated	VBN	O
,	,	O
the	DT	O
position	NN	O
numbering	NN	O
of	IN	O
amino	NN	O
acid	NN	O
residues	NNS	O
recited	VBN	O
herein	NN	O
is	VBZ	O
relative	JJ	O
to	TO	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
SEQUENCE:1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
A	DT	O
“	JJ	O
variant	NN	O
”	NN	O
is	VBZ	O
a	DT	O
polypeptide	JJ	O
comprising	VBG	O
a	DT	O
sequence	NN	O
which	WDT	O
differs	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	JJ	O
position	NN	O
(	(	O
s	JJ	O
)	)	O
from	IN	O
that	DT	O
of	IN	O
a	DT	O
parent	NN	O
polypeptide	NN	O
sequence	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
parent	NN	O
polypeptide	NN	O
”	NNP	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
the	DT	O
polypeptide	NN	O
sequence	NN	O
to	TO	O
be	VB	O
modified	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
A	DT	O
“	JJ	O
fragment	NN	O
”	NN	O
or	CC	O
“	JJ	O
subsequence	NN	O
”	NN	O
is	VBZ	O
any	DT	O
portion	NN	O
of	IN	O
an	DT	O
entire	JJ	O
sequence	NN	O
,	,	O
up	RB	O
to	TO	O
but	CC	O
not	RB	O
including	VBG	O
the	DT	O
entire	JJ	O
sequence	NN	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
fragment	NN	O
or	CC	O
subsequence	NN	O
refers	NNS	O
to	TO	O
a	DT	O
sequence	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
or	CC	O
nucleic	JJ	O
acids	NNS	O
that	WDT	O
comprises	VBZ	O
a	DT	O
part	NN	O
of	IN	O
a	DT	O
longer	JJR	O
sequence	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
(	(	O
e.g.	NN	O
,	,	O
polypeptide	NN	O
)	)	O
or	CC	O
nucleic	JJ	O
acids	NNS	O
(	(	O
e.g.	NN	O
,	,	O
polynucleotide	NN	O
)	)	O
.	.	O
A	DT	O
polypeptide	NN	O
,	,	O
nucleic	JJ	O
acid	NN	O
,	,	O
or	CC	O
other	JJ	O
component	NN	O
is	VBZ	O
“	RB	O
isolated	JJ	O
”	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
partially	RB	O
or	CC	O
completely	RB	O
separated	VBN	O
from	IN	O
components	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
normally	RB	O
associated	VBN	O
(	(	O
other	JJ	O
peptides	NNS	O
,	,	O
polypeptides	NNS	O
,	,	O
proteins	NNS	O
(	(	O
including	VBG	O
complexes	NNS	O
,	,	O
e.g.	NN	O
,	,	O
polymerases	NNS	O
and	CC	O
ribosomes	NNS	O
which	WDT	O
may	MD	O
accompany	VB	O
a	DT	O
native	JJ	O
sequence	NN	O
)	)	O
,	,	O
nucleic	JJ	O
acids	NNS	O
,	,	O
cells	NNS	O
,	,	O
synthetic	JJ	O
reagents	NNS	O
,	,	O
cellular	JJ	O
contaminants	NNS	O
,	,	O
cellular	JJ	O
components	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
e.g.	RB	O
,	,	O
such	JJ	O
as	IN	O
from	IN	O
other	JJ	O
components	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
normally	RB	O
associated	VBN	O
in	IN	O
the	DT	O
cell	NN	O
from	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
originally	RB	O
derived	VBN	O
.	.	O
A	DT	O
polypeptide	NN	O
,	,	O
nucleic	JJ	O
acid	NN	O
,	,	O
or	CC	O
other	JJ	O
component	NN	O
is	VBZ	O
isolated	VBN	O
when	WRB	O
it	PRP	O
is	VBZ	O
partially	RB	O
or	CC	O
completely	RB	O
recovered	VBD	O
or	CC	O
separated	VBN	O
from	IN	O
other	JJ	O
components	NNS	O
of	IN	O
its	PRP$	O
natural	JJ	O
environment	NN	O
such	JJ	O
that	IN	O
it	PRP	O
is	VBZ	O
the	DT	O
predominant	JJ	O
species	NNS	O
present	VBP	O
in	IN	O
a	DT	O
composition	NN	O
,	,	O
mixture	NN	O
,	,	O
or	CC	O
collection	NN	O
of	IN	O
components	NNS	O
(	(	O
i.e	NN	O
.	.	O
on	IN	O
a	DT	O
molar	JJ	O
basis	NN	O
it	PRP	O
is	VBZ	O
more	RBR	O
abundant	JJ	O
than	IN	O
any	DT	O
other	JJ	O
individual	JJ	O
species	NNS	O
in	IN	O
the	DT	O
composition	NN	O
)	)	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
the	DT	O
preparation	NN	O
consists	VBZ	O
of	IN	O
more	JJR	O
than	IN	O
about	RB	O
60	CD	O
%	NN	O
,	,	O
70	CD	O
%	NN	O
or	CC	O
75	CD	O
%	NN	O
,	,	O
typically	RB	O
more	JJR	O
than	IN	O
about	RB	O
80	CD	O
%	NN	O
,	,	O
or	CC	O
preferably	RB	O
more	JJR	O
than	IN	O
about	RB	O
90	CD	O
%	NN	O
of	IN	O
the	DT	O
isolated	JJ	O
species	NNS	O
.	.	O
A	DT	O
“	NNP	O
substantially	RB	O
pure	VBP	O
”	CD	O
or	CC	O
“	VB	O
isolated	JJ	O
”	NNP	O
nucleic	JJ	O
acid	NN	O
(	(	O
e.g.	JJ	O
,	,	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
)	)	O
,	,	O
polypeptide	RB	O
,	,	O
protein	NN	O
,	,	O
or	CC	O
composition	NN	O
also	RB	O
means	VBZ	O
where	WRB	O
the	DT	O
object	NN	O
species	NNS	O
(	(	O
e.g.	NN	O
,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
)	)	O
comprises	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
,	,	O
60	CD	O
,	,	O
or	CC	O
70	CD	O
percent	NN	O
by	IN	O
weight	NN	O
(	(	O
on	IN	O
a	DT	O
molar	JJ	O
basis	NN	O
)	)	O
of	IN	O
all	DT	O
macromolecular	JJ	O
species	NNS	O
present	VBP	O
.	.	O
A	DT	O
substantially	RB	O
pure	NN	O
or	CC	O
isolated	JJ	O
composition	NN	O
can	MD	O
also	RB	O
comprise	VB	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
,	,	O
90	CD	O
,	,	O
or	CC	O
95	CD	O
percent	NN	O
by	IN	O
weight	NN	O
of	IN	O
all	DT	O
macromolecular	JJ	O
species	NNS	O
present	VBP	O
in	IN	O
the	DT	O
composition	NN	O
.	.	O
An	DT	O
isolated	JJ	O
object	NN	O
species	NNS	O
can	MD	O
also	RB	O
be	VB	O
purified	VBN	O
to	TO	O
essential	JJ	O
homogeneity	NN	O
(	(	O
contaminant	JJ	O
species	NNS	O
can	MD	O
not	RB	O
be	VB	O
detected	VBN	O
in	IN	O
the	DT	O
composition	NN	O
by	IN	O
conventional	JJ	O
detection	NN	O
methods	NNS	O
)	)	O
wherein	VBP	O
the	DT	O
composition	NN	O
consists	VBZ	O
essentially	RB	O
of	IN	O
derivatives	NNS	O
of	IN	O
a	DT	O
single	JJ	O
macromolecular	NN	O
species	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
purified	VBD	O
”	NNP	O
generally	RB	O
denotes	VBZ	O
that	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
polypeptide	NN	O
,	,	O
or	CC	O
protein	NN	O
gives	VBZ	O
rise	NN	O
to	TO	O
essentially	RB	O
one	CD	O
band	NN	O
in	IN	O
an	DT	O
electrophoretic	JJ	O
gel	NN	O
.	.	O
It	PRP	O
typically	RB	O
means	VBZ	O
that	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
polypeptide	NN	O
,	,	O
or	CC	O
protein	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
%	NN	O
pure	NN	O
,	,	O
60	CD	O
%	NN	O
pure	NN	O
,	,	O
70	CD	O
%	NN	O
pure	NN	O
,	,	O
75	CD	O
%	NN	O
pure	NN	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
about	IN	O
85	CD	O
%	NN	O
pure	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
pure	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
isolated	VBD	O
nucleic	JJ	O
acid	JJ	O
”	NN	O
may	MD	O
refer	VB	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
(	(	O
e.g.	JJ	O
,	,	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
)	)	O
that	WDT	O
is	VBZ	O
not	RB	O
immediately	RB	O
contiguous	JJ	O
with	IN	O
both	DT	O
of	IN	O
the	DT	O
coding	NN	O
sequences	NNS	O
with	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
immediately	RB	O
contiguous	JJ	O
(	(	O
i.e.	FW	O
,	,	O
one	CD	O
at	IN	O
the	DT	O
5′	CD	O
and	CC	O
one	CD	O
at	IN	O
the	DT	O
3′	CD	O
end	NN	O
)	)	O
in	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
genome	NN	O
of	IN	O
the	DT	O
organism	NN	O
from	IN	O
which	WDT	O
the	DT	O
nucleic	NN	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
derived	VBN	O
.	.	O
Thus	RB	O
,	,	O
this	DT	O
term	NN	O
includes	VBZ	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
cDNA	NN	O
or	CC	O
a	DT	O
genomic	JJ	O
DNA	NNP	O
fragment	NN	O
produced	VBN	O
by	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
or	CC	O
restriction	NN	O
endonuclease	NN	O
treatment	NN	O
,	,	O
whether	IN	O
such	JJ	O
cDNA	NN	O
or	CC	O
genomic	JJ	O
DNA	NNP	O
fragment	NN	O
is	VBZ	O
incorporated	VBN	O
into	IN	O
a	DT	O
vector	NN	O
,	,	O
integrated	VBN	O
into	IN	O
the	DT	O
genome	NN	O
of	IN	O
the	DT	O
same	JJ	O
or	CC	O
a	DT	O
different	JJ	O
species	NNS	O
than	IN	O
the	DT	O
organism	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
virus	NN	O
,	,	O
from	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
originally	RB	O
derived	VBN	O
,	,	O
linked	VBN	O
to	TO	O
an	DT	O
additional	JJ	O
coding	NN	O
sequence	NN	O
to	TO	O
form	VB	O
a	DT	O
hybrid	JJ	O
gene	NN	O
encoding	VBG	O
a	DT	O
chimeric	JJ	O
polypeptide	NN	O
,	,	O
or	CC	O
independent	JJ	O
of	IN	O
any	DT	O
other	JJ	O
DNA	NN	O
sequences	NNS	O
.	.	O
The	DT	O
DNA	NN	O
may	MD	O
be	VB	O
double-stranded	JJ	O
or	CC	O
single-stranded	JJ	O
,	,	O
sense	NN	O
or	CC	O
antisense	NN	O
.	.	O
A	DT	O
“	JJ	O
recombinant	JJ	O
polynucleotide	NN	O
”	NN	O
or	CC	O
a	DT	O
“	JJ	O
recombinant	JJ	O
polypeptide	NN	O
”	NN	O
is	VBZ	O
a	DT	O
non-naturally	RB	O
occurring	VBG	O
polynucleotide	NN	O
or	CC	O
polypeptide	NN	O
which	WDT	O
may	MD	O
include	VB	O
nucleic	JJ	O
acid	NN	O
or	CC	O
amino	NN	O
acid	NN	O
sequences	NNS	O
,	,	O
respectively	RB	O
,	,	O
from	IN	O
more	JJR	O
than	IN	O
one	CD	O
source	NN	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
,	,	O
which	WDT	O
source	NN	O
nucleic	NN	O
acid	NN	O
or	CC	O
polypeptide	NN	O
can	MD	O
be	VB	O
a	DT	O
naturally	RB	O
occurring	VBG	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
,	,	O
or	CC	O
can	MD	O
itself	PRP	O
have	VB	O
been	VBN	O
subjected	VBN	O
to	TO	O
mutagenesis	NN	O
or	CC	O
other	JJ	O
type	NN	O
of	IN	O
modification	NN	O
.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
may	MD	O
be	VB	O
deemed	VBN	O
“	JJ	O
recombinant	NN	O
”	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
synthetic	JJ	O
or	CC	O
artificial	JJ	O
or	CC	O
engineered	VBN	O
,	,	O
or	CC	O
derived	VBN	O
from	IN	O
a	DT	O
synthetic	JJ	O
or	CC	O
artificial	JJ	O
or	CC	O
engineered	JJ	O
polypeptide	NN	O
or	CC	O
nucleic	JJ	O
acid	NN	O
.	.	O
A	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
(	(	O
e.g.	JJ	O
,	,	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
)	)	O
can	MD	O
be	VB	O
made	VBN	O
by	IN	O
the	DT	O
combination	NN	O
(	(	O
e.g.	JJ	O
,	,	O
artificial	JJ	O
combination	NN	O
)	)	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
segments	NNS	O
of	IN	O
sequence	NN	O
that	WDT	O
are	VBP	O
not	RB	O
typically	RB	O
included	VBN	O
together	RB	O
,	,	O
not	RB	O
typically	RB	O
associated	VBN	O
with	IN	O
one	CD	O
another	DT	O
,	,	O
or	CC	O
are	VBP	O
otherwise	RB	O
typically	RB	O
separated	VBN	O
from	IN	O
one	CD	O
another	DT	O
.	.	O
A	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
can	MD	O
comprise	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
formed	VBN	O
by	IN	O
the	DT	O
joining	NN	O
together	RB	O
or	CC	O
combination	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
segments	NNS	O
from	IN	O
different	JJ	O
sources	NNS	O
and/or	VBP	O
artificially	RB	O
synthesized	VBN	O
.	.	O
A	DT	O
“	JJ	O
recombinant	JJ	O
polypeptide	NN	O
”	NNP	O
often	RB	O
refers	VBZ	O
to	TO	O
a	DT	O
polypeptide	NN	O
that	WDT	O
results	NNS	O
from	IN	O
a	DT	O
cloned	VBN	O
or	CC	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
The	DT	O
source	NN	O
polynucleotides	NNS	O
or	CC	O
polypeptides	NNS	O
from	IN	O
which	WDT	O
the	DT	O
different	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
are	VBP	O
derived	VBN	O
are	VBP	O
sometimes	RB	O
homologous	JJ	O
(	(	O
i.e.	FW	O
,	,	O
have	VBP	O
,	,	O
or	CC	O
encode	VB	O
a	DT	O
polypeptide	NN	O
that	WDT	O
encodes	VBZ	O
,	,	O
the	DT	O
same	JJ	O
or	CC	O
a	DT	O
similar	JJ	O
structure	NN	O
and/or	NN	O
function	NN	O
)	)	O
,	,	O
and	CC	O
are	VBP	O
often	RB	O
from	IN	O
different	JJ	O
isolates	NNS	O
,	,	O
serotypes	NNS	O
,	,	O
strains	NNS	O
,	,	O
species	NNS	O
,	,	O
of	IN	O
organism	NN	O
or	CC	O
from	IN	O
different	JJ	O
disease	NN	O
states	NNS	O
,	,	O
for	IN	O
example	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
recombinant	NN	O
”	NN	O
when	WRB	O
used	VBN	O
with	IN	O
reference	NN	O
,	,	O
e.g.	NN	O
,	,	O
to	TO	O
a	DT	O
cell	NN	O
,	,	O
polynucleotide	NN	O
,	,	O
vector	NN	O
,	,	O
protein	NN	O
,	,	O
or	CC	O
polypeptide	VB	O
typically	RB	O
indicates	VBZ	O
that	IN	O
the	DT	O
cell	NN	O
,	,	O
polynucleotide	NN	O
,	,	O
or	CC	O
vector	NN	O
has	VBZ	O
been	VBN	O
modified	VBN	O
by	IN	O
the	DT	O
introduction	NN	O
of	IN	O
a	DT	O
heterologous	JJ	O
(	(	O
or	CC	O
foreign	JJ	O
)	)	O
nucleic	JJ	O
acid	NN	O
or	CC	O
the	DT	O
alteration	NN	O
of	IN	O
a	DT	O
native	JJ	O
nucleic	NN	O
acid	NN	O
,	,	O
or	CC	O
that	IN	O
the	DT	O
protein	NN	O
or	CC	O
polypeptide	NN	O
has	VBZ	O
been	VBN	O
modified	VBN	O
by	IN	O
the	DT	O
introduction	NN	O
of	IN	O
a	DT	O
heterologous	JJ	O
amino	NN	O
acid	NN	O
,	,	O
or	CC	O
that	IN	O
the	DT	O
cell	NN	O
is	VBZ	O
derived	VBN	O
from	IN	O
a	DT	O
cell	NN	O
so	RB	O
modified	JJ	O
.	.	O
Recombinant	JJ	O
cells	NNS	O
express	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
found	VBN	O
in	IN	O
the	DT	O
native	JJ	O
(	(	O
non-recombinant	JJ	O
)	)	O
form	NN	O
of	IN	O
the	DT	O
cell	NN	O
or	CC	O
express	JJ	O
native	JJ	O
nucleic	NN	O
acid	NN	O
sequences	NNS	O
that	WDT	O
would	MD	O
otherwise	RB	O
be	VB	O
abnormally	RB	O
expressed	VBN	O
,	,	O
under-expressed	JJ	O
,	,	O
or	CC	O
not	RB	O
expressed	VBN	O
at	IN	O
all	DT	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
recombinant	NN	O
”	NN	O
when	WRB	O
used	VBN	O
with	IN	O
reference	NN	O
to	TO	O
a	DT	O
cell	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
cell	NN	O
replicates	VBZ	O
a	DT	O
heterologous	JJ	O
nucleic	NN	O
acid	NN	O
,	,	O
or	CC	O
expresses	VBZ	O
a	DT	O
polypeptide	NN	O
encoded	VBN	O
by	IN	O
a	DT	O
heterologous	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
Recombinant	JJ	O
cells	NNS	O
can	MD	O
contain	VB	O
coding	JJ	O
sequences	NNS	O
that	WDT	O
are	VBP	O
not	RB	O
found	VBN	O
within	IN	O
the	DT	O
native	JJ	O
(	(	O
non-recombinant	JJ	O
)	)	O
form	NN	O
of	IN	O
the	DT	O
cell	NN	O
.	.	O
Recombinant	JJ	O
cells	NNS	O
can	MD	O
also	RB	O
contain	VB	O
coding	VBG	O
sequences	NNS	O
found	VBN	O
in	IN	O
the	DT	O
native	JJ	O
form	NN	O
of	IN	O
the	DT	O
cell	NN	O
wherein	VBZ	O
the	DT	O
coding	NN	O
sequences	NNS	O
are	VBP	O
modified	VBN	O
and	CC	O
re-introduced	JJ	O
into	IN	O
the	DT	O
cell	NN	O
by	IN	O
artificial	JJ	O
means	NNS	O
.	.	O
The	DT	O
term	NN	O
also	RB	O
encompasses	VBZ	O
cells	NNS	O
that	WDT	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
endogenous	JJ	O
to	TO	O
the	DT	O
cell	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
modified	VBN	O
without	IN	O
removing	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
from	IN	O
the	DT	O
cell	NN	O
;	:	O
such	JJ	O
modifications	NNS	O
include	VBP	O
those	DT	O
obtained	VBN	O
by	IN	O
gene	NN	O
replacement	NN	O
,	,	O
site-specific	JJ	O
mutation	NN	O
,	,	O
recombination	NN	O
,	,	O
and	CC	O
related	JJ	O
techniques	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
recombinantly	RB	O
produced	VBD	O
”	JJ	O
refers	NNS	O
to	TO	O
an	DT	O
artificial	JJ	O
combination	NN	O
usually	RB	O
accomplished	VBN	O
by	IN	O
either	DT	O
chemical	JJ	O
synthesis	NN	O
means	VBZ	O
,	,	O
recursive	JJ	O
sequence	NN	O
recombination	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
segments	NNS	O
or	CC	O
other	JJ	O
diversity	NN	O
generation	NN	O
methods	NNS	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
e.g.	NN	O
,	,	O
shuffling	VBG	O
)	)	O
of	IN	O
nucleotides	NNS	O
,	,	O
or	CC	O
manipulation	NN	O
of	IN	O
isolated	JJ	O
segments	NNS	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
genetic	JJ	O
engineering	NN	O
techniques	NNS	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
“	RB	O
Recombinantly	RB	O
expressed	VBN	O
”	NNP	O
typically	RB	O
refers	VBZ	O
to	TO	O
techniques	VB	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
in	IN	O
vitro	NN	O
and	CC	O
transfer	NN	O
of	IN	O
the	DT	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
into	IN	O
cells	NNS	O
in	IN	O
vivo	NN	O
,	,	O
in	IN	O
vitro	NN	O
,	,	O
or	CC	O
ex	VB	O
vivo	NN	O
where	WRB	O
it	PRP	O
may	MD	O
be	VB	O
expressed	VBN	O
or	CC	O
propagated	VBN	O
.	.	O
An	DT	O
“	JJ	O
immunogen	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
capable	JJ	O
of	IN	O
provoking	VBG	O
an	DT	O
immune	JJ	O
response	NN	O
,	,	O
and	CC	O
includes	VBZ	O
,	,	O
e.g.	NN	O
,	,	O
antigens	NNS	O
,	,	O
autoantigens	NNS	O
that	IN	O
play	VBP	O
a	DT	O
role	NN	O
in	IN	O
induction	NN	O
of	IN	O
autoimmune	NN	O
diseases	NNS	O
,	,	O
and	CC	O
tumor-associated	JJ	O
antigens	NNS	O
expressed	VBN	O
on	IN	O
cancer	NN	O
cells	NNS	O
.	.	O
An	DT	O
immune	JJ	O
response	NN	O
generally	RB	O
refers	VBZ	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
a	DT	O
cellular	JJ	O
or	CC	O
antibody-mediated	JJ	O
response	NN	O
to	TO	O
an	DT	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
antigen	NN	O
or	CC	O
fragment	JJ	O
thereof	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
encoding	VBG	O
such	JJ	O
agent	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
such	PDT	O
a	DT	O
response	NN	O
comprises	VBZ	O
a	DT	O
production	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
or	CC	O
a	DT	O
combination	NN	O
of	IN	O
CTLs	NNP	O
,	,	O
B	NNP	O
cells	NNS	O
,	,	O
or	CC	O
various	JJ	O
classes	NNS	O
of	IN	O
T	NNP	O
cells	NNS	O
that	WDT	O
are	VBP	O
directed	VBN	O
specifically	RB	O
to	TO	O
antigen-presenting	JJ	O
cells	NNS	O
expressing	VBG	O
the	DT	O
antigen	NN	O
of	IN	O
interest	NN	O
.	.	O
An	DT	O
“	JJ	O
antigen	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
that	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
eliciting	VBG	O
the	DT	O
formation	NN	O
of	IN	O
antibodies	NNS	O
in	IN	O
a	DT	O
host	NN	O
or	CC	O
generating	VBG	O
a	DT	O
specific	JJ	O
population	NN	O
of	IN	O
lymphocytes	NNS	O
reactive	VBP	O
with	IN	O
that	DT	O
substance	NN	O
.	.	O
Antigens	NNS	O
are	VBP	O
typically	RB	O
macromolecules	NNS	O
(	(	O
e.g.	NN	O
,	,	O
proteins	NNS	O
and	CC	O
polysaccharides	NNS	O
)	)	O
that	WDT	O
are	VBP	O
foreign	JJ	O
to	TO	O
the	DT	O
host	NN	O
.	.	O
An	DT	O
“	NN	O
adjuvant	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
substance	NN	O
that	WDT	O
enhances	VBZ	O
an	DT	O
antigen	NN	O
's	POS	O
immune-stimulating	JJ	O
properties	NNS	O
or	CC	O
the	DT	O
pharmacological	JJ	O
effect	NN	O
(	(	O
s	NN	O
)	)	O
of	IN	O
a	DT	O
drug	NN	O
.	.	O
An	DT	O
adjuvant	NN	O
may	MD	O
non-specifically	RB	O
enhance	VB	O
the	DT	O
immune	JJ	O
response	NN	O
to	TO	O
an	DT	O
antigen	NN	O
.	.	O
“	NN	O
Freund	NNP	O
's	POS	O
Complete	NNP	O
Adjuvant	NNP	O
,	,	O
”	NNP	O
for	IN	O
example	NN	O
,	,	O
is	VBZ	O
an	DT	O
emulsion	NN	O
of	IN	O
oil	NN	O
and	CC	O
water	NN	O
containing	VBG	O
an	DT	O
immunogen	NN	O
,	,	O
an	DT	O
emulsifying	NN	O
agent	NN	O
and	CC	O
mycobacteria	NN	O
.	.	O
Another	DT	O
example	NN	O
,	,	O
“	NNP	O
Freund	NNP	O
's	POS	O
incomplete	JJ	O
adjuvant	NN	O
,	,	O
”	EX	O
is	VBZ	O
the	DT	O
same	JJ	O
,	,	O
but	CC	O
without	IN	O
mycobacteria	NNS	O
.	.	O
A	DT	O
“	JJ	O
vector	NN	O
”	NN	O
is	VBZ	O
a	DT	O
component	NN	O
or	CC	O
composition	NN	O
for	IN	O
facilitating	VBG	O
cell	NN	O
transduction	NN	O
or	CC	O
transfection	NN	O
by	IN	O
a	DT	O
selected	VBN	O
nucleic	NN	O
acid	NN	O
,	,	O
or	CC	O
expression	NN	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
in	IN	O
the	DT	O
cell	NN	O
.	.	O
Vectors	NNS	O
include	VBP	O
,	,	O
e.g.	JJ	O
,	,	O
plasmids	NNS	O
,	,	O
cosmids	NNS	O
,	,	O
viruses	NNS	O
,	,	O
YACs	NNP	O
,	,	O
bacteria	NN	O
,	,	O
poly-lysine	JJ	O
,	,	O
etc	FW	O
.	.	O
An	DT	O
“	JJ	O
expression	NN	O
vector	NN	O
”	NNP	O
is	VBZ	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
construct	NN	O
or	CC	O
sequence	NN	O
,	,	O
generated	VBN	O
recombinantly	RB	O
or	CC	O
synthetically	RB	O
,	,	O
with	IN	O
a	DT	O
series	NN	O
of	IN	O
specific	JJ	O
nucleic	JJ	O
acid	NN	O
elements	NNS	O
that	WDT	O
permit	VBP	O
transcription	NN	O
of	IN	O
a	DT	O
particular	JJ	O
nucleic	NN	O
acid	NN	O
in	IN	O
a	DT	O
host	NN	O
cell	NN	O
.	.	O
The	DT	O
expression	NN	O
vector	NN	O
can	MD	O
be	VB	O
part	NN	O
of	IN	O
a	DT	O
plasmid	NN	O
,	,	O
virus	NN	O
,	,	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
fragment	NN	O
.	.	O
The	DT	O
expression	NN	O
vector	NN	O
typically	RB	O
includes	VBZ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
transcribed	VBN	O
operably	RB	O
linked	VBN	O
to	TO	O
a	DT	O
promoter	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
transcribed	VBN	O
is	VBZ	O
typically	RB	O
under	IN	O
the	DT	O
direction	NN	O
or	CC	O
control	NN	O
of	IN	O
the	DT	O
promoter	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
subject	JJ	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
includes	VBZ	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
an	DT	O
organism	NN	O
;	:	O
a	DT	O
mammal	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
human	JJ	O
,	,	O
non-human	JJ	O
primate	NN	O
(	(	O
e.g.	JJ	O
,	,	O
baboon	NN	O
,	,	O
orangutan	NN	O
,	,	O
monkey	NN	O
)	)	O
,	,	O
mouse	RB	O
,	,	O
pig	NN	O
,	,	O
cow	NN	O
,	,	O
goat	NN	O
,	,	O
cat	NN	O
,	,	O
rabbit	NN	O
,	,	O
rat	NN	O
,	,	O
guinea	NN	O
pig	NN	O
,	,	O
hamster	NN	O
,	,	O
horse	NN	O
,	,	O
monkey	NN	O
,	,	O
sheep	NN	O
,	,	O
or	CC	O
other	JJ	O
non-human	JJ	O
mammal	NN	O
;	:	O
a	DT	O
non-mammal	JJ	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
non-mammalian	JJ	O
vertebrate	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
bird	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
chicken	NN	O
or	CC	O
duck	NN	O
)	)	O
or	CC	O
a	DT	O
fish	JJ	O
,	,	O
and	CC	O
a	DT	O
non-mammalian	JJ	O
invertebrate	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
pharmaceutical	JJ	O
composition	NN	O
”	NN	O
means	VBZ	O
a	DT	O
composition	NN	O
suitable	NN	O
for	IN	O
pharmaceutical	JJ	O
use	NN	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
including	VBG	O
an	DT	O
animal	NN	O
or	CC	O
human	NN	O
.	.	O
A	DT	O
pharmaceutical	JJ	O
composition	NN	O
generally	RB	O
comprises	VBZ	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
active	JJ	O
agent	NN	O
and	CC	O
a	DT	O
carrier	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
effective	JJ	O
amount	NN	O
”	NNP	O
means	VBZ	O
a	DT	O
dosage	NN	O
or	CC	O
amount	NN	O
sufficient	JJ	O
to	TO	O
produce	VB	O
a	DT	O
desired	JJ	O
result	NN	O
.	.	O
The	DT	O
desired	JJ	O
result	NN	O
may	MD	O
comprise	VB	O
an	DT	O
objective	NN	O
or	CC	O
subjective	JJ	O
improvement	NN	O
in	IN	O
the	DT	O
recipient	NN	O
of	IN	O
the	DT	O
dosage	NN	O
or	CC	O
amount	NN	O
.	.	O
A	DT	O
“	JJ	O
prophylactic	JJ	O
treatment	NN	O
”	NN	O
is	VBZ	O
a	DT	O
treatment	NN	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
does	VBZ	O
not	RB	O
display	VB	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
disease	NN	O
,	,	O
pathology	NN	O
,	,	O
or	CC	O
medical	JJ	O
disorder	NN	O
,	,	O
or	CC	O
displays	VBZ	O
only	RB	O
early	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
disease	NN	O
,	,	O
pathology	NN	O
,	,	O
or	CC	O
disorder	NN	O
,	,	O
such	JJ	O
that	IN	O
treatment	NN	O
is	VBZ	O
administered	VBN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
diminishing	NN	O
,	,	O
preventing	VBG	O
,	,	O
or	CC	O
decreasing	VBG	O
the	DT	O
risk	NN	O
of	IN	O
developing	VBG	O
the	DT	O
disease	NN	O
,	,	O
pathology	NN	O
,	,	O
or	CC	O
medical	JJ	O
disorder	NN	O
.	.	O
A	DT	O
prophylactic	JJ	O
treatment	NN	O
functions	NNS	O
as	IN	O
a	DT	O
preventative	JJ	O
treatment	NN	O
against	IN	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
.	.	O
A	DT	O
“	JJ	O
prophylactic	JJ	O
activity	NN	O
”	NNP	O
is	VBZ	O
an	DT	O
activity	NN	O
of	IN	O
an	DT	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
vector	NN	O
,	,	O
gene	NN	O
,	,	O
polypeptide	RB	O
,	,	O
protein	NN	O
,	,	O
substance	NN	O
,	,	O
or	CC	O
composition	NN	O
thereof	NN	O
that	IN	O
,	,	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
does	VBZ	O
not	RB	O
display	VB	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
or	CC	O
disorder	NN	O
,	,	O
or	CC	O
who	WP	O
displays	VBZ	O
only	RB	O
early	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
,	,	O
or	CC	O
disorder	NN	O
,	,	O
diminishes	NNS	O
,	,	O
prevents	NNS	O
,	,	O
or	CC	O
decreases	VBZ	O
the	DT	O
risk	NN	O
of	IN	O
the	DT	O
subject	JJ	O
developing	VBG	O
a	DT	O
pathology	NN	O
,	,	O
disease	NN	O
,	,	O
or	CC	O
disorder	NN	O
.	.	O
A	DT	O
“	NNP	O
prophylactically	RB	O
useful	JJ	O
”	JJ	O
agent	NN	O
or	CC	O
compound	NN	O
(	(	O
e.g.	JJ	O
,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
)	)	O
refers	NNS	O
to	TO	O
an	DT	O
agent	NN	O
or	CC	O
compound	NN	O
that	WDT	O
is	VBZ	O
useful	JJ	O
in	IN	O
diminishing	VBG	O
,	,	O
preventing	VBG	O
,	,	O
treating	VBG	O
,	,	O
or	CC	O
decreasing	VBG	O
development	NN	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
or	CC	O
disorder	NN	O
.	.	O
A	DT	O
“	JJ	O
therapeutic	JJ	O
treatment	NN	O
”	NN	O
is	VBZ	O
a	DT	O
treatment	NN	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
who	WP	O
displays	VBZ	O
symptoms	NNS	O
or	CC	O
signs	NNS	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
,	,	O
or	CC	O
disorder	NN	O
,	,	O
in	IN	O
which	WDT	O
treatment	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
the	DT	O
subject	NN	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
diminishing	VBG	O
or	CC	O
eliminating	VBG	O
those	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
,	,	O
or	CC	O
disorder	NN	O
.	.	O
A	DT	O
“	JJ	O
therapeutic	JJ	O
activity	NN	O
”	NNP	O
is	VBZ	O
an	DT	O
activity	NN	O
of	IN	O
an	DT	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
vector	NN	O
,	,	O
gene	NN	O
,	,	O
polypeptide	RB	O
,	,	O
protein	NN	O
,	,	O
substance	NN	O
,	,	O
or	CC	O
composition	NN	O
thereof	NN	O
,	,	O
that	WDT	O
eliminates	VBZ	O
or	CC	O
diminishes	VBZ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
pathology	NN	O
,	,	O
disease	NN	O
or	CC	O
disorder	NN	O
,	,	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	JJ	O
suffering	VBG	O
from	IN	O
such	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
.	.	O
A	DT	O
“	NNP	O
therapeutically	RB	O
useful	JJ	O
”	JJ	O
agent	NN	O
or	CC	O
compound	NN	O
(	(	O
e.g.	JJ	O
,	,	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
)	)	O
indicates	VBZ	O
that	IN	O
an	DT	O
agent	NN	O
or	CC	O
compound	NN	O
is	VBZ	O
useful	JJ	O
in	IN	O
diminishing	VBG	O
,	,	O
treating	VBG	O
,	,	O
or	CC	O
eliminating	VBG	O
such	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
a	DT	O
pathology	NN	O
,	,	O
disease	NN	O
or	CC	O
disorder	NN	O
.	.	O
Modes	NNS	O
of	IN	O
Practicing	VBG	O
the	DT	O
Invention	NNP	O
2′,5′-oligoadenylate	JJ	O
synthetases	NNS	O
(	(	O
OAS	NNP	O
)	)	O
are	VBP	O
a	DT	O
family	NN	O
of	IN	O
IFN-inducible	JJ	O
,	,	O
RNA	NNP	O
dependent	NN	O
effector	NN	O
enzymes	VBZ	O
that	IN	O
synthesize	VB	O
short	JJ	O
2′	CD	O
to	TO	O
5′	CD	O
linked	VBN	O
oligoadenylate	NN	O
(	(	O
2-5A	JJ	O
)	)	O
molecules	NNS	O
from	IN	O
ATP	NNP	O
.	.	O
2-5A	JJ	O
molecules	NNS	O
bind	IN	O
to	TO	O
and	CC	O
activate	VB	O
the	DT	O
RNAseL	NNP	O
enzyme	NN	O
,	,	O
which	WDT	O
once	RB	O
activated	VBD	O
,	,	O
degrades	VBZ	O
viral	JJ	O
and	CC	O
cellular	JJ	O
RNAs	NNP	O
and	CC	O
blocks	NNS	O
cellular	JJ	O
protein	NN	O
synthesis	NN	O
.	.	O
OAS	NNP	O
enzymes	VBZ	O
constitute	VBP	O
an	DT	O
important	JJ	O
part	NN	O
of	IN	O
the	DT	O
nonspecific	JJ	O
immune	NN	O
defense	NN	O
against	IN	O
viral	JJ	O
infections	NNS	O
and	CC	O
have	VBP	O
been	VBN	O
used	VBN	O
as	IN	O
a	DT	O
cellular	JJ	O
marker	NN	O
for	IN	O
viral	JJ	O
infection	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
role	NN	O
in	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
discussed	VBD	O
herein	NN	O
,	,	O
OAS	NNP	O
activity	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
other	JJ	O
disease	NN	O
states	NNS	O
,	,	O
particularly	RB	O
those	DT	O
in	IN	O
which	WDT	O
a	DT	O
viral	JJ	O
infection	NN	O
plays	VBZ	O
a	DT	O
role	NN	O
.	.	O
While	IN	O
specific	JJ	O
pathogenic	JJ	O
mechanisms	NNS	O
are	VBP	O
subjects	NNS	O
of	IN	O
current	JJ	O
analysis	NN	O
,	,	O
viral	JJ	O
infections	NNS	O
are	VBP	O
believed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
diseases	NNS	O
such	JJ	O
as	IN	O
diabetes	NNS	O
.	.	O
Lymphocytic	JJ	O
OAS	NNP	O
activity	NN	O
is	VBZ	O
significantly	RB	O
elevated	VBN	O
in	IN	O
patients	NNS	O
with	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
,	,	O
suggesting	VBG	O
that	IN	O
OAS	NNP	O
may	MD	O
be	VB	O
an	DT	O
important	JJ	O
link	NN	O
between	IN	O
viral	JJ	O
infections	NNS	O
and	CC	O
disease	NN	O
development	NN	O
.	.	O
In	IN	O
a	DT	O
study	NN	O
involving	VBG	O
diabetic	JJ	O
twins	NNS	O
from	IN	O
monozygotic	JJ	O
twin	NN	O
pairs	NNS	O
,	,	O
Bonnevie-Nielsen	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
Clin	NNP	I
Immunol	NNP	I
.	.	I
2000	CD	I
July	NNP	I
;	:	I
96	CD	I
(	(	I
1	CD	I
)	)	I
:11-8	NN	I
)	)	I
showed	VBD	O
that	IN	O
OAS	NNP	O
is	VBZ	O
persistently	RB	O
activated	VBN	O
in	IN	O
both	DT	O
recent-onset	JJ	O
and	CC	O
long-standing	JJ	O
type	NN	O
1	CD	O
diabetes	NNS	O
.	.	O
Continuously	RB	O
elevated	JJ	O
OAS	NNP	O
activity	NN	O
in	IN	O
type	NN	O
1	CD	O
diabetes	NN	O
is	VBZ	O
clearly	RB	O
different	JJ	O
from	IN	O
a	DT	O
normal	JJ	O
antiviral	JJ	O
response	NN	O
and	CC	O
might	MD	O
indicate	VB	O
a	DT	O
chronic	JJ	O
stimulation	NN	O
of	IN	O
the	DT	O
enzyme	NN	O
,	,	O
a	DT	O
failure	NN	O
of	IN	O
down	JJ	O
regulatory	JJ	O
mechanisms	NNS	O
,	,	O
or	CC	O
an	DT	O
aberrant	JJ	O
response	NN	O
to	TO	O
endogenous	JJ	O
or	CC	O
exogenous	JJ	O
viruses	NNS	O
or	CC	O
their	PRP$	O
products	NNS	O
.	.	O
A	DT	O
more	RBR	O
direct	JJ	O
link	NN	O
between	IN	O
a	DT	O
viral	JJ	O
infection	NN	O
and	CC	O
the	DT	O
development	NN	O
of	IN	O
diabetes	NNS	O
is	VBZ	O
exemplified	VBN	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
studies	NNS	O
showing	VBG	O
that	IN	O
between	IN	O
13	CD	O
and	CC	O
33	CD	O
%	NN	O
of	IN	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
C	NNP	O
have	VBP	O
diabetes	NNS	O
mellitus	NNS	O
(	(	O
type	JJ	O
2	CD	O
diabetes	NNS	O
)	)	O
,	,	O
a	DT	O
level	NN	O
that	WDT	O
is	VBZ	O
significantly	RB	O
increased	VBN	O
compared	VBN	O
with	IN	O
that	DT	O
in	IN	O
matched	VBN	O
healthy	JJ	O
controls	NNS	O
or	CC	O
patients	NNS	O
with	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
(	(	O
Knobler	NNP	B
et	RB	I
al	RB	I
.	.	I
Am	NNP	I
J	NNP	I
Gastroenterol	NNP	I
.	.	I
2003	CD	I
December	NNP	I
;	:	I
98	CD	I
(	(	I
12	CD	I
)	)	I
:2751-6	NN	I
)	)	O
.	.	O
While	IN	O
OAS	NNP	O
has	VBZ	O
not	RB	O
to	TO	O
date	NN	O
been	VBN	O
reported	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
diabetes	NNS	O
mellitus	VBP	O
following	VBG	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
a	DT	O
useful	JJ	O
marker	NN	O
for	IN	O
the	DT	O
antiviral	JJ	O
response	NN	O
system	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
results	NNS	O
reported	VBD	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
illustrate	NN	O
that	IN	O
if	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
is	VBZ	O
causally	RB	O
related	VBN	O
to	TO	O
diabetes	NNS	O
mellitus	NNS	O
,	,	O
inhibition	NN	O
or	CC	O
abolition	NN	O
of	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
using	VBG	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
be	VB	O
advantageous	JJ	O
in	IN	O
preventing	VBG	O
or	CC	O
alleviating	VBG	O
development	NN	O
of	IN	O
diabetes	NNS	O
mellitus	NNS	O
.	.	O
A	DT	O
further	JJ	O
published	VBN	O
study	NN	O
has	VBZ	O
shown	VBN	O
that	IN	O
OAS	NNP	O
plays	VBZ	O
an	DT	O
essential	JJ	O
role	NN	O
in	IN	O
wound	NN	O
healing	NN	O
and	CC	O
its	PRP$	O
pathological	JJ	O
disorders	NNS	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
venous	JJ	O
ulcers	NNS	O
and	CC	O
diabetes-associated	JJ	O
poorly-healing	JJ	O
wounds	NNS	O
(	(	O
WO	NNP	O
02/090552	CD	O
)	)	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
poor	JJ	O
wound	NN	O
healing	NN	O
,	,	O
OAS	NNP	O
mRNA	NN	O
levels	NNS	O
in	IN	O
the	DT	O
affected	JJ	O
tissues	NNS	O
were	VBD	O
reduced	VBN	O
,	,	O
rather	RB	O
than	IN	O
elevated	VBN	O
as	IN	O
in	IN	O
lymphocytes	NNS	O
derived	VBN	O
from	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
type	JJ	O
1	CD	O
diabetes	NNS	O
.	.	O
These	DT	O
findings	NNS	O
point	NN	O
to	TO	O
OAS	NNP	O
as	IN	O
an	DT	O
etiologically	RB	O
important	JJ	O
marker	NN	O
of	IN	O
immune	JJ	O
reactions	NNS	O
in	IN	O
diabetes	NNS	O
and	CC	O
diabetes-related	JJ	O
wound	NN	O
healing	NN	O
.	.	O
OAS	NNP	O
may	MD	O
also	RB	O
play	VB	O
an	DT	O
intermediary	JJ	O
role	NN	O
in	IN	O
cell	NN	O
processes	NNS	O
involved	VBN	O
in	IN	O
prostate	NN	O
cancer	NN	O
.	.	O
A	DT	O
primary	JJ	O
biochemical	JJ	O
function	NN	O
of	IN	O
OAS	NNP	O
is	VBZ	O
to	TO	O
promote	VB	O
the	DT	O
activity	NN	O
of	IN	O
RNaseL	NNP	O
,	,	O
a	DT	O
uniquely-regulated	JJ	O
endoribonuclease	NN	O
that	WDT	O
is	VBZ	O
enzymatically	RB	O
stimulated	VBN	O
by	IN	O
2-5A	JJ	O
molecules	NNS	O
.	.	O
RNaseL	NNP	O
has	VBZ	O
a	DT	O
well-established	JJ	O
role	NN	O
in	IN	O
mediating	VBG	O
the	DT	O
antiviral	JJ	O
effects	NNS	O
of	IN	O
IFN	NNP	O
,	,	O
and	CC	O
is	VBZ	O
a	DT	O
strong	JJ	O
candidate	NN	O
for	IN	O
the	DT	O
hereditary	JJ	O
prostate	NN	O
cancer	NN	O
1	CD	O
allele	NN	O
(	(	O
HPC1	NNP	O
)	)	O
.	.	O
Mutations	NNS	O
in	IN	O
RNaseL	NNP	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
predispose	VB	O
men	NNS	O
to	TO	O
an	DT	O
increased	VBN	O
incidence	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
,	,	O
which	WDT	O
in	IN	O
some	DT	O
cases	NNS	O
reflect	VBP	O
more	RBR	O
aggressive	JJ	O
disease	NN	O
and/or	NN	O
decreased	VBD	O
age	NN	O
of	IN	O
onset	NN	O
compared	VBN	O
with	IN	O
non	JJ	O
RNase	NNP	O
L-linked	JJ	O
cases	NNS	O
.	.	O
Xiang	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Cancer	NNP	I
Res	NNP	I
.	.	I
2003	CD	I
Oct.	NNP	I
15	CD	I
;	:	I
63	CD	I
(	(	I
20	CD	I
)	)	I
:6795-801	NN	I
)	)	I
demonstrated	VBD	O
that	IN	O
biostable	JJ	O
phosphorothiolate	JJ	O
analogs	NNS	O
of	IN	O
2-5A	JJ	O
induced	JJ	O
RNaseL	NNP	O
activity	NN	O
and	CC	O
caused	VBD	O
apoptosis	NN	O
in	IN	O
cultures	NNS	O
of	IN	O
late-stage	JJ	O
metastatic	JJ	O
human	JJ	O
prostate	NN	O
cancer	NN	O
cell	NN	O
lines	NNS	O
.	.	O
Their	PRP$	O
findings	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
elevation	NN	O
of	IN	O
OAS	NNP	O
activity	NN	O
with	IN	O
a	DT	O
concurrent	JJ	O
increase	NN	O
in	IN	O
2-5A	JJ	O
levels	NNS	O
may	MD	O
facilitate	VB	O
the	DT	O
destruction	NN	O
of	IN	O
cancer	NN	O
cells	NNS	O
through	IN	O
a	DT	O
potent	JJ	O
apoptotic	JJ	O
pathway	NN	O
.	.	O
Thus	RB	O
,	,	O
use	NN	O
of	IN	O
compositions	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
find	VB	O
utility	NN	O
in	IN	O
the	DT	O
detection	NN	O
,	,	O
treatment	NN	O
and/or	JJ	O
prevention	NN	O
of	IN	O
prostate	NN	O
cancer	NN	O
.	.	O
OAS	NNP	O
may	MD	O
further	RB	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
normal	JJ	O
cell	NN	O
growth	NN	O
regulation	NN	O
,	,	O
either	CC	O
through	IN	O
its	PRP$	O
regulation	NN	O
of	IN	O
RNaseL	NNP	O
or	CC	O
through	RB	O
another	DT	O
as	IN	O
yet	RB	O
undiscovered	JJ	O
pathway	NN	O
.	.	O
There	EX	O
is	VBZ	O
considerable	JJ	O
evidence	NN	O
to	TO	O
support	VB	O
the	DT	O
importance	NN	O
of	IN	O
OAS	NNP	O
in	IN	O
negatively	RB	O
regulating	VBG	O
cell	NN	O
growth	NN	O
.	.	O
Rysiecki	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
J.	NNP	I
Interferon	NNP	I
Res	NNP	I
.	.	I
1989	CD	I
December	NNP	I
;	:	I
9	CD	I
(	(	I
6	CD	I
)	)	I
:649-57	NN	I
)	)	I
demonstrated	VBD	O
that	IN	O
stable	JJ	O
transfection	NN	O
of	IN	O
human	JJ	O
OAS	NNP	O
into	IN	O
a	DT	O
glioblastoma	NN	O
cell	NN	O
line	NN	O
results	NNS	O
in	IN	O
reduced	JJ	O
cellular	JJ	O
proliferation	NN	O
.	.	O
OAS	NNP	O
levels	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
measurable	JJ	O
in	IN	O
several	JJ	O
studies	NNS	O
comparing	VBG	O
quiescent	JJ	O
versus	NN	O
proliferating	VBG	O
cell	NN	O
lines	NNS	O
(	(	O
e.g	NN	O
.	.	O
Hassel	NNP	B
and	CC	I
Ts	NNP	I
'	POS	I
O	NNP	I
,	,	I
Mol	NNP	I
Carcinog	NNP	I
.	.	I
1992	CD	I
;	:	I
5	CD	I
(	(	I
1	CD	I
)	)	I
:41-51	NN	I
and	CC	O
Kimchi	NNP	B
et	FW	I
al.	NN	I
,	,	I
Eur	NNP	I
J	NNP	I
Biochem	NNP	I
.	.	I
1981	CD	I
;	:	I
114	CD	I
(	(	I
1	CD	I
)	)	I
:5-10	NN	I
)	)	O
and	CC	O
in	IN	O
each	DT	O
case	NN	O
the	DT	O
OAS	NNP	O
levels	NNS	O
were	VBD	O
greatest	JJS	O
in	IN	O
quiescent	NN	O
cells	NNS	O
.	.	O
Other	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
correlation	NN	O
between	IN	O
OAS	NNP	O
level	NN	O
and	CC	O
cell	NN	O
cycle	NN	O
phase	NN	O
,	,	O
with	IN	O
OAS	NNP	O
levels	NNS	O
rising	VBG	O
sharply	RB	O
during	IN	O
late	JJ	O
S	NNP	O
phase	NN	O
and	CC	O
then	RB	O
dropping	VBG	O
abruptly	RB	O
in	IN	O
G2	NNP	O
(	(	O
Wells	NNP	B
and	CC	I
Mallucci	NNP	I
,	,	I
Exp	NNP	I
Cell	NNP	I
Res	NNP	I
.	.	I
1985	CD	I
JulY	NNP	I
;	:	I
159	CD	I
(	(	I
1	CD	I
)	)	I
:27-36	NN	I
)	)	O
.	.	O
Several	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
a	DT	O
correlation	NN	O
between	IN	O
the	DT	O
induction	NN	O
of	IN	O
OAS	NNP	O
and	CC	O
the	DT	O
onset	NN	O
of	IN	O
antiproliferative	JJ	O
effects	NNS	O
following	VBG	O
stimulation	NN	O
with	IN	O
various	JJ	O
forms	NNS	O
of	IN	O
interferon	NN	O
(	(	O
see	VB	O
Player	NNP	B
and	CC	I
Torrence	NNP	I
,	,	I
Pharmacol	NNP	I
Ther	NNP	I
.	.	I
1998	CD	I
May	NNP	I
;	:	I
78	CD	I
(	(	I
2	CD	I
)	)	I
:55-113	NN	I
)	)	O
.	.	O
Induction	NN	O
of	IN	O
OAS	NNP	O
has	VBZ	O
also	RB	O
been	VBN	O
shown	VBN	O
during	IN	O
cell	NN	O
differentiation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Salzberg	NNP	B
et	CC	I
al.	NN	I
,	,	I
J	NNP	I
Cell	NNP	I
Sci	NNP	I
.	.	I
1996	CD	I
June	NNP	I
;	:	I
109	CD	I
(	(	I
Pt	NNP	I
6	CD	I
)	)	I
:1517-26	NN	I
and	CC	O
Schwartz	NNP	B
and	CC	I
Nilson	NNP	I
,	,	I
Mol	NNP	I
Cell	NNP	I
Biol	NNP	I
.	.	I
1989	CD	I
September	NNP	I
;	:	I
9	CD	I
(	(	I
9	CD	I
)	)	I
:3897-903	NN	I
)	)	O
.	.	O
Other	JJ	O
reports	NNS	O
of	IN	O
induction	NN	O
of	IN	O
OAS	NNP	O
by	IN	O
platelet	NN	O
derived	VBN	O
growth	NN	O
factor	NN	O
(	(	O
PDGF	NNP	O
)	)	O
(	(	O
Zullo	NNP	B
et	RB	I
al	RB	I
.	.	I
Cell	NNP	I
.	.	I
1985	CD	I
December	NNP	I
;	:	I
43	CD	I
(	(	I
3	CD	I
Pt	NNP	I
2	CD	I
)	)	I
:793-800	NN	I
)	)	O
and	CC	O
under	IN	O
conditions	NNS	O
of	IN	O
heat-shock	NN	O
induced	JJ	O
growth	NN	O
(	(	O
Chousterman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
.	.	I
1987	CD	I
Apr	NNP	I
.	.	I
5	CD	I
;	:	I
262	CD	I
(	(	I
10	CD	I
)	)	I
:4806-11	NN	I
)	)	O
lead	NN	O
to	TO	O
the	DT	O
hypothesis	NN	O
that	IN	O
induction	NN	O
of	IN	O
OAS	NNP	O
is	VBZ	O
a	DT	O
normal	JJ	O
cell	NN	O
growth	NN	O
control	NN	O
mechanism	NN	O
.	.	O
Thus	RB	O
,	,	O
use	NN	O
of	IN	O
compositions	NNS	O
and	CC	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
may	MD	O
find	VB	O
broad	JJ	O
utility	NN	O
in	IN	O
the	DT	O
detection	NN	O
,	,	O
treatment	NN	O
and/or	JJ	O
prevention	NN	O
of	IN	O
cancer	NN	O
or	CC	O
in	IN	O
the	DT	O
promotion	NN	O
of	IN	O
cellular	JJ	O
or	CC	O
tissue	JJ	O
growth	NN	O
or	CC	O
tissue	NN	O
regeneration	NN	O
.	.	O
Therapeutic	JJ	O
Agents	NNS	O
for	IN	O
Restoring	VBG	O
and/or	JJ	O
Enhancing	NNP	O
OAS	NNP	O
Function	NNP	O
As	IN	O
described	VBN	O
previously	RB	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
advantageous	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
virus	JJ	O
infection	NN	O
or	CC	O
other	JJ	O
indications	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
cancer	NN	O
,	,	O
diabetes	VBZ	O
mellitus	NN	O
,	,	O
inflammation	NN	O
,	,	O
tissue	NN	O
regeneration	NN	O
,	,	O
and	CC	O
wound	IN	O
healing	NN	O
.	.	O
The	DT	O
discussion	NN	O
below	IN	O
pertains	NNS	O
to	TO	O
administration	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
foregoing	NN	O
proteins	VBZ	O
or	CC	O
polypeptides	NNS	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
a	DT	O
naturally	RB	O
purified	JJ	O
product	NN	O
,	,	O
or	CC	O
a	DT	O
product	NN	O
of	IN	O
chemical	JJ	O
synthetic	JJ	O
procedures	NNS	O
,	,	O
or	CC	O
produced	VBN	O
by	IN	O
recombinant	JJ	O
techniques	NNS	O
from	IN	O
a	DT	O
prokaryotic	JJ	O
or	CC	O
eukaryotic	JJ	O
host	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
bacterial	JJ	O
,	,	O
yeast	RB	O
,	,	O
higher	JJR	O
plant	NN	O
,	,	O
insect	NN	O
and	CC	O
mammalian	JJ	O
cells	NNS	O
in	IN	O
culture	NN	O
)	)	O
of	IN	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Depending	VBG	O
upon	IN	O
the	DT	O
host	NN	O
employed	VBN	O
in	IN	O
a	DT	O
recombinant	JJ	O
production	NN	O
procedure	NN	O
,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
glycosylated	VBN	O
with	IN	O
mammalian	JJ	O
or	CC	O
other	JJ	O
eukaryotic	JJ	O
carbohydrates	NNS	O
or	CC	O
may	MD	O
be	VB	O
non-glycosylated	JJ	O
.	.	O
Polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
include	VB	O
an	DT	O
initial	JJ	O
methionine	NN	O
amino	NN	O
acid	NN	O
residue	NN	O
(	(	O
at	IN	O
position	NN	O
minus	FW	O
1	CD	O
)	)	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
also	RB	O
include	VBP	O
the	DT	O
protein	NN	O
sequences	NNS	O
defined	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
and	CC	O
derivatives	NNS	O
thereof	VBP	O
including	VBG	O
analogs	NNS	O
and	CC	O
fragments	NNS	O
that	WDT	O
function	VBP	O
similarly	RB	O
to	TO	O
the	DT	O
FIG	NNP	O
.	.	O
1	CD	O
forms	NNS	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
may	MD	O
be	VB	O
replaced	VBN	O
by	IN	O
conserved	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
,	,	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
function	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
is	VBZ	O
maintained	VBN	O
.	.	O
The	DT	O
polypeptides	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
by	IN	O
expression	NN	O
of	IN	O
such	JJ	O
polypeptides	NNS	O
in	IN	O
vivo	NN	O
,	,	O
which	WDT	O
is	VBZ	O
often	RB	O
referred	VBN	O
to	TO	O
as	IN	O
gene	NN	O
therapy	NN	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
cells	NNS	O
may	MD	O
be	VB	O
transduced	VBN	O
with	IN	O
a	DT	O
polynucleotide	NN	O
(	(	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
)	)	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
ex	VBP	O
vivo	NNS	O
,	,	O
with	IN	O
those	DT	O
transduced	JJ	O
cells	NNS	O
then	RB	O
being	VBG	O
provided	VBN	O
to	TO	O
a	DT	O
patient	NN	O
to	TO	O
be	VB	O
treated	VBN	O
with	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Such	JJ	O
methods	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cells	NNS	O
may	MD	O
be	VB	O
transduced	VBN	O
by	IN	O
procedures	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
retroviral	JJ	O
particle	NN	O
containing	VBG	O
RNA	NNP	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Similarly	RB	O
,	,	O
transduction	NN	O
of	IN	O
cells	NNS	O
may	MD	O
be	VB	O
accomplished	VBN	O
in	IN	O
vivo	NN	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
in	IN	O
vivo	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
procedures	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
As	IN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
a	DT	O
producer	NN	O
cell	NN	O
for	IN	O
producing	VBG	O
a	DT	O
retroviral	JJ	O
particle	NN	O
containing	VBG	O
RNA	NNP	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
a	DT	O
patient	NN	O
for	IN	O
transduction	NN	O
in	IN	O
vivo	NN	O
and	CC	O
expression	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
in	IN	O
vivo	NN	O
.	.	O
These	DT	O
and	CC	O
other	JJ	O
methods	NNS	O
for	IN	O
administering	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
by	IN	O
such	JJ	O
methods	NNS	O
should	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
from	IN	O
the	DT	O
teachings	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
expression	NN	O
vehicle	NN	O
for	IN	O
transducing	VBG	O
cells	NNS	O
may	MD	O
be	VB	O
other	JJ	O
than	IN	O
a	DT	O
retrovirus	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
adenovirus	NN	O
which	WDT	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
transduce	VB	O
cells	NNS	O
in	IN	O
vivo	NN	O
after	IN	O
combination	NN	O
with	IN	O
a	DT	O
suitable	JJ	O
delivery	NN	O
vehicle	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
able	JJ	O
,	,	O
as	IN	O
part	NN	O
of	IN	O
their	PRP$	O
native	JJ	O
function	NN	O
,	,	O
to	TO	O
transduce	VB	O
across	IN	O
a	DT	O
cell	NN	O
membrane	NN	O
and	CC	O
mediate	VB	O
their	PRP$	O
antiviral	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
delivery	NN	O
vector	NN	O
or	CC	O
expression	NN	O
vehicle	NN	O
.	.	O
The	DT	O
mechanism	NN	O
of	IN	O
polypeptide	JJ	O
transduction	NN	O
is	VBZ	O
likely	JJ	O
absorptive	JJ	O
endocytosis	NN	O
or	CC	O
lipid	JJ	O
raft-mediated	JJ	O
macropinocytosis	NN	O
,	,	O
with	IN	O
significant	JJ	O
amounts	NNS	O
of	IN	O
the	DT	O
active	JJ	O
polypeptide	NN	O
being	VBG	O
present	JJ	O
in	IN	O
the	DT	O
cytoplasm	NN	O
and	CC	O
in	IN	O
detergent	NN	O
insoluble	JJ	O
membrane	NN	O
fractions	NNS	O
of	IN	O
treated	JJ	O
cells	NNS	O
as	IN	O
demonstrated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
5	CD	O
.	.	O
The	DT	O
essentially	RB	O
basic	JJ	O
and	CC	O
positively	RB	O
charged	VBN	O
character	NN	O
of	IN	O
the	DT	O
proteins	NNS	O
likely	JJ	O
mediates	VBZ	O
this	DT	O
unusual	JJ	O
characteristic	NN	O
,	,	O
making	VBG	O
the	DT	O
polypeptides	NNS	O
themselves	PRP	O
effective	JJ	O
pharmaceutical	JJ	O
compositions	NNS	O
without	IN	O
the	DT	O
need	NN	O
for	IN	O
carriers	NNS	O
to	TO	O
increase	VB	O
cell	NN	O
permeability	NN	O
.	.	O
The	DT	O
cell	NN	O
transduction	NN	O
properties	NNS	O
of	IN	O
basic	JJ	O
,	,	O
positively	RB	O
charged	VBN	O
proteins	NNS	O
has	VBZ	O
been	VBN	O
previously	RB	O
described	VBN	O
and	CC	O
is	VBZ	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
Ryser	NNP	B
and	CC	I
Hancock	NNP	I
,	,	I
Science	NNP	I
.	.	I
1965	CD	I
Oct.	NNP	I
22	CD	I
;	:	I
150	CD	I
(	(	I
695	CD	I
)	)	I
:501-3	NN	I
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
clear	JJ	O
from	IN	O
FIG	NNP	O
.	.	O
2	CD	O
and	CC	O
FIG	NNP	O
.	.	O
3	CD	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
that	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
affect	VB	O
an	DT	O
antiviral	JJ	O
function	NN	O
in	IN	O
cell	NN	O
culture	NN	O
that	WDT	O
can	MD	O
only	RB	O
be	VB	O
mediated	VBN	O
by	IN	O
transduction	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
into	IN	O
the	DT	O
cell	NN	O
.	.	O
Class	NN	O
III	NNP	O
modifications	NNS	O
to	TO	O
the	DT	O
reference	NN	O
polypeptide	IN	O
increase	VB	O
their	PRP$	O
basic	JJ	O
charge	NN	O
and	CC	O
therefore	VB	O
their	PRP$	O
cell	NN	O
permeability	NN	O
(	(	O
compare	JJ	O
FIG	NNP	O
.	.	O
3	LS	O
with	IN	O
FIG	NNP	O
.	.	O
4	CD	O
)	)	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
where	WRB	O
the	DT	O
polypeptides	NNS	O
are	VBP	O
prepared	VBN	O
as	IN	O
a	DT	O
liquid	JJ	O
formulation	NN	O
and	CC	O
administered	VBN	O
by	IN	O
injection	NN	O
,	,	O
preferably	RB	O
the	DT	O
solution	NN	O
is	VBZ	O
an	DT	O
isotonic	JJ	O
salt	NN	O
solution	NN	O
containing	VBG	O
140	CD	O
millimolar	JJ	O
sodium	NN	O
chloride	NN	O
and	CC	O
10	CD	O
millimolar	JJ	O
calcium	NN	O
at	IN	O
pH	JJ	O
7.4	CD	O
.	.	O
The	DT	O
injection	NN	O
may	MD	O
be	VB	O
administered	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
,	,	O
preferably	RB	O
in	IN	O
a	DT	O
dose	NN	O
of	IN	O
about	IN	O
1	CD	O
μg/kg	NNS	O
body	NN	O
weight	VBD	O
to	TO	O
about	IN	O
5	CD	O
mg/kg	NNS	O
body	NN	O
weight	VBD	O
daily	RB	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
routes	NNS	O
of	IN	O
administration	NN	O
,	,	O
health	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
employed	VBN	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
suitable	JJ	O
pharmaceutical	JJ	O
carrier	NN	O
.	.	O
Such	JJ	O
compositions	NNS	O
comprise	VBP	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
and	CC	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
or	CC	O
excipient	NN	O
.	.	O
Such	JJ	O
a	DT	O
carrier	NN	O
includes	VBZ	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
saline	VB	O
,	,	O
buffered	VBN	O
saline	NN	O
,	,	O
dextrose	VB	O
,	,	O
water	NN	O
,	,	O
glycerol	NN	O
,	,	O
ethanol	NN	O
,	,	O
and	CC	O
combinations	NNS	O
thereof	VBP	O
.	.	O
The	DT	O
formulation	NN	O
should	MD	O
suit	VB	O
the	DT	O
mode	NN	O
of	IN	O
administration	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
by	IN	O
chemically	RB	O
linking	VBG	O
the	DT	O
polypeptide	NN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
to	TO	O
enhance	VB	O
the	DT	O
activity	NN	O
,	,	O
cellular	JJ	O
distribution	NN	O
,	,	O
or	CC	O
cellular	JJ	O
uptake	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Such	JJ	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
include	VBP	O
lipids	NNS	O
such	JJ	O
as	IN	O
cholesterol	NN	O
,	,	O
cholic	JJ	O
acid	NN	O
,	,	O
thioether	RB	O
,	,	O
aliphatic	JJ	O
chains	NNS	O
,	,	O
phospholipids	NNS	O
and	CC	O
their	PRP$	O
derivatives	NNS	O
,	,	O
polyamines	NNS	O
,	,	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
,	,	O
palmityl	JJ	O
moieties	NNS	O
,	,	O
and	CC	O
others	NNS	O
as	IN	O
disclosed	VBN	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,514,758	CD	O
,	,	O
5,565,552	CD	O
,	,	O
5,567,810	CD	O
,	,	O
5,574,142	CD	O
,	,	O
5,585,481	CD	O
,	,	O
5,587,371	CD	O
,	,	O
5,597,696	CD	O
and	CC	O
5,958,773	CD	O
.	.	O
The	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
target	VB	O
specific	JJ	O
cell	NN	O
types	NNS	O
for	IN	O
a	DT	O
particular	JJ	O
disease	NN	O
indication	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
liver	VB	O
cells	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
hepatitis	NN	O
C	NNP	O
infection	NN	O
.	.	O
As	IN	O
can	MD	O
be	VB	O
appreciated	VBN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
suitable	JJ	O
methods	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
that	IN	O
achieve	VBP	O
the	DT	O
described	NN	O
targeting	VBG	O
goals	NNS	O
and	CC	O
include	VBP	O
,	,	O
without	IN	O
limitation	NN	O
,	,	O
liposomal	JJ	O
targeting	NN	O
,	,	O
receptor-mediated	JJ	O
endocytosis	NN	O
,	,	O
and	CC	O
antibody-antigen	JJ	O
binding	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
asiaglycoprotein	NNS	O
receptor	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
target	VB	O
liver	RB	O
cells	NNS	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
a	DT	O
galactose	JJ	O
moiety	NN	O
to	TO	O
the	DT	O
polypeptide	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
mannose	JJ	O
moieties	NNS	O
may	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
(	(	O
s	NN	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
target	VB	O
the	DT	O
mannose	JJ	O
receptor	NN	O
found	VBD	O
on	IN	O
macrophages	NNS	O
and	CC	O
liver	NN	O
cells	NNS	O
.	.	O
As	IN	O
one	CD	O
skilled	VBD	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
,	,	O
multiple	JJ	O
delivery	NN	O
and	CC	O
targeting	VBG	O
methods	NNS	O
may	MD	O
be	VB	O
combined	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
targeted	VBN	O
to	TO	O
liver	VB	O
cells	NNS	O
by	IN	O
encapsulation	NN	O
within	IN	O
liposomes	NNS	O
,	,	O
such	JJ	O
liposomes	NNS	O
being	VBG	O
conjugated	VBN	O
to	TO	O
galactose	VB	O
for	IN	O
targeting	VBG	O
to	TO	O
the	DT	O
asialoglycoprotein	NN	O
receptor	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
pharmaceutical	JJ	O
pack	NN	O
or	CC	O
kit	VB	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
containers	NNS	O
filled	VBD	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
ingredients	NNS	O
of	IN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Associated	VBN	O
with	IN	O
such	JJ	O
container	NN	O
(	(	O
s	PRP	O
)	)	O
can	MD	O
be	VB	O
a	DT	O
notice	NN	O
in	IN	O
the	DT	O
form	NN	O
prescribed	VBN	O
by	IN	O
a	DT	O
governmental	JJ	O
agency	NN	O
regulating	VBG	O
the	DT	O
manufacture	NN	O
,	,	O
use	NN	O
or	CC	O
sale	NN	O
of	IN	O
pharmaceuticals	NNS	O
or	CC	O
biological	JJ	O
products	NNS	O
,	,	O
which	WDT	O
notice	VBZ	O
reflects	VBZ	O
approval	NN	O
by	IN	O
the	DT	O
agency	NN	O
of	IN	O
manufacture	NN	O
,	,	O
use	NN	O
or	CC	O
sale	NN	O
for	IN	O
human	JJ	O
administration	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
employed	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
other	JJ	O
therapeutic	JJ	O
compounds	NNS	O
.	.	O
When	WRB	O
the	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
used	VBN	O
as	IN	O
a	DT	O
pharmaceutical	JJ	O
,	,	O
they	PRP	O
can	MD	O
be	VB	O
given	VBN	O
to	TO	O
mammals	NNS	O
,	,	O
in	IN	O
a	DT	O
suitable	JJ	O
vehicle	NN	O
.	.	O
When	WRB	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
used	VBN	O
as	IN	O
a	DT	O
pharmaceutical	JJ	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
they	PRP	O
are	VBP	O
given	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
therapeutically	RB	O
effective	JJ	O
doses	NNS	O
of	IN	O
about	IN	O
10	CD	O
μg/kg	NNS	O
body	NN	O
weight	VBD	O
to	TO	O
about	IN	O
10	CD	O
mg/kg	NNS	O
body	NN	O
weight	VBD	O
daily	RB	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
routes	NNS	O
of	IN	O
administration	NN	O
,	,	O
health	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
amount	NN	O
given	VBN	O
is	VBZ	O
preferably	RB	O
adequate	JJ	O
to	TO	O
achieve	VB	O
prevention	NN	O
or	CC	O
inhibition	NN	O
of	IN	O
infection	NN	O
by	IN	O
a	DT	O
virus	NN	O
,	,	O
preferably	RB	O
a	DT	O
flavivirus	NN	O
,	,	O
most	RBS	O
preferably	RB	O
RSV	NNP	O
and	CC	O
HCV	NNP	O
,	,	O
prevention	NN	O
or	CC	O
treatment	NN	O
of	IN	O
cancer	NN	O
,	,	O
inflammation	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
or	CC	O
other	JJ	O
diseases	NNS	O
.	.	O
The	DT	O
proteins	NNS	O
,	,	O
their	PRP$	O
fragments	NNS	O
or	CC	O
other	JJ	O
derivatives	NNS	O
,	,	O
or	CC	O
analogs	NNS	O
thereof	NNS	O
,	,	O
or	CC	O
cells	NNS	O
expressing	VBG	O
them	PRP	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
immunogen	NN	O
to	TO	O
produce	VB	O
antibodies	NNS	O
thereto	NN	O
.	.	O
These	DT	O
antibodies	NNS	O
can	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
polyclonal	JJ	O
,	,	O
monoclonal	JJ	O
,	,	O
chimeric	JJ	O
,	,	O
single	JJ	O
chain	NN	O
,	,	O
Fab	NNP	O
fragments	NNS	O
,	,	O
or	CC	O
the	DT	O
product	NN	O
of	IN	O
an	DT	O
Fab	NNP	O
expression	NN	O
library	NN	O
.	.	O
Various	JJ	O
procedures	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
polyclonal	JJ	O
antibodies	NNS	O
.	.	O
Antibodies	NNS	O
generated	VBN	O
against	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
direct	JJ	O
injection	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
into	IN	O
an	DT	O
animal	NN	O
or	CC	O
by	IN	O
administering	VBG	O
the	DT	O
polypeptide	NN	O
to	TO	O
an	DT	O
animal	NN	O
,	,	O
preferably	RB	O
a	DT	O
nonhuman	NN	O
.	.	O
The	DT	O
antibody	NN	O
so	RB	O
obtained	VBN	O
will	MD	O
then	RB	O
bind	VB	O
the	DT	O
polypeptide	NN	O
itself	PRP	O
.	.	O
In	IN	O
this	DT	O
manner	NN	O
,	,	O
even	RB	O
a	DT	O
sequence	NN	O
encoding	VBG	O
only	RB	O
a	DT	O
fragment	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
generate	VB	O
antibodies	NNS	O
binding	VBG	O
the	DT	O
whole	JJ	O
native	JJ	O
polypeptide	NN	O
.	.	O
Moreover	RB	O
,	,	O
a	DT	O
panel	NN	O
of	IN	O
such	JJ	O
antibodies	NNS	O
specific	VBP	O
to	TO	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
polypeptides	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
For	IN	O
preparation	NN	O
of	IN	O
monoclonal	JJ	O
antibodies	NNS	O
,	,	O
any	DT	O
technique	NN	O
which	WDT	O
provides	VBZ	O
antibodies	NNS	O
produced	VBN	O
by	IN	O
continuous	JJ	O
cell	NN	O
line	NN	O
cultures	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
Examples	NNS	O
include	VBP	O
the	DT	O
hybridoma	NN	O
technique	NN	O
(	(	O
Kohler	NNP	B
and	CC	I
Milstein	NNP	I
,	,	I
1975	CD	I
,	,	I
Nature	NNP	I
,	,	I
256:495-597	JJ	I
)	)	O
,	,	O
the	DT	O
trioma	NN	O
technique	NN	O
,	,	O
the	DT	O
human	JJ	O
B-cell	NNP	O
hybridoma	NN	O
technique	NN	O
(	(	O
Kozbor	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
1983	CD	I
,	,	I
Immunology	NNP	I
Today	NNP	I
4:72	CD	I
)	)	O
,	,	O
and	CC	O
the	DT	O
EBV-hybridoma	NNP	O
technique	NN	O
to	TO	O
produce	VB	O
human	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
(	(	O
Coe	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
1985	CD	I
,	,	I
Monoclonal	NNP	I
Antibodies	NNPS	I
and	CC	I
Cancer	NNP	I
Therapy	NNP	I
,	,	I
Alan	NNP	I
R.	NNP	I
Liss	NNP	I
,	,	I
Inc.	NNP	I
pp	NN	I
.	.	I
77-96	JJ	I
)	)	O
.	.	O
Techniques	NNS	O
described	VBN	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
single	JJ	O
chain	NN	O
antibodies	NNS	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,946,778	CD	O
)	)	O
can	MD	O
be	VB	O
adapted	VBN	O
to	TO	O
produce	VB	O
single	JJ	O
chain	NN	O
antibodies	NNS	O
to	TO	O
immunogenic	VB	O
polypeptide	JJ	O
products	NNS	O
of	IN	O
this	DT	O
invention	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
methods	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
localization	NN	O
and	CC	O
activity	NN	O
of	IN	O
the	DT	O
protein	NN	O
sequences	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
e.g.	NN	O
,	,	O
for	IN	O
imaging	VBG	O
these	DT	O
proteins	NNS	O
,	,	O
measuring	VBG	O
levels	NNS	O
thereof	VBN	O
in	IN	O
appropriate	JJ	O
physiological	JJ	O
samples	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
polypeptides	NNS	O
that	WDT	O
differ	VBP	O
from	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
by	IN	O
1	CD	O
to	TO	O
34	CD	O
amino	NN	O
acids	NNS	O
,	,	O
such	JJ	O
differences	NNS	O
may	MD	O
include	VB	O
substitutions	NNS	O
,	,	O
insertions	NNS	O
,	,	O
deletions	NNS	O
,	,	O
the	DT	O
incorporation	NN	O
of	IN	O
modified	VBN	O
amino	NN	O
acids	NNS	O
or	CC	O
amino	NN	O
acid	JJ	O
derivatives	NNS	O
,	,	O
and	CC	O
the	DT	O
addition	NN	O
or	CC	O
deletion	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
from	IN	O
the	DT	O
C-terminus	NNP	O
or	CC	O
N-terminus	NNP	O
of	IN	O
the	DT	O
polypeptides	NNS	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
therapeutic	JJ	O
and	CC	O
prophylactic	JJ	O
uses	NNS	O
of	IN	O
these	DT	O
polypeptides	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
treatment	NN	O
of	IN	O
virus	NN	O
infection	NN	O
,	,	O
neoplasm	RB	O
,	,	O
cancer	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
and	CC	O
to	TO	O
promote	VB	O
cell	NN	O
growth	NN	O
and	CC	O
differentiation	NN	O
and	CC	O
tissue	NN	O
regeneration	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
polynucleotides	NNS	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
uses	VBZ	O
thereof	JJ	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
uses	NNS	O
in	IN	O
manufacturing	VBG	O
the	DT	O
polypeptides	NNS	O
,	,	O
as	IN	O
gene	NN	O
therapies	NNS	O
,	,	O
as	IN	O
diagnostic	JJ	O
tools	NNS	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
following	JJ	O
classes	NNS	O
of	IN	O
polypeptide	NN	O
:	:	O
Class	NN	O
I	PRP	O
Polypeptide	VBP	O
Modifications	PDT	O
The	DT	O
Class	NN	O
I	PRP	O
modifications	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
represent	NN	O
enzymatically	RB	O
inactive	JJ	O
oligoadenylate	NN	O
synthetase	NN	O
forms	NNS	O
created	VBN	O
by	IN	O
mutation	NN	O
of	IN	O
the	DT	O
magnesium	NN	O
binding	VBG	O
site	NN	O
of	IN	O
the	DT	O
native	JJ	O
protein	NN	O
.	.	O
These	DT	O
enzymatically	RB	O
inactive	JJ	O
polypeptides	NNS	O
retain	VBP	O
antiviral	JJ	O
activity	NN	O
and	CC	O
constitute	NN	O
novel	JJ	O
therapeutic	JJ	O
compositions	NNS	O
under	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
antiviral	JJ	O
activity	NN	O
of	IN	O
a	DT	O
Class	NN	O
I	PRP	O
modified	VBD	O
polypeptide	NN	O
is	VBZ	O
demonstrated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
3	CD	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
all	DT	O
enzymatically	RB	O
inactive	JJ	O
forms	NNS	O
of	IN	O
the	DT	O
oligoadenylate	NN	O
synthetases	NNS	O
,	,	O
such	JJ	O
forms	NNS	O
being	VBG	O
those	DT	O
that	WDT	O
do	VBP	O
not	RB	O
synthesize	VB	O
2-prime-5-prime	JJ	O
oligaodenylates	NNS	O
,	,	O
and	CC	O
uses	VBZ	O
thereof	NN	O
.	.	O
Class	NNP	O
II	NNP	O
Polypeptide	NNP	O
Modifications	NNP	O
The	DT	O
Class	NNP	O
II	NNP	O
modifications	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
represent	NN	O
mutant	JJ	O
oligoadenylate	NN	O
synthetase	NN	O
forms	NNS	O
that	WDT	O
have	VBP	O
increased	VBN	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
stability	NN	O
by	IN	O
virtue	NN	O
of	IN	O
the	DT	O
removal	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
highly-reactive	JJ	O
,	,	O
sulfhydryl-containing	JJ	O
cysteine	NN	O
residues	NNS	O
.	.	O
Removal	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
sulfhydryl	JJ	O
groups	NNS	O
prevents	NNS	O
protein	JJ	O
aggregation	NN	O
during	IN	O
purification	NN	O
and	CC	O
handling	NN	O
and	CC	O
obviates	VBZ	O
the	DT	O
need	NN	O
for	IN	O
supplementary	JJ	O
reducing	VBG	O
agent	NN	O
during	IN	O
bulk	JJ	O
drug	NN	O
product	NN	O
manufacturing	NN	O
.	.	O
Removal	NN	O
or	CC	O
replacement	NN	O
of	IN	O
cysteine	NN	O
residues	NNS	O
increases	VBZ	O
drug	NN	O
stability	NN	O
in	IN	O
excipients	NNS	O
suitable	JJ	O
for	IN	O
in-human	JJ	O
use	NN	O
.	.	O
Cysteines	NNS	O
that	WDT	O
can	MD	O
be	VB	O
removed	VBN	O
or	CC	O
modified	VBN	O
while	IN	O
preserving	VBG	O
the	DT	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
include	VBP	O
the	DT	O
cysteines	NNS	O
at	IN	O
positions	NNS	O
25	CD	O
,	,	O
38	CD	O
,	,	O
and	CC	O
54	CD	O
of	IN	O
the	DT	O
reference	NN	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	JJ	O
sequence	NN	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
The	DT	O
cysteine	NN	O
at	IN	O
position	NN	O
25	CD	O
is	VBZ	O
surface	NN	O
exposed	VBN	O
and	CC	O
modified	VBN	O
by	IN	O
iodoacetamide	NN	O
in	IN	O
the	DT	O
porcine	JJ	O
form	NN	O
.	.	O
This	DT	O
cysteine	NN	O
is	VBZ	O
neither	RB	O
strongly	RB	O
conserved	VBN	O
nor	CC	O
does	VBZ	O
it	PRP	O
have	VB	O
a	DT	O
strong	JJ	O
interaction	NN	O
with	IN	O
any	DT	O
other	JJ	O
functional	JJ	O
group	NN	O
of	IN	O
the	DT	O
protein	NN	O
.	.	O
The	DT	O
cysteine	NN	O
at	IN	O
position	NN	O
38	CD	O
with	IN	O
reference	NN	O
to	TO	O
FIG	NNP	O
.	.	O
1	CD	O
is	VBZ	O
also	RB	O
solvent	JJ	O
exposed	VBN	O
and	CC	O
modified	VBN	O
by	IN	O
iodoacetamide	NN	O
in	IN	O
the	DT	O
porcine	NN	O
structure	NN	O
.	.	O
This	DT	O
cysteine	NN	O
forms	VBZ	O
a	DT	O
weak	JJ	O
hydrogen	NN	O
bond	NN	O
to	TO	O
the	DT	O
valine	NN	O
58	CD	O
backbone	NN	O
and	CC	O
is	VBZ	O
poorly	RB	O
conserved	VBN	O
.	.	O
Cysteine	NNP	O
54	CD	O
hydrogen	NN	O
bonds	NNS	O
to	TO	O
the	DT	O
valine	NN	O
53	CD	O
backbone	NN	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
conserved	VBN	O
and	CC	O
appears	VBZ	O
to	TO	O
have	VB	O
no	DT	O
important	JJ	O
interaction	NN	O
elsewhere	RB	O
on	IN	O
the	DT	O
structure	NN	O
.	.	O
Because	IN	O
of	IN	O
their	PRP$	O
solvent	NN	O
exposure	NN	O
,	,	O
weak	JJ	O
interaction	NN	O
with	IN	O
other	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
protein	NN	O
structure	NN	O
,	,	O
and	CC	O
poor	JJ	O
conservation	NN	O
,	,	O
each	DT	O
of	IN	O
these	DT	O
three	CD	O
amino	NN	O
acids	NNS	O
can	MD	O
be	VB	O
deleted	VBN	O
or	CC	O
modified	VBN	O
to	TO	O
increase	VB	O
oxidation	NN	O
resistance	NN	O
and	CC	O
protein	NN	O
stability	NN	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
while	IN	O
preserving	VBG	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
activity	NN	O
.	.	O
The	DT	O
remaining	VBG	O
seven	CD	O
cysteine	JJ	O
residues	NNS	O
can	MD	O
be	VB	O
modified	VBN	O
with	IN	O
varying	VBG	O
degrees	NNS	O
of	IN	O
reduction	NN	O
in	IN	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
activity	NN	O
.	.	O
Cysteine	NNP	O
45	CD	O
is	VBZ	O
in	IN	O
a	DT	O
hydrophobic	JJ	O
pocket	NN	O
and	CC	O
conserved	VBN	O
in	IN	O
the	DT	O
active	JJ	O
(	(	O
C-terminal	JJ	O
)	)	O
domains	NNS	O
of	IN	O
OAS2	NNP	O
and	CC	O
3	CD	O
.	.	O
Cysteine	NNP	O
109	CD	O
is	VBZ	O
in	IN	O
a	DT	O
hydrophobic	JJ	O
pocket	NN	O
.	.	O
Cysteine	NNP	O
177	CD	O
is	VBZ	O
buried	VBN	O
and	CC	O
possibly	RB	O
hydrogen	VB	O
bonds	NNS	O
to	TO	O
the	DT	O
polypeptide	NN	O
backbone	NN	O
.	.	O
Cysteine	NNP	O
189	CD	O
is	VBZ	O
buried	VBN	O
,	,	O
hydrogen	NN	O
bonds	NNS	O
to	TO	O
glutamine	VB	O
91	CD	O
and	CC	O
phenylalanine	VB	O
153	CD	O
,	,	O
and	CC	O
is	VBZ	O
highly	RB	O
conserved	VBN	O
.	.	O
Cysteine	NNP	O
219	CD	O
is	VBZ	O
located	VBN	O
in	IN	O
a	DT	O
hydrophobic	JJ	O
neighborhood	NN	O
and	CC	O
possibly	RB	O
hydrogen	VB	O
bonds	NNS	O
with	IN	O
tryptophan	JJ	O
215	CD	O
.	.	O
Further	RB	O
,	,	O
this	DT	O
amino	NN	O
acid	NN	O
is	VBZ	O
relatively	RB	O
well	RB	O
conserved	VBN	O
in	IN	O
OAS1	NNP	O
,	,	O
2	CD	O
,	,	O
and	CC	O
3	CD	O
.	.	O
Cysteine	NNP	O
269	CD	O
is	VBZ	O
surface	NN	O
exposed	VBN	O
,	,	O
but	CC	O
hydrogen	NN	O
bonds	NNS	O
to	TO	O
the	DT	O
backbone	NN	O
of	IN	O
the	DT	O
conserved	JJ	O
leucine	NN	O
291	CD	O
and	CC	O
is	VBZ	O
itself	PRP	O
highly	RB	O
conserved	VBD	O
.	.	O
Finally	RB	O
,	,	O
cysteine	NN	O
331	CD	O
is	VBZ	O
buried	VBN	O
within	IN	O
the	DT	O
structure	NN	O
and	CC	O
hydrogen	NN	O
bonds	NNS	O
with	IN	O
the	DT	O
backbone	NN	O
of	IN	O
leucine	JJ	O
4	CD	O
.	.	O
For	IN	O
these	DT	O
reasons	NNS	O
,	,	O
the	DT	O
foregoing	VBG	O
seven	CD	O
cysteine	JJ	O
residues	NNS	O
respond	VBP	O
more	JJR	O
poorly	RB	O
to	TO	O
modification	NN	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
all	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptides	NNS	O
that	WDT	O
are	VBP	O
modified	VBN	O
to	TO	O
reduce	VB	O
oxidative	JJ	O
potential	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Class	NN	O
III	NNP	O
Polypeptide	NNP	O
Modifications	NNP	O
The	DT	O
Class	NNP	O
III	NNP	O
modifications	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
result	NN	O
in	IN	O
polypeptides	NNS	O
having	VBG	O
increased	VBN	O
cell	NN	O
permeability	NN	O
by	IN	O
virtue	NN	O
of	IN	O
the	DT	O
addition	NN	O
of	IN	O
basic	JJ	O
residues	NNS	O
at	IN	O
the	DT	O
amino-terminus	NN	O
of	IN	O
the	DT	O
proteins	NNS	O
.	.	O
Histidine	NNP	O
,	,	O
arginine	NN	O
,	,	O
and	CC	O
lysine	NN	O
residues	NNS	O
all	DT	O
increase	VBP	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
the	DT	O
native	JJ	O
protein	NN	O
.	.	O
As	IN	O
one	CD	O
skilled	VBD	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
,	,	O
any	DT	O
length	NN	O
of	IN	O
homopolymeric	JJ	O
basic	JJ	O
residues	NNS	O
can	MD	O
increase	VB	O
polypeptide	RB	O
cell	JJ	O
permeability	NN	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,847,240	CD	O
)	)	O
.	.	O
Modification	NN	O
of	IN	O
the	DT	O
amino	NN	O
terminus	NN	O
of	IN	O
the	DT	O
protein	NN	O
preserves	VBZ	O
full	JJ	O
enzymatic	JJ	O
activity	NN	O
while	IN	O
increasing	VBG	O
cell	NN	O
permeability	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
increased	VBN	O
more	JJR	O
than	IN	O
ten-fold	JJ	O
by	IN	O
addition	NN	O
of	IN	O
a	DT	O
Class	NNP	O
III	NNP	O
modification	NN	O
.	.	O
Nevertheless	RB	O
,	,	O
all	DT	O
of	IN	O
the	DT	O
oligoadenylate	JJ	O
synthetases	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
some	DT	O
cell	NN	O
penetrating	VBG	O
ability	NN	O
,	,	O
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
Class	NNP	O
III	NNP	O
modification	NN	O
.	.	O
It	PRP	O
is	VBZ	O
therefore	RB	O
the	DT	O
intention	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
include	VB	O
uses	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
including	VBG	O
the	DT	O
parent	NN	O
polypeptide	NN	O
of	IN	O
SEQUENCE:1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
,	,	O
FIG	NNP	O
.	.	O
1	CD	O
,	,	O
and	CC	O
any	DT	O
fragments	NNS	O
or	CC	O
subsequences	NNS	O
thereof	RB	O
,	,	O
to	TO	O
mediate	VB	O
an	DT	O
increase	NN	O
in	IN	O
cell	JJ	O
permeability	NN	O
of	IN	O
any	DT	O
other	JJ	O
molecule	NN	O
.	.	O
Said	JJ	O
increase	NN	O
in	IN	O
cell	NN	O
permeability	NN	O
can	MD	O
be	VB	O
affected	VBN	O
by	IN	O
any	DT	O
covalent	NN	O
or	CC	O
non-covalent	JJ	O
attachment	NN	O
between	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
the	DT	O
molecule	NN	O
in	IN	O
need	NN	O
of	IN	O
increased	VBN	O
cell	NN	O
permeability	NN	O
.	.	O
Class	NN	O
IV	NNP	O
Polypeptide	NNP	O
Modifications	NNP	O
The	DT	O
Class	NNP	O
IV	NNP	O
modifications	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
result	NN	O
in	IN	O
polypeptides	NNS	O
having	VBG	O
increased	VBN	O
serum	JJ	O
stability	NN	O
,	,	O
reduced	VBN	O
immunogenicity	NN	O
,	,	O
reduced	VBN	O
susceptibility	NN	O
to	TO	O
nucleases	NNS	O
in	IN	O
vivo	NN	O
,	,	O
and	CC	O
increased	VBD	O
cell	NN	O
permeability	NN	O
by	IN	O
virtue	NN	O
of	IN	O
their	PRP$	O
modification	NN	O
with	IN	O
polyethylene	JJ	O
glycol	NN	O
.	.	O
As	IN	O
one	CD	O
skilled	VBD	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
,	,	O
numerous	JJ	O
methods	NNS	O
of	IN	O
derivatization	NN	O
of	IN	O
proteins	NNS	O
with	IN	O
polyethylene	NN	O
glycol	NNS	O
are	VBP	O
known	VBN	O
.	.	O
Preferred	JJ	O
embodiments	NNS	O
include	VBP	O
the	DT	O
derivatization	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
reactive	JJ	O
cysteine	NN	O
residues	NNS	O
using	VBG	O
a	DT	O
maleimide	NN	O
coupling	VBG	O
reagent	NN	O
to	TO	O
a	DT	O
single	JJ	O
or	CC	O
branched-chain	JJ	O
polyethylene	NN	O
glycol	NN	O
of	IN	O
40	CD	O
kilodaltons	NNS	O
or	CC	O
less	JJR	O
in	IN	O
molecular	JJ	O
weight	NN	O
.	.	O
Such	JJ	O
polyethylene	NN	O
coupled	VBD	O
polypeptides	NNS	O
retain	VBP	O
full	JJ	O
enzymatic	JJ	O
activity	NN	O
as	IN	O
demonstrated	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
Pegylation	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
at	IN	O
one	CD	O
or	CC	O
more	JJR	O
solvent	JJ	O
exposed	VBN	O
cysteines	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
the	DT	O
cysteines	NNS	O
at	IN	O
position	NN	O
25	CD	O
,	,	O
38	CD	O
,	,	O
and	CC	O
54	CD	O
,	,	O
is	VBZ	O
also	RB	O
envisioned	VBN	O
.	.	O
Further	RB	O
,	,	O
modification	NN	O
or	CC	O
mutation	NN	O
of	IN	O
the	DT	O
protein	NN	O
to	TO	O
remove	VB	O
one	CD	O
or	CC	O
more	JJR	O
solvent	JJ	O
exposed	VBN	O
cysteines	NNS	O
(	(	O
a	DT	O
Class	NN	O
II	NNP	O
modification	NN	O
)	)	O
in	IN	O
order	NN	O
to	TO	O
facilitate	VB	O
the	DT	O
preferential	JJ	O
polyethylene	NN	O
glycol	JJ	O
derivatization	NN	O
of	IN	O
any	DT	O
other	JJ	O
cysteine	NN	O
(	(	O
a	DT	O
Class	NN	O
IV	NNP	O
modification	NN	O
)	)	O
is	VBZ	O
also	RB	O
envisioned	VBN	O
by	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
all	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptides	NNS	O
that	WDT	O
are	VBP	O
conjugated	VBN	O
to	TO	O
a	DT	O
non-polypeptide	JJ	O
moiety	NN	O
,	,	O
such	JJ	O
moieties	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
polymer	VB	O
molecules	NNS	O
,	,	O
sugar	NN	O
moieties	NNS	O
,	,	O
lipophilic	JJ	O
compounds	NNS	O
,	,	O
or	CC	O
organic	JJ	O
derivatizing	NN	O
agents	NNS	O
.	.	O
Class	NN	O
V	NNP	O
Polypeptide	NNP	O
Modifications	NNP	O
The	DT	O
Class	NNP	O
V	NNP	O
modifications	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
represent	VBP	O
additional	JJ	O
polypeptide	NN	O
forms	NNS	O
that	WDT	O
also	RB	O
possess	VBP	O
desirable	JJ	O
pharmaceutical	JJ	O
properties	NNS	O
.	.	O
These	DT	O
modifications	NNS	O
are	VBP	O
derived	VBN	O
in	IN	O
order	NN	O
to	TO	O
achieve	VB	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
simplify	VB	O
recombinant	JJ	O
vector	NN	O
construction	NN	O
;	:	O
optimize	VB	O
the	DT	O
ribosomal	JJ	O
binding	NN	O
site	NN	O
;	:	O
improve	VB	O
manufacturability	NN	O
in	IN	O
E.	NNP	O
coli	NNS	O
;	:	O
and	CC	O
increase	VB	O
amino	NN	O
acid	JJ	O
similarity	NN	O
with	IN	O
other	JJ	O
identified	JJ	O
OAS	NNP	O
polypeptides	NNS	O
,	,	O
while	IN	O
maintaining	VBG	O
desirable	JJ	O
pharmaceutical	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
anti-viral	JJ	O
or	CC	O
anti-cancer	JJ	O
activity	NN	O
.	.	O
Pharmaceutical	JJ	O
Compositions	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
as	IN	O
active	JJ	O
ingredients	NNS	O
for	IN	O
a	DT	O
therapeutic	JJ	O
application	NN	O
.	.	O
These	DT	O
compositions	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
method	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
general	JJ	O
the	DT	O
pharmaceutical	JJ	O
composition	NN	O
for	IN	O
inhibiting	VBG	O
virus	JJ	O
infection	NN	O
,	,	O
cancer	NN	O
,	,	O
neoplasm	RB	O
,	,	O
inflammation	NN	O
,	,	O
or	CC	O
other	JJ	O
disease	NN	O
in	IN	O
a	DT	O
mammal	NN	O
or	CC	O
subject	JJ	O
includes	VBZ	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
polypeptide	NN	O
as	IN	O
described	VBN	O
above	IN	O
needed	VBN	O
for	IN	O
the	DT	O
practice	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
a	DT	O
fragment	JJ	O
thereof	NN	O
shown	VBN	O
to	TO	O
have	VB	O
the	DT	O
same	JJ	O
effect	NN	O
,	,	O
and	CC	O
a	DT	O
pharmaceutically	RB	O
physiologically	RB	O
acceptable	JJ	O
carrier	NN	O
or	CC	O
diluent	NN	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
can	MD	O
be	VB	O
composed	VBN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
in	IN	O
combination	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
composition	NN	O
may	MD	O
further	RB	O
be	VB	O
composed	VBN	O
of	IN	O
a	DT	O
single	JJ	O
polypeptide	NN	O
that	WDT	O
contains	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
modifications	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
within	IN	O
a	DT	O
contiguous	JJ	O
molecule	NN	O
.	.	O
The	DT	O
compositions	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
,	,	O
subcutaneously	RB	O
,	,	O
or	CC	O
parenterally	RB	O
including	VBG	O
intravenous	JJ	O
,	,	O
intraarterial	JJ	O
,	,	O
intramuscular	JJ	O
,	,	O
intraperitoneally	RB	O
,	,	O
and	CC	O
intranasal	JJ	O
administration	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
intrathecal	JJ	O
and	CC	O
infusion	NN	O
techniques	NNS	O
as	IN	O
required	VBN	O
.	.	O
The	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
,	,	O
diluents	NNS	O
,	,	O
adjuvants	NNS	O
and	CC	O
vehicles	NNS	O
as	RB	O
well	RB	O
as	IN	O
implant	JJ	O
carriers	NNS	O
generally	RB	O
refer	VBP	O
to	TO	O
inert	VB	O
,	,	O
non-toxic	JJ	O
solid	JJ	O
or	CC	O
liquid	JJ	O
fillers	NNS	O
,	,	O
diluents	NNS	O
or	CC	O
encapsulating	VBG	O
material	NN	O
not	RB	O
reacting	VBG	O
with	IN	O
the	DT	O
active	JJ	O
ingredients	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Cationic	JJ	O
lipids	NNS	O
may	MD	O
also	RB	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
composition	NN	O
to	TO	O
facilitate	VB	O
polypeptide	JJ	O
uptake	NN	O
.	.	O
Implants	NNS	O
of	IN	O
the	DT	O
compounds	NNS	O
are	VBP	O
also	RB	O
useful	JJ	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
sterile	JJ	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
compositions	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
to	TO	O
which	WDT	O
a	DT	O
detectable	JJ	O
label	NN	O
is	VBZ	O
attached	VBN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
fluorescent	NN	O
,	,	O
chemiluminescent	NN	O
or	CC	O
radioactive	JJ	O
molecule	NN	O
.	.	O
Another	DT	O
example	NN	O
is	VBZ	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
which	WDT	O
may	MD	O
be	VB	O
formulated	VBN	O
by	IN	O
known	VBN	O
techniques	NNS	O
using	VBG	O
known	JJ	O
materials	NNS	O
,	,	O
see	VBP	O
,	,	O
Remington	NNP	B
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed	NNP	I
.	.	I
(	(	I
1990	CD	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
18042	CD	I
)	)	I
pp	NN	I
.	.	I
1435-1712	CD	I
,	,	O
which	WDT	O
are	VBP	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Generally	RB	O
,	,	O
the	DT	O
formulation	NN	O
will	MD	O
depend	VB	O
on	IN	O
a	DT	O
variety	NN	O
of	IN	O
factors	NNS	O
such	JJ	O
as	IN	O
administration	NN	O
,	,	O
stability	NN	O
,	,	O
production	NN	O
concerns	NNS	O
and	CC	O
other	JJ	O
factors	NNS	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
may	MD	O
be	VB	O
administered	VBN	O
by	IN	O
injection	NN	O
or	CC	O
by	IN	O
pulmonary	JJ	O
administration	NN	O
via	IN	O
inhalation	NN	O
.	.	O
Enteric	JJ	O
dosage	NN	O
forms	NNS	O
may	MD	O
also	RB	O
be	VB	O
available	JJ	O
,	,	O
and	CC	O
therefore	RB	O
oral	JJ	O
administration	NN	O
may	MD	O
be	VB	O
effective	JJ	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
liposomes	NNS	O
or	CC	O
other	JJ	O
microcarriers	NNS	O
for	IN	O
delivery	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
gels	NNS	O
or	CC	O
other	JJ	O
compositions	NNS	O
for	IN	O
sustained	JJ	O
release	NN	O
.	.	O
Although	IN	O
preferred	VBN	O
compositions	NNS	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
use	NN	O
to	TO	O
which	WDT	O
the	DT	O
composition	NN	O
will	MD	O
be	VB	O
put	VBN	O
,	,	O
generally	RB	O
,	,	O
for	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
preferred	JJ	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
those	DT	O
prepared	JJ	O
for	IN	O
subcutaneous	JJ	O
injection	NN	O
or	CC	O
for	IN	O
pulmonary	JJ	O
administration	NN	O
via	IN	O
inhalation	NN	O
,	,	O
although	IN	O
the	DT	O
particular	JJ	O
formulations	NNS	O
for	IN	O
each	DT	O
type	NN	O
of	IN	O
administration	NN	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
specific	JJ	O
polypeptide	NN	O
.	.	O
Therapeutic	JJ	O
formulations	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
or	CC	O
polypeptide	VB	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
typically	RB	O
administered	VBN	O
in	IN	O
a	DT	O
composition	NN	O
that	WDT	O
includes	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
or	CC	O
excipients	NNS	O
.	.	O
Such	JJ	O
pharmaceutical	JJ	O
compositions	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
in	IN	O
a	DT	O
manner	NN	O
known	VBN	O
per	IN	O
se	NN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
polypeptide	JJ	O
pharmaceutical	JJ	O
that	WDT	O
is	VBZ	O
sufficiently	RB	O
storage-stable	JJ	O
and	CC	O
is	VBZ	O
suitable	JJ	O
for	IN	O
administration	NN	O
to	TO	O
humans	NNS	O
or	CC	O
animals	NNS	O
.	.	O
The	DT	O
polypeptides	NNS	O
or	CC	O
polypeptide	VB	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
“	NNP	O
as	IN	O
is	VBZ	O
”	JJ	O
and/or	NN	O
in	IN	O
a	DT	O
salt	JJ	O
form	NN	O
thereof	NN	O
.	.	O
Suitable	JJ	O
salts	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
salts	NNS	O
with	IN	O
alkali	JJ	O
metals	NNS	O
or	CC	O
alkaline	VB	O
earth	JJ	O
metals	NNS	O
,	,	O
such	JJ	O
as	IN	O
sodium	NN	O
,	,	O
potassium	NN	O
,	,	O
calcium	NN	O
and	CC	O
magnesium	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
e.g	NN	O
.	.	O
zinc	NN	O
salts	NNS	O
.	.	O
These	DT	O
salts	NNS	O
or	CC	O
complexes	NNS	O
may	MD	O
by	IN	O
present	NN	O
as	IN	O
a	DT	O
crystalline	NN	O
and/or	RB	O
amorphous	JJ	O
structure	NN	O
.	.	O
“	NNS	O
Pharmaceutically	NNP	O
acceptable	JJ	O
”	NN	O
means	VBZ	O
a	DT	O
carrier	NN	O
or	CC	O
excipient	NN	O
that	WDT	O
at	IN	O
the	DT	O
dosages	NNS	O
and	CC	O
concentrations	NNS	O
employed	VBD	O
does	VBZ	O
not	RB	O
cause	VB	O
any	DT	O
untoward	JJ	O
effects	NNS	O
in	IN	O
the	DT	O
patients	NNS	O
to	TO	O
whom	WP	O
it	PRP	O
is	VBZ	O
administered	VBN	O
.	.	O
Such	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
and	CC	O
excipients	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
see	VB	O
Remington	NNP	B
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
edition	NN	I
,	,	I
A.	NNP	I
R.	NNP	I
Gennaro	NNP	I
,	,	I
Ed.	NNP	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Company	NNP	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Pharmaceutical	JJ	B
Formulation	NNP	I
Development	NNP	I
of	IN	I
Peptides	NNP	I
and	CC	I
Proteins	NNP	I
,	,	I
S.	NNP	I
Frokjaer	NNP	I
and	CC	I
L.	NNP	I
Hovgaard	NNP	I
,	,	I
Eds.	NNP	I
,	,	I
Taylor	NNP	I
&	CC	I
Francis	NNP	I
(	(	I
2000	CD	I
)	)	I
;	:	O
and	CC	O
Handbook	NNP	B
of	IN	I
Pharmaceutical	NNP	I
Excipients	NNP	I
,	,	I
3rd	CD	I
edition	NN	I
,	,	I
A.	NNP	I
Kibbe	NNP	I
,	,	I
Ed.	NNP	I
,	,	I
Pharmaceutical	NNP	I
Press	NNP	I
(	(	I
2000	CD	I
)	)	I
)	)	O
.	.	O
The	DT	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
administered	VBN	O
alone	RB	O
or	CC	O
in	IN	O
conjunction	NN	O
with	IN	O
other	JJ	O
therapeutic	JJ	O
agents	NNS	O
.	.	O
Ribavirin	NNP	O
and	CC	O
interferon	NN	O
alpha	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
HCV	NNP	O
infection	NN	O
when	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
.	.	O
Their	PRP$	O
efficacy	NN	O
in	IN	O
combination	NN	O
exceeds	VBZ	O
the	DT	O
efficacy	NN	O
of	IN	O
either	CC	O
drug	NN	O
product	NN	O
when	WRB	O
used	VBN	O
alone	RB	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
administered	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
interferon	NN	O
,	,	O
ribavirin	VB	O
and/or	IN	O
a	DT	O
variety	NN	O
of	IN	O
small	JJ	O
molecules	NNS	O
that	WDT	O
are	VBP	O
being	VBG	O
developed	VBN	O
against	IN	O
both	DT	O
viral	JJ	O
targets	NNS	O
(	(	O
viral	JJ	O
proteases	NNS	O
,	,	O
viral	JJ	O
polymerase	NN	O
,	,	O
assembly	NN	O
of	IN	O
viral	JJ	O
replication	NN	O
complexes	NNS	O
)	)	O
and	CC	O
host	$	O
targets	NNS	O
(	(	O
host	NN	O
proteases	NNS	O
required	VBN	O
for	IN	O
viral	JJ	O
processing	NN	O
,	,	O
host	NN	O
kinases	NNS	O
required	VBN	O
for	IN	O
phosphorylation	NN	O
of	IN	O
viral	JJ	O
targets	NNS	O
such	JJ	O
as	IN	O
NS5A	NNP	O
and	CC	O
inhibitors	NNS	O
of	IN	O
host	NN	O
factors	NNS	O
required	VBD	O
to	TO	O
efficiently	RB	O
utilize	VB	O
the	DT	O
viral	JJ	O
IRES	NNP	O
)	)	O
.	.	O
Cytokines	NNS	O
may	MD	O
be	VB	O
co-administered	JJ	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
IL-2	NNP	O
,	,	O
IL-12	NNP	O
,	,	O
IL-23	NNP	O
,	,	O
IL-27	NNP	O
,	,	O
or	CC	O
IFN-gamma	NNP	O
.	.	O
These	DT	O
agents	NNS	O
may	MD	O
be	VB	O
incorporated	VBN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
same	JJ	O
pharmaceutical	JJ	O
composition	NN	O
or	CC	O
may	MD	O
be	VB	O
administered	VBN	O
separately	RB	O
from	IN	O
the	DT	O
polypeptides	NNS	O
or	CC	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
either	CC	O
concurrently	RB	O
or	CC	O
in	IN	O
accordance	NN	O
with	IN	O
another	DT	O
treatment	NN	O
schedule	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
polypeptides	NNS	O
,	,	O
polypeptide	VB	O
conjugates	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
adjuvant	NN	O
to	TO	O
other	JJ	O
therapies	NNS	O
.	.	O
A	DT	O
“	JJ	O
patient	NN	O
”	NN	O
for	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
includes	VBZ	O
both	CC	O
humans	NNS	O
and	CC	O
other	JJ	O
mammals	NNS	O
.	.	O
Thus	RB	O
the	DT	O
methods	NNS	O
are	VBP	O
applicable	JJ	O
to	TO	O
both	DT	O
human	JJ	O
therapy	NN	O
and	CC	O
veterinary	JJ	O
applications	NNS	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
composition	NN	O
comprising	VBG	O
the	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
forms	NNS	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
a	DT	O
liquid	NN	O
,	,	O
gel	NN	O
,	,	O
lyophilized	VBN	O
,	,	O
or	CC	O
as	IN	O
a	DT	O
compressed	JJ	O
solid	NN	O
.	.	O
The	DT	O
preferred	JJ	O
form	NN	O
will	MD	O
depend	VB	O
upon	IN	O
the	DT	O
particular	JJ	O
indication	NN	O
being	VBG	O
treated	VBN	O
and	CC	O
will	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
one	CD	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
administration	NN	O
of	IN	O
the	DT	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
,	,	O
including	VBG	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
orally	RB	O
,	,	O
subcutaneously	RB	O
,	,	O
intravenously	RB	O
,	,	O
intracerebrally	RB	O
,	,	O
intranasally	RB	O
,	,	O
transdermally	RB	O
,	,	O
intraperitoneally	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
intrapulmonary	JJ	O
,	,	O
intrathecally	RB	O
,	,	O
vaginally	RB	O
,	,	O
rectally	RB	O
,	,	O
intraocularly	RB	O
,	,	O
or	CC	O
in	IN	O
any	DT	O
other	JJ	O
acceptable	JJ	O
manner	NN	O
.	.	O
The	DT	O
formulations	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
continuously	RB	O
by	IN	O
infusion	NN	O
,	,	O
although	IN	O
bolus	JJ	O
injection	NN	O
is	VBZ	O
acceptable	JJ	O
,	,	O
using	VBG	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
pumps	NNS	O
(	(	O
e.g.	NN	O
,	,	O
subcutaneous	JJ	O
osmotic	JJ	O
pumps	NNS	O
)	)	O
or	CC	O
implantation	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
the	DT	O
formulations	NNS	O
may	MD	O
be	VB	O
directly	RB	O
applied	VBN	O
as	IN	O
a	DT	O
solution	NN	O
or	CC	O
spray	NN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
a	DT	O
pharmaceutical	JJ	O
composition	NN	O
is	VBZ	O
a	DT	O
solution	NN	O
designed	VBN	O
for	IN	O
parenteral	JJ	O
administration	NN	O
.	.	O
Although	IN	O
in	IN	O
many	JJ	O
cases	NNS	O
pharmaceutical	JJ	O
solution	NN	O
formulations	NNS	O
are	VBP	O
provided	VBN	O
in	IN	O
liquid	JJ	O
form	NN	O
,	,	O
appropriate	NN	O
for	IN	O
immediate	JJ	O
use	NN	O
,	,	O
such	JJ	O
parenteral	JJ	O
formulations	NNS	O
may	MD	O
also	RB	O
be	VB	O
provided	VBN	O
in	IN	O
frozen	JJ	O
or	CC	O
in	IN	O
lyophilized	JJ	O
form	NN	O
.	.	O
In	IN	O
the	DT	O
former	JJ	O
case	NN	O
,	,	O
the	DT	O
composition	NN	O
must	MD	O
be	VB	O
thawed	VBN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O
The	DT	O
latter	JJ	O
form	NN	O
is	VBZ	O
often	RB	O
used	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
active	JJ	O
compound	NN	O
contained	VBN	O
in	IN	O
the	DT	O
composition	NN	O
under	IN	O
a	DT	O
wider	JJR	O
variety	NN	O
of	IN	O
storage	NN	O
conditions	NNS	O
,	,	O
as	IN	O
it	PRP	O
is	VBZ	O
recognized	VBN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
lyophilized	VBD	O
preparations	NNS	O
are	VBP	O
generally	RB	O
more	RBR	O
stable	JJ	O
than	IN	O
their	PRP$	O
liquid	JJ	O
counterparts	NNS	O
.	.	O
Such	JJ	O
lyophilized	JJ	O
preparations	NNS	O
are	VBP	O
reconstituted	VBN	O
prior	RB	O
to	TO	O
use	VB	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
diluents	NNS	O
such	JJ	O
as	IN	O
sterile	JJ	O
water	NN	O
for	IN	O
injection	NN	O
or	CC	O
sterile	JJ	O
physiological	JJ	O
saline	NN	O
solution	NN	O
.	.	O
Parenterals	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
for	IN	O
storage	NN	O
as	IN	O
lyophilized	JJ	O
formulations	NNS	O
or	CC	O
aqueous	JJ	O
solutions	NNS	O
by	IN	O
mixing	VBG	O
,	,	O
as	IN	O
appropriate	JJ	O
,	,	O
the	DT	O
polypeptide	NN	O
having	VBG	O
the	DT	O
desired	JJ	O
degree	NN	O
of	IN	O
purity	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
,	,	O
excipients	NNS	O
or	CC	O
stabilizers	NNS	O
typically	RB	O
employed	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
termed	VBN	O
“	JJ	O
excipients	NNS	O
”	NN	O
)	)	O
,	,	O
for	IN	O
example	NN	O
buffering	NN	O
agents	NNS	O
,	,	O
stabilizing	VBG	O
agents	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
isotonifiers	NNS	O
,	,	O
non-ionic	JJ	O
detergents	NNS	O
,	,	O
antioxidants	NNS	O
and/or	VBP	O
other	JJ	O
miscellaneous	JJ	O
additives	NNS	O
.	.	O
Buffering	VBG	O
agents	NNS	O
help	VB	O
to	TO	O
maintain	VB	O
the	DT	O
pH	NN	O
in	IN	O
the	DT	O
range	NN	O
which	WDT	O
approximates	VBZ	O
physiological	JJ	O
conditions	NNS	O
.	.	O
They	PRP	O
are	VBP	O
typically	RB	O
present	JJ	O
at	IN	O
a	DT	O
concentration	NN	O
ranging	VBG	O
from	IN	O
about	IN	O
2	CD	O
mM	NNS	O
to	TO	O
about	IN	O
50	CD	O
mM	NNS	O
.	.	O
Suitable	JJ	O
buffering	NN	O
agents	NNS	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
both	DT	O
organic	JJ	O
and	CC	O
inorganic	JJ	O
acids	NNS	O
and	CC	O
salts	NNS	O
thereof	VBP	O
such	JJ	O
as	IN	O
citrate	NN	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
monosodium	NN	O
citrate-disodium	NN	O
citrate	NN	O
mixture	NN	O
,	,	O
citric	JJ	O
acid-trisodium	JJ	O
citrate	NN	O
mixture	NN	O
,	,	O
citric	JJ	O
acid-monosodium	JJ	O
citrate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
succinate	JJ	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
succinic	JJ	O
acid-monosodium	NN	O
succinate	NN	O
mixture	NN	O
,	,	O
succinic	JJ	O
acid-sodium	NN	O
hydroxide	NN	O
mixture	NN	O
,	,	O
succinic	JJ	O
acid-disodium	NN	O
succinate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
tartrate	JJ	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
tartaric	JJ	O
acid-sodium	JJ	O
tartrate	NN	O
mixture	NN	O
,	,	O
tartaric	JJ	O
acid-potassium	JJ	O
tartrate	NN	O
mixture	NN	O
,	,	O
tartaric	JJ	O
acid-sodium	JJ	O
hydroxide	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
fumarate	JJ	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
fumaric	JJ	O
acid-monosodium	JJ	O
fumarate	NN	O
mixture	NN	O
,	,	O
fumaric	JJ	O
acid-disodium	JJ	O
fumarate	NN	O
mixture	NN	O
,	,	O
monosodium	NN	O
fumarate-disodium	JJ	O
fumarate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
gluconate	JJ	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
gluconic	JJ	O
acid-sodium	NN	O
glyconate	NN	O
mixture	NN	O
,	,	O
gluconic	JJ	O
acid-sodium	NN	O
hydroxide	NN	O
mixture	NN	O
,	,	O
gluconic	JJ	O
acid-potassium	NN	O
glyuconate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
oxalate	JJ	O
buffer	NN	O
(	(	O
e.g.	JJ	O
,	,	O
oxalic	JJ	O
acid-sodium	JJ	O
oxalate	NN	O
mixture	NN	O
,	,	O
oxalic	JJ	O
acid-sodium	JJ	O
hydroxide	NN	O
mixture	NN	O
,	,	O
oxalic	JJ	O
acid-potassium	JJ	O
oxalate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
lactate	JJ	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
lactic	JJ	O
acid-sodium	NN	O
lactate	NN	O
mixture	NN	O
,	,	O
lactic	JJ	O
acid-sodium	NN	O
hydroxide	NN	O
mixture	NN	O
,	,	O
lactic	JJ	O
acid-potassium	NN	O
lactate	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
and	CC	O
acetate	NN	O
buffers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
acetic	JJ	O
acid-sodium	NN	O
acetate	NN	O
mixture	NN	O
,	,	O
acetic	JJ	O
acid-sodium	NN	O
hydroxide	NN	O
mixture	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Additional	JJ	O
possibilities	NNS	O
are	VBP	O
phosphate	JJ	O
buffers	NNS	O
,	,	O
histidine	NN	O
buffers	NNS	O
and	CC	O
trimethylamine	NN	O
salts	NNS	O
such	JJ	O
as	IN	O
Tris	NNP	O
.	.	O
Preservatives	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
retard	VB	O
microbial	JJ	O
growth	NN	O
,	,	O
and	CC	O
are	VBP	O
typically	RB	O
added	VBN	O
in	IN	O
amounts	NNS	O
of	IN	O
about	RB	O
0.2	CD	O
%	NN	O
-1	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
.	.	O
Suitable	JJ	O
preservatives	NNS	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
phenol	NN	O
,	,	O
benzyl	NN	O
alcohol	NN	O
,	,	O
meta-cresol	NN	O
,	,	O
methyl	NN	O
paraben	NN	O
,	,	O
propyl	NN	O
paraben	NN	O
,	,	O
octadecyldimethylbenzyl	JJ	O
ammonium	NN	O
chloride	NN	O
,	,	O
benzalkonium	NN	O
halides	NNS	O
(	(	O
e.g.	NN	O
,	,	O
benzalkonium	NN	O
chloride	NN	O
,	,	O
bromide	NN	O
or	CC	O
iodide	NN	O
)	)	O
,	,	O
hexamethonium	JJ	O
chloride	NN	O
,	,	O
alkyl	JJ	O
parabens	NNS	O
such	JJ	O
as	IN	O
methyl	NN	O
or	CC	O
propyl	NN	O
paraben	NN	O
,	,	O
catechol	NN	O
,	,	O
resorcinol	NN	O
,	,	O
cyclohexanol	NN	O
and	CC	O
3-pentanol	JJ	O
.	.	O
Isotonicifiers	NNS	O
are	VBP	O
added	VBN	O
to	TO	O
ensure	VB	O
isotonicity	NN	O
of	IN	O
liquid	JJ	O
compositions	NNS	O
and	CC	O
include	VBP	O
polyhydric	JJ	O
sugar	NN	O
alcohols	NNS	O
,	,	O
preferably	RB	O
trihydric	JJ	O
or	CC	O
higher	JJR	O
sugar	NN	O
alcohols	NNS	O
,	,	O
such	JJ	O
as	IN	O
glycerin	NN	O
,	,	O
erythritol	NN	O
,	,	O
arabitol	NN	O
,	,	O
xylitol	NNP	O
,	,	O
sorbitol	NN	O
and	CC	O
mannitol	NN	O
.	.	O
Polyhydric	JJ	O
alcohols	NNS	O
can	MD	O
be	VB	O
present	JJ	O
in	IN	O
an	DT	O
amount	NN	O
between	IN	O
0.1	CD	O
%	NN	O
and	CC	O
25	CD	O
%	NN	O
by	IN	O
weight	NN	O
,	,	O
typically	RB	O
1	CD	O
%	NN	O
to	TO	O
5	CD	O
%	NN	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
relative	JJ	O
amounts	NNS	O
of	IN	O
the	DT	O
other	JJ	O
ingredients	NNS	O
.	.	O
Stabilizers	NNS	O
refer	VBP	O
to	TO	O
a	DT	O
broad	JJ	O
category	NN	O
of	IN	O
excipients	NNS	O
which	WDT	O
can	MD	O
range	VB	O
in	IN	O
function	NN	O
from	IN	O
a	DT	O
bulking	NN	O
agent	NN	O
to	TO	O
an	DT	O
additive	JJ	O
which	WDT	O
solubilizes	VBZ	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
or	CC	O
helps	VBZ	O
to	TO	O
prevent	VB	O
denaturation	NN	O
or	CC	O
adherence	NN	O
to	TO	O
the	DT	O
container	NN	O
wall	NN	O
.	.	O
Typical	JJ	O
stabilizers	NNS	O
can	MD	O
be	VB	O
polyhydric	JJ	O
sugar	NN	O
alcohols	NNS	O
(	(	O
enumerated	VBN	O
above	IN	O
)	)	O
;	:	O
amino	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
arginine	NN	O
,	,	O
lysine	NN	O
,	,	O
glycine	NN	O
,	,	O
glutamine	NN	O
,	,	O
asparagine	NN	O
,	,	O
histidine	NN	O
,	,	O
alanine	NN	O
,	,	O
ornithine	NN	O
,	,	O
L-leucine	NNP	O
,	,	O
2-phenylalanine	JJ	O
,	,	O
glutamic	JJ	O
acid	NN	O
,	,	O
threonine	NN	O
,	,	O
etc.	FW	O
,	,	O
organic	JJ	O
sugars	NNS	O
or	CC	O
sugar	NN	O
alcohols	NNS	O
,	,	O
such	JJ	O
as	IN	O
lactose	JJ	O
,	,	O
trehalose	JJ	O
,	,	O
stachyose	JJ	O
,	,	O
mannitol	NN	O
,	,	O
sorbitol	NN	O
,	,	O
xylitol	NNP	O
,	,	O
ribitol	NN	O
,	,	O
myoinisitol	NN	O
,	,	O
galactitol	NN	O
,	,	O
glycerol	NN	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
including	VBG	O
cyclitols	NNS	O
such	JJ	O
as	IN	O
inositol	NN	O
;	:	O
polyethylene	CC	O
glycol	NN	O
;	:	O
amino	CC	O
acid	JJ	O
polymers	NNS	O
;	:	O
sulfur-containing	JJ	O
reducing	NN	O
agents	NNS	O
,	,	O
such	JJ	O
as	IN	O
urea	JJ	O
,	,	O
glutathione	NN	O
,	,	O
thioctic	JJ	O
acid	NN	O
,	,	O
sodium	NN	O
thioglycolate	NN	O
,	,	O
thioglycerol	NN	O
,	,	O
alpha-monothioglycerol	NN	O
and	CC	O
sodium	NN	O
thiosulfate	NN	O
;	:	O
low	JJ	O
molecular	JJ	O
weight	NN	O
polypeptides	NNS	O
(	(	O
i.e.	FW	O
,	,	O
<	FW	O
10	CD	O
residues	NNS	O
)	)	O
;	:	O
proteins	NNS	O
such	JJ	O
as	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
,	,	O
bovine	NN	O
serum	NN	O
albumin	NN	O
,	,	O
gelatin	NN	O
or	CC	O
immunoglobulins	NNS	O
;	:	O
hydrophilic	JJ	O
polymers	NNS	O
such	JJ	O
as	IN	O
polyvinylpyrrolidone	NN	O
;	:	O
monosaccharides	NNS	O
such	JJ	O
as	IN	O
xylose	JJ	O
,	,	O
mannose	JJ	O
,	,	O
fructose	JJ	O
and	CC	O
glucose	JJ	O
;	:	O
disaccharides	NNS	O
such	JJ	O
as	IN	O
lactose	JJ	O
,	,	O
maltose	JJ	O
and	CC	O
sucrose	JJ	O
;	:	O
trisaccharides	NNS	O
such	JJ	O
as	IN	O
raffinose	NN	O
,	,	O
and	CC	O
polysaccharides	NNS	O
such	JJ	O
as	IN	O
dextran	NN	O
.	.	O
Stabilizers	NNS	O
are	VBP	O
typically	RB	O
present	JJ	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
from	IN	O
0.1	CD	O
to	TO	O
10,000	CD	O
parts	NNS	O
by	IN	O
weight	NN	O
based	VBN	O
on	IN	O
the	DT	O
active	JJ	O
protein	NN	O
weight	NN	O
.	.	O
Non-ionic	JJ	O
surfactants	NNS	O
or	CC	O
detergents	NNS	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
“	JJ	O
wetting	VBG	O
agents	NNS	O
”	NNP	O
)	)	O
may	MD	O
be	VB	O
present	JJ	O
to	TO	O
help	VB	O
solubilize	VB	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
as	RB	O
well	RB	O
as	IN	O
to	TO	O
protect	VB	O
the	DT	O
therapeutic	JJ	O
polypeptide	NN	O
against	IN	O
agitation-induced	JJ	O
aggregation	NN	O
,	,	O
which	WDT	O
also	RB	O
permits	VBZ	O
the	DT	O
formulation	NN	O
to	TO	O
be	VB	O
exposed	VBN	O
to	TO	O
shear	VB	O
surface	NN	O
stress	NN	O
without	IN	O
causing	VBG	O
denaturation	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Suitable	JJ	O
non-ionic	JJ	O
surfactants	NNS	O
include	VBP	O
polysorbates	NNS	O
(	(	O
20	CD	O
,	,	O
80	CD	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
polyoxamers	NNS	O
(	(	O
184	CD	O
,	,	O
188	CD	O
etc	NN	O
.	.	O
)	)	O
,	,	O
Pluronic®	NNP	O
polyols	VBZ	O
,	,	O
polyoxyethylene	JJ	O
sorbitan	NN	O
monoethers	NNS	O
(	(	O
Tween®-20	NNP	O
,	,	O
Tween®-80	NNP	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Additional	NNP	O
miscellaneous	JJ	O
excipients	NNS	O
include	VBP	O
bulking	VBG	O
agents	NNS	O
or	CC	O
fillers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
starch	NN	O
)	)	O
,	,	O
chelating	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
EDTA	NNP	O
)	)	O
,	,	O
antioxidants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
ascorbic	JJ	O
acid	NN	O
,	,	O
methionine	NN	O
,	,	O
vitamin	FW	O
E	NNP	O
)	)	O
and	CC	O
cosolvents	NNS	O
.	.	O
The	DT	O
active	JJ	O
ingredient	NN	O
may	MD	O
also	RB	O
be	VB	O
entrapped	VBN	O
in	IN	O
microcapsules	NNS	O
prepared	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
coascervation	NN	O
techniques	NNS	O
or	CC	O
by	IN	O
interfacial	JJ	O
polymerization	NN	O
,	,	O
for	IN	O
example	NN	O
hydroxymethylcellulose	NN	O
,	,	O
gelatin	NN	O
or	CC	O
poly-	NN	O
(	(	O
methylmethacylate	NN	O
)	)	O
microcapsules	NNS	O
,	,	O
in	IN	O
colloidal	JJ	O
drug	NN	O
delivery	NN	O
systems	NNS	O
(	(	O
for	IN	O
example	NN	O
liposomes	NNS	O
,	,	O
albumin	NN	O
microspheres	NNS	O
,	,	O
microemulsions	NNS	O
,	,	O
nano-particles	NNS	O
and	CC	O
nanocapsules	NNS	O
)	)	O
or	CC	O
in	IN	O
macroemulsions	NNS	O
.	.	O
Such	JJ	O
techniques	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
Remington	NNP	O
's	POS	O
Pharmaceutical	NNP	O
Sciences	NNPS	O
,	,	O
supra	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
the	DT	O
composition	NN	O
is	VBZ	O
a	DT	O
liquid	JJ	O
composition	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
aqueous	JJ	O
composition	NN	O
,	,	O
and	CC	O
comprises	VBZ	O
a	DT	O
sulfoalkyl	NN	O
ether	RB	O
cyclodextrin	JJ	O
derivative	NN	O
.	.	O
Parenteral	JJ	O
formulations	NNS	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
in	IN	O
vivo	JJ	O
administration	NN	O
must	MD	O
be	VB	O
sterile	JJ	O
.	.	O
This	DT	O
is	VBZ	O
readily	RB	O
accomplished	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
filtration	NN	O
through	IN	O
sterile	JJ	O
filtration	NN	O
membranes	NNS	O
.	.	O
Suitable	JJ	O
examples	NNS	O
of	IN	O
sustained-release	JJ	O
preparations	NNS	O
include	VBP	O
semi-permeable	JJ	O
matrices	NNS	O
of	IN	O
solid	JJ	O
hydrophobic	NN	O
polymers	NNS	O
containing	VBG	O
the	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
,	,	O
the	DT	O
matrices	NNS	O
having	VBG	O
a	DT	O
suitable	JJ	O
form	NN	O
such	JJ	O
as	IN	O
a	DT	O
film	NN	O
or	CC	O
microcapsules	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
sustained-release	JJ	O
matrices	NNS	O
include	VBP	O
polyesters	NNS	O
,	,	O
hydrogels	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
poly	NN	O
(	(	O
2-hydroxyethyl-methacrylate	JJ	O
)	)	O
or	CC	O
poly	NN	O
(	(	O
vinylalcohol	NN	O
)	)	O
)	)	O
,	,	O
polylactides	NNS	O
,	,	O
copolymers	NNS	O
of	IN	O
L-glutamic	NNP	O
acid	NN	O
and	CC	O
ethyl-L-glutamate	JJ	O
,	,	O
non-degradable	JJ	O
ethylene-vinyl	JJ	O
acetate	NN	O
,	,	O
degradable	JJ	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
copolymers	NNS	O
such	JJ	O
as	IN	O
the	DT	O
ProLease®	NNP	O
technology	NN	O
or	CC	O
Lupron	NNP	O
Depot®	NNP	O
(	(	O
injectable	JJ	O
microspheres	NNS	O
composed	VBN	O
of	IN	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
copolymer	NN	O
and	CC	O
leuprolide	JJ	O
acetate	NN	O
)	)	O
,	,	O
and	CC	O
poly-D-	NN	O
(	(	O
−	NNP	O
)	)	O
-3-hydroxybutyric	JJ	O
acid	NN	O
.	.	O
While	IN	O
polymers	NNS	O
such	JJ	O
as	IN	O
ethylene-vinyl	JJ	O
acetate	NN	O
and	CC	O
lactic	JJ	O
acid-glycolic	JJ	O
acid	NN	O
enable	JJ	O
release	NN	O
of	IN	O
molecules	NNS	O
for	IN	O
long	RB	O
periods	NNS	O
such	JJ	O
as	IN	O
up	IN	O
to	TO	O
or	CC	O
over	IN	O
100	CD	O
days	NNS	O
,	,	O
certain	JJ	O
hydrogels	NNS	O
release	VBP	O
proteins	NNS	O
for	IN	O
shorter	JJR	O
time	NN	O
periods	NNS	O
.	.	O
When	WRB	O
encapsulated	VBN	O
polypeptides	NNS	O
remain	VBP	O
in	IN	O
the	DT	O
body	NN	O
for	IN	O
a	DT	O
long	JJ	O
time	NN	O
,	,	O
they	PRP	O
may	MD	O
denature	VB	O
or	CC	O
aggregate	VB	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
exposure	NN	O
to	TO	O
moisture	VB	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
loss	NN	O
of	IN	O
biological	JJ	O
activity	NN	O
and	CC	O
possible	JJ	O
changes	NNS	O
in	IN	O
immunogenicity	NN	O
.	.	O
Rational	JJ	O
strategies	NNS	O
can	MD	O
be	VB	O
devised	VBN	O
for	IN	O
stabilization	NN	O
depending	VBG	O
on	IN	O
the	DT	O
mechanism	NN	O
involved	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
aggregation	NN	O
mechanism	NN	O
is	VBZ	O
discovered	VBN	O
to	TO	O
be	VB	O
intermolecular	JJ	O
S—S	NNP	O
bond	NN	O
formation	NN	O
through	IN	O
thio-disulfide	JJ	O
interchange	NN	O
,	,	O
stabilization	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
modifying	VBG	O
sulfhydryl	NN	O
residues	NNS	O
,	,	O
lyophilizing	VBG	O
from	IN	O
acidic	JJ	O
solutions	NNS	O
,	,	O
controlling	VBG	O
moisture	NN	O
content	NN	O
,	,	O
using	VBG	O
appropriate	JJ	O
additives	NNS	O
,	,	O
and	CC	O
developing	VBG	O
specific	JJ	O
polymer	NN	O
matrix	NN	O
compositions	NNS	O
.	.	O
Oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
peptides	NNS	O
and	CC	O
peptide	NN	O
conjugates	NNS	O
is	VBZ	O
an	DT	O
intended	JJ	O
practice	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
oral	JJ	O
administration	NN	O
,	,	O
the	DT	O
pharmaceutical	JJ	O
composition	NN	O
may	MD	O
be	VB	O
in	IN	O
solid	JJ	O
or	CC	O
liquid	JJ	O
form	NN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
capsule	NN	O
,	,	O
tablet	NN	O
,	,	O
suspension	NN	O
,	,	O
emulsion	NN	O
or	CC	O
solution	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
composition	NN	O
is	VBZ	O
preferably	RB	O
made	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
dosage	NN	O
unit	NN	O
containing	VBG	O
a	DT	O
given	VBN	O
amount	NN	O
of	IN	O
the	DT	O
active	JJ	O
ingredient	NN	O
.	.	O
A	DT	O
suitable	JJ	O
daily	JJ	O
dose	NN	O
for	IN	O
a	DT	O
human	JJ	O
or	CC	O
other	JJ	O
mammal	NN	O
may	MD	O
vary	VB	O
widely	RB	O
depending	VBG	O
on	IN	O
the	DT	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
and	CC	O
other	JJ	O
factors	NNS	O
,	,	O
but	CC	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
persons	NNS	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
using	VBG	O
routine	JJ	O
methods	NNS	O
.	.	O
Solid	JJ	O
dosage	NN	O
forms	NNS	O
for	IN	O
oral	JJ	O
administration	NN	O
may	MD	O
include	VB	O
capsules	NNS	O
,	,	O
tablets	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
powders	NNS	O
and	CC	O
granules	NNS	O
.	.	O
In	IN	O
such	JJ	O
solid	JJ	O
dosage	NN	O
forms	NNS	O
,	,	O
the	DT	O
active	JJ	O
compound	NN	O
may	MD	O
be	VB	O
admixed	VBN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
inert	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
sucrose	NN	O
,	,	O
lactose	JJ	O
,	,	O
or	CC	O
starch	NN	O
.	.	O
Such	JJ	O
dosage	NN	O
forms	NNS	O
may	MD	O
also	RB	O
comprise	VB	O
,	,	O
as	IN	O
is	VBZ	O
normal	JJ	O
practice	NN	O
,	,	O
additional	JJ	O
substances	NNS	O
,	,	O
e.g.	NN	O
,	,	O
lubricating	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
magnesium	NN	O
stearate	NN	O
.	.	O
In	IN	O
the	DT	O
case	NN	O
of	IN	O
capsules	NNS	O
,	,	O
tablets	NNS	O
and	CC	O
pills	NNS	O
,	,	O
the	DT	O
dosage	NN	O
forms	NNS	O
may	MD	O
also	RB	O
comprise	VB	O
buffering	VBG	O
agents	NNS	O
.	.	O
Tablets	NNS	O
and	CC	O
pills	NNS	O
can	MD	O
additionally	RB	O
be	VB	O
prepared	VBN	O
with	IN	O
enteric	JJ	O
coatings	NNS	O
.	.	O
The	DT	O
polypeptides	NNS	O
or	CC	O
conjugates	NNS	O
may	MD	O
be	VB	O
admixed	VBN	O
with	IN	O
adjuvants	NNS	O
such	JJ	O
as	IN	O
lactose	JJ	O
,	,	O
sucrose	JJ	O
,	,	O
starch	JJ	O
powder	NN	O
,	,	O
cellulose	JJ	O
esters	NNS	O
of	IN	O
alkanoic	JJ	O
acids	NNS	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
talc	NN	O
,	,	O
magnesium	NN	O
stearate	NN	O
,	,	O
magnesium	NN	O
oxide	NN	O
,	,	O
sodium	NN	O
and	CC	O
calcium	NN	O
salts	NNS	O
of	IN	O
phosphoric	NN	O
and	CC	O
sulphuric	JJ	O
acids	NNS	O
,	,	O
acacia	NN	O
,	,	O
gelatin	NN	O
,	,	O
sodium	NN	O
alginate	NN	O
,	,	O
polyvinyl-pyrrolidine	NN	O
,	,	O
and/or	JJ	O
polyvinyl	NN	O
alcohol	NN	O
,	,	O
and	CC	O
tableted	VBD	O
or	CC	O
encapsulated	VBN	O
for	IN	O
conventional	JJ	O
administration	NN	O
.	.	O
Alternatively	RB	O
,	,	O
they	PRP	O
may	MD	O
be	VB	O
dissolved	VBN	O
in	IN	O
saline	NN	O
,	,	O
water	NN	O
,	,	O
polyethylene	NN	O
glycol	NN	O
,	,	O
propylene	NN	O
glycol	NN	O
,	,	O
ethanol	NN	O
,	,	O
oils	NNS	O
(	(	O
such	JJ	O
as	IN	O
corn	NN	O
oil	NN	O
,	,	O
peanut	NN	O
oil	NN	O
,	,	O
cottonseed	VB	O
oil	NN	O
or	CC	O
sesame	VB	O
oil	NN	O
)	)	O
,	,	O
tragacanth	JJ	O
gum	NN	O
,	,	O
and/or	RB	O
various	JJ	O
buffers	NNS	O
.	.	O
Other	JJ	O
adjuvants	NNS	O
and	CC	O
modes	NNS	O
of	IN	O
administration	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
pharmaceutical	JJ	O
art	NN	O
.	.	O
The	DT	O
carrier	NN	O
or	CC	O
diluent	NN	O
may	MD	O
include	VB	O
time	NN	O
delay	JJ	O
material	NN	O
,	,	O
such	JJ	O
as	IN	O
glyceryl	JJ	O
monostearate	NN	O
or	CC	O
glyceryl	JJ	O
distearate	NN	O
alone	RB	O
or	CC	O
with	IN	O
a	DT	O
wax	NN	O
,	,	O
or	CC	O
other	JJ	O
materials	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
may	MD	O
be	VB	O
subjected	VBN	O
to	TO	O
conventional	JJ	O
pharmaceutical	JJ	O
operations	NNS	O
such	JJ	O
as	IN	O
sterilization	NN	O
and/or	NN	O
may	MD	O
contain	VB	O
conventional	JJ	O
adjuvants	NNS	O
such	JJ	O
as	IN	O
preservatives	NNS	O
,	,	O
stabilizers	NNS	O
,	,	O
wetting	VBG	O
agents	NNS	O
,	,	O
emulsifiers	NNS	O
,	,	O
buffers	NNS	O
,	,	O
fillers	NNS	O
,	,	O
etc.	FW	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
disclosed	VBN	O
elsewhere	RB	O
herein	NN	O
.	.	O
Liquid	NNP	O
dosage	NN	O
forms	NNS	O
for	IN	O
oral	JJ	O
administration	NN	O
may	MD	O
include	VB	O
pharmaceutically	RB	O
acceptable	JJ	O
emulsions	NNS	O
,	,	O
solutions	NNS	O
,	,	O
suspensions	NNS	O
,	,	O
syrups	NNS	O
and	CC	O
elixirs	NNS	O
containing	VBG	O
inert	JJ	O
diluents	NNS	O
commonly	RB	O
used	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
water	NN	O
.	.	O
Such	JJ	O
compositions	NNS	O
may	MD	O
also	RB	O
comprise	VB	O
adjuvants	NNS	O
such	JJ	O
as	IN	O
wetting	VBG	O
agents	NNS	O
,	,	O
sweeteners	NNS	O
,	,	O
flavoring	VBG	O
agents	NNS	O
and	CC	O
perfuming	VBG	O
agents	NNS	O
.	.	O
Formulations	NNS	O
suitable	JJ	O
for	IN	O
pulmonary	JJ	O
administration	NN	O
are	VBP	O
intended	VBN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Formulations	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
with	IN	O
a	DT	O
nebulizer	NN	O
,	,	O
either	CC	O
jet	NN	O
or	CC	O
ultrasonic	JJ	O
,	,	O
will	MD	O
typically	RB	O
comprise	VB	O
the	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
dissolved	VBN	O
in	IN	O
water	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
,	,	O
e.g.	UH	O
,	,	O
about	RB	O
0.01	CD	O
to	TO	O
25	CD	O
mg	NN	O
of	IN	O
conjugate	NN	O
per	IN	O
mL	NN	O
of	IN	O
solution	NN	O
,	,	O
preferably	RB	O
about	IN	O
0.1	CD	O
to	TO	O
10	CD	O
mg/mL	NNS	O
.	.	O
The	DT	O
formulation	NN	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
buffer	NN	O
and	CC	O
a	DT	O
simple	JJ	O
sugar	NN	O
(	(	O
e.g.	NN	O
,	,	O
for	IN	O
protein	JJ	O
stabilization	NN	O
and	CC	O
regulation	NN	O
of	IN	O
osmotic	JJ	O
pressure	NN	O
)	)	O
,	,	O
and/or	JJ	O
human	JJ	O
serum	NN	O
albumin	NN	O
ranging	VBG	O
in	IN	O
concentration	NN	O
from	IN	O
0.1	CD	O
to	TO	O
10	CD	O
mg/ml	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
buffers	NNS	O
that	WDT	O
may	MD	O
be	VB	O
used	VBN	O
are	VBP	O
sodium	JJ	O
acetate	NN	O
,	,	O
citrate	NN	O
and	CC	O
glycine	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
buffer	NN	O
will	MD	O
have	VB	O
a	DT	O
composition	NN	O
and	CC	O
molarity	NN	O
suitable	JJ	O
to	TO	O
adjust	VB	O
the	DT	O
solution	NN	O
to	TO	O
a	DT	O
pH	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
3	CD	O
to	TO	O
9	CD	O
.	.	O
Generally	RB	O
,	,	O
buffer	JJR	O
molarities	NNS	O
of	IN	O
from	IN	O
1	CD	O
mM	NNS	O
to	TO	O
50	CD	O
mM	NNS	O
are	VBP	O
suitable	JJ	O
for	IN	O
this	DT	O
purpose	NN	O
.	.	O
Examples	NNS	O
of	IN	O
sugars	NNS	O
which	WDT	O
can	MD	O
be	VB	O
utilized	VBN	O
are	VBP	O
lactose	JJ	O
,	,	O
maltose	JJ	O
,	,	O
mannitol	NN	O
,	,	O
sorbitol	NN	O
,	,	O
trehalose	NN	O
,	,	O
and	CC	O
xylose	RB	O
,	,	O
usually	RB	O
in	IN	O
amounts	NNS	O
ranging	VBG	O
from	IN	O
1	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
by	IN	O
weight	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
The	DT	O
nebulizer	JJ	O
formulation	NN	O
may	MD	O
also	RB	O
contain	VB	O
a	DT	O
surfactant	NN	O
to	TO	O
reduce	VB	O
or	CC	O
prevent	VB	O
surface	NN	O
induced	JJ	O
aggregation	NN	O
of	IN	O
the	DT	O
protein	NN	O
caused	VBN	O
by	IN	O
atomization	NN	O
of	IN	O
the	DT	O
solution	NN	O
in	IN	O
forming	VBG	O
the	DT	O
aerosol	NN	O
.	.	O
Various	JJ	O
conventional	JJ	O
surfactants	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
,	,	O
such	JJ	O
as	IN	O
polyoxyethylene	NN	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
and	CC	O
alcohols	NNS	O
,	,	O
and	CC	O
polyoxyethylene	JJ	O
sorbitan	NN	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
.	.	O
Amounts	NNS	O
will	MD	O
generally	RB	O
range	VB	O
between	IN	O
0.001	CD	O
%	NN	O
and	CC	O
4	CD	O
%	NN	O
by	IN	O
weight	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
An	DT	O
especially	RB	O
preferred	JJ	O
surfactant	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
this	DT	O
invention	NN	O
is	VBZ	O
polyoxyethylene	JJ	O
sorbitan	JJ	O
monooleate	NN	O
.	.	O
Specific	JJ	O
formulations	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
generating	VBG	O
suitable	JJ	O
dispersions	NNS	O
of	IN	O
liquid	JJ	O
particles	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
described	VBN	O
in	IN	O
WO	NNP	O
94/20069	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,915,378	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,960,792	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,957,124	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,934,272	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,915,378	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,855,564	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,826,570	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,522,385	CD	O
which	WDT	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Formulations	NNS	O
for	IN	O
use	NN	O
with	IN	O
a	DT	O
metered	VBN	O
dose	NN	O
inhaler	NN	O
device	NN	O
will	MD	O
generally	RB	O
comprise	VB	O
a	DT	O
finely	RB	O
divided	VBN	O
powder	NN	O
.	.	O
This	DT	O
powder	NN	O
may	MD	O
be	VB	O
produced	VBN	O
by	IN	O
lyophilizing	VBG	O
and	CC	O
then	RB	O
milling	VBG	O
a	DT	O
liquid	JJ	O
conjugate	NN	O
formulation	NN	O
and	CC	O
may	MD	O
also	RB	O
contain	VB	O
a	DT	O
stabilizer	NN	O
such	JJ	O
as	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
(	(	O
HSA	NNP	O
)	)	O
.	.	O
Typically	RB	O
,	,	O
more	JJR	O
than	IN	O
0.5	CD	O
%	NN	O
(	(	O
w/w	NN	O
)	)	O
HSA	NNP	O
is	VBZ	O
added	VBN	O
.	.	O
Additionally	RB	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
sugars	NNS	O
or	CC	O
sugar	NN	O
alcohols	NNS	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
preparation	NN	O
if	IN	O
necessary	JJ	O
.	.	O
Examples	NNS	O
include	VBP	O
lactose	JJ	O
maltose	JJ	O
,	,	O
mannitol	NN	O
,	,	O
sorbitol	NN	O
,	,	O
sorbitose	RB	O
,	,	O
trehalose	RB	O
,	,	O
xylitol	NNP	O
,	,	O
and	CC	O
xylose	RB	O
.	.	O
The	DT	O
amount	NN	O
added	VBD	O
to	TO	O
the	DT	O
formulation	NN	O
can	MD	O
range	VB	O
from	IN	O
about	RB	O
0.01	CD	O
to	TO	O
200	CD	O
%	NN	O
(	(	O
w/w	NN	O
)	)	O
,	,	O
preferably	RB	O
from	IN	O
approximately	RB	O
1	CD	O
to	TO	O
50	CD	O
%	NN	O
,	,	O
of	IN	O
the	DT	O
conjugate	NN	O
present	NN	O
.	.	O
Such	JJ	O
formulations	NNS	O
are	VBP	O
then	RB	O
lyophilized	VBN	O
and	CC	O
milled	VBN	O
to	TO	O
the	DT	O
desired	VBN	O
particle	NN	O
size	NN	O
.	.	O
The	DT	O
properly	JJ	O
sized	VBN	O
particles	NNS	O
are	VBP	O
then	RB	O
suspended	VBN	O
in	IN	O
a	DT	O
propellant	NN	O
with	IN	O
the	DT	O
aid	NN	O
of	IN	O
a	DT	O
surfactant	NN	O
.	.	O
The	DT	O
propellant	NN	O
may	MD	O
be	VB	O
any	DT	O
conventional	JJ	O
material	NN	O
employed	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
chlorofluorocarbon	NN	O
,	,	O
a	DT	O
hydrochlorofluorocarbon	NN	O
,	,	O
a	DT	O
hydrofluorocarbon	NN	O
,	,	O
or	CC	O
a	DT	O
hydrocarbon	NN	O
,	,	O
including	VBG	O
trichlorofluoromethane	NN	O
,	,	O
dichlorodifluoromethane	NN	O
,	,	O
dichlorotetrafluoroethanol	NN	O
,	,	O
and	CC	O
1,1,1,2-tetrafluoroethane	JJ	O
,	,	O
or	CC	O
combinations	NNS	O
thereof	VBP	O
.	.	O
Suitable	JJ	O
surfactants	NNS	O
include	VBP	O
sorbitan	JJ	O
trioleate	NN	O
and	CC	O
soya	NN	O
lecithin	NN	O
.	.	O
Oleic	NNP	O
acid	NN	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
as	IN	O
a	DT	O
surfactant	NN	O
.	.	O
This	DT	O
mixture	NN	O
is	VBZ	O
then	RB	O
loaded	VBN	O
into	IN	O
the	DT	O
delivery	NN	O
device	NN	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
a	DT	O
commercially	RB	O
available	JJ	O
metered	VBN	O
dose	JJ	O
inhaler	NN	O
suitable	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
Ventolin	NNP	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Glaxo	NNP	O
Inc.	NNP	O
,	,	O
Research	NNP	O
Triangle	NNP	O
Park	NNP	O
,	,	O
N.C.	NNP	O
,	,	O
USA	NNP	O
.	.	O
Formulations	NNS	O
for	IN	O
powder	NN	O
inhalers	NNS	O
will	MD	O
comprise	VB	O
a	DT	O
finely	RB	O
divided	VBN	O
dry	JJ	O
powder	NN	O
containing	VBG	O
polypeptides	NNS	O
or	CC	O
polypeptide	VB	O
conjugates	NNS	O
and	CC	O
may	MD	O
also	RB	O
include	VB	O
a	DT	O
bulking	JJ	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
lactose	JJ	O
,	,	O
sorbitol	JJ	O
,	,	O
sucrose	JJ	O
,	,	O
or	CC	O
mannitol	NN	O
in	IN	O
amounts	NNS	O
which	WDT	O
facilitate	VBP	O
dispersal	NN	O
of	IN	O
the	DT	O
powder	NN	O
from	IN	O
the	DT	O
device	NN	O
,	,	O
e.g.	NN	O
,	,	O
50	CD	O
%	NN	O
to	TO	O
90	CD	O
%	NN	O
by	IN	O
weight	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
The	DT	O
particles	NNS	O
of	IN	O
the	DT	O
powder	NN	O
shall	MD	O
have	VB	O
aerodynamic	JJ	O
properties	NNS	O
in	IN	O
the	DT	O
lung	NN	O
corresponding	VBG	O
to	TO	O
particles	NNS	O
with	IN	O
a	DT	O
density	NN	O
of	IN	O
about	IN	O
1	CD	O
g/cm2	NNS	O
having	VBG	O
a	DT	O
median	JJ	O
diameter	NN	O
less	JJR	O
than	IN	O
10	CD	O
micrometers	NNS	O
,	,	O
preferably	RB	O
between	IN	O
0.5	CD	O
and	CC	O
5	CD	O
micrometers	NNS	O
,	,	O
most	JJS	O
preferably	RB	O
of	IN	O
between	IN	O
1.5	CD	O
and	CC	O
3.5	CD	O
micrometers	NNS	O
.	.	O
An	DT	O
example	NN	O
of	IN	O
a	DT	O
powder	NN	O
inhaler	NN	O
suitable	NN	O
for	IN	O
use	NN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
teachings	NNS	O
herein	NN	O
is	VBZ	O
the	DT	O
Spinhaler	NNP	O
powder	NN	O
inhaler	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Fisons	NNP	O
Corp.	NNP	O
,	,	O
Bedford	NNP	O
,	,	O
Mass.	NNP	O
,	,	O
USA	NNP	O
.	.	O
The	DT	O
powders	NNS	O
for	IN	O
these	DT	O
devices	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
and/or	RB	O
delivered	VBN	O
by	IN	O
methods	NNS	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,997,848	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,993,783	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,985,248	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,976,574	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,922,354	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,785,049	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,654,007	CD	O
.	.	O
Mechanical	JJ	O
devices	NNS	O
designed	VBN	O
for	IN	O
pulmonary	JJ	O
delivery	NN	O
of	IN	O
therapeutic	JJ	O
products	NNS	O
,	,	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
nebulizers	NNS	O
,	,	O
metered	VBD	O
dose	JJ	O
inhalers	NNS	O
,	,	O
and	CC	O
powder	NN	O
inhalers	NNS	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
familiar	JJ	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Specific	JJ	O
examples	NNS	O
of	IN	O
commercially	RB	O
available	JJ	O
devices	NNS	O
suitable	JJ	O
for	IN	O
the	DT	O
practice	NN	O
of	IN	O
this	DT	O
invention	NN	O
are	VBP	O
the	DT	O
Ultravent	NNP	O
nebulizer	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Mallinckrodt	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo.	NNP	O
,	,	O
USA	NNP	O
;	:	O
the	DT	O
Acorn	NNP	O
II	NNP	O
nebulizer	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Marquest	NNP	O
Medical	NNP	O
Products	NNP	O
,	,	O
Englewood	NNP	O
,	,	O
Colo.	NNP	O
,	,	O
USA	NNP	O
;	:	O
the	DT	O
Ventolin	NNP	O
metered	VBD	O
dose	JJ	O
inhaler	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Glaxo	NNP	O
Inc.	NNP	O
,	,	O
Research	NNP	O
Triangle	NNP	O
Park	NNP	O
,	,	O
N.C.	NNP	O
,	,	O
USA	NNP	O
;	:	O
the	DT	O
Spinhaler	NNP	O
powder	NN	O
inhaler	NN	O
,	,	O
manufactured	VBN	O
by	IN	O
Fisons	NNP	O
Corp.	NNP	O
,	,	O
Bedford	NNP	O
,	,	O
Mass.	NNP	O
,	,	O
USA	NNP	O
the	DT	O
“	NNP	O
standing	VBG	O
cloud	JJ	O
”	NNP	O
device	NN	O
of	IN	O
Nektar	NNP	O
Therapeutics	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
San	NNP	O
Carlos	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
USA	NNP	O
;	:	O
the	DT	O
AIR	NNP	O
inhaler	NN	O
manufactured	VBN	O
by	IN	O
Alkermes	NNP	O
,	,	O
Cambridge	NNP	O
,	,	O
Mass.	NNP	O
,	,	O
USA	NNP	O
;	:	O
and	CC	O
the	DT	O
AERx	NNP	O
pulmonary	JJ	O
drug	NN	O
delivery	NN	O
system	NN	O
manufactured	VBN	O
by	IN	O
Aradigm	NNP	O
Corporation	NNP	O
,	,	O
Hayward	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
USA	NNP	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
kits	NNS	O
including	VBG	O
the	DT	O
polypeptides	NNS	O
,	,	O
conjugates	NNS	O
,	,	O
polynucleotides	NNS	O
,	,	O
expression	NN	O
vectors	NNS	O
,	,	O
cells	NNS	O
,	,	O
methods	NNS	O
,	,	O
compositions	NNS	O
,	,	O
and	CC	O
systems	NNS	O
,	,	O
and	CC	O
apparatuses	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Kits	NNS	O
of	IN	O
the	DT	O
invention	NN	O
optionally	RB	O
comprise	VB	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
of	IN	O
the	DT	O
invention	NN	O
:	:	O
(	(	O
1	CD	O
)	)	O
an	DT	O
apparatus	NN	O
,	,	O
system	NN	O
,	,	O
system	NN	O
component	NN	O
,	,	O
or	CC	O
apparatus	RB	O
component	JJ	O
as	IN	O
described	JJ	O
herein	NN	O
;	:	O
(	(	O
2	CD	O
)	)	O
at	IN	O
least	JJS	O
one	CD	O
kit	NN	O
component	NN	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
or	CC	O
polynucleotide	NN	O
of	IN	O
the	DT	O
invention	NN	O
;	:	O
a	DT	O
plasmid	JJ	O
expression	NN	O
vector	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
;	:	O
a	DT	O
cell	NN	O
expressing	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
;	:	O
or	CC	O
a	DT	O
composition	NN	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
any	DT	O
such	JJ	O
component	NN	O
;	:	O
(	(	O
3	CD	O
)	)	O
instructions	NNS	O
for	IN	O
practicing	VBG	O
any	DT	O
method	NN	O
described	VBD	O
herein	NNS	O
,	,	O
including	VBG	O
a	DT	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
method	NN	O
,	,	O
instructions	NNS	O
for	IN	O
using	VBG	O
any	DT	O
component	NN	O
identified	VBN	O
in	IN	O
(	(	O
2	CD	O
)	)	O
or	CC	O
any	DT	O
composition	NN	O
of	IN	O
any	DT	O
such	JJ	O
component	NN	O
;	:	O
and/or	CC	O
instructions	NNS	O
for	IN	O
operating	VBG	O
any	DT	O
apparatus	NN	O
,	,	O
system	NN	O
or	CC	O
component	NN	O
described	VBN	O
herein	NN	O
;	:	O
(	(	O
4	CD	O
)	)	O
a	DT	O
container	NN	O
for	IN	O
holding	VBG	O
said	VBD	O
at	IN	O
least	JJS	O
one	CD	O
such	JJ	O
component	NN	O
or	CC	O
composition	NN	O
,	,	O
and	CC	O
(	(	O
5	CD	O
)	)	O
packaging	NN	O
materials	NNS	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
apparatus	NN	O
,	,	O
component	NN	O
,	,	O
composition	NN	O
,	,	O
or	CC	O
kit	VB	O
described	VBN	O
above	IN	O
and	CC	O
herein	NN	O
,	,	O
for	IN	O
the	DT	O
practice	NN	O
of	IN	O
any	DT	O
method	NN	O
or	CC	O
assay	VB	O
described	VBN	O
herein	RB	O
,	,	O
and/or	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
apparatus	NN	O
,	,	O
component	NN	O
,	,	O
composition	NN	O
,	,	O
or	CC	O
kit	VB	O
to	TO	O
practice	NN	O
any	DT	O
assay	NN	O
or	CC	O
method	NN	O
described	VBN	O
herein	NN	O
.	.	O
Chemical	NNP	O
Modifications	NNP	O
,	,	O
Conjugates	NNP	O
,	,	O
and	CC	O
Fusions	NNP	O
Any	NNP	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
present	JJ	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
larger	JJR	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
e.g	NN	O
.	.	O
a	DT	O
fusion	NN	O
protein	NN	O
,	,	O
such	JJ	O
as	IN	O
occurs	NNS	O
upon	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
domains	NNS	O
or	CC	O
subsequences	NNS	O
for	IN	O
stabilization	NN	O
or	CC	O
detection	NN	O
or	CC	O
purification	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
A	DT	O
polypeptide	JJ	O
purification	NN	O
subsequence	NN	O
may	MD	O
include	VB	O
,	,	O
e.g.	FW	O
,	,	O
an	DT	O
epitope	NN	O
tag	NN	O
,	,	O
a	DT	O
FLAG	NNP	O
tag	NN	O
,	,	O
a	DT	O
polyhistidine	NN	O
sequence	NN	O
,	,	O
a	DT	O
GST	NNP	O
fusion	NN	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
detection/purification	NN	O
subsequence	NN	O
or	CC	O
“	VB	O
tag	JJ	O
”	NNP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
These	DT	O
additional	JJ	O
domains	NNS	O
or	CC	O
subsequences	NNS	O
either	CC	O
have	VBP	O
little	JJ	O
or	CC	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
removed	VBN	O
by	IN	O
post	NN	O
synthesis	NN	O
processing	VBG	O
steps	NNS	O
such	JJ	O
as	IN	O
by	IN	O
treatment	NN	O
with	IN	O
a	DT	O
protease	NN	O
,	,	O
inclusion	NN	O
of	IN	O
an	DT	O
intein	NN	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
invention	NN	O
includes	VBZ	O
fusion	NN	O
proteins	NNS	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
,	,	O
fused	VBD	O
to	TO	O
an	DT	O
Ig	NNP	O
molecule	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
human	JJ	O
IgG	NNP	O
Fc	NNP	O
(	(	O
“	JJ	O
fragment	NN	O
crystallizable	NN	O
,	,	O
”	''	O
or	CC	O
fragment	JJ	O
complement	NN	O
binding	VBG	O
)	)	O
hinge	NN	O
,	,	O
CH2	NNP	O
domain	NN	O
and	CC	O
CH3	NNP	O
domain	NN	O
,	,	O
and	CC	O
nucleotide	RB	O
sequences	NNS	O
encoding	VBG	O
such	JJ	O
fusion	NN	O
protein	NN	O
.	.	O
Fc	NNP	O
is	VBZ	O
the	DT	O
portion	NN	O
of	IN	O
the	DT	O
antibody	NN	O
responsible	JJ	O
for	IN	O
binding	VBG	O
to	TO	O
antibody	NN	O
receptors	NNS	O
on	IN	O
cells	NNS	O
and	CC	O
the	DT	O
C1q	NNP	O
component	NN	O
of	IN	O
complement	NN	O
.	.	O
These	DT	O
fusion	NN	O
proteins	NNS	O
and	CC	O
their	PRP$	O
encoding	NN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
useful	JJ	O
as	IN	O
prophylactic	JJ	O
and/or	NN	O
therapeutic	JJ	O
drugs	NNS	O
or	CC	O
as	IN	O
diagnostic	JJ	O
tools	NNS	O
(	(	O
see	VB	O
also	RB	O
,	,	O
e.g.	RB	O
,	,	O
Challita-Eid	NNP	B
,	,	I
P.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1998	CD	I
)	)	I
J.	NNP	I
Immunol	NNP	I
.	.	I
160:3419-3426	JJ	I
;	:	O
Sturmhoefel	NNP	B
,	,	I
K.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1999	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
59:4964-4972	CD	I
)	)	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
includes	VBZ	O
fusion	NN	O
proteins	NNS	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
fused	VBN	O
to	TO	O
an	DT	O
albumin	NN	O
molecule	NN	O
,	,	O
such	JJ	O
as	IN	O
human	JJ	O
serum	NN	O
albumin	NN	O
(	(	O
HSA	NNP	O
)	)	O
,	,	O
as	IN	O
described	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,876,969	CD	O
,	,	O
and	CC	O
nucleotide	RB	O
sequences	NNS	O
encoding	VBG	O
the	DT	O
fusion	NN	O
protein	NN	O
.	.	O
The	DT	O
Ig	NNP	O
and	CC	O
albumin	JJ	O
fusion	NN	O
proteins	NNS	O
may	MD	O
exhibit	VB	O
increased	JJ	O
polypeptide	NN	O
serum	VBD	O
half-life	JJ	O
and/or	JJ	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
,	,	O
reduced	VBD	O
polypeptide	JJ	O
antigenicity	NN	O
,	,	O
increased	VBD	O
polypeptide	JJ	O
storage	NN	O
stability	NN	O
,	,	O
or	CC	O
increasing	VBG	O
bioavailability	NN	O
,	,	O
e.g	NN	O
.	.	O
increased	VBN	O
AUCsc	NNP	O
,	,	O
and	CC	O
are	VBP	O
thus	RB	O
may	MD	O
be	VB	O
useful	JJ	O
as	IN	O
prophylactic	JJ	O
and/or	NN	O
therapeutic	JJ	O
drugs	NNS	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
an	DT	O
inherent	JJ	O
ability	NN	O
to	TO	O
transduce	VB	O
across	IN	O
cellular	JJ	O
membranes	NNS	O
and	CC	O
affect	JJ	O
therapeutic	JJ	O
functions	NNS	O
within	IN	O
cells	NNS	O
.	.	O
The	DT	O
invention	NN	O
therefore	RB	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
enhance	VB	O
the	DT	O
cell	NN	O
permeability	NN	O
or	CC	O
transducibility	NN	O
of	IN	O
any	DT	O
other	JJ	O
molecule	NN	O
.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
any	DT	O
fragment	NN	O
or	CC	O
subfragment	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
enhance	VB	O
the	DT	O
cell	NN	O
permeability	NN	O
of	IN	O
any	DT	O
other	JJ	O
molecule	NN	O
,	,	O
such	JJ	O
fragments	NNS	O
or	CC	O
subfragments	NNS	O
being	VBG	O
of	IN	O
about	IN	O
5	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
of	IN	O
about	IN	O
10	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
such	JJ	O
as	IN	O
15	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
e.g	NN	O
.	.	O
about	IN	O
20	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
of	IN	O
about	IN	O
25	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
of	IN	O
about	IN	O
30	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
such	JJ	O
as	IN	O
35	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
of	IN	O
about	IN	O
35-50	JJ	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
of	IN	O
about	IN	O
50-100	JJ	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
such	JJ	O
as	IN	O
75	CD	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
e.g	NN	O
.	.	O
100-125	JJ	O
amino	NN	O
acids	NNS	O
in	IN	O
length	NN	O
.	.	O
Any	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
comprise	VB	O
one	CD	O
or	CC	O
more	JJR	O
modified	JJ	O
amino	NN	O
acid	NN	O
.	.	O
The	DT	O
modified	VBN	O
amino	NN	O
acid	NN	O
may	MD	O
be	VB	O
,	,	O
e.g.	VB	O
,	,	O
a	DT	O
glycosylated	JJ	O
amino	NN	O
acid	NN	O
,	,	O
a	DT	O
PEGylated	NNP	O
amino	NN	O
acid	NN	O
,	,	O
a	DT	O
farnesylated	JJ	O
amino	NN	O
acid	NN	O
,	,	O
an	DT	O
acetylated	JJ	O
amino	NN	O
acid	NN	O
,	,	O
a	DT	O
biotinylated	VBN	O
amino	NN	O
acid	NN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
conjugated	VBD	O
to	TO	O
a	DT	O
lipid	JJ	O
moiety	NN	O
,	,	O
or	CC	O
an	DT	O
amino	JJ	O
acid	NN	O
conjugated	VBD	O
to	TO	O
an	DT	O
organic	JJ	O
derivatizing	NN	O
agent	NN	O
.	.	O
The	DT	O
presence	NN	O
of	IN	O
modified	VBN	O
amino	NN	O
acids	NNS	O
may	MD	O
be	VB	O
advantageous	JJ	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
(	(	O
a	DT	O
)	)	O
increasing	VBG	O
polypeptide	JJ	O
serum	NN	O
half-life	JJ	O
and/or	JJ	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
,	,	O
(	(	O
b	NN	O
)	)	O
reducing	VBG	O
polypeptide	JJ	O
antigenicity	NN	O
,	,	O
(	(	O
c	NN	O
)	)	O
increasing	VBG	O
polypeptide	JJ	O
storage	NN	O
stability	NN	O
,	,	O
or	CC	O
(	(	O
d	NN	O
)	)	O
increasing	VBG	O
bioavailability	NN	O
,	,	O
e.g	NN	O
.	.	O
increasing	VBG	O
the	DT	O
AUCsc	NNP	O
.	.	O
Amino	NNP	O
acid	NN	O
(	(	O
s	NN	O
)	)	O
are	VBP	O
modified	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
co-translationally	RB	O
or	CC	O
post-translationally	RB	O
during	IN	O
recombinant	JJ	O
production	NN	O
(	(	O
e.g.	JJ	O
,	,	O
N-linked	JJ	O
glycosylation	NN	O
at	IN	O
N-X-S/T	NNP	O
motifs	NNS	O
during	IN	O
expression	NN	O
in	IN	O
mammalian	JJ	O
cells	NNS	O
)	)	O
or	CC	O
modified	VBN	O
by	IN	O
synthetic	JJ	O
means	NNS	O
.	.	O
Pegylated	NNP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
modifications	NNS	O
described	VBD	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
and	CC	O
as	RB	O
implemented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
a	DT	O
conjugate	NN	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
non-polypeptide	JJ	O
moiety	NN	O
attached	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
,	,	O
such	JJ	O
as	IN	O
e.g	NN	O
.	.	O
those	DT	O
modified	VBN	O
polypeptides	NNS	O
described	VBD	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
and	CC	O
as	RB	O
implemented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
polypeptides	NNS	O
that	WDT	O
differ	VBP	O
from	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
by	IN	O
1	CD	O
to	TO	O
34	CD	O
amino	NN	O
acid	JJ	O
substitutions	NNS	O
or	CC	O
insertions	NNS	O
where	WRB	O
such	JJ	O
substitutions	NNS	O
or	CC	O
insertions	NNS	O
introduce	VBP	O
one	CD	O
or	CC	O
more	JJR	O
attachment	JJ	O
groups	NNS	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
substitution	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
for	IN	O
a	DT	O
different	JJ	O
residue	NN	O
which	WDT	O
comprises	VBZ	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
,	,	O
or	CC	O
by	IN	O
insertion	NN	O
of	IN	O
an	DT	O
additional	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
which	WDT	O
comprises	VBZ	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
conjugate	NN	O
”	NNP	O
(	(	O
or	CC	O
interchangeably	RB	O
“	JJ	O
polypeptide	NN	O
conjugate	NN	O
”	NN	O
or	CC	O
“	NN	O
conjugated	VBN	O
polypeptide	IN	O
”	NNP	O
)	)	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
a	DT	O
heterogeneous	JJ	O
(	(	O
in	IN	O
the	DT	O
sense	NN	O
of	IN	O
composite	JJ	O
)	)	O
molecule	NN	O
formed	VBN	O
by	IN	O
the	DT	O
covalent	JJ	O
attachment	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
non-polypeptide	JJ	O
moieties	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
covalent	NN	O
attachment	NN	O
”	NN	O
means	VBZ	O
that	IN	O
the	DT	O
polypeptide	NN	O
and	CC	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
are	VBP	O
either	DT	O
directly	RB	O
covalently	RB	O
joined	VBN	O
to	TO	O
one	CD	O
another	DT	O
,	,	O
or	CC	O
else	RB	O
are	VBP	O
indirectly	RB	O
covalently	RB	O
joined	VBN	O
to	TO	O
one	CD	O
another	DT	O
through	IN	O
an	DT	O
intervening	JJ	O
moiety	NN	O
or	CC	O
moieties	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
bridge	NN	O
,	,	O
spacer	NN	O
,	,	O
or	CC	O
linkage	VB	O
moiety	NN	O
or	CC	O
moieties	NNS	O
.	.	O
Preferably	RB	O
,	,	O
a	DT	O
conjugated	JJ	O
polypeptide	NN	O
is	VBZ	O
soluble	JJ	O
at	IN	O
relevant	JJ	O
concentrations	NNS	O
and	CC	O
conditions	NNS	O
,	,	O
i.e	NN	O
.	.	O
soluble	JJ	O
in	IN	O
physiological	JJ	O
fluids	NNS	O
such	JJ	O
as	IN	O
blood	NN	O
.	.	O
Examples	NNS	O
of	IN	O
conjugated	JJ	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
glycosylated	VBN	O
and/or	RB	O
PEGylated	NNP	O
polypeptides	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
non-conjugated	JJ	O
polypeptide	NN	O
”	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
polypeptide	JJ	O
part	NN	O
of	IN	O
the	DT	O
conjugated	JJ	O
polypeptide	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
non-polypeptide	JJ	O
moiety	NN	O
”	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
mean	VB	O
a	DT	O
molecule	NN	O
that	WDT	O
is	VBZ	O
capable	JJ	O
of	IN	O
conjugating	VBG	O
to	TO	O
an	DT	O
attachment	JJ	O
group	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Preferred	NNP	O
examples	NNS	O
of	IN	O
non-polypeptide	JJ	O
moieties	NNS	O
include	VBP	O
polymer	JJ	O
molecules	NNS	O
,	,	O
sugar	NN	O
moieties	NNS	O
,	,	O
lipophilic	JJ	O
compounds	NNS	O
,	,	O
or	CC	O
organic	JJ	O
derivatizing	NN	O
agents	NNS	O
,	,	O
in	IN	O
particular	JJ	O
polymer	NN	O
molecules	NNS	O
or	CC	O
sugar	NN	O
moieties	NNS	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
understood	JJ	O
that	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
through	IN	O
an	DT	O
attachment	JJ	O
group	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Except	IN	O
where	WRB	O
the	DT	O
number	NN	O
of	IN	O
non-polypeptide	JJ	O
moieties	NNS	O
,	,	O
such	JJ	O
as	IN	O
polymer	NN	O
molecule	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
attached	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
expressly	RB	O
indicated	VBN	O
,	,	O
every	DT	O
reference	NN	O
to	TO	O
“	VB	O
a	DT	O
non-polypeptide	JJ	O
moiety	NN	O
”	NN	O
attached	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
or	CC	O
otherwise	RB	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
shall	MD	O
be	VB	O
a	DT	O
reference	NN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
non-polypeptide	JJ	O
moieties	NNS	O
attached	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
polymer	NN	O
molecule	NN	O
”	NNP	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
molecule	NN	O
formed	VBN	O
by	IN	O
covalent	JJ	O
linkage	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
monomers	NNS	O
,	,	O
wherein	VBP	O
none	NN	O
of	IN	O
the	DT	O
monomers	NNS	O
is	VBZ	O
an	DT	O
amino	JJ	O
acid	NN	O
residue	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
polymer	NN	O
”	NN	O
may	MD	O
be	VB	O
used	VBN	O
interchangeably	RB	O
with	IN	O
the	DT	O
term	NN	O
“	NNP	O
polymer	NN	O
molecule	NN	O
”	NNP	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
sugar	NN	O
moiety	NN	O
”	NNP	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
a	DT	O
carbohydrate	NN	O
molecule	NN	O
attached	VBN	O
by	IN	O
in	IN	O
vivo	NN	O
or	CC	O
in	IN	O
vitro	JJ	O
glycosylation	NN	O
,	,	O
such	JJ	O
as	IN	O
N-	NNP	O
or	CC	O
O-glycosylation	NNP	O
.	.	O
An	DT	O
“	JJ	O
N-glycosylation	NNP	O
site	NN	O
”	NN	O
has	VBZ	O
the	DT	O
sequence	NN	O
N-X-S/T/C	NNP	O
,	,	O
wherein	NN	O
X	NNP	O
is	VBZ	O
any	DT	O
amino	JJ	O
acid	NN	O
residue	JJ	O
except	IN	O
proline	NN	O
,	,	O
N	NNP	O
is	VBZ	O
asparagine	JJ	O
and	CC	O
S/T/C	NNP	O
is	VBZ	O
either	DT	O
serine	NN	O
,	,	O
threonine	NN	O
or	CC	O
cysteine	NN	O
,	,	O
preferably	RB	O
serine	NN	O
or	CC	O
threonine	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
threonine	NN	O
.	.	O
An	DT	O
“	JJ	O
O-glycosylation	NNP	O
site	NN	O
”	NN	O
comprises	VBZ	O
the	DT	O
OH-group	NNP	O
of	IN	O
a	DT	O
serine	NN	O
or	CC	O
threonine	NN	O
residue	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
attachment	NN	O
group	NN	O
”	NNP	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
an	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
group	NN	O
capable	JJ	O
of	IN	O
coupling	VBG	O
to	TO	O
the	DT	O
relevant	JJ	O
non-polypeptide	JJ	O
moiety	NN	O
such	JJ	O
as	IN	O
a	DT	O
polymer	NN	O
molecule	NN	O
or	CC	O
a	DT	O
sugar	JJ	O
moiety	NN	O
.	.	O
For	IN	O
in	IN	O
vivo	JJ	O
N-glycosylation	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
attachment	NN	O
group	NN	O
”	NNP	O
is	VBZ	O
used	VBN	O
in	IN	O
an	DT	O
unconventional	JJ	O
way	NN	O
to	TO	O
indicate	VB	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
constituting	VBG	O
an	DT	O
N-glycosylation	JJ	O
site	NN	O
(	(	O
with	IN	O
the	DT	O
sequence	NN	O
N-X-S/T/C	NNP	O
,	,	O
wherein	NN	O
X	NNP	O
is	VBZ	O
any	DT	O
amino	JJ	O
acid	NN	O
residue	JJ	O
except	IN	O
proline	NN	O
,	,	O
N	NNP	O
is	VBZ	O
asparagine	JJ	O
and	CC	O
S/T/C	NNP	O
is	VBZ	O
either	DT	O
serine	NN	O
,	,	O
threonine	NN	O
or	CC	O
cysteine	NN	O
,	,	O
preferably	RB	O
serine	NN	O
or	CC	O
threonine	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
threonine	NN	O
)	)	O
.	.	O
Although	IN	O
the	DT	O
asparagine	JJ	O
residue	NN	O
of	IN	O
the	DT	O
N-glycosylation	NNP	O
site	NN	O
is	VBZ	O
the	DT	O
one	NN	O
to	TO	O
which	WDT	O
the	DT	O
sugar	NN	O
moiety	NN	O
is	VBZ	O
attached	VBN	O
during	IN	O
glycosylation	NN	O
,	,	O
such	JJ	O
attachment	NN	O
can	MD	O
not	RB	O
be	VB	O
achieved	VBN	O
unless	IN	O
the	DT	O
other	JJ	O
amino	NN	O
acid	IN	O
residues	NNS	O
of	IN	O
the	DT	O
N-glycosylation	NNP	O
site	NN	O
is	VBZ	O
present	JJ	O
.	.	O
Accordingly	RB	O
,	,	O
when	WRB	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
a	DT	O
sugar	NN	O
moiety	NN	O
and	CC	O
the	DT	O
conjugation	NN	O
is	VBZ	O
to	TO	O
be	VB	O
achieved	VBN	O
by	IN	O
N-glycosylation	NNP	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
”	NN	O
as	IN	O
used	VBN	O
in	IN	O
connection	NN	O
with	IN	O
alterations	NNS	O
of	IN	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
to	TO	O
be	VB	O
understood	JJ	O
as	IN	O
one	CD	O
,	,	O
two	CD	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
constituting	VBG	O
an	DT	O
N-glycosylation	JJ	O
site	NN	O
is/are	NN	O
to	TO	O
be	VB	O
altered	VBN	O
in	IN	O
such	JJ	O
a	DT	O
manner	NN	O
that	IN	O
either	CC	O
a	DT	O
functional	JJ	O
N-glycosylation	NNP	O
site	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
,	,	O
removed	VBN	O
from	IN	O
said	VBD	O
sequence	NN	O
,	,	O
or	CC	O
a	DT	O
functional	JJ	O
N-glycosylation	NNP	O
site	NN	O
is	VBZ	O
retained	VBN	O
in	IN	O
the	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
(	(	O
e.g	NN	O
.	.	O
by	IN	O
substituting	VBG	O
a	DT	O
serine	NN	O
residue	NN	O
,	,	O
which	WDT	O
already	RB	O
constitutes	VBZ	O
part	NN	O
of	IN	O
an	DT	O
N-glycosylation	NNP	O
site	NN	O
,	,	O
with	IN	O
a	DT	O
threonine	NN	O
residue	NN	O
and	CC	O
vice	NN	O
versa	NN	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
introduce	NN	O
”	NNP	O
(	(	O
i.e.	FW	O
,	,	O
an	DT	O
“	NN	O
introduced	VBD	O
”	NNP	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
“	JJ	O
introduction	NN	O
”	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
)	)	O
is	VBZ	O
primarily	RB	O
intended	VBN	O
to	TO	O
mean	VB	O
substitution	NN	O
of	IN	O
an	DT	O
existing	VBG	O
amino	NN	O
acid	NN	O
residue	NN	O
for	IN	O
another	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
but	CC	O
may	MD	O
also	RB	O
mean	VB	O
insertion	NN	O
of	IN	O
an	DT	O
additional	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
remove	VB	O
”	NNP	O
(	(	O
i.e.	FW	O
,	,	O
a	DT	O
“	NN	O
removed	VBN	O
”	NNP	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
“	NNP	O
removal	NN	O
”	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
)	)	O
is	VBZ	O
primarily	RB	O
intended	VBN	O
to	TO	O
mean	VB	O
substitution	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
to	TO	O
be	VB	O
removed	VBN	O
for	IN	O
another	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
but	CC	O
may	MD	O
also	RB	O
mean	VB	O
deletion	NN	O
(	(	O
without	IN	O
substitution	NN	O
)	)	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
to	TO	O
be	VB	O
removed	VBN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
”	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
indicate	VB	O
that	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
is	VBZ	O
one	CD	O
to	TO	O
which	WDT	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
binds	NNS	O
(	(	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
an	DT	O
introduced	JJ	O
amino	NN	O
acid	NNS	O
residue	VBP	O
)	)	O
or	CC	O
would	MD	O
have	VB	O
bound	VBN	O
(	(	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
a	DT	O
removed	VBN	O
amino	NN	O
acid	NN	O
residue	NN	O
)	)	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
”	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
its	PRP$	O
normal	JJ	O
meaning	NN	O
,	,	O
i.e	NN	O
.	.	O
the	DT	O
time	NN	O
at	IN	O
which	WDT	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
still	RB	O
present	JJ	O
in	IN	O
the	DT	O
body/target	NN	O
organ	NN	O
,	,	O
or	CC	O
the	DT	O
time	NN	O
at	IN	O
which	WDT	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
initial	JJ	O
value	NN	O
.	.	O
The	DT	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	NN	O
may	MD	O
be	VB	O
determined	VBN	O
in	IN	O
an	DT	O
experimental	JJ	O
animal	NN	O
,	,	O
such	JJ	O
as	IN	O
rat	NN	O
,	,	O
mouse	NN	O
,	,	O
rabbit	NN	O
,	,	O
dog	NN	O
or	CC	O
monkey	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
is	VBZ	O
determined	VBN	O
in	IN	O
a	DT	O
non-human	JJ	O
primate	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
monkey	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
may	MD	O
be	VB	O
determined	VBN	O
for	IN	O
a	DT	O
sample	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
administered	VBN	O
intravenously	RB	O
or	CC	O
subcutaneously	RB	O
.	.	O
As	IN	O
an	DT	O
alternative	NN	O
to	TO	O
determining	VBG	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	NN	O
,	,	O
“	JJ	O
serum	NN	O
half-life	JJ	O
”	NN	O
may	MD	O
be	VB	O
determined	VBN	O
,	,	O
i.e	NN	O
.	.	O
the	DT	O
time	NN	O
at	IN	O
which	WDT	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
circulates	VBZ	O
in	IN	O
the	DT	O
plasma	NN	O
or	CC	O
bloodstream	NN	O
prior	RB	O
to	TO	O
being	VBG	O
cleared	VBN	O
.	.	O
Determination	NN	O
of	IN	O
serum	JJ	O
half-life	NN	O
is	VBZ	O
often	RB	O
more	RBR	O
simple	JJ	O
than	IN	O
determining	VBG	O
the	DT	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	NN	O
and	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
serum	JJ	O
half-life	NN	O
is	VBZ	O
usually	RB	O
a	DT	O
good	JJ	O
indication	NN	O
of	IN	O
the	DT	O
magnitude	NN	O
of	IN	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	NN	O
.	.	O
Alternatively	RB	O
terms	NNS	O
to	TO	O
serum	VB	O
half-life	JJ	O
include	NN	O
“	NNP	O
plasma	VBZ	O
half-life	JJ	O
”	NNP	O
,	,	O
“	NNP	O
circulating	VBG	O
half-life	JJ	O
”	NN	O
,	,	O
“	NNP	O
serum	VBD	O
clearance	NN	O
”	NN	O
,	,	O
“	NNP	O
plasma	VBZ	O
clearance	NN	O
”	NN	O
and	CC	O
“	JJ	O
clearance	NN	O
half-life	JJ	O
”	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
serum	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
its	PRP$	O
normal	JJ	O
meaning	NN	O
,	,	O
i.e	NN	O
.	.	O
as	IN	O
blood	NN	O
plasma	NN	O
without	IN	O
fibrinogen	NN	O
and	CC	O
other	JJ	O
clotting	VBG	O
factors	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
increased	VBD	O
”	NN	O
as	IN	O
used	VBN	O
about	IN	O
the	DT	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
or	CC	O
serum	JJ	O
half-life	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
indicate	VB	O
that	IN	O
the	DT	O
relevant	JJ	O
half-life	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
statistically	RB	O
significantly	RB	O
increased	VBN	O
relative	NN	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
reference	NN	O
molecule	NN	O
or	CC	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
Thus	RB	O
,	,	O
interesting	VBG	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
those	DT	O
which	WDT	O
have	VBP	O
an	DT	O
increased	VBN	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
or	CC	O
an	DT	O
increased	VBN	O
serum	NN	O
half-life	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
molecule	NN	O
mentioned	VBN	O
above	IN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
AUCsc	NNP	O
”	NNP	O
or	CC	O
“	NNP	O
Area	NNP	O
Under	IN	O
the	DT	O
Curve	NNP	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
”	NNP	O
is	VBZ	O
used	VBN	O
in	IN	O
its	PRP$	O
normal	JJ	O
meaning	NN	O
,	,	O
i.e.	FW	O
,	,	O
as	IN	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
drug	NN	O
concentration	NN	O
vs.	FW	O
time	NN	O
curve	NN	O
,	,	O
where	WRB	O
the	DT	O
conjugated	VBN	O
molecule	NN	O
has	VBZ	O
been	VBN	O
administered	VBN	O
subcutaneously	RB	O
to	TO	O
an	DT	O
experimental	JJ	O
animal	NN	O
.	.	O
Once	RB	O
the	DT	O
experimental	JJ	O
drug	NN	O
concentration	NN	O
time	NN	O
points	NNS	O
have	VBP	O
been	VBN	O
determined	VBN	O
,	,	O
the	DT	O
AUCsc	NNP	O
may	MD	O
conveniently	RB	O
be	VB	O
calculated	VBN	O
by	IN	O
a	DT	O
computer	NN	O
program	NN	O
,	,	O
such	JJ	O
as	IN	O
GraphPad	NNP	O
Prism	NNP	O
3.01	CD	O
The	DT	O
term	NN	O
“	NNP	O
increased	VBD	O
”	NN	O
as	IN	O
used	VBN	O
about	IN	O
the	DT	O
AUGsc	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
indicate	VB	O
that	IN	O
the	DT	O
Area	NNP	O
Under	IN	O
the	DT	O
Curve	NNP	O
for	IN	O
a	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
,	,	O
is	VBZ	O
statistically	RB	O
significantly	RB	O
increased	VBN	O
relative	NN	O
to	TO	O
that	DT	O
of	IN	O
a	DT	O
reference	NN	O
molecule	NN	O
or	CC	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
,	,	O
when	WRB	O
determined	VBN	O
under	IN	O
comparable	JJ	O
conditions	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
Tmax	NNP	O
,	,	O
sc	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
about	IN	O
the	DT	O
time	NN	O
point	NN	O
in	IN	O
the	DT	O
drug	NN	O
concentration	NN	O
vs.	FW	O
time	NN	O
curve	NN	O
where	WRB	O
the	DT	O
highest	JJS	O
drug	NN	O
concentration	NN	O
in	IN	O
serum	NN	O
is	VBZ	O
observed	VBN	O
.	.	O
By	IN	O
removing	VBG	O
and/or	JJ	O
introducing	VBG	O
amino	NN	O
acid	NN	O
residues	NNS	O
comprising	VBG	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
specifically	RB	O
adapt	VB	O
the	DT	O
polypeptide	NN	O
so	RB	O
as	IN	O
to	TO	O
make	VB	O
the	DT	O
molecule	NN	O
more	RBR	O
susceptible	JJ	O
to	TO	O
conjugation	NN	O
to	TO	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
of	IN	O
choice	NN	O
,	,	O
to	TO	O
optimize	VB	O
the	DT	O
conjugation	NN	O
pattern	NN	O
(	(	O
e.g	NN	O
.	.	O
to	TO	O
ensure	VB	O
an	DT	O
optimal	JJ	O
distribution	NN	O
of	IN	O
non-polypeptide	JJ	O
moieties	NNS	O
on	IN	O
the	DT	O
surface	NN	O
of	IN	O
the	DT	O
oliagoadenylate	JJ	O
synthetase	NN	O
molecule	NN	O
and	CC	O
thereby	NN	O
,	,	O
e.g.	NN	O
,	,	O
effectively	RB	O
shield	VBN	O
epitopes	NNS	O
and	CC	O
other	JJ	O
surface	NN	O
parts	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
without	IN	O
significantly	RB	O
impairing	VBG	O
the	DT	O
function	NN	O
thereof	NN	O
)	)	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
by	IN	O
introduction	NN	O
of	IN	O
attachment	NN	O
groups	NNS	O
,	,	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	NN	O
is	VBZ	O
altered	VBN	O
in	IN	O
the	DT	O
content	NN	O
of	IN	O
the	DT	O
specific	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
to	TO	O
which	WDT	O
the	DT	O
relevant	JJ	O
non-polypeptide	JJ	O
moiety	NN	O
binds	NNS	O
,	,	O
whereby	WRB	O
a	DT	O
more	RBR	O
efficient	JJ	O
,	,	O
specific	JJ	O
and/or	VBP	O
extensive	JJ	O
conjugation	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O
By	IN	O
removal	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
attachment	JJ	O
groups	NNS	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
avoid	VB	O
conjugation	NN	O
to	TO	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
in	IN	O
parts	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
in	IN	O
which	WDT	O
such	JJ	O
conjugation	NN	O
is	VBZ	O
disadvantageous	JJ	O
,	,	O
e.g.	RB	O
,	,	O
to	TO	O
an	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
located	VBN	O
at	IN	O
or	CC	O
near	IN	O
a	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
since	IN	O
conjugation	NN	O
at	IN	O
such	PDT	O
a	DT	O
site	NN	O
may	MD	O
result	VB	O
in	IN	O
inactivation	NN	O
or	CC	O
reduced	VBN	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
activity	NN	O
of	IN	O
the	DT	O
resulting	VBG	O
conjugate	NN	O
)	)	O
.	.	O
Further	RB	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
advantageous	JJ	O
to	TO	O
remove	VB	O
an	DT	O
attachment	NN	O
group	NN	O
located	VBD	O
close	RB	O
to	TO	O
another	DT	O
attachment	NN	O
group	NN	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
understood	JJ	O
that	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
a	DT	O
non-polypeptide	JJ	O
moiety	NN	O
,	,	O
whether	IN	O
it	PRP	O
be	VB	O
removed	VBN	O
or	CC	O
introduced	VBN	O
,	,	O
is	VBZ	O
selected	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
and	CC	O
,	,	O
in	IN	O
some	DT	O
instances	NNS	O
,	,	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
conjugation	NN	O
method	NN	O
to	TO	O
be	VB	O
used	VBN	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
when	WRB	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
a	DT	O
polymer	NN	O
molecule	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
polyethylene	NN	O
glycol	NN	O
or	CC	O
polyalkylene	NN	O
oxide	RB	O
derived	VBD	O
molecule	NN	O
,	,	O
amino	JJ	O
acid	NN	O
residues	NNS	O
capable	JJ	O
of	IN	O
functioning	VBG	O
as	IN	O
an	DT	O
attachment	JJ	O
group	NN	O
may	MD	O
be	VB	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
cysteine	NN	O
,	,	O
lysine	NN	O
(	(	O
and/or	IN	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
group	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
)	)	O
,	,	O
aspartic	JJ	O
acid	NN	O
,	,	O
glutamic	JJ	O
acid	NN	O
,	,	O
histidine	NN	O
and	CC	O
arginine	NN	O
.	.	O
When	WRB	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
a	DT	O
sugar	NN	O
moiety	NN	O
,	,	O
the	DT	O
attachment	NN	O
group	NN	O
is	VBZ	O
an	DT	O
in	IN	O
vivo	NN	O
or	CC	O
in	IN	O
vitro	JJ	O
N-	JJ	O
or	CC	O
O-glycosylation	JJ	O
site	NN	O
,	,	O
preferably	RB	O
an	DT	O
N-glycosylation	JJ	O
site	NN	O
.	.	O
In	IN	O
case	NN	O
of	IN	O
removal	NN	O
of	IN	O
an	DT	O
attachment	NN	O
group	NN	O
,	,	O
the	DT	O
relevant	JJ	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
such	JJ	O
group	NN	O
and	CC	O
occupying	VBG	O
a	DT	O
position	NN	O
as	IN	O
defined	VBN	O
above	IN	O
may	MD	O
be	VB	O
substituted	VBN	O
with	IN	O
a	DT	O
different	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
that	WDT	O
does	VBZ	O
not	RB	O
comprise	VB	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
in	IN	O
question	NN	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
deleted	VBN	O
.	.	O
Removal	NN	O
of	IN	O
an	DT	O
N-glycosylation	NNP	O
group	NN	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
accomplished	VBN	O
by	IN	O
insertion	NN	O
or	CC	O
removal	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
reside	NN	O
within	IN	O
the	DT	O
motif	JJ	O
N-X-S/T/C	NNP	O
.	.	O
In	IN	O
case	NN	O
of	IN	O
introduction	NN	O
of	IN	O
an	DT	O
attachment	NN	O
group	NN	O
,	,	O
an	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
such	JJ	O
group	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
the	DT	O
position	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
substitution	NN	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
occupying	VBG	O
such	JJ	O
position	NN	O
.	.	O
The	DT	O
exact	JJ	O
number	NN	O
of	IN	O
attachment	JJ	O
groups	NNS	O
available	JJ	O
for	IN	O
conjugation	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
effect	NN	O
desired	VBD	O
to	TO	O
be	VB	O
achieved	VBN	O
by	IN	O
conjugation	NN	O
.	.	O
The	DT	O
effect	NN	O
to	TO	O
be	VB	O
obtained	VBN	O
is	VBZ	O
,	,	O
e.g.	RB	O
,	,	O
dependent	NN	O
on	IN	O
the	DT	O
nature	NN	O
and	CC	O
degree	NN	O
of	IN	O
conjugation	NN	O
(	(	O
e.g	NN	O
.	.	O
the	DT	O
identity	NN	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
,	,	O
the	DT	O
number	NN	O
of	IN	O
non-polypeptide	JJ	O
moieties	NNS	O
desirable	JJ	O
or	CC	O
possible	JJ	O
to	TO	O
conjugate	VB	O
to	TO	O
the	DT	O
polypeptide	NN	O
,	,	O
where	WRB	O
they	PRP	O
should	MD	O
be	VB	O
conjugated	VBN	O
or	CC	O
where	WRB	O
conjugation	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
if	IN	O
reduced	VBN	O
immunogenicity	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
the	DT	O
number	NN	O
(	(	O
and	CC	O
location	NN	O
of	IN	O
)	)	O
attachment	NN	O
groups	NNS	O
should	MD	O
be	VB	O
sufficient	JJ	O
to	TO	O
shield	VB	O
most	JJS	O
or	CC	O
all	DT	O
epitopes	NNS	O
.	.	O
This	DT	O
is	VBZ	O
normally	RB	O
obtained	VBN	O
when	WRB	O
a	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
shielded	VBN	O
.	.	O
Effective	JJ	O
shielding	NN	O
of	IN	O
epitopes	NNS	O
is	VBZ	O
normally	RB	O
achieved	VBN	O
when	WRB	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
attachment	JJ	O
groups	NNS	O
available	JJ	O
for	IN	O
conjugation	NN	O
is	VBZ	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
1-6	JJ	O
attachment	NN	O
groups	NNS	O
,	,	O
e.g.	RB	O
,	,	O
1-5	JJ	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
1-3	JJ	O
,	,	O
such	JJ	O
as	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
or	CC	O
3	CD	O
attachment	JJ	O
groups	NNS	O
.	.	O
Functional	NNP	O
in	IN	O
vivo	JJ	O
half-life	NN	O
is	VBZ	O
i.a	JJ	O
.	.	O
dependent	NN	O
on	IN	O
the	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
,	,	O
and	CC	O
the	DT	O
number	NN	O
of	IN	O
attachment	JJ	O
groups	NNS	O
needed	VBN	O
for	IN	O
providing	VBG	O
increased	JJ	O
half-life	JJ	O
thus	RB	O
depends	VBZ	O
on	IN	O
the	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
in	IN	O
question	NN	O
.	.	O
Some	DT	O
such	JJ	O
conjugates	NNS	O
comprise	VBP	O
1-6	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
1-5	JJ	O
,	,	O
such	JJ	O
as	IN	O
1-3	JJ	O
,	,	O
e.g	NN	O
.	.	O
1	CD	O
,	,	O
2	CD	O
,	,	O
or	CC	O
3	CD	O
non-polypeptide	JJ	O
moieties	NNS	O
each	DT	O
having	VBG	O
a	DT	O
MW	NNP	O
of	IN	O
about	IN	O
2-40	JJ	O
kDa	NN	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
2	CD	O
kDa	NNS	O
,	,	O
about	RB	O
5	CD	O
kDa	NNS	O
,	,	O
about	RB	O
12	CD	O
kDa	NNS	O
,	,	O
about	RB	O
15	CD	O
kDa	NNS	O
,	,	O
about	RB	O
20	CD	O
kDa	NNS	O
,	,	O
about	RB	O
30	CD	O
kDa	NNS	O
,	,	O
or	CC	O
about	IN	O
40	CD	O
kDa	NNS	O
.	.	O
In	IN	O
the	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
some	DT	O
,	,	O
most	JJS	O
,	,	O
or	CC	O
substantially	RB	O
all	DT	O
conjugatable	JJ	O
attachment	NN	O
groups	NNS	O
are	VBP	O
occupied	VBN	O
by	IN	O
the	DT	O
relevant	JJ	O
non-polypeptide	JJ	O
moiety	NN	O
.	.	O
The	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
exhibit	VB	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	VBG	O
improved	JJ	O
properties	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
conjugate	NN	O
may	MD	O
exhibit	VB	O
a	DT	O
reduced	JJ	O
immunogenicity	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
,	,	O
e.g	NN	O
.	.	O
a	DT	O
reduction	NN	O
of	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
reduction	NN	O
of	IN	O
at	IN	O
least	JJS	O
of	IN	O
25	CD	O
%	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
reduction	NN	O
of	IN	O
at	IN	O
least	JJS	O
of	IN	O
50	CD	O
%	NN	O
,	,	O
e.g	NN	O
.	.	O
a	DT	O
reduction	NN	O
of	IN	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
compared	VBN	O
to	TO	O
the	DT	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
the	DT	O
conjugate	NN	O
may	MD	O
exhibit	VB	O
a	DT	O
reduced	JJ	O
reaction	NN	O
or	CC	O
no	DT	O
reaction	NN	O
with	IN	O
neutralizing	VBG	O
antibodies	NNS	O
from	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
parent	NN	O
polypeptide	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
reduction	NN	O
of	IN	O
neutralization	NN	O
of	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
,	,	O
such	JJ	O
as	IN	O
of	IN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
,	,	O
e.g.	NN	O
,	,	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
the	DT	O
conjugate	NN	O
may	MD	O
exhibit	VB	O
an	DT	O
increased	JJ	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
and/or	NN	O
increased	VBD	O
serum	JJ	O
half-life	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
molecule	NN	O
or	CC	O
as	RB	O
compared	VBN	O
to	TO	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
Particular	JJ	O
preferred	VBN	O
conjugates	NNS	O
are	VBP	O
such	JJ	O
conjugates	NNS	O
where	WRB	O
the	DT	O
ratio	NN	O
between	IN	O
the	DT	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
(	(	O
or	CC	O
serum	VB	O
half-life	JJ	O
)	)	O
of	IN	O
said	VBD	O
conjugate	NN	O
and	CC	O
the	DT	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	NN	O
(	(	O
or	CC	O
serum	VB	O
half-life	JJ	O
)	)	O
of	IN	O
said	VBD	O
reference	NN	O
molecule	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
1.25	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
1.50	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
1.75	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
2	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
3	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
4	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
5	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
6	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
7	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
8	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
9	CD	O
,	,	O
e.g	NN	O
.	.	O
10-100	JJ	O
.	.	O
As	IN	O
mentioned	VBN	O
above	IN	O
,	,	O
the	DT	O
half-life	NN	O
is	VBZ	O
conveniently	RB	O
determined	VBN	O
in	IN	O
an	DT	O
experimental	JJ	O
animal	NN	O
,	,	O
such	JJ	O
as	IN	O
rat	NN	O
or	CC	O
monkey	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
based	VBN	O
on	IN	O
intravenous	JJ	O
,	,	O
subcutaneous	JJ	O
,	,	O
or	CC	O
other	JJ	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
the	DT	O
conjugate	NN	O
may	MD	O
exhibit	VB	O
an	DT	O
increased	JJ	O
bioavailability	NN	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
molecule	NN	O
or	CC	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
conjugate	NN	O
may	MD	O
exhibit	VB	O
an	DT	O
increased	JJ	O
AUCsc	NNP	O
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
molecule	NN	O
or	CC	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
Thus	RB	O
,	,	O
exemplary	JJ	O
conjugates	NNS	O
are	VBP	O
such	JJ	O
conjugates	NNS	O
where	WRB	O
the	DT	O
ratio	NN	O
between	IN	O
the	DT	O
AUCsc	NNP	O
of	IN	O
said	VBD	O
conjugate	NN	O
and	CC	O
the	DT	O
AUCsc	NNP	O
of	IN	O
said	VBD	O
reference	NN	O
molecule	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
1.25	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
1.5	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
2	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
3	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
4	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
5	CD	O
or	CC	O
at	IN	O
least	JJS	O
6	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
7	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
8	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
9	CD	O
or	CC	O
at	IN	O
least	JJS	O
10	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
12	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
14	CD	O
,	,	O
e.g	NN	O
.	.	O
at	IN	O
least	JJS	O
16	CD	O
,	,	O
at	IN	O
least	JJS	O
18	CD	O
or	CC	O
at	IN	O
least	JJS	O
20	CD	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
,	,	O
intravenously	RB	O
,	,	O
intrathecally	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
intraperitoneally	RB	O
,	,	O
or	CC	O
by	IN	O
ingestion	NN	O
or	CC	O
inhalation	NN	O
,	,	O
in	IN	O
particular	JJ	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
in	IN	O
an	DT	O
experimental	JJ	O
animal	NN	O
such	JJ	O
as	IN	O
rat	NN	O
or	CC	O
monkey	NN	O
.	.	O
Analogously	RB	O
,	,	O
some	DT	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
such	JJ	O
conjugates	NNS	O
wherein	VBP	O
the	DT	O
ratio	NN	O
between	IN	O
Tmax	NNP	O
for	IN	O
said	VBD	O
conjugate	NN	O
and	CC	O
Tmax	NNP	O
for	IN	O
said	VBD	O
reference	NN	O
molecule	NN	O
,	,	O
or	CC	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
,	,	O
is	VBZ	O
at	IN	O
least	JJS	O
1.2	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
1.4	CD	O
,	,	O
e.g	NN	O
.	.	O
at	IN	O
least	JJS	O
1.6	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
1.8	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
2	CD	O
,	,	O
e.g.	NN	O
,	,	O
at	IN	O
least	JJS	O
2.5	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
3	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
4	CD	O
,	,	O
e.g	NN	O
.	.	O
at	IN	O
least	JJS	O
5	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
6	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
7	CD	O
,	,	O
e.g	NN	O
.	.	O
at	IN	O
least	JJS	O
8	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
9	CD	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
10	CD	O
,	,	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
,	,	O
intravenously	RB	O
,	,	O
intrathecally	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
intraperitoneally	RB	O
,	,	O
or	CC	O
by	IN	O
ingestion	NN	O
or	CC	O
inhalation	NN	O
,	,	O
in	IN	O
particular	JJ	O
when	WRB	O
administered	VBN	O
subcutaneously	RB	O
in	IN	O
an	DT	O
experimental	JJ	O
animal	NN	O
such	JJ	O
as	IN	O
rat	NN	O
or	CC	O
monkey	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
the	DT	O
magnitude	NN	O
of	IN	O
the	DT	O
antiviral	JJ	O
,	,	O
anticancer	JJ	O
,	,	O
anti-neoplastic	JJ	O
,	,	O
anti-inflammatory	JJ	O
,	,	O
pro-regenerative	JJ	O
or	CC	O
other	JJ	O
therapeutic	JJ	O
activity	NN	O
of	IN	O
a	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
about	IN	O
75	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
25	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
%	NN	O
)	)	O
or	CC	O
increased	VBN	O
(	(	O
e.g	NN	O
.	.	O
by	IN	O
at	IN	O
least	JJS	O
about	IN	O
10	CD	O
%	NN	O
)	)	O
or	CC	O
is	VBZ	O
about	IN	O
equal	JJ	O
(	(	O
e.g	NN	O
.	.	O
within	IN	O
about	RB	O
+/−10	CD	O
%	NN	O
or	CC	O
about	IN	O
+/−5	CD	O
%	NN	O
)	)	O
to	TO	O
that	DT	O
of	IN	O
the	DT	O
corresponding	JJ	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
a	DT	O
conjugate	NN	O
comprising	NN	O
at	IN	O
least	JJS	O
one	CD	O
non-polypeptide	JJ	O
moiety	NN	O
conjugated	VBD	O
to	TO	O
at	IN	O
least	JJS	O
one	CD	O
lysine	NN	O
residue	JJ	O
and/or	NN	O
to	TO	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
group	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
most	RBS	O
particularly	RB	O
the	DT	O
polypeptides	NNS	O
described	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
a	DT	O
conjugate	NN	O
comprising	NN	O
at	IN	O
least	JJS	O
one	CD	O
non-polypeptide	JJ	O
moiety	NN	O
conjugated	VBD	O
to	TO	O
at	IN	O
least	JJS	O
one	CD	O
lysine	NN	O
residue	NN	O
,	,	O
or	CC	O
to	TO	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
group	NN	O
,	,	O
of	IN	O
a	DT	O
polypeptide	NN	O
comprising	VBG	O
a	DT	O
sequence	NN	O
which	WDT	O
differs	NNS	O
in	IN	O
1	CD	O
to	TO	O
34	CD	O
amino	NN	O
acid	JJ	O
positions	NNS	O
from	IN	O
SEQUENCE:1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Some	DT	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
a	DT	O
polypeptide	NN	O
sequence	NN	O
comprising	VBG	O
a	DT	O
substitution	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
for	IN	O
a	DT	O
different	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
or	CC	O
a	DT	O
deletion	NN	O
of	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
which	WDT	O
removes	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
lysines	NNS	O
from	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
one	CD	O
or	CC	O
more	JJR	O
lysine	JJ	O
residue	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
be	VB	O
removed	VBN	O
may	MD	O
be	VB	O
substituted	VBN	O
with	IN	O
any	DT	O
other	JJ	O
amino	NN	O
acid	NNS	O
,	,	O
may	MD	O
be	VB	O
substituted	VBN	O
with	IN	O
an	DT	O
Arg	NNP	O
(	(	O
R	NNP	O
)	)	O
,	,	O
His	PRP$	O
(	(	O
H	NNP	O
)	)	O
or	CC	O
Gln	NNP	O
(	(	O
Q	NNP	O
)	)	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
deleted	VBN	O
.	.	O
In	IN	O
instances	NNS	O
where	WRB	O
amine-reactive	JJ	O
conjugation	NN	O
chemistries	NNS	O
are	VBP	O
employed	VBN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
advantageous	JJ	O
to	TO	O
avoid	VB	O
or	CC	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
conjugation	NN	O
to	TO	O
histidine	VB	O
residues	NNS	O
.	.	O
Therefore	RB	O
,	,	O
some	DT	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
a	DT	O
polypeptide	NN	O
sequence	NN	O
comprising	VBG	O
a	DT	O
substitution	NN	O
or	CC	O
a	DT	O
deletion	NN	O
which	WDT	O
removes	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
histidines	NNS	O
from	IN	O
any	DT	O
polypeptide	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
one	CD	O
or	CC	O
more	JJR	O
histidine	JJ	O
residue	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
be	VB	O
removed	VBN	O
may	MD	O
be	VB	O
substituted	VBN	O
with	IN	O
any	DT	O
other	JJ	O
amino	NN	O
acid	NNS	O
,	,	O
may	MD	O
be	VB	O
substituted	VBN	O
with	IN	O
an	DT	O
Arg	NNP	O
(	(	O
R	NNP	O
)	)	O
,	,	O
Lys	NNP	O
(	(	O
L	NNP	O
)	)	O
or	CC	O
Gln	NNP	O
(	(	O
Q	NNP	O
)	)	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
deleted	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
or	CC	O
in	IN	O
addition	NN	O
,	,	O
some	DT	O
conjugates	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
a	DT	O
polypeptide	NN	O
sequence	NN	O
comprising	VBG	O
a	DT	O
modification	NN	O
which	WDT	O
introduces	VBZ	O
a	DT	O
lysine	NN	O
into	IN	O
a	DT	O
position	NN	O
that	WDT	O
is	VBZ	O
occupied	VBN	O
in	IN	O
the	DT	O
parent	NN	O
sequence	NN	O
by	IN	O
an	DT	O
amino	NN	O
acid	NN	O
residue	NN	O
that	WDT	O
is	VBZ	O
exposed	VBN	O
to	TO	O
the	DT	O
surface	NN	O
of	IN	O
the	DT	O
molecule	NN	O
,	,	O
e.g.	NN	O
,	,	O
one	CD	O
that	WDT	O
has	VBZ	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
of	IN	O
its	PRP$	O
side	NN	O
chain	NN	O
exposed	VBD	O
to	TO	O
the	DT	O
surface	NN	O
.	.	O
Non-polypeptide	JJ	O
moieties	NNS	O
contemplated	VBN	O
for	IN	O
this	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
polymer	NN	O
molecules	NNS	O
,	,	O
such	JJ	O
as	IN	O
PEG	NNP	O
or	CC	O
mPEG	NN	O
or	CC	O
mPEG2	NN	O
.	.	O
The	DT	O
conjugation	NN	O
between	IN	O
the	DT	O
lysine-containing	JJ	O
polypeptide	NN	O
and	CC	O
the	DT	O
polymer	NN	O
molecule	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
any	DT	O
suitable	JJ	O
manner	NN	O
as	IN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
An	DT	O
exemplary	JJ	O
method	NN	O
for	IN	O
PEGylating	VBG	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
to	TO	O
covalently	RB	O
attach	VB	O
PEG	NNP	O
to	TO	O
lysine	VB	O
residues	NNS	O
using	VBG	O
lysine-reactive	JJ	O
PEGs	NNP	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
highly	RB	O
specific	JJ	O
,	,	O
lysine-reactive	JJ	O
PEGs	NNP	O
(	(	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
succinimidyl	JJ	O
propionate	NN	O
(	(	O
SPA	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
butanoate	NN	O
(	(	O
SBA	NNP	O
)	)	O
,	,	O
N-hydroxylsuccinimide	NNP	O
(	(	O
NHS	NNP	O
)	)	O
,	,	O
and	CC	O
aldehyde	NN	O
(	(	O
e.g.	JJ	O
,	,	O
ButyrALD	NNP	O
)	)	O
)	)	O
and	CC	O
different	JJ	O
size	NN	O
linear	NN	O
or	CC	O
branched	VBN	O
PEGs	NNP	O
(	(	O
e.g.	JJ	O
,	,	O
2-40	JJ	O
kDa	NN	O
,	,	O
such	JJ	O
as	IN	O
2	CD	O
kDa	NN	O
,	,	O
5	CD	O
kDa	NN	O
,	,	O
12	CD	O
kDa	NN	O
,	,	O
15	CD	O
kDa	NN	O
,	,	O
20	CD	O
kDa	NN	O
,	,	O
30	CD	O
kDa	NN	O
,	,	O
or	CC	O
40	CD	O
kDa	NN	O
)	)	O
are	VBP	O
commercially	RB	O
available	JJ	O
,	,	O
e.g	NN	O
.	.	O
from	IN	O
Nektar	NNP	O
Therapeutics	NNP	O
Inc.	NNP	O
,	,	O
Huntsville	NNP	O
,	,	O
Ala.	NNP	O
,	,	O
USA	NNP	O
,	,	O
or	CC	O
SunBio	NNP	O
,	,	O
Anyang	NNP	O
City	NNP	O
,	,	O
South	NNP	O
Korea	NNP	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
composition	NN	O
comprising	VBG	O
a	DT	O
population	NN	O
of	IN	O
conjugates	NNS	O
wherein	VBP	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
conjugates	NNS	O
of	IN	O
said	VBD	O
population	NN	O
each	DT	O
contain	VBP	O
a	DT	O
single	JJ	O
non-polypeptide	JJ	O
moiety	NN	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
a	DT	O
single	JJ	O
polymer	NN	O
molecule	NN	O
,	,	O
e.g.	NN	O
,	,	O
a	DT	O
single	JJ	O
PEG	NNP	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
linear	JJ	O
PEG	NNP	O
or	CC	O
a	DT	O
branched	JJ	O
PEG	NNP	O
)	)	O
covalently	RB	O
attached	VBN	O
to	TO	O
a	DT	O
single	JJ	O
lysine	NN	O
residue	NN	O
or	CC	O
N-terminal	JJ	O
amino	NN	O
group	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
“	NN	O
monoconjugated	VBN	O
”	NNP	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
a	DT	O
“	NN	O
monoPEGylated	VBN	O
”	NNP	O
)	)	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
comprises	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
“	JJ	O
positional	JJ	O
isomers	NNS	O
”	CD	O
of	IN	O
said	VBD	O
conjugate	NN	O
,	,	O
wherein	WP	O
each	DT	O
positional	JJ	O
isomer	NN	O
contains	VBZ	O
a	DT	O
single	JJ	O
non-polypeptide	JJ	O
moiety	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
single	JJ	O
PEG	NNP	O
molecule	NN	O
)	)	O
covalently	RB	O
attached	VBN	O
to	TO	O
a	DT	O
single	JJ	O
lysine	NN	O
residue	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
The	DT	O
invention	NN	O
includes	VBZ	O
a	DT	O
monoPEGylated	JJ	O
composition	NN	O
comprising	VBG	O
a	DT	O
population	NN	O
of	IN	O
conjugates	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
majority	NN	O
of	IN	O
the	DT	O
conjugates	NNS	O
of	IN	O
said	VBD	O
population	NN	O
are	VBP	O
positional	JJ	O
isomers	NNS	O
each	DT	O
containing	VBG	O
a	DT	O
single	JJ	O
PEG	NNP	O
molecule	NN	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
a	DT	O
linear	JJ	O
or	CC	O
branched	VBN	O
PEG	NNP	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
2	CD	O
kDa	NN	O
,	,	O
5	CD	O
kDa	NN	O
,	,	O
12	CD	O
kDa	NN	O
,	,	O
15	CD	O
kDa	NN	O
,	,	O
20	CD	O
kDa	NN	O
,	,	O
30	CD	O
kDa	NN	O
,	,	O
or	CC	O
40	CD	O
kDa	NNS	O
mPEG	NN	O
or	CC	O
mPEG2	VB	O
molecule	NN	O
)	)	O
covalently	RB	O
attached	VBN	O
to	TO	O
a	DT	O
single	JJ	O
lysine	NN	O
residue	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
a	DT	O
conjugate	NN	O
comprising	NN	O
at	IN	O
least	JJS	O
one	CD	O
non-polypeptide	JJ	O
moiety	NN	O
conjugated	VBD	O
to	TO	O
at	IN	O
least	JJS	O
one	CD	O
cysteine	NN	O
residue	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
or	CC	O
a	DT	O
polypeptide	JJ	O
comprising	VBG	O
a	DT	O
sequence	NN	O
which	WDT	O
differs	NNS	O
in	IN	O
1	CD	O
to	TO	O
34	CD	O
amino	NN	O
acid	JJ	O
positions	NNS	O
from	IN	O
SEQUENCE:1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
Some	DT	O
conjugates	NNS	O
according	VBG	O
to	TO	O
this	DT	O
aspect	JJ	O
comprise	NN	O
at	IN	O
least	JJS	O
one	CD	O
introduced	JJ	O
cysteine	NN	O
residue	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
conjugation	NN	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
cysteine	JJ	O
residues	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
including	VBG	O
Cys25	NNP	O
,	,	O
Cys38	NNP	O
,	,	O
Cys45	NNP	O
,	,	O
Cys54	NNP	O
,	,	O
Cys109	NNP	O
,	,	O
Cys177	NNP	O
,	,	O
Cys189	NNP	O
,	,	O
Cys219	NNP	O
,	,	O
Cys269	NNP	O
,	,	O
or	CC	O
Cys331	NNP	O
.	.	O
Included	VBN	O
among	IN	O
these	DT	O
conjugates	NNS	O
are	VBP	O
those	DT	O
defined	VBN	O
as	IN	O
Class	NNP	O
IV	NNP	O
in	IN	O
FIG	NNP	O
.	.	O
1	CD	O
and	CC	O
as	RB	O
implemented	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
cysteine	JJ	O
residues	NNS	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
enable	VB	O
conjugation	NN	O
of	IN	O
a	DT	O
non-polypeptide	JJ	O
moiety	NN	O
at	IN	O
a	DT	O
location	NN	O
other	JJ	O
than	IN	O
Cys25	NNP	O
,	,	O
Cys38	NNP	O
,	,	O
Cys45	NNP	O
,	,	O
Cys54	NNP	O
,	,	O
Cys109	NNP	O
,	,	O
Cys177	NNP	O
,	,	O
Cys189	NNP	O
,	,	O
Cys219	NNP	O
,	,	O
Cys269	NNP	O
,	,	O
or	CC	O
Cys331	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
understood	JJ	O
that	IN	O
while	IN	O
the	DT	O
examples	NNS	O
of	IN	O
modifications	NNS	O
or	CC	O
conjugations	NNS	O
to	TO	O
the	DT	O
parent	NN	O
polypeptide	NN	O
are	VBP	O
generally	RB	O
provided	VBN	O
herein	RB	O
relative	JJ	O
to	TO	O
the	DT	O
sequence	NN	O
SEQUENCE:1	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
)	)	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
(	(	O
or	CC	O
relative	VB	O
to	TO	O
some	DT	O
other	JJ	O
specified	JJ	O
sequence	NN	O
)	)	O
,	,	O
the	DT	O
disclosed	JJ	O
modifications	NNS	O
may	MD	O
also	RB	O
be	VB	O
made	VBN	O
in	IN	O
equivalent	JJ	O
amino	NN	O
acid	JJ	O
positions	NNS	O
of	IN	O
the	DT	O
other	JJ	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
described	VBD	O
herein	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
only	RB	O
a	DT	O
single	JJ	O
cysteine	NN	O
residue	NN	O
is	VBZ	O
introduced	VBN	O
in	IN	O
order	NN	O
to	TO	O
avoid	VB	O
formation	NN	O
of	IN	O
disulfide	NN	O
bridges	NNS	O
between	IN	O
two	CD	O
or	CC	O
more	JJR	O
introduced	JJ	O
cysteine	NN	O
residues	NNS	O
.	.	O
Non-polypeptide	JJ	O
moieties	NNS	O
contemplated	VBN	O
in	IN	O
this	DT	O
aspect	NN	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
polymer	NN	O
molecules	NNS	O
,	,	O
such	JJ	O
as	IN	O
PEG	NNP	O
or	CC	O
mPEG	NNS	O
and	CC	O
others	NNS	O
as	IN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
conjugation	NN	O
between	IN	O
the	DT	O
cysteine-containing	JJ	O
polypeptide	NN	O
and	CC	O
the	DT	O
polymer	NN	O
molecule	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
any	DT	O
suitable	JJ	O
manner	NN	O
as	IN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
An	DT	O
exemplary	JJ	O
method	NN	O
for	IN	O
PEGylating	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
to	TO	O
covalently	RB	O
attach	VB	O
PEG	NNP	O
to	TO	O
cysteine	VB	O
residues	NNS	O
using	VBG	O
cysteine-reactive	JJ	O
PEGs	NNP	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
highly	RB	O
specific	JJ	O
,	,	O
cysteine-reactive	JJ	O
PEGs	NNP	O
with	IN	O
different	JJ	O
groups	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
orthopyridyl-disulfide	JJ	O
(	(	O
OPSS	NNP	O
)	)	O
,	,	O
maleimide	RB	O
(	(	O
MAL	NNP	O
)	)	O
and	CC	O
vinylsulfone	NN	O
(	(	O
VS	NNP	O
)	)	O
)	)	O
and	CC	O
different	JJ	O
size	NN	O
linear	NN	O
or	CC	O
branched	VBN	O
PEGs	NNP	O
(	(	O
e.g.	JJ	O
,	,	O
2-40	JJ	O
kDa	NN	O
,	,	O
such	JJ	O
as	IN	O
2	CD	O
kDa	NN	O
,	,	O
5	CD	O
kDa	NN	O
,	,	O
12	CD	O
kDa	NN	O
,	,	O
15	CD	O
kDa	NN	O
,	,	O
20	CD	O
kDa	NN	O
,	,	O
30	CD	O
kDa	NN	O
,	,	O
or	CC	O
40	CD	O
kDa	NN	O
)	)	O
are	VBP	O
commercially	RB	O
available	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
from	IN	O
Nektar	NNP	O
Therapeutics	NNP	O
Inc.	NNP	O
,	,	O
Huntsville	NNP	O
,	,	O
Ala.	NNP	O
,	,	O
USA	NNP	O
,	,	O
or	CC	O
SunBio	NNP	O
,	,	O
Anyang	NNP	O
City	NNP	O
,	,	O
South	NNP	O
Korea	NNP	O
.	.	O
As	IN	O
indicated	VBN	O
above	IN	O
,	,	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
generally	RB	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
a	DT	O
polymer	NN	O
molecule	NN	O
,	,	O
a	DT	O
lipophilic	JJ	O
compound	NN	O
,	,	O
a	DT	O
sugar	NN	O
moiety	NN	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
way	NN	O
of	IN	O
in	IN	O
vivo	JJ	O
N-glycosylation	NN	O
)	)	O
and	CC	O
an	DT	O
organic	JJ	O
derivatizing	NN	O
agent	NN	O
.	.	O
All	DT	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
confer	VB	O
desirable	JJ	O
properties	NNS	O
to	TO	O
the	DT	O
polypeptide	JJ	O
part	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
,	,	O
such	JJ	O
as	IN	O
reduced	JJ	O
immunogenicity	NN	O
,	,	O
increased	VBD	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
,	,	O
increased	JJ	O
serum	NN	O
half-life	NN	O
,	,	O
increased	VBN	O
bioavailability	NN	O
and/or	NN	O
increased	VBD	O
AUCsc	NNP	O
.	.	O
The	DT	O
polypeptide	JJ	O
part	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
is	VBZ	O
often	RB	O
conjugated	VBN	O
to	TO	O
only	RB	O
one	CD	O
type	NN	O
of	IN	O
non-polypeptide	JJ	O
moiety	NN	O
,	,	O
but	CC	O
may	MD	O
also	RB	O
be	VB	O
conjugated	VBN	O
to	TO	O
two	CD	O
or	CC	O
more	JJR	O
different	JJ	O
types	NNS	O
of	IN	O
non-polypeptide	JJ	O
moieties	NNS	O
,	,	O
e.g.	NN	O
,	,	O
to	TO	O
a	DT	O
polymer	NN	O
molecule	NN	O
and	CC	O
a	DT	O
sugar	NN	O
moiety	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
conjugation	NN	O
to	TO	O
two	CD	O
or	CC	O
more	JJR	O
different	JJ	O
non-polypeptide	JJ	O
moieties	NNS	O
may	MD	O
be	VB	O
done	VBN	O
simultaneously	RB	O
or	CC	O
sequentially	RB	O
.	.	O
The	DT	O
choice	NN	O
of	IN	O
non-polypeptide	JJ	O
moiety/moieties	NNS	O
,	,	O
depends	VBZ	O
especially	RB	O
on	IN	O
the	DT	O
effect	NN	O
desired	VBD	O
to	TO	O
be	VB	O
achieved	VBN	O
by	IN	O
the	DT	O
conjugation	NN	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
sugar	NN	O
moieties	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
particularly	RB	O
useful	JJ	O
for	IN	O
reducing	VBG	O
immunogenicity	NN	O
,	,	O
whereas	JJ	O
polymer	NN	O
molecules	NNS	O
such	JJ	O
as	IN	O
PEG	NNP	O
are	VBP	O
of	IN	O
particular	JJ	O
use	NN	O
for	IN	O
increasing	VBG	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
and/or	NN	O
serum	NN	O
half-life	NN	O
.	.	O
Using	VBG	O
a	DT	O
combination	NN	O
of	IN	O
a	DT	O
polymer	NN	O
molecule	NN	O
and	CC	O
a	DT	O
sugar	NN	O
moiety	NN	O
may	MD	O
enhance	VB	O
the	DT	O
reduction	NN	O
in	IN	O
immunogenicity	NN	O
and	CC	O
the	DT	O
increase	NN	O
in	IN	O
functional	JJ	O
in	IN	O
vivo	NN	O
or	CC	O
serum	JJ	O
half-life	NN	O
.	.	O
For	IN	O
conjugation	NN	O
to	TO	O
a	DT	O
lipophilic	JJ	O
compound	NN	O
,	,	O
the	DT	O
following	JJ	O
polypeptide	NN	O
groups	NNS	O
may	MD	O
function	VB	O
as	IN	O
attachment	JJ	O
groups	NNS	O
:	:	O
the	DT	O
N-terminus	NNP	O
or	CC	O
C-terminus	NNP	O
of	IN	O
the	DT	O
polypeptide	NN	O
,	,	O
the	DT	O
hydroxy	JJ	O
groups	NNS	O
of	IN	O
the	DT	O
amino	NN	O
acid	NN	O
residues	NNS	O
Ser	NNP	O
,	,	O
Thr	NNP	O
or	CC	O
Tyr	NNP	O
,	,	O
the	DT	O
epsilon-amino	JJ	O
group	NN	O
of	IN	O
Lys	NNP	O
,	,	O
the	DT	O
SH	NNP	O
group	NN	O
of	IN	O
Cys	NNP	O
or	CC	O
the	DT	O
carboxyl	JJ	O
group	NN	O
of	IN	O
Asp	NNP	O
and	CC	O
Glu	NNP	O
.	.	O
The	DT	O
polypeptide	NN	O
and	CC	O
the	DT	O
lipophilic	JJ	O
compound	NN	O
may	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
each	DT	O
other	JJ	O
either	CC	O
directly	RB	O
or	CC	O
by	IN	O
use	NN	O
of	IN	O
a	DT	O
linker	NN	O
.	.	O
The	DT	O
lipophilic	JJ	O
compound	NN	O
may	MD	O
be	VB	O
a	DT	O
natural	JJ	O
compound	NN	O
such	JJ	O
as	IN	O
a	DT	O
saturated	JJ	O
or	CC	O
unsaturated	JJ	O
fatty	JJ	O
acid	NN	O
,	,	O
a	DT	O
fatty	JJ	O
acid	NN	O
diketone	NN	O
,	,	O
a	DT	O
terpene	NN	O
,	,	O
a	DT	O
prostaglandin	NN	O
,	,	O
a	DT	O
vitamin	NN	O
,	,	O
a	DT	O
carotenoid	NN	O
or	CC	O
steroid	NN	O
,	,	O
or	CC	O
a	DT	O
synthetic	JJ	O
compound	NN	O
such	JJ	O
as	IN	O
a	DT	O
carbon	NN	O
acid	NN	O
,	,	O
an	DT	O
alcohol	NN	O
,	,	O
an	DT	O
amine	NN	O
and	CC	O
sulphonic	JJ	O
acid	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
alkyl	NNS	O
,	,	O
aryl	NN	O
,	,	O
alkenyl	NN	O
or	CC	O
other	JJ	O
multiple	JJ	O
unsaturated	JJ	O
compounds	NNS	O
.	.	O
The	DT	O
conjugation	NN	O
between	IN	O
the	DT	O
polypeptide	NN	O
and	CC	O
the	DT	O
lipophilic	JJ	O
compound	NN	O
,	,	O
optionally	RB	O
through	IN	O
a	DT	O
linker	NN	O
may	MD	O
be	VB	O
done	VBN	O
according	VBG	O
to	TO	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
e.g	NN	O
.	.	O
as	IN	O
described	VBN	O
by	IN	O
Bodanszky	NNP	O
in	IN	O
Peptide	NNP	B
Synthesis	NNP	I
,	,	I
John	NNP	I
Wiley	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
1976	CD	I
and	CC	O
in	IN	O
WO	NNP	O
96/12505	CD	O
.	.	O
The	DT	O
polymer	NN	O
molecule	NN	O
to	TO	O
be	VB	O
coupled	VBN	O
to	TO	O
the	DT	O
polypeptide	NN	O
may	MD	O
be	VB	O
any	DT	O
suitable	JJ	O
polymer	NN	O
molecule	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
natural	JJ	O
or	CC	O
synthetic	JJ	O
homo-polymer	NN	O
or	CC	O
heteropolymer	NN	O
,	,	O
typically	RB	O
with	IN	O
a	DT	O
molecular	JJ	O
weight	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
about	IN	O
300-100,000	CD	O
Da	NNP	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
1000-50,000	CD	O
Da	NNP	O
,	,	O
e.g	NN	O
.	.	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
about	IN	O
1000-40,000	CD	O
Da	NNP	O
.	.	O
More	RBR	O
particularly	RB	O
,	,	O
the	DT	O
polymer	NN	O
molecule	NN	O
,	,	O
such	JJ	O
as	IN	O
PEG	NNP	O
,	,	O
in	IN	O
particular	JJ	O
mPEG	NN	O
,	,	O
will	MD	O
typically	RB	O
have	VB	O
a	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
2	CD	O
,	,	O
5	CD	O
,	,	O
10	CD	O
,	,	O
12	CD	O
,	,	O
15	CD	O
,	,	O
20	CD	O
,	,	O
30	CD	O
,	,	O
40	CD	O
or	CC	O
50	CD	O
kDa	NNS	O
,	,	O
in	IN	O
particular	JJ	O
a	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
5	CD	O
kDa	NNS	O
,	,	O
about	RB	O
10	CD	O
kDa	NNS	O
,	,	O
about	RB	O
12	CD	O
kDa	NNS	O
,	,	O
about	RB	O
15	CD	O
kDa	NNS	O
,	,	O
about	RB	O
20	CD	O
kDa	NNS	O
,	,	O
about	RB	O
30	CD	O
kDa	NNS	O
or	CC	O
about	IN	O
40	CD	O
kDa	NNS	O
.	.	O
The	DT	O
PEG	NNP	O
molecule	NN	O
may	MD	O
be	VB	O
branched	VBN	O
(	(	O
e.g.	NN	O
,	,	O
mPEG2	NN	O
)	)	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
unbranched	VBN	O
(	(	O
i.e.	FW	O
,	,	O
linear	VBP	O
)	)	O
.	.	O
When	WRB	O
used	VBN	O
about	IN	O
polymer	NN	O
molecules	NNS	O
herein	RB	O
,	,	O
the	DT	O
word	NN	O
“	VBZ	O
about	IN	O
”	NNP	O
indicates	VBZ	O
an	DT	O
approximate	JJ	O
average	NN	O
molecular	JJ	O
weight	NN	O
and	CC	O
reflects	VBZ	O
the	DT	O
fact	NN	O
that	IN	O
there	EX	O
will	MD	O
normally	RB	O
be	VB	O
a	DT	O
certain	JJ	O
molecular	JJ	O
weight	NN	O
distribution	NN	O
in	IN	O
a	DT	O
given	VBN	O
polymer	NN	O
preparation	NN	O
.	.	O
Examples	NNS	O
of	IN	O
homo-polymers	NNS	O
include	VBP	O
a	DT	O
polyol	NN	O
(	(	O
i.e.	JJ	O
,	,	O
poly-OH	JJ	O
)	)	O
,	,	O
a	DT	O
polyamine	NN	O
(	(	O
i.e	NN	O
.	.	O
poly-NH2	NN	O
)	)	O
and	CC	O
a	DT	O
polycarboxylic	JJ	O
acid	NN	O
(	(	O
i.e	NN	O
.	.	O
poly-COOH	NN	O
)	)	O
.	.	O
A	DT	O
hetero-polymer	NN	O
is	VBZ	O
a	DT	O
polymer	NN	O
which	WDT	O
comprises	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
different	JJ	O
coupling	NN	O
groups	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
hydroxyl	NN	O
group	NN	O
and	CC	O
an	DT	O
amine	NN	O
group	NN	O
.	.	O
Examples	NNS	O
of	IN	O
suitable	JJ	O
polymer	NN	O
molecules	NNS	O
include	VBP	O
polymer	JJ	O
molecules	NNS	O
selected	VBN	O
from	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
polyalkylene	NN	O
oxide	NN	O
(	(	O
PAO	NNP	O
)	)	O
,	,	O
including	VBG	O
polyalkylene	NN	O
glycol	NN	O
(	(	O
PAG	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
and	CC	O
polypropylene	JJ	O
glycol	NN	O
(	(	O
PPG	NNP	O
)	)	O
,	,	O
branched	VBN	O
PEGs	NNP	O
(	(	O
PEG2	NNP	O
)	)	O
,	,	O
poly-vinyl	JJ	O
alcohol	NN	O
(	(	O
PVA	NNP	O
)	)	O
,	,	O
poly-carboxylate	JJ	O
,	,	O
poly-	JJ	O
(	(	O
vinylpyrolidone	NN	O
)	)	O
,	,	O
polyethylene-co-maleic	JJ	O
acid	NN	O
anhydride	NN	O
,	,	O
polystyrene-co-malic	JJ	O
acid	NN	O
anhydride	NN	O
,	,	O
dextran	JJ	O
including	VBG	O
carboxymethyl-dextran	NN	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
biopolymer	NN	O
suitable	NN	O
for	IN	O
reducing	VBG	O
immunogenicity	NN	O
and/or	NN	O
increasing	VBG	O
functional	JJ	O
in	IN	O
vivo	JJ	O
half-life	JJ	O
and/or	NN	O
serum	NN	O
half-life	NN	O
.	.	O
Generally	RB	O
,	,	O
polyalkylene	JJ	O
glycol-derived	JJ	O
polymers	NNS	O
are	VBP	O
biocompatible	JJ	O
,	,	O
non-toxic	JJ	O
,	,	O
non-antigenic	JJ	O
,	,	O
non-immunogenic	JJ	O
,	,	O
have	VBP	O
various	JJ	O
water	NN	O
solubility	NN	O
properties	NNS	O
,	,	O
and	CC	O
are	VBP	O
easily	RB	O
excreted	VBN	O
from	IN	O
living	VBG	O
organisms	NNS	O
.	.	O
PEG	NNP	O
is	VBZ	O
the	DT	O
preferred	JJ	O
polymer	NN	O
molecule	NN	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
since	IN	O
it	PRP	O
has	VBZ	O
only	RB	O
few	JJ	O
reactive	JJ	O
groups	NNS	O
capable	JJ	O
of	IN	O
cross-linking	NN	O
compared	VBN	O
to	TO	O
e.g.	VB	O
,	,	O
polysaccharides	NNS	O
such	JJ	O
as	IN	O
dextran	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
monofunctional	JJ	O
PEG	NNP	O
,	,	O
e.g.	NN	O
,	,	O
monomethoxypolyethylene	NN	O
glycol	NN	O
(	(	O
mPEG	NN	O
)	)	O
,	,	O
is	VBZ	O
of	IN	O
interest	NN	O
since	IN	O
its	PRP$	O
coupling	VBG	O
chemistry	NN	O
is	VBZ	O
relatively	RB	O
simple	JJ	O
(	(	O
only	RB	O
one	CD	O
reactive	JJ	O
group	NN	O
is	VBZ	O
available	JJ	O
for	IN	O
conjugating	VBG	O
with	IN	O
attachment	JJ	O
groups	NNS	O
on	IN	O
the	DT	O
polypeptide	NN	O
)	)	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
risk	NN	O
of	IN	O
cross-linking	NN	O
is	VBZ	O
eliminated	VBN	O
,	,	O
the	DT	O
resulting	VBG	O
polypeptide	NN	O
conjugates	NNS	O
are	VBP	O
more	RBR	O
homogeneous	JJ	O
and	CC	O
the	DT	O
reaction	NN	O
of	IN	O
the	DT	O
polymer	NN	O
molecules	NNS	O
with	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
easier	JJR	O
to	TO	O
control	VB	O
.	.	O
To	TO	O
effect	NN	O
covalent	JJ	O
attachment	NN	O
of	IN	O
the	DT	O
polymer	NN	O
molecule	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
the	DT	O
polypeptide	NN	O
,	,	O
the	DT	O
hydroxyl	JJ	O
end	NN	O
groups	NNS	O
of	IN	O
the	DT	O
polymer	NN	O
molecule	NN	O
must	MD	O
be	VB	O
provided	VBN	O
in	IN	O
activated	JJ	O
form	NN	O
,	,	O
i.e	NN	O
.	.	O
with	IN	O
reactive	JJ	O
functional	JJ	O
groups	NNS	O
(	(	O
examples	NNS	O
of	IN	O
which	WDT	O
include	VBP	O
primary	JJ	O
amino	NN	O
groups	NNS	O
,	,	O
hydrazide	NN	O
(	(	O
HZ	NNP	O
)	)	O
,	,	O
thiol	RB	O
,	,	O
succinate	NN	O
(	(	O
SUC	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
succinate	NN	O
(	(	O
SS	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
succinamide	NN	O
(	(	O
SSA	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
propionate	NN	O
(	(	O
SPA	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
butanoate	NN	O
(	(	O
SBA	NNP	O
)	)	O
,	,	O
succinimidyl	JJ	O
carboxymethylate	NN	O
(	(	O
SCM	NNP	O
)	)	O
,	,	O
benzotriazole	JJ	O
carbonate	NN	O
(	(	O
BTC	NNP	O
)	)	O
,	,	O
N-hydroxysuccinimide	NNP	O
(	(	O
NHS	NNP	O
)	)	O
,	,	O
aldehyde	RB	O
,	,	O
nitrophenylcarbonate	NN	O
(	(	O
NPC	NNP	O
)	)	O
,	,	O
and	CC	O
tresylate	NN	O
(	(	O
TRES	NNP	O
)	)	O
)	)	O
.	.	O
Suitably	RB	O
activated	VBN	O
polymer	NN	O
molecules	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
from	IN	O
Nektar	NNP	O
Therapeutics	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Huntsville	NNP	O
,	,	O
Ala.	NNP	O
,	,	O
USA	NNP	O
;	:	O
PolyMASC	NNP	O
Pharmaceuticals	NNP	O
plc	NN	O
,	,	O
UK	NNP	O
;	:	O
or	CC	O
SunBio	NNP	O
Corporation	NNP	O
,	,	O
Anyang	NNP	O
City	NNP	O
,	,	O
South	NNP	O
Korea	NNP	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
polymer	NN	O
molecules	NNS	O
can	MD	O
be	VB	O
activated	VBN	O
by	IN	O
conventional	JJ	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
e.g	NN	O
.	.	O
as	IN	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
90/13540	CD	O
.	.	O
Specific	JJ	O
examples	NNS	O
of	IN	O
activated	JJ	O
linear	NN	O
or	CC	O
branched	VBN	O
polymer	NN	O
molecules	NNS	O
suitable	JJ	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
described	VBN	O
in	IN	O
the	DT	O
Nektar	NNP	B
Therapeutics	NNP	I
,	,	I
Inc.	NNP	I
2003	CD	I
Catalog	NNP	I
(	(	I
“	NNP	I
Nektar	NNP	I
Molecule	NNP	I
Engineering	NNP	I
:	:	I
Polyethylene	NNP	I
Glycol	NNP	I
and	CC	I
Derivatives	NNP	I
for	IN	I
Advanced	NNP	I
Pegylation	NNP	I
,	,	I
Catalog	NNP	I
2003	CD	I
”	NNP	I
)	)	I
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
.	.	O
Specific	JJ	O
examples	NNS	O
of	IN	O
activated	JJ	O
PEG	NNP	O
polymers	NNS	O
include	VBP	O
the	DT	O
following	JJ	O
linear	JJ	O
PEGs	NNP	O
:	:	O
NHS-PEG	JJ	O
,	,	O
SPA-PEG	JJ	O
,	,	O
SSPA-PEG	JJ	O
,	,	O
SBA-PEG	JJ	O
,	,	O
SS-PEG	JJ	O
,	,	O
SSA-PEG	JJ	O
,	,	O
SC-PEG	JJ	O
,	,	O
SG-PEG	JJ	O
,	,	O
SCM-PEG	JJ	O
,	,	O
NOR-PEG	JJ	O
,	,	O
BTC-PEG	NNP	O
,	,	O
EPDX-PEG	NNP	O
,	,	O
NCO-PEG	NNP	O
,	,	O
NPC-PEG	NNP	O
,	,	O
CDI-PEG	NNP	O
,	,	O
ALD-PEG	NNP	O
,	,	O
TRES-PEG	NNP	O
,	,	O
VS-PEG	NNP	O
,	,	O
OPSS-PEG	NNP	O
,	,	O
IODO-PEG	NNP	O
,	,	O
and	CC	O
MAL-PEG	NNP	O
,	,	O
and	CC	O
branched	VBD	O
PEGs	NNP	O
,	,	O
such	JJ	O
as	IN	O
PEG2-NHS	NNP	O
,	,	O
PEG2-MAL	NNP	O
,	,	O
and	CC	O
those	DT	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,932,462	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,643,575	CD	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
following	JJ	O
publications	NNS	O
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
,	,	O
disclose	VB	O
useful	JJ	O
polymer	NN	O
molecules	NNS	O
and/or	VBP	O
PEGylation	NNP	O
chemistries	NNS	O
:	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,824,778	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,476,653	CD	O
,	,	O
WO	NNP	O
97/32607	CD	O
,	,	O
EP	NNP	O
229,108	CD	O
,	,	O
EP	NNP	O
402,378	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,902,502	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,281,698	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,122,614	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,219,564	CD	O
,	,	O
WO	NNP	O
92/16555	CD	O
,	,	O
WO	NNP	O
94/04193	CD	O
,	,	O
WO	NNP	O
94/14758	CD	O
,	,	O
WO	NNP	O
94/17039	CD	O
,	,	O
WO	NNP	O
94/18247	CD	O
,	,	O
WO	NNP	O
94/28024	CD	O
,	,	O
WO	NNP	O
95/00162	CD	O
,	,	O
WO	NNP	O
95/11924	CD	O
,	,	O
WO95/13090	NNP	O
,	,	O
WO	NNP	O
95/33490	CD	O
,	,	O
WO	NNP	O
96/00080	CD	O
,	,	O
WO	NNP	O
97/18832	CD	O
,	,	O
WO	NNP	O
98/41562	CD	O
,	,	O
WO	NNP	O
98/48837	CD	O
,	,	O
WO	NNP	O
99/32134	CD	O
,	,	O
WO	NNP	O
99/32139	CD	O
,	,	O
WO	NNP	O
99/32140	CD	O
,	,	O
WO	NNP	O
96/40791	CD	O
,	,	O
WO	NNP	O
98/32466	CD	O
,	,	O
WO	NNP	O
95/06058	CD	O
,	,	O
EP	NNP	O
439	CD	O
508	CD	O
,	,	O
WO	NNP	O
97/03106	CD	O
,	,	O
WO	NNP	O
96/21469	CD	O
,	,	O
WO	NNP	O
95/13312	CD	O
,	,	O
EP	NNP	O
921	CD	O
131	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,736,625	CD	O
,	,	O
WO	NNP	O
98/05363	CD	O
,	,	O
EP	NNP	O
809	CD	O
996	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,629,384	CD	O
,	,	O
WO	NNP	O
96/41813	CD	O
,	,	O
WO	NNP	O
96/07670	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,473,034	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,516,673	CD	O
,	,	O
EP	NNP	O
605	CD	O
963	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,382,657	CD	O
,	,	O
EP	NNP	O
510	CD	O
356	CD	O
,	,	O
EP	NNP	O
400	CD	O
472	CD	O
,	,	O
EP	NNP	O
183	CD	O
503	CD	O
and	CC	O
EP	NNP	O
154	CD	O
316	CD	O
.	.	O
The	DT	O
conjugation	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
and	CC	O
the	DT	O
activated	JJ	O
polymer	NN	O
molecules	NNS	O
is	VBZ	O
conducted	VBN	O
by	IN	O
use	NN	O
of	IN	O
any	DT	O
conventional	JJ	O
method	NN	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
following	JJ	O
references	NNS	O
(	(	O
which	WDT	O
also	RB	O
describe	VBP	O
suitable	JJ	O
methods	NNS	O
for	IN	O
activation	NN	O
of	IN	O
polymer	NN	O
molecules	NNS	O
)	)	O
:	:	O
Harris	NNP	B
and	CC	I
Zalipsky	NNP	I
,	,	I
eds.	NN	I
,	,	I
Poly	NNP	I
(	(	I
ethylene	JJ	I
glycol	NN	I
)	)	I
Chemistry	NN	I
and	CC	I
Biological	NNP	I
Applications	NNP	I
,	,	I
AZC	NNP	I
,	,	I
Washington	NNP	I
;	:	O
R.	NNP	B
F.	NNP	I
Taylor	NNP	I
,	,	I
(	(	I
1991	CD	I
)	)	I
,	,	I
“	JJ	I
Protein	NNP	I
immobilisation	NN	I
.	.	I
Fundamental	JJ	I
and	CC	I
applications	NNS	I
”	VBP	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
N.Y.	NNP	I
;	:	O
S.	NNP	B
S.	NNP	I
Wong	NNP	I
,	,	I
(	(	I
1992	CD	I
)	)	I
,	,	I
“	JJ	I
Chemistry	NNP	I
of	IN	I
Protein	NNP	I
Conjugation	NNP	I
and	CC	I
Crosslinking	NNP	I
”	NNP	I
,	,	I
CRC	NNP	I
Press	NNP	I
,	,	I
Boca	NNP	I
Raton	NNP	I
;	:	O
G.	NNP	B
T.	NNP	I
Hermanson	NNP	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1993	CD	I
)	)	I
,	,	I
“	NNP	I
Immobilized	NNP	I
Affinity	NNP	I
Ligand	NNP	I
Techniques	NNP	I
”	NNP	I
,	,	I
Academic	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
York	NNP	I
.	.	O
For	IN	O
PEGylation	NNP	O
of	IN	O
cysteine	NN	O
residues	NNS	O
,	,	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
usually	RB	O
treated	VBN	O
with	IN	O
a	DT	O
reducing	VBG	O
agent	NN	O
,	,	O
such	JJ	O
as	IN	O
dithiothreitol	NN	O
(	(	O
DDT	NNP	O
)	)	O
prior	RB	O
to	TO	O
PEGylation	NNP	O
.	.	O
The	DT	O
reducing	NN	O
agent	NN	O
is	VBZ	O
subsequently	RB	O
removed	VBN	O
by	IN	O
any	DT	O
conventional	JJ	O
method	NN	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
desalting	VBG	O
.	.	O
Conjugation	NN	O
of	IN	O
PEG	NNP	O
to	TO	O
a	DT	O
cysteine	NN	O
residue	NN	O
typically	RB	O
takes	VBZ	O
place	NN	O
in	IN	O
a	DT	O
suitable	JJ	O
buffer	NN	O
at	IN	O
pH	JJ	O
6-9	JJ	O
at	IN	O
temperatures	NNS	O
varying	VBG	O
from	IN	O
4°	CD	O
C.	NNP	O
to	TO	O
25°	CD	O
C.	NNP	O
for	IN	O
periods	NNS	O
up	RB	O
to	TO	O
about	IN	O
16	CD	O
hours	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
activated	JJ	O
PEG	NNP	O
polymers	NNS	O
for	IN	O
coupling	VBG	O
to	TO	O
cysteine	VB	O
residues	NNS	O
include	VBP	O
the	DT	O
following	JJ	O
linear	NN	O
and	CC	O
branched	VBD	O
PEGs	NNP	O
:	:	O
vinylsulfone-PEG	JJ	O
(	(	O
PEG-VS	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
vinylsulfone-mPEG	JJ	O
(	(	O
mPEG-VS	JJ	O
)	)	O
;	:	O
orthopyridyl-disulfide-PEG	JJ	O
(	(	O
PEG-OPSS	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
orthopyridyl-disulfide-mPE-G	JJ	O
(	(	O
mPEG-OPSS	JJ	O
)	)	O
;	:	O
and	CC	O
maleimide-PEG	JJ	O
(	(	O
PEG-MAL	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
maleimide-mPEG	JJ	O
(	(	O
mPEG-MAL	JJ	O
)	)	O
and	CC	O
branched	VBN	O
maleimide-mPEG2	NN	O
(	(	O
mPEG2-MAL	JJ	O
)	)	O
.	.	O
Pegylation	NN	O
of	IN	O
lysines	NNS	O
often	RB	O
employs	VBZ	O
PEG-N-hydroxylsuccinimide	NNP	O
(	(	O
e.g.	JJ	O
,	,	O
mPEG-NHS	JJ	O
or	CC	O
mPEG2-NHS	NN	O
)	)	O
,	,	O
or	CC	O
esters	NNS	O
such	JJ	O
as	IN	O
PEG	NNP	O
succinimidyl	NN	O
propionate	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mPEG-SPA	JJ	O
)	)	O
or	CC	O
PEG	NNP	O
succinimidyl	JJ	O
butanoate	NN	O
(	(	O
e.g.	JJ	O
,	,	O
mPEG-SBA	JJ	O
)	)	O
.	.	O
One	CD	O
or	CC	O
more	JJR	O
PEGs	NNS	O
can	MD	O
be	VB	O
attached	VBN	O
to	TO	O
a	DT	O
protein	NN	O
within	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
pH	JJ	O
8-9.5	CD	O
at	IN	O
room	NN	O
temperature	NN	O
if	IN	O
about	IN	O
equimolar	JJ	O
amounts	NNS	O
of	IN	O
PEG	NNP	O
and	CC	O
protein	NN	O
are	VBP	O
mixed	JJ	O
.	.	O
A	DT	O
molar	JJ	O
ratio	NN	O
of	IN	O
PEG	NNP	O
to	TO	O
protein	VB	O
amino	JJ	O
groups	NNS	O
of	IN	O
1-5	JJ	O
to	TO	O
1	CD	O
will	MD	O
usually	RB	O
suffice	VB	O
.	.	O
Increasing	VBG	O
pH	NN	O
increases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
reaction	NN	O
,	,	O
while	IN	O
lowering	VBG	O
pH	NN	O
reduces	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
reaction	NN	O
.	.	O
These	DT	O
highly	RB	O
reactive	JJ	O
active	JJ	O
esters	NNS	O
can	MD	O
couple	VB	O
at	IN	O
physiological	JJ	O
pH	NN	O
,	,	O
but	CC	O
less	RBR	O
reactive	JJ	O
derivatives	NNS	O
typically	RB	O
require	VBP	O
higher	JJR	O
pH	NN	O
.	.	O
Low	JJ	O
temperatures	NNS	O
may	MD	O
also	RB	O
be	VB	O
employed	VBN	O
if	IN	O
a	DT	O
labile	NN	O
protein	NN	O
is	VBZ	O
being	VBG	O
used	VBN	O
.	.	O
Under	IN	O
low	JJ	O
temperature	NN	O
conditions	NNS	O
,	,	O
a	DT	O
longer	JJR	O
reaction	NN	O
time	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
N-terminal	JJ	O
PEGylation	NNP	O
is	VBZ	O
facilitated	VBN	O
by	IN	O
the	DT	O
difference	NN	O
between	IN	O
the	DT	O
pKa	NN	O
values	NNS	O
of	IN	O
the	DT	O
alpha-amino	JJ	O
group	NN	O
of	IN	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
acid	NN	O
(	(	O
about	IN	O
6	CD	O
to	TO	O
8.0	CD	O
)	)	O
and	CC	O
the	DT	O
epsilon-amino	JJ	O
group	NN	O
of	IN	O
lysine	NN	O
(	(	O
about	IN	O
10	CD	O
)	)	O
.	.	O
PEGylation	NN	O
of	IN	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
group	NN	O
often	RB	O
employs	VBZ	O
PEG-aldehydes	NNS	O
(	(	O
such	JJ	O
as	IN	O
mPEG-propionaldehyde	JJ	O
or	CC	O
mPEG-butylaldehyde	JJ	O
)	)	O
,	,	O
which	WDT	O
are	VBP	O
more	RBR	O
selective	JJ	O
for	IN	O
amines	NNS	O
and	CC	O
thus	RB	O
are	VBP	O
less	RBR	O
likely	JJ	O
to	TO	O
react	VB	O
with	IN	O
the	DT	O
imidazole	JJ	O
group	NN	O
of	IN	O
histidine	NN	O
;	:	O
in	IN	O
addition	NN	O
,	,	O
PEG	NNP	O
reagents	NNS	O
used	VBD	O
for	IN	O
lysine	JJ	O
conjugation	NN	O
(	(	O
such	JJ	O
as	IN	O
mPEG-SPA	JJ	O
,	,	O
mPEG-SBA	JJ	O
,	,	O
or	CC	O
mPEG-NHS	NNS	O
)	)	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
conjugation	NN	O
of	IN	O
the	DT	O
N-terminal	JJ	O
amine	NN	O
.	.	O
Conjugation	NN	O
of	IN	O
a	DT	O
PEG-aldehyde	NNP	O
to	TO	O
the	DT	O
N-terminal	NNP	O
amino	NN	O
group	NN	O
typically	RB	O
takes	VBZ	O
place	NN	O
in	IN	O
a	DT	O
suitable	JJ	O
buffer	NN	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
100	CD	O
mM	NN	O
sodium	NN	O
acetate	NN	O
or	CC	O
100	CD	O
mM	JJ	O
sodium	NN	O
bisphosphate	NN	O
buffer	NN	O
with	IN	O
20	CD	O
mM	NNS	O
sodium	JJ	O
cyanoborohydride	NN	O
)	)	O
at	IN	O
pH	NN	O
about	IN	O
5.0	CD	O
overnight	NN	O
at	IN	O
temperatures	NNS	O
varying	VBG	O
from	IN	O
about	IN	O
4°	CD	O
C.	NNP	O
to	TO	O
25°	CD	O
C.	NNP	O
Useful	NNP	O
N-terminal	JJ	O
PEGylation	NNP	O
methods	NNS	O
and	CC	O
chemistries	NNS	O
are	VBP	O
also	RB	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,985,265	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,077,939	CD	O
,	,	O
both	DT	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
Typically	RB	O
,	,	O
linear	JJ	O
PEG	NNP	O
or	CC	O
mPEG	NN	O
polymers	NNS	O
will	MD	O
have	VB	O
a	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
5	CD	O
kDa	NNS	O
,	,	O
about	RB	O
10	CD	O
kDa	NNS	O
,	,	O
about	RB	O
12	CD	O
kDa	NNS	O
,	,	O
about	RB	O
15	CD	O
kDa	NNS	O
,	,	O
about	RB	O
20	CD	O
kDa	NNS	O
,	,	O
or	CC	O
about	IN	O
30	CD	O
kDa	NNS	O
.	.	O
Branched	VBN	O
PEG	NNP	O
(	(	O
PEG2	NNP	O
or	CC	O
mPEG2	NN	O
)	)	O
polymers	NNS	O
will	MD	O
typically	RB	O
have	VB	O
a	DT	O
molecular	JJ	O
weight	NN	O
of	IN	O
about	IN	O
10	CD	O
kDa	NNS	O
,	,	O
about	RB	O
20	CD	O
kDa	NNS	O
,	,	O
or	CC	O
about	IN	O
40	CD	O
kDa	NNS	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
the	DT	O
higher-molecular	JJ	O
weight	NN	O
branched	VBD	O
PEG2	NNP	O
reagents	NNS	O
,	,	O
such	JJ	O
as	IN	O
20	CD	O
kDa	NN	O
or	CC	O
40	CD	O
kDa	NN	O
PEG2	NNP	O
,	,	O
including	VBG	O
e.g	NN	O
.	.	O
mPEG2-NHS	NN	O
for	IN	O
lysine	JJ	O
PEGylation	NNP	O
,	,	O
mPEG2-MAL	NN	O
for	IN	O
cysteine	NN	O
PEGylation	NNP	O
,	,	O
or	CC	O
MPEG2-aldehyde	NNP	O
for	IN	O
N-terminal	NNP	O
PEGylation	NNP	O
(	(	O
all	DT	O
available	JJ	O
from	IN	O
Nektar	NNP	O
Therapeutics	NNP	O
,	,	O
Inc	NNP	O
,	,	O
Huntsville	NNP	O
Ala.	NNP	O
)	)	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
The	DT	O
branched	JJ	O
structure	NN	O
of	IN	O
the	DT	O
PEG2	NNP	O
compound	NN	O
results	NNS	O
in	IN	O
a	DT	O
relatively	RB	O
large	JJ	O
molecular	JJ	O
volume	NN	O
,	,	O
so	RB	O
fewer	JJR	O
attached	JJ	O
molecules	NNS	O
(	(	O
or	CC	O
,	,	O
one	CD	O
attached	VBN	O
molecule	NN	O
)	)	O
may	MD	O
impart	VB	O
the	DT	O
desired	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
PEGylated	NNP	O
molecule	NN	O
.	.	O
The	DT	O
skilled	JJ	O
person	NN	O
will	MD	O
be	VB	O
aware	JJ	O
that	IN	O
the	DT	O
activation	NN	O
method	NN	O
and/or	JJ	O
conjugation	NN	O
chemistry	NN	O
to	TO	O
be	VB	O
used	VBN	O
depends	VBZ	O
on	IN	O
the	DT	O
attachment	NN	O
group	NN	O
(	(	O
s	PRP	O
)	)	O
of	IN	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
functional	JJ	O
groups	NNS	O
of	IN	O
the	DT	O
polymer	NN	O
(	(	O
e.g.	NN	O
,	,	O
being	VBG	O
amino	NN	O
,	,	O
hydroxyl	NN	O
,	,	O
carboxyl	NN	O
,	,	O
aldehyde	NN	O
or	CC	O
sulfhydryl	NN	O
)	)	O
.	.	O
The	DT	O
PEGylation	NN	O
may	MD	O
be	VB	O
directed	VBN	O
towards	NNS	O
conjugation	NN	O
to	TO	O
all	DT	O
available	JJ	O
attachment	NN	O
groups	NNS	O
on	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
i.e	NN	O
.	.	O
such	JJ	O
attachment	NN	O
groups	NNS	O
that	WDT	O
are	VBP	O
exposed	VBN	O
at	IN	O
the	DT	O
surface	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
)	)	O
or	CC	O
may	MD	O
be	VB	O
directed	VBN	O
towards	NNS	O
specific	JJ	O
attachment	NN	O
groups	NNS	O
,	,	O
e.g	NN	O
.	.	O
cysteine	NN	O
residues	NNS	O
,	,	O
lysine	NN	O
residues	NNS	O
,	,	O
or	CC	O
the	DT	O
N-terminal	JJ	O
amino	NN	O
group	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
conjugation	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
one	CD	O
step	NN	O
or	CC	O
in	IN	O
a	DT	O
stepwise	NN	O
manner	NN	O
(	(	O
e.g.	JJ	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
WO	NNP	O
99/55377	CD	O
)	)	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
the	DT	O
polymer	NN	O
conjugation	NN	O
is	VBZ	O
performed	VBN	O
under	IN	O
conditions	NNS	O
aiming	VBG	O
at	IN	O
reacting	VBG	O
as	IN	O
many	JJ	O
of	IN	O
the	DT	O
available	JJ	O
polymer	NN	O
attachment	NN	O
groups	NNS	O
as	IN	O
possible	JJ	O
with	IN	O
polymer	JJ	O
molecules	NNS	O
.	.	O
This	DT	O
is	VBZ	O
achieved	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
suitable	JJ	O
molar	JJ	O
excess	NN	O
of	IN	O
the	DT	O
polymer	NN	O
in	IN	O
relation	NN	O
to	TO	O
the	DT	O
polypeptide	NN	O
.	.	O
Typical	JJ	O
molar	JJ	O
ratios	NNS	O
of	IN	O
activated	JJ	O
polymer	NN	O
molecules	NNS	O
to	TO	O
polypeptide	VB	O
are	VBP	O
up	RB	O
to	TO	O
about	IN	O
1000-1	JJ	O
,	,	O
such	JJ	O
as	IN	O
up	IN	O
to	TO	O
about	IN	O
200-1	CD	O
or	CC	O
up	RB	O
to	TO	O
about	IN	O
100-1	NNS	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
the	DT	O
ratio	NN	O
may	MD	O
be	VB	O
somewhat	RB	O
lower	JJR	O
,	,	O
however	RB	O
,	,	O
such	JJ	O
as	IN	O
up	IN	O
to	TO	O
about	IN	O
50-1	JJ	O
,	,	O
10-1	JJ	O
or	CC	O
5-1	JJ	O
.	.	O
Also	RB	O
equimolar	JJ	O
ratios	NNS	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
contemplated	VBN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
to	TO	O
couple	VB	O
the	DT	O
polymer	NN	O
molecules	NNS	O
to	TO	O
the	DT	O
polypeptide	NN	O
through	IN	O
a	DT	O
linker	NN	O
.	.	O
Suitable	JJ	O
linkers	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
the	DT	O
skilled	JJ	O
person	NN	O
.	.	O
A	DT	O
preferred	JJ	O
example	NN	O
is	VBZ	O
cyanuric	JJ	O
chloride	NN	O
(	(	O
Abuchowski	NNP	B
et	RB	I
al.	RB	I
,	,	I
(	(	I
1977	CD	I
)	)	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
252	CD	I
,	,	I
3578-3581	CD	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,179,337	CD	O
;	:	O
Shafer	NNP	B
et	FW	I
al.	NN	I
,	,	I
(	(	I
1986	CD	I
)	)	I
,	,	I
J.	NNP	I
Polym	NNP	I
.	.	I
Sci	NNP	I
.	.	I
Polym	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Ed.	NNP	I
,	,	I
24	CD	I
,	,	I
375-378	JJ	I
)	)	O
.	.	O
Subsequent	JJ	O
to	TO	O
the	DT	O
conjugation	NN	O
residual	JJ	O
activated	VBD	O
polymer	NN	O
molecules	NNS	O
are	VBP	O
blocked	VBN	O
according	VBG	O
to	TO	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
addition	NN	O
of	IN	O
primary	JJ	O
amine	NN	O
to	TO	O
the	DT	O
reaction	NN	O
mixture	NN	O
,	,	O
and	CC	O
the	DT	O
resulting	VBG	O
inactivated	JJ	O
polymer	NN	O
molecules	NNS	O
removed	VBN	O
by	IN	O
a	DT	O
suitable	JJ	O
method	NN	O
.	.	O
Covalent	NN	O
in	IN	O
vitro	JJ	O
coupling	NN	O
of	IN	O
a	DT	O
sugar	NN	O
moiety	NN	O
to	TO	O
amino	VB	O
acid	JJ	O
residues	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
modify	VB	O
or	CC	O
increase	VB	O
the	DT	O
number	NN	O
or	CC	O
profile	NN	O
of	IN	O
sugar	NN	O
substituents	NNS	O
.	.	O
Depending	VBG	O
on	IN	O
the	DT	O
coupling	NN	O
mode	NN	O
used	VBN	O
,	,	O
the	DT	O
carbohydrate	NN	O
(	(	O
s	PRP	O
)	)	O
may	MD	O
be	VB	O
attached	VBN	O
to	TO	O
:	:	O
a	DT	O
)	)	O
arginine	NN	O
and	CC	O
histidine	NN	O
(	(	O
Lundblad	NNP	B
and	CC	I
Noyes	NNP	I
,	,	I
Chemical	NNP	I
Reagents	NNP	I
for	IN	I
Protein	NNP	I
Modification	NNP	I
,	,	I
CRC	NNP	I
Press	NNP	I
Inc.	NNP	I
Boca	NNP	I
Raton	NNP	I
,	,	I
Fla.	NNP	I
)	)	O
,	,	O
b	NN	O
)	)	O
free	JJ	O
carboxyl	NN	O
groups	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
of	IN	O
the	DT	O
C-terminal	NNP	O
amino	NN	O
acid	NN	O
residue	NN	O
,	,	O
asparagine	NN	O
or	CC	O
glutamine	NN	O
)	)	O
,	,	O
c	VBP	O
)	)	O
free	JJ	O
sulfhydryl	NN	O
groups	NNS	O
such	JJ	O
as	IN	O
that	DT	O
of	IN	O
cysteine	NN	O
,	,	O
d	NN	O
)	)	O
free	JJ	O
hydroxyl	NN	O
groups	NNS	O
such	JJ	O
as	IN	O
those	DT	O
of	IN	O
serine	NN	O
,	,	O
threonine	NN	O
,	,	O
tyrosine	NN	O
or	CC	O
hydroxyproline	NN	O
,	,	O
e	NN	O
)	)	O
aromatic	JJ	O
residues	NNS	O
such	JJ	O
as	IN	O
those	DT	O
of	IN	O
phenylalanine	NN	O
or	CC	O
tryptophan	NN	O
or	CC	O
f	NN	O
)	)	O
the	DT	O
amide	JJ	O
group	NN	O
of	IN	O
glutamine	NN	O
.	.	O
These	DT	O
amino	JJ	O
acid	NN	O
residues	NNS	O
constitute	VBP	O
examples	NNS	O
of	IN	O
attachment	NN	O
groups	NNS	O
for	IN	O
a	DT	O
sugar	NN	O
moiety	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
introduced	VBN	O
and/or	RB	O
removed	VBN	O
in	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Suitable	JJ	O
methods	NNS	O
of	IN	O
in	IN	O
vitro	NN	O
coupling	NN	O
are	VBP	O
described	VBN	O
in	IN	O
WO	NNP	O
87/05330	CD	O
and	CC	O
in	IN	O
Aplin	NNP	B
et	CC	I
al.	NN	I
,	,	I
CRC	NNP	I
Crit	NNP	I
Rev	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
pp	NN	I
.	.	I
259-306	CD	I
,	,	I
1981	CD	I
.	.	O
The	DT	O
in	IN	O
vitro	JJ	O
coupling	NN	O
of	IN	O
sugar	NN	O
moieties	NNS	O
or	CC	O
PEG	NNP	O
to	TO	O
protein-	NN	O
and	CC	O
peptide-bound	JJ	O
Gln-residues	NNS	O
can	MD	O
also	RB	O
be	VB	O
carried	VBN	O
out	RP	O
by	IN	O
transglutaminases	NNS	O
(	(	O
TGases	NNPS	O
)	)	O
,	,	O
e.g	UH	O
.	.	O
as	IN	O
described	VBN	O
by	IN	O
Sato	NNP	B
et	FW	I
al.	NN	I
,	,	I
1996	CD	I
Biochemistry	NNP	I
35	CD	I
,	,	I
13072-13080	CD	I
or	CC	O
in	IN	O
EP	NNP	O
725145	CD	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
achieve	VB	O
in	IN	O
vivo	JJ	O
glycosylation	NN	O
of	IN	O
an	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
modified	VBN	O
by	IN	O
introduction	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
glycosylation	NN	O
sites	NNS	O
,	,	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
the	DT	O
polypeptide	JJ	O
part	NN	O
of	IN	O
the	DT	O
conjugate	NN	O
is	VBZ	O
inserted	VBN	O
in	IN	O
a	DT	O
glycosylating	NN	O
,	,	O
eukaryotic	JJ	O
expression	NN	O
host	NN	O
.	.	O
The	DT	O
expression	NN	O
host	NN	O
cell	NN	O
may	MD	O
be	VB	O
selected	VBN	O
from	IN	O
fungal	JJ	O
(	(	O
filamentous	JJ	O
fungal	NN	O
or	CC	O
yeast	NN	O
)	)	O
,	,	O
insect	JJ	O
,	,	O
mammalian	JJ	O
animal	NN	O
cells	NNS	O
,	,	O
from	IN	O
transgenic	JJ	O
plant	NN	O
cells	NNS	O
or	CC	O
from	IN	O
transgenic	JJ	O
animals	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
glycosylation	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
the	DT	O
human	JJ	O
body	NN	O
when	WRB	O
using	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
the	DT	O
polypeptide	JJ	O
part	NN	O
of	IN	O
a	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
or	CC	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
gene	NN	O
therapy	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
the	DT	O
host	NN	O
cell	NN	O
is	VBZ	O
a	DT	O
mammalian	JJ	O
cell	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
CHO	NNP	O
cell	NN	O
,	,	O
a	DT	O
COS	NNP	O
cell	NN	O
,	,	O
a	DT	O
BHK	NNP	O
or	CC	O
HEK	NNP	O
cell	NN	O
,	,	O
e.g.	NN	O
,	,	O
HEK293	NNP	O
,	,	O
or	CC	O
an	DT	O
insect	JJ	O
cell	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
SF9	NNP	O
cell	NN	O
,	,	O
or	CC	O
a	DT	O
yeast	NN	O
cell	NN	O
,	,	O
e.g	NN	O
.	.	O
Saccharomyces	NNS	O
cerevisiae	NN	O
,	,	O
Pichia	NNP	O
pastoris	NN	O
or	CC	O
any	DT	O
other	JJ	O
suitable	JJ	O
glycosylating	VBG	O
host	NN	O
,	,	O
e.g	NN	O
.	.	O
as	IN	O
described	VBN	O
further	RB	O
below	IN	O
.	.	O
Optionally	RB	O
,	,	O
sugar	NN	O
moieties	NNS	O
attached	VBN	O
to	TO	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	NN	O
by	IN	O
in	IN	O
vivo	JJ	O
glycosylation	NN	O
are	VBP	O
further	JJ	O
modified	VBN	O
by	IN	O
use	NN	O
of	IN	O
glycosyltransferases	NNS	O
,	,	O
e.g.	NN	O
,	,	O
using	VBG	O
the	DT	O
GlycoAdvance™	NNP	O
technology	NN	O
marketed	VBN	O
by	IN	O
Neose	NNP	O
,	,	O
Horsham	NNP	O
,	,	O
Pa.	NNP	O
,	,	O
USA	NNP	O
.	.	O
Thereby	RB	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
,	,	O
e.g.	VB	O
,	,	O
increase	VB	O
the	DT	O
sialyation	NN	O
of	IN	O
the	DT	O
glycosylated	JJ	O
oligoadenylate	NN	O
synthetase	NN	O
polypeptide	NN	O
following	VBG	O
expression	NN	O
and	CC	O
in	IN	O
vivo	JJ	O
glycosylation	NN	O
by	IN	O
CHO	NNP	O
cells	NNS	O
.	.	O
Covalent	JJ	O
modification	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
performed	VBN	O
by	IN	O
reacting	VBG	O
(	(	O
an	DT	O
)	)	O
attachment	NN	O
group	NN	O
(	(	O
s	PRP	O
)	)	O
of	IN	O
the	DT	O
polypeptide	NN	O
with	IN	O
an	DT	O
organic	JJ	O
derivatizing	NN	O
agent	NN	O
.	.	O
Suitable	JJ	O
derivatizing	VBG	O
agents	NNS	O
and	CC	O
methods	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cysteinyl	NN	O
residues	NNS	O
most	RBS	O
commonly	RB	O
are	VBP	O
reacted	VBN	O
with	IN	O
alpha-haloacetates	NNS	O
(	(	O
and	CC	O
corresponding	VBG	O
amines	NNS	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
chloroacetic	JJ	O
acid	NN	O
or	CC	O
chloroacetamide	NN	O
,	,	O
to	TO	O
give	VB	O
carboxymethyl	NN	O
or	CC	O
carboxyamidomethyl	NN	O
derivatives	NNS	O
.	.	O
Cysteinyl	NNP	O
residues	NNS	O
also	RB	O
are	VBP	O
derivatized	VBN	O
by	IN	O
reaction	NN	O
with	IN	O
bromotrifluoroacetone	NN	O
,	,	O
alpha-bromo-beta-	JJ	O
(	(	O
4-imidozoyl-	JJ	O
)	)	O
propionic	JJ	O
acid	NN	O
,	,	O
chloroacetyl	NN	O
phosphate	NN	O
,	,	O
N-alkylmaleimides	NNP	O
,	,	O
3-nitro-2-pyridyl	JJ	O
disulfide	NN	O
,	,	O
methyl	JJ	O
2-pyridyl	JJ	O
disulfide	NN	O
,	,	O
p-chloromercuribenzoate	JJ	O
,	,	O
2-chloromercuri-4-nitrophenol	JJ	O
,	,	O
or	CC	O
chloro-7-nitrobenzo-2-oxa-1,3-diazole	NN	O
.	.	O
Histidyl	NNP	O
residues	NNS	O
are	VBP	O
derivatized	VBN	O
by	IN	O
reaction	NN	O
with	IN	O
diethylpyrocarbonate	NN	O
at	IN	O
pH	JJ	O
5.5-7.0	JJ	O
because	IN	O
this	DT	O
agent	NN	O
is	VBZ	O
relatively	RB	O
specific	JJ	O
for	IN	O
the	DT	O
histidyl	JJ	O
side	NN	O
chain	NN	O
.	.	O
Para-bromophenacyl	NNP	O
bromide	NN	O
is	VBZ	O
also	RB	O
useful	JJ	O
;	:	O
the	DT	O
reaction	NN	O
is	VBZ	O
preferably	RB	O
performed	VBN	O
in	IN	O
0.1	CD	O
M	NNP	O
sodium	NN	O
cacodylate	NN	O
at	IN	O
pH	JJ	O
6.0	CD	O
.	.	O
Lysinyl	NNP	O
and	CC	O
amino	JJ	O
terminal	NN	O
residues	NNS	O
are	VBP	O
reacted	VBN	O
with	IN	O
succinic	JJ	O
or	CC	O
other	JJ	O
carboxylic	JJ	O
acid	NN	O
anhydrides	NNS	O
.	.	O
Derivatization	NN	O
with	IN	O
these	DT	O
agents	NNS	O
has	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
reversing	VBG	O
the	DT	O
charge	NN	O
of	IN	O
the	DT	O
lysinyl	NN	O
residues	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
reagents	NNS	O
for	IN	O
derivatizing	VBG	O
alpha-amino-containing	JJ	O
residues	NNS	O
include	VBP	O
imidoesters	NNS	O
such	JJ	O
as	IN	O
methyl	JJ	O
picolinimidate	NN	O
;	:	O
pyridoxal	JJ	O
phosphate	NN	O
;	:	O
pyridoxal	CC	O
;	:	O
chloroborohydride	NN	O
;	:	O
trinitrobenzenesulfonic	JJ	O
acid	NN	O
;	:	O
O-methylisourea	NNP	O
;	:	O
2,4-pentanedione	CD	O
;	:	O
and	CC	O
transaminase-catalyzed	JJ	O
reaction	NN	O
with	IN	O
glyoxylate	NN	O
.	.	O
Arginyl	NNP	O
residues	NNS	O
are	VBP	O
modified	VBN	O
by	IN	O
reaction	NN	O
with	IN	O
one	CD	O
or	CC	O
several	JJ	O
conventional	JJ	O
reagents	NNS	O
,	,	O
among	IN	O
them	PRP	O
phenylglyoxal	VBP	O
,	,	O
2,3-butanedione	JJ	O
,	,	O
1,2-cyclohexanedione	JJ	O
,	,	O
and	CC	O
ninhydrin	RB	O
.	.	O
Derivatization	NN	O
of	IN	O
arginine	NN	O
residues	NNS	O
requires	VBZ	O
that	IN	O
the	DT	O
reaction	NN	O
be	VB	O
performed	VBN	O
in	IN	O
alkaline	JJ	O
conditions	NNS	O
because	IN	O
of	IN	O
the	DT	O
high	JJ	O
pKa	NN	O
of	IN	O
the	DT	O
guanidine	JJ	O
functional	JJ	O
group	NN	O
.	.	O
Furthermore	RB	O
,	,	O
these	DT	O
reagents	NNS	O
may	MD	O
react	VB	O
with	IN	O
the	DT	O
groups	NNS	O
of	IN	O
lysine	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
arginine	NN	O
guanidino	NN	O
group	NN	O
.	.	O
Carboxyl	NNP	O
side	NN	O
groups	NNS	O
(	(	O
aspartyl	NN	O
or	CC	O
glutamyl	NN	O
or	CC	O
C-terminal	JJ	O
amino	NN	O
acid	IN	O
residue	NN	O
)	)	O
are	VBP	O
selectively	RB	O
modified	VBN	O
by	IN	O
reaction	NN	O
with	IN	O
carbodiimides	NNS	O
(	(	O
R—N-double	JJ	O
bond-C-double	JJ	O
bond-N—R′	NN	O
)	)	O
,	,	O
where	WRB	O
R	NNP	O
and	CC	O
R′	NNP	O
are	VBP	O
different	JJ	O
alkyl	NN	O
groups	NNS	O
,	,	O
such	JJ	O
as	IN	O
1-cyclohexyl-3-	JJ	O
(	(	O
2-morpholinyl-4-ethyl	JJ	O
)	)	O
carbodiimide	NN	O
or	CC	O
1-ethyl-3-	JJ	O
(	(	O
4-azonia-4,4-dimethylpentyl	JJ	O
)	)	O
carbodiimide	NN	O
.	.	O
Furthermore	RB	O
,	,	O
aspartyl	NN	O
and	CC	O
glutamyl	NN	O
residues	NNS	O
are	VBP	O
converted	VBN	O
to	TO	O
asparaginyl	VB	O
and	CC	O
glutaminyl	VB	O
residues	NNS	O
by	IN	O
reaction	NN	O
with	IN	O
ammonium	NN	O
ions	NNS	O
.	.	O
Since	IN	O
excessive	JJ	O
polymer	NN	O
conjugation	NN	O
may	MD	O
lead	VB	O
to	TO	O
a	DT	O
loss	NN	O
of	IN	O
activity	NN	O
of	IN	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptides	NNS	O
to	TO	O
which	WDT	O
the	DT	O
polymer	NN	O
is	VBZ	O
conjugated	VBN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
advantageous	JJ	O
to	TO	O
remove	VB	O
attachment	NN	O
groups	NNS	O
located	VBN	O
at	IN	O
the	DT	O
functional	JJ	O
site	NN	O
or	CC	O
to	TO	O
block	VB	O
the	DT	O
functional	JJ	O
site	NN	O
prior	RB	O
to	TO	O
conjugation	NN	O
.	.	O
These	DT	O
latter	JJ	O
strategies	NNS	O
constitute	VBP	O
further	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
the	DT	O
first	JJ	O
strategy	NN	O
being	VBG	O
exemplified	VBN	O
further	RBR	O
above	IN	O
,	,	O
e.g	NN	O
.	.	O
by	IN	O
removal	NN	O
of	IN	O
lysine	NN	O
residues	NNS	O
which	WDT	O
may	MD	O
be	VB	O
located	VBN	O
close	RB	O
to	TO	O
a	DT	O
functional	JJ	O
site	NN	O
)	)	O
.	.	O
More	RBR	O
specifically	RB	O
,	,	O
according	VBG	O
to	TO	O
the	DT	O
second	JJ	O
strategy	NN	O
the	DT	O
conjugation	NN	O
between	IN	O
the	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
polypeptide	NN	O
and	CC	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
conducted	VBN	O
under	IN	O
conditions	NNS	O
where	WRB	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
blocked	VBN	O
by	IN	O
a	DT	O
helper	NN	O
molecule	NN	O
capable	JJ	O
of	IN	O
binding	VBG	O
to	TO	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
helper	NN	O
molecule	NN	O
is	VBZ	O
one	CD	O
which	WDT	O
specifically	RB	O
recognizes	VBZ	O
a	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
helper	NN	O
molecule	NN	O
may	MD	O
be	VB	O
an	DT	O
antibody	NN	O
,	,	O
in	IN	O
particular	JJ	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
recognizing	VBG	O
the	DT	O
polypeptide	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
the	DT	O
helper	NN	O
molecule	NN	O
may	MD	O
be	VB	O
a	DT	O
neutralizing	JJ	O
monoclonal	JJ	O
antibody	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
before	IN	O
effecting	VBG	O
conjugation	NN	O
.	.	O
This	DT	O
ensures	VBZ	O
that	IN	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
shielded	VBN	O
or	CC	O
protected	VBN	O
and	CC	O
consequently	RB	O
unavailable	JJ	O
for	IN	O
derivatization	NN	O
by	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
such	JJ	O
as	IN	O
a	DT	O
polymer	NN	O
.	.	O
Following	VBG	O
its	PRP$	O
elution	NN	O
from	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
,	,	O
the	DT	O
conjugate	NN	O
between	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
and	CC	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
recovered	VBN	O
with	IN	O
at	IN	O
least	JJS	O
a	DT	O
partially	RB	O
preserved	VBN	O
functional	JJ	O
site	NN	O
.	.	O
The	DT	O
subsequent	JJ	O
conjugation	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
having	VBG	O
a	DT	O
blocked	JJ	O
functional	JJ	O
site	NN	O
to	TO	O
a	DT	O
polymer	NN	O
,	,	O
a	DT	O
lipophilic	JJ	O
compound	NN	O
,	,	O
an	DT	O
organic	JJ	O
derivatizing	NN	O
agent	NN	O
or	CC	O
any	DT	O
other	JJ	O
compound	NN	O
is	VBZ	O
conducted	VBN	O
in	IN	O
the	DT	O
normal	JJ	O
way	NN	O
.	.	O
Irrespective	NNP	O
of	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
to	TO	O
be	VB	O
used	VBN	O
to	TO	O
shield	VB	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
from	IN	O
conjugation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
that	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
is	VBZ	O
free	JJ	O
from	IN	O
or	CC	O
comprises	VBZ	O
only	RB	O
a	DT	O
few	JJ	O
attachment	NN	O
groups	NNS	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
of	IN	O
choice	NN	O
in	IN	O
parts	NNS	O
of	IN	O
the	DT	O
molecule	NN	O
where	WRB	O
the	DT	O
conjugation	NN	O
to	TO	O
such	JJ	O
groups	NNS	O
would	MD	O
hamper	VB	O
the	DT	O
desorption	NN	O
of	IN	O
the	DT	O
conjugated	JJ	O
polypeptide	NN	O
from	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
.	.	O
Hereby	NNP	O
,	,	O
selective	JJ	O
conjugation	NN	O
to	TO	O
attachment	VB	O
groups	NNS	O
present	JJ	O
in	IN	O
non-shielded	JJ	O
parts	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
and	CC	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
reuse	VB	O
the	DT	O
helper	NN	O
molecule	NN	O
for	IN	O
repeated	JJ	O
cycles	NNS	O
of	IN	O
conjugation	NN	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
if	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
is	VBZ	O
a	DT	O
polymer	JJ	O
molecule	NN	O
such	JJ	O
as	IN	O
PEG	NNP	O
,	,	O
which	WDT	O
has	VBZ	O
the	DT	O
epsilon	NN	O
amino	NN	O
group	NN	O
of	IN	O
a	DT	O
lysine	NN	O
or	CC	O
N-terminal	JJ	O
amino	NN	O
acid	NN	O
residue	NN	O
as	IN	O
an	DT	O
attachment	NN	O
group	NN	O
,	,	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
that	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
is	VBZ	O
substantially	RB	O
free	JJ	O
from	IN	O
conjugatable	JJ	O
epsilon	NN	O
amino	NN	O
groups	NNS	O
,	,	O
preferably	RB	O
free	JJ	O
from	IN	O
any	DT	O
epsilon	NN	O
amino	NN	O
groups	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
in	IN	O
some	DT	O
instances	NNS	O
the	DT	O
helper	NN	O
molecule	NN	O
is	VBZ	O
a	DT	O
protein	NN	O
or	CC	O
peptide	NN	O
capable	JJ	O
of	IN	O
binding	VBG	O
to	TO	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
,	,	O
which	WDT	O
protein	VBP	O
or	CC	O
peptide	VBP	O
is	VBZ	O
free	JJ	O
from	IN	O
any	DT	O
conjugatable	JJ	O
attachment	NN	O
groups	NNS	O
for	IN	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
of	IN	O
choice	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
helper	NN	O
molecule	NN	O
is	VBZ	O
first	RB	O
covalently	RB	O
linked	VBN	O
to	TO	O
a	DT	O
solid	JJ	O
phase	NN	O
such	JJ	O
as	IN	O
column	NN	O
packing	NN	O
materials	NNS	O
,	,	O
for	IN	O
instance	NN	O
Sephadex	NNP	O
or	CC	O
agarose	JJ	O
beads	NNS	O
,	,	O
or	CC	O
a	DT	O
surface	NN	O
,	,	O
e.g	NN	O
.	.	O
reaction	NN	O
vessel	NN	O
.	.	O
Subsequently	RB	O
,	,	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
loaded	VBN	O
onto	IN	O
the	DT	O
column	NN	O
material	NN	O
carrying	VBG	O
the	DT	O
helper	NN	O
molecule	NN	O
and	CC	O
conjugation	NN	O
carried	VBD	O
out	RP	O
according	VBG	O
to	TO	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
This	DT	O
procedure	NN	O
allows	VBZ	O
the	DT	O
polypeptide	NN	O
conjugate	NN	O
to	TO	O
be	VB	O
separated	VBN	O
from	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
by	IN	O
elution	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
conjugate	NN	O
is	VBZ	O
eluted	VBN	O
by	IN	O
conventional	JJ	O
techniques	NNS	O
under	IN	O
physico-chemical	JJ	O
conditions	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
lead	VB	O
to	TO	O
a	DT	O
substantive	JJ	O
degradation	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
conjugate	NN	O
.	.	O
The	DT	O
fluid	NN	O
phase	NN	O
containing	VBG	O
the	DT	O
polypeptide	NN	O
conjugate	NN	O
is	VBZ	O
separated	VBN	O
from	IN	O
the	DT	O
solid	JJ	O
phase	NN	O
to	TO	O
which	WDT	O
the	DT	O
helper	NN	O
molecule	NN	O
remains	VBZ	O
covalently	RB	O
linked	VBN	O
.	.	O
The	DT	O
separation	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
other	JJ	O
ways	NNS	O
.	.	O
For	IN	O
instance	NN	O
,	,	O
the	DT	O
helper	NN	O
molecule	NN	O
may	MD	O
be	VB	O
derivatized	VBN	O
with	IN	O
a	DT	O
second	JJ	O
molecule	NN	O
(	(	O
e.g.	JJ	O
,	,	O
biotin	NN	O
)	)	O
that	WDT	O
can	MD	O
be	VB	O
recognized	VBN	O
by	IN	O
a	DT	O
specific	JJ	O
binder	NN	O
(	(	O
e.g.	JJ	O
,	,	O
streptavidin	NN	O
)	)	O
.	.	O
The	DT	O
specific	JJ	O
binder	NN	O
may	MD	O
be	VB	O
linked	VBN	O
to	TO	O
a	DT	O
solid	JJ	O
phase	NN	O
thereby	RB	O
allowing	VBG	O
the	DT	O
separation	NN	O
of	IN	O
the	DT	O
polypeptide	JJ	O
conjugate	NN	O
from	IN	O
the	DT	O
helper	JJR	O
molecule-second	NN	O
molecule	NN	O
complex	NN	O
through	IN	O
passage	NN	O
over	IN	O
a	DT	O
second	JJ	O
helper-solid	JJ	O
phase	NN	O
column	NN	O
which	WDT	O
will	MD	O
retain	VB	O
,	,	O
upon	IN	O
subsequent	JJ	O
elution	NN	O
,	,	O
the	DT	O
helper	JJR	O
molecule-second	NN	O
molecule	NN	O
complex	NN	O
,	,	O
but	CC	O
not	RB	O
the	DT	O
polypeptide	NN	O
conjugate	NN	O
.	.	O
The	DT	O
polypeptide	JJ	O
conjugate	NN	O
may	MD	O
be	VB	O
released	VBN	O
from	IN	O
the	DT	O
helper	NN	O
molecule	NN	O
in	IN	O
any	DT	O
appropriate	JJ	O
fashion	NN	O
.	.	O
De-protection	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
providing	VBG	O
conditions	NNS	O
in	IN	O
which	WDT	O
the	DT	O
helper	NN	O
molecule	NN	O
dissociates	VBZ	O
from	IN	O
the	DT	O
functional	JJ	O
site	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
to	TO	O
which	WDT	O
it	PRP	O
is	VBZ	O
bound	VBN	O
;	:	O
for	IN	O
instance	NN	O
,	,	O
a	DT	O
complex	NN	O
between	IN	O
an	DT	O
antibody	NN	O
to	TO	O
which	WDT	O
a	DT	O
polymer	NN	O
is	VBZ	O
conjugated	VBN	O
and	CC	O
an	DT	O
anti-idiotypic	JJ	O
antibody	NN	O
can	MD	O
be	VB	O
dissociated	VBN	O
by	IN	O
adjusting	VBG	O
the	DT	O
pH	NN	O
to	TO	O
an	DT	O
acid	NN	O
or	CC	O
alkaline	NN	O
pH	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
the	DT	O
oligoadenylate	NN	O
synthetase	NN	O
polypeptide	NN	O
is	VBZ	O
expressed	VBN	O
as	IN	O
a	DT	O
fusion	NN	O
protein	NN	O
with	IN	O
a	DT	O
tag	NN	O
,	,	O
i.e	NN	O
.	.	O
an	DT	O
amino	NN	O
acid	NN	O
sequence	NN	O
or	CC	O
peptide	NN	O
made	VBD	O
up	IN	O
of	IN	O
typically	RB	O
1-30	JJ	O
,	,	O
such	JJ	O
as	IN	O
1-20	JJ	O
or	CC	O
1-15	JJ	O
or	CC	O
1-10	JJ	O
or	CC	O
1-5	JJ	O
amino	NN	O
acid	NN	O
residues	NNS	O
,	,	O
e.g.	NN	O
,	,	O
added	VBD	O
to	TO	O
the	DT	O
N-terminus	NNP	O
or	CC	O
to	TO	O
the	DT	O
C-terminus	NNP	O
of	IN	O
the	DT	O
polypeptide	NN	O
.	.	O
Besides	IN	O
allowing	VBG	O
for	IN	O
fast	NN	O
and	CC	O
easy	JJ	O
purification	NN	O
,	,	O
the	DT	O
tag	NN	O
is	VBZ	O
a	DT	O
convenient	JJ	O
tool	NN	O
for	IN	O
achieving	VBG	O
conjugation	NN	O
between	IN	O
the	DT	O
tagged	VBN	O
polypeptide	NN	O
and	CC	O
the	DT	O
non-polypeptide	JJ	O
moiety	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
the	DT	O
tag	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
achieving	VBG	O
conjugation	NN	O
in	IN	O
microtiter	NN	O
plates	NNS	O
or	CC	O
other	JJ	O
carriers	NNS	O
,	,	O
such	JJ	O
as	IN	O
paramagnetic	JJ	O
beads	NNS	O
,	,	O
to	TO	O
which	WDT	O
the	DT	O
tagged	VBN	O
polypeptide	NN	O
can	MD	O
be	VB	O
immobilised	VBN	O
via	IN	O
the	DT	O
tag	NN	O
.	.	O
The	DT	O
conjugation	NN	O
to	TO	O
the	DT	O
tagged	VBN	O
polypeptide	NN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
microtiter	NN	O
plates	NNS	O
has	VBZ	O
the	DT	O
advantage	NN	O
that	IN	O
the	DT	O
tagged	JJ	O
polypeptide	NN	O
can	MD	O
be	VB	O
immobilised	VBN	O
in	IN	O
the	DT	O
microtiter	NN	O
plates	VBZ	O
directly	RB	O
from	IN	O
the	DT	O
culture	NN	O
broth	NN	O
(	(	O
in	IN	O
principle	NN	O
without	IN	O
any	DT	O
purification	NN	O
)	)	O
and	CC	O
subjected	VBN	O
to	TO	O
conjugation	NN	O
.	.	O
Thereby	RB	O
,	,	O
the	DT	O
total	JJ	O
number	NN	O
of	IN	O
process	JJ	O
steps	NNS	O
(	(	O
from	IN	O
expression	NN	O
to	TO	O
conjugation	NN	O
)	)	O
can	MD	O
be	VB	O
reduced	VBN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
tag	NN	O
may	MD	O
function	VB	O
as	IN	O
a	DT	O
spacer	NN	O
molecule	NN	O
ensuring	VBG	O
an	DT	O
improved	JJ	O
accessibility	NN	O
to	TO	O
the	DT	O
immobilised	JJ	O
polypeptide	NN	O
to	TO	O
be	VB	O
conjugated	VBN	O
.	.	O
The	DT	O
conjugation	NN	O
using	VBG	O
a	DT	O
tagged	JJ	O
polypeptide	NN	O
may	MD	O
be	VB	O
to	TO	O
any	DT	O
of	IN	O
the	DT	O
non-polypeptide	JJ	O
moieties	NNS	O
disclosed	VBN	O
herein	RB	O
,	,	O
e.g	NN	O
.	.	O
to	TO	O
a	DT	O
polymer	NN	O
molecule	NN	O
such	JJ	O
as	IN	O
PEG	NNP	O
.	.	O
The	DT	O
identity	NN	O
of	IN	O
the	DT	O
specific	JJ	O
tag	NN	O
to	TO	O
be	VB	O
used	VBN	O
is	VBZ	O
not	RB	O
critical	JJ	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
tag	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
being	VBG	O
expressed	VBN	O
with	IN	O
the	DT	O
polypeptide	NN	O
and	CC	O
is	VBZ	O
capable	JJ	O
of	IN	O
being	VBG	O
immunobilised	VBN	O
on	IN	O
a	DT	O
suitable	JJ	O
surface	NN	O
or	CC	O
carrier	NN	O
material	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
suitable	JJ	O
tags	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
,	,	O
e.g	NN	O
.	.	O
from	IN	O
Unizyme	NNP	O
Laboratories	NNPS	O
,	,	O
Denmark	NNP	O
.	.	O
Antibodies	NNS	O
against	IN	O
such	JJ	O
tags	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
,	,	O
e.g	NN	O
.	.	O
from	IN	O
ADI	NNP	O
,	,	O
Ayes	NNP	O
Lab	NNP	O
and	CC	O
Research	NNP	O
Diagnostics	NNPS	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
modified	VBN	O
or	CC	O
mutant	JJ	O
oligoadenylate	NN	O
synthetases	NNS	O
with	IN	O
increased	VBN	O
cell	NN	O
permeability	NN	O
,	,	O
such	JJ	O
increased	VBN	O
cell	NN	O
permeability	NN	O
being	VBG	O
affected	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
basic	JJ	O
amino	NN	O
acids	NNS	O
residues	NNS	O
(	(	O
e.g.	NN	O
,	,	O
arginine	NN	O
,	,	O
lysine	NN	O
,	,	O
histidine	NN	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
basic	JJ	O
residue	NN	O
,	,	O
such	JJ	O
as	IN	O
two	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
e.g.	NN	O
,	,	O
three	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
four	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
e.g.	NN	O
,	,	O
five	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
six	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
e.g.	NN	O
,	,	O
about	IN	O
10	CD	O
basic	JJ	O
residues	NNS	O
,	,	O
e.g	NN	O
.	.	O
1-10	JJ	O
basic	JJ	O
residues	NNS	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
5-10	JJ	O
basic	JJ	O
residues	NNS	O
,	,	O
such	JJ	O
as	IN	O
about	IN	O
10-15	JJ	O
basic	JJ	O
residues	NNS	O
,	,	O
e.g.	NN	O
,	,	O
5-20	JJ	O
basic	JJ	O
residues	NNS	O
,	,	O
said	VBD	O
residues	NNS	O
being	VBG	O
added	VBN	O
anywhere	RB	O
within	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
at	IN	O
the	DT	O
N-terminus	NNP	O
or	CC	O
C-terminus	NNP	O
.	.	O
Polynucleotides	NNS	O
and	CC	O
Methods	NNS	O
of	IN	O
Mutagenesis	NNP	O
The	DT	O
invention	NN	O
includes	VBZ	O
nucleic	JJ	O
acids	NNS	O
and	CC	O
polynucleotides	NNS	O
that	WDT	O
encode	VBP	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
includes	VBZ	O
compositions	NNS	O
produced	VBN	O
by	IN	O
digesting	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
with	IN	O
a	DT	O
restriction	NN	O
endonuclease	NN	O
,	,	O
an	DT	O
RNAse	NNP	O
,	,	O
or	CC	O
a	DT	O
DNAse	NNP	O
(	(	O
e.g.	RB	O
,	,	O
as	IN	O
is	VBZ	O
performed	VBN	O
in	IN	O
certain	JJ	O
of	IN	O
the	DT	O
recombination	NN	O
formats	NNS	O
elsewhere	RB	O
in	IN	O
the	DT	O
specification	NN	O
)	)	O
;	:	O
and	CC	O
compositions	NNS	O
produced	VBN	O
by	IN	O
fragmenting	VBG	O
or	CC	O
shearing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
by	IN	O
mechanical	JJ	O
means	NNS	O
(	(	O
e.g.	NN	O
,	,	O
sonication	NN	O
,	,	O
vortexing	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
)	)	O
,	,	O
which	WDT	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
provide	VB	O
substrates	NNS	O
for	IN	O
recombination	NN	O
in	IN	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
compositions	NNS	O
produced	VBN	O
by	IN	O
cleaving	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
cleaving	NN	O
may	MD	O
comprise	VB	O
mechanical	JJ	O
,	,	O
chemical	NN	O
,	,	O
or	CC	O
enzymatic	JJ	O
cleavage	NN	O
,	,	O
and	CC	O
the	DT	O
enzymatic	JJ	O
cleavage	NN	O
may	MD	O
comprise	VB	O
cleavage	NN	O
with	IN	O
a	DT	O
restriction	NN	O
endonuclease	NN	O
,	,	O
an	DT	O
RNAse	NNP	O
,	,	O
or	CC	O
a	DT	O
DNAse	NNP	O
.	.	O
Also	RB	O
included	VBN	O
in	IN	O
the	DT	O
invention	NN	O
are	VBP	O
compositions	NNS	O
produced	VBN	O
by	IN	O
a	DT	O
process	NN	O
comprising	VBG	O
incubating	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
fragmented	JJ	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
ribonucleotide	NN	O
or	CC	O
deoxyribonucleotide	VB	O
triphosphates	NNS	O
and	CC	O
a	DT	O
nucleic	JJ	O
acid	NN	O
polymerase	NN	O
.	.	O
This	DT	O
resulting	VBG	O
composition	NN	O
forms	NNS	O
a	DT	O
recombination	NN	O
mixture	NN	O
for	IN	O
many	JJ	O
of	IN	O
the	DT	O
recombination	NN	O
formats	NNS	O
noted	VBD	O
above	IN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	JJ	O
polymerase	NN	O
may	MD	O
be	VB	O
an	DT	O
RNA	NNP	O
polymerase	NN	O
,	,	O
a	DT	O
DNA	NN	O
polymerase	NN	O
,	,	O
or	CC	O
an	DT	O
RNA-directed	JJ	O
DNA	NN	O
polymerase	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
“	JJ	O
reverse	NN	O
transcriptase	NN	O
”	NNP	O
)	)	O
;	:	O
the	DT	O
polymerase	NN	O
can	MD	O
be	VB	O
,	,	O
e.g.	VB	O
,	,	O
a	DT	O
thermostable	JJ	O
DNA	NN	O
polymerase	NN	O
(	(	O
e.g.	JJ	O
,	,	O
VENT	NNP	O
,	,	O
TAQ	NNP	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
)	)	O
.	.	O
Similarly	RB	O
,	,	O
compositions	NNS	O
comprising	VBG	O
sets	NNS	O
of	IN	O
oligonucleotides	NNS	O
corresponding	VBG	O
to	TO	O
more	JJR	O
than	IN	O
one	CD	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
as	IN	O
recombination	NN	O
substrates	NNS	O
and	CC	O
are	VBP	O
a	DT	O
feature	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
convenience	NN	O
,	,	O
these	DT	O
fragmented	VBN	O
,	,	O
sheared	VBN	O
,	,	O
or	CC	O
oligonucleotide	RB	O
synthesized	JJ	O
mixtures	NNS	O
are	VBP	O
referred	VBN	O
to	TO	O
as	IN	O
fragmented	JJ	O
nucleic	JJ	O
acid	NN	O
sets	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
an	DT	O
isolated	JJ	O
or	CC	O
recombinant	JJ	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
produced	VBN	O
by	IN	O
mutating	VBG	O
or	CC	O
recombining	VBG	O
at	IN	O
least	JJS	O
one	CD	O
polynucleotide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Polynucleotides	NNS	O
,	,	O
oligonucleotides	NNS	O
,	,	O
and	CC	O
nucleic	JJ	O
acid	NN	O
fragments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
standard	JJ	O
solid-phase	NN	O
methods	NNS	O
,	,	O
according	VBG	O
to	TO	O
known	VBN	O
synthetic	JJ	O
methods	NNS	O
.	.	O
Typically	RB	O
,	,	O
fragments	NNS	O
of	IN	O
up	IN	O
to	TO	O
about	IN	O
100	CD	O
bases	NNS	O
are	VBP	O
individually	RB	O
synthesized	VBN	O
,	,	O
then	RB	O
joined	VBD	O
(	(	O
e.g.	NN	O
,	,	O
by	IN	O
enzymatic	JJ	O
or	CC	O
chemical	JJ	O
ligation	NN	O
methods	NNS	O
,	,	O
or	CC	O
polymerase	NN	O
mediated	VBN	O
recombination	NN	O
methods	NNS	O
)	)	O
to	TO	O
form	VB	O
essentially	RB	O
any	DT	O
desired	JJ	O
continuous	JJ	O
sequence	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
polynucleotides	NNS	O
and	CC	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
chemical	NN	O
synthesis	NN	O
using	VBG	O
,	,	O
e.g.	NN	O
,	,	O
classical	JJ	O
phosphoramidite	NN	O
method	NN	O
described	VBN	O
by	IN	O
,	,	O
e.g.	NN	O
,	,	O
Beaucage	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1981	CD	I
)	)	I
Tetrahedron	NNP	I
Letters	NNP	I
22:1859-69	JJ	I
,	,	O
or	CC	O
the	DT	O
method	NN	O
described	VBN	O
by	IN	O
Matthes	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
EMBO	NNP	I
J	NNP	I
3:801-05	CD	I
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
is	VBZ	O
typically	RB	O
practiced	VBN	O
in	IN	O
automated	JJ	O
synthetic	JJ	O
methods	NNS	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
phosphoramidite	NN	O
method	NN	O
,	,	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
an	DT	O
automatic	JJ	O
DNA	NNP	O
synthesizer	NN	O
,	,	O
purified	VBN	O
,	,	O
annealed	VBN	O
,	,	O
ligated	VBN	O
and	CC	O
cloned	VBN	O
into	IN	O
appropriate	JJ	O
vectors	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
essentially	RB	O
any	DT	O
polynucleotide	NN	O
can	MD	O
be	VB	O
custom	VBN	O
ordered	VBN	O
from	IN	O
any	DT	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
commercial	JJ	O
sources	NNS	O
,	,	O
such	JJ	O
as	IN	O
Operon	NNP	O
Technologies	NNPS	O
Inc.	NNP	O
(	(	O
Alameda	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
many	JJ	O
others	NNS	O
.	.	O
Similarly	RB	O
,	,	O
peptides	NNS	O
and	CC	O
antibodies	NNS	O
can	MD	O
be	VB	O
custom	VBN	O
ordered	VBN	O
from	IN	O
any	DT	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources	NNS	O
,	,	O
e.g.	NN	O
,	,	O
Celtek	NNP	O
Peptides	NNP	O
(	(	O
Nashville	NNP	O
,	,	O
Term	NNP	O
.	.	O
)	)	O
;	:	O
Washington	NNP	O
Biotechnology	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Baltimore	NNP	O
Md	NNP	O
.	.	O
)	)	O
;	:	O
Global	NNP	O
Peptide	NNP	O
Services	NNP	O
(	(	O
Ft.	NNP	O
Collin	NNP	O
Colo.	NNP	O
)	)	O
,	,	O
and	CC	O
many	JJ	O
others	NNS	O
.	.	O
Certain	NNP	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
obtained	VBN	O
by	IN	O
screening	VBG	O
cDNA	NN	O
libraries	NNS	O
(	(	O
e.g.	NN	O
,	,	O
libraries	NNS	O
generated	VBN	O
by	IN	O
recombining	VBG	O
homologous	JJ	O
nucleic	JJ	O
acids	NNS	O
as	IN	O
in	IN	O
typical	JJ	O
recursive	JJ	O
sequence	NN	O
recombination	NN	O
methods	NNS	O
)	)	O
using	VBG	O
oligonucleotide	JJ	O
probes	NNS	O
that	WDT	O
can	MD	O
hybridize	VB	O
to	TO	O
or	CC	O
PCR-amplify	NNP	O
polynucleotides	NNS	O
which	WDT	O
encode	VBP	O
OAS	NNP	O
polypeptides	NNS	O
and	CC	O
fragments	NNS	O
of	IN	O
those	DT	O
polypeptides	NNS	O
.	.	O
Procedures	NNS	O
for	IN	O
screening	VBG	O
and	CC	O
isolating	VBG	O
cDNA	NN	O
clones	NNS	O
are	VBP	O
well-known	JJ	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
techniques	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Berger	NNP	B
and	CC	I
Kimmel	NNP	I
,	,	I
Guide	NNP	I
to	TO	I
Molecular	NNP	I
Cloning	NNP	I
Techniques	NNP	I
,	,	I
Methods	NNP	I
in	IN	I
Enzymol	NNP	I
.	.	I
Vol	NNP	I
.	.	I
152	CD	I
,	,	I
Acad	NNP	I
.	.	I
Press	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
San	NNP	I
Diego	NNP	I
,	,	I
Calif.	NNP	I
(	(	I
“	NNP	I
Berger	NNP	I
”	NNP	I
)	)	I
;	:	O
J.	NNP	B
Sambrook	NNP	I
and	CC	I
D.	NNP	I
W.	NNP	I
Russell	NNP	I
,	,	I
Molecular	NNP	I
Cloning	NNP	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
Third	NNP	I
Edition	NNP	I
.	.	I
Cold	JJ	I
Spring	NN	I
Harbor	NNP	I
Press	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
(	(	I
“	JJ	I
Sambrook	NNP	I
”	NNP	I
)	)	I
;	:	O
and	CC	O
F.	NNP	B
M.	NNP	I
Ausubel	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1987-2005	CD	I
)	)	I
Current	NN	I
Protocols	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
.	.	I
Wiley	NNP	I
Interscience	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
(	(	I
“	NNP	I
Ausubel	NNP	I
”	NNP	I
)	)	I
.	.	O
Some	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
altering	VBG	O
a	DT	O
naturally	RB	O
occurring	VBG	O
sequence	NN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
mutagenesis	NN	O
,	,	O
recursive	JJ	O
sequence	NN	O
recombination	NN	O
(	(	O
e.g.	JJ	O
,	,	O
shuffling	VBG	O
)	)	O
,	,	O
or	CC	O
oligonucleotide	JJ	O
recombination	NN	O
.	.	O
In	IN	O
other	JJ	O
cases	NNS	O
,	,	O
such	JJ	O
polynucleotides	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
silico	NN	O
or	CC	O
through	IN	O
oligonucleotide	JJ	O
recombination	NN	O
methods	NNS	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
references	NNS	O
cited	VBD	O
herein	NN	O
.	.	O
As	IN	O
described	VBN	O
in	IN	O
more	JJR	O
detail	NN	O
herein	NN	O
,	,	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
polynucleotides	NNS	O
that	WDT	O
encode	VBP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
polynucleotide	JJ	O
sequences	NNS	O
complementary	VBP	O
to	TO	O
these	DT	O
polynucleotide	JJ	O
sequences	NNS	O
,	,	O
and	CC	O
polynucleotides	NNS	O
that	IN	O
hybridize	NN	O
under	IN	O
at	IN	O
least	JJS	O
stringent	JJ	O
conditions	NNS	O
to	TO	O
the	DT	O
sequences	NNS	O
defined	VBD	O
herein	NN	O
.	.	O
A	DT	O
coding	NN	O
sequence	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
particular	JJ	O
polypeptide	NN	O
or	CC	O
domain	NN	O
,	,	O
region	NN	O
,	,	O
or	CC	O
fragment	NN	O
of	IN	O
said	VBD	O
polypeptide	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
RNA	NNP	O
or	CC	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
DNA	NNP	O
,	,	O
and	CC	O
include	VBP	O
mRNA	NNS	O
,	,	O
cRNA	NN	O
,	,	O
synthetic	JJ	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
,	,	O
and	CC	O
cDNA	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
may	MD	O
be	VB	O
double-stranded	JJ	O
or	CC	O
single-stranded	JJ	O
,	,	O
and	CC	O
if	IN	O
single-stranded	JJ	O
,	,	O
can	MD	O
be	VB	O
the	DT	O
coding	VBG	O
strand	NN	O
or	CC	O
the	DT	O
non-coding	JJ	O
(	(	O
anti-sense	JJ	O
,	,	O
complementary	JJ	O
)	)	O
strand	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
the	DT	O
coding	VBG	O
sequence	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
i	NN	O
)	)	O
in	IN	O
isolation	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
additional	JJ	O
coding	NN	O
sequences	NNS	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
encode	VB	O
,	,	O
e.g.	FW	O
,	,	O
a	DT	O
fusion	NN	O
protein	NN	O
,	,	O
a	DT	O
pre-protein	NN	O
,	,	O
a	DT	O
prepro-protein	JJ	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
,	,	O
(	(	O
iii	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
non-coding	JJ	O
sequences	NNS	O
,	,	O
such	JJ	O
as	IN	O
introns	NNS	O
,	,	O
control	NN	O
elements	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
promoter	NN	O
(	(	O
e.g.	UH	O
,	,	O
naturally	RB	O
occurring	VBG	O
or	CC	O
recombinant	JJ	O
or	CC	O
shuffled	JJ	O
promoter	NN	O
)	)	O
,	,	O
a	DT	O
terminator	NN	O
element	NN	O
,	,	O
or	CC	O
5′	CD	O
and/or	JJ	O
3′	CD	O
untranslated	JJ	O
regions	NNS	O
effective	JJ	O
for	IN	O
expression	NN	O
of	IN	O
the	DT	O
coding	VBG	O
sequence	NN	O
in	IN	O
a	DT	O
suitable	JJ	O
host	NN	O
,	,	O
and/or	NN	O
(	(	O
iv	NN	O
)	)	O
in	IN	O
a	DT	O
vector	NN	O
,	,	O
cell	NN	O
,	,	O
or	CC	O
host	NN	O
environment	NN	O
in	IN	O
which	WDT	O
the	DT	O
coding	NN	O
sequence	NN	O
is	VBZ	O
a	DT	O
heterologous	JJ	O
gene	NN	O
.	.	O
Polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
found	VBN	O
in	IN	O
combination	NN	O
with	IN	O
typical	JJ	O
compositional	JJ	O
formulations	NNS	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
including	VBG	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
carriers	NNS	O
,	,	O
buffers	NNS	O
,	,	O
adjuvants	NNS	O
,	,	O
excipients	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
as	IN	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Polynucleotide	NN	O
fragments	NNS	O
typically	RB	O
comprise	VBP	O
at	IN	O
least	JJS	O
about	IN	O
200	CD	O
nucleotide	JJ	O
bases	NNS	O
,	,	O
such	JJ	O
as	IN	O
at	IN	O
least	JJS	O
about	IN	O
250	CD	O
,	,	O
300	CD	O
,	,	O
350	CD	O
,	,	O
400	CD	O
,	,	O
450	CD	O
,	,	O
460	CD	O
,	,	O
470	CD	O
,	,	O
or	CC	O
more	JJR	O
bases	NNS	O
.	.	O
The	DT	O
nucleotide	JJ	O
fragments	NNS	O
of	IN	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
hybridize	VB	O
under	IN	O
highly	RB	O
stringent	JJ	O
conditions	NNS	O
to	TO	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
described	VBD	O
herein	JJ	O
and/or	JJ	O
encode	NN	O
amino	NN	O
acid	NN	O
sequences	NNS	O
having	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
properties	NNS	O
of	IN	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
described	VBD	O
herein	NN	O
.	.	O
As	IN	O
will	MD	O
be	VB	O
understood	VBN	O
by	IN	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
it	PRP	O
can	MD	O
be	VB	O
advantageous	JJ	O
to	TO	O
modify	VB	O
a	DT	O
coding	NN	O
sequence	NN	O
to	TO	O
enhance	VB	O
its	PRP$	O
expression	NN	O
in	IN	O
a	DT	O
particular	JJ	O
host	NN	O
.	.	O
The	DT	O
genetic	JJ	O
code	NN	O
is	VBZ	O
redundant	JJ	O
with	IN	O
64	CD	O
possible	JJ	O
codons	NNS	O
,	,	O
but	CC	O
most	JJS	O
organisms	NNS	O
preferentially	RB	O
use	VBP	O
a	DT	O
subset	NN	O
of	IN	O
these	DT	O
codons	NNS	O
.	.	O
The	DT	O
codons	NNS	O
that	WDT	O
are	VBP	O
utilized	JJ	O
most	RBS	O
often	RB	O
in	IN	O
a	DT	O
species	NNS	O
are	VBP	O
considered	VBN	O
optimal	JJ	O
codons	NNS	O
,	,	O
and	CC	O
those	DT	O
not	RB	O
utilized	JJ	O
very	RB	O
often	RB	O
are	VBP	O
classified	VBN	O
as	IN	O
rare	JJ	O
or	CC	O
low-usage	JJ	O
codons	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Zhang	NNP	B
,	,	I
S.	NNP	I
P.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Gene	NNP	I
105:61-72	JJ	I
)	)	O
.	.	O
Codons	NNS	O
can	MD	O
be	VB	O
substituted	VBN	O
to	TO	O
reflect	VB	O
the	DT	O
preferred	JJ	O
codon	NN	O
usage	NN	O
of	IN	O
the	DT	O
host	NN	O
,	,	O
a	DT	O
process	NN	O
sometimes	RB	O
termed	VBD	O
“	JJ	O
codon	NN	O
optimization	NN	O
”	NN	O
or	CC	O
“	NN	O
controlling	VBG	O
for	IN	O
species	NNS	O
codon	VBP	O
bias.	JJ	O
”	NNP	O
Modified	NNP	O
coding	VBG	O
sequence	NN	O
containing	VBG	O
codons	NNS	O
preferred	VBN	O
by	IN	O
a	DT	O
particular	JJ	O
prokaryotic	NN	O
or	CC	O
eukaryotic	JJ	O
host	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Murray	NNP	B
,	,	I
E.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Nuc	NNP	I
Acids	NNP	I
Res	NNP	I
17:477-508	CD	I
;	:	O
Griswold	NNP	B
et	FW	I
al.	NN	I
,	,	I
(	(	I
2003	CD	I
)	)	I
Protein	NNP	I
Expr	NNP	I
.	.	I
Purif	NNP	I
.	.	I
27	CD	I
(	(	I
1	CD	I
)	)	I
:	:	I
134-42	JJ	I
)	)	O
can	MD	O
be	VB	O
prepared	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
to	TO	O
increase	VB	O
the	DT	O
rate	NN	O
of	IN	O
translation	NN	O
or	CC	O
to	TO	O
produce	VB	O
recombinant	JJ	O
RNA	NNP	O
transcripts	NNS	O
having	VBG	O
desirable	JJ	O
properties	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
longer	RBR	O
half-life	JJ	O
,	,	O
as	IN	O
compared	VBN	O
with	IN	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
a	DT	O
non-optimized	JJ	O
sequence	NN	O
.	.	O
Translation	NNP	O
stop	JJ	O
codons	NNS	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
reflect	VB	O
host	NN	O
preference	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
preferred	VBD	O
stop	JJ	O
codons	NNS	O
for	IN	O
S.	NNP	O
cerevisiae	NN	O
and	CC	O
mammals	NNS	O
are	VBP	O
UAA	NNP	O
and	CC	O
UGA	NNP	O
respectively	RB	O
.	.	O
The	DT	O
preferred	JJ	O
stop	NN	O
codon	NN	O
for	IN	O
monocotyledonous	JJ	O
plants	NNS	O
is	VBZ	O
UGA	NNP	O
,	,	O
whereas	JJ	O
insects	NNS	O
and	CC	O
E.	NNP	O
coli	NNS	O
prefer	VBP	O
to	TO	O
use	VB	O
UAA	NNP	O
as	IN	O
the	DT	O
stop	NN	O
codon	NN	O
(	(	O
Dalphin	NNP	B
,	,	I
M.	NNP	I
E.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
24:216-218	JJ	I
)	)	O
.	.	O
The	DT	O
polynucleotide	JJ	O
sequences	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
engineered	VBN	O
in	IN	O
order	NN	O
to	TO	O
alter	VB	O
a	DT	O
coding	NN	O
sequence	NN	O
of	IN	O
the	DT	O
invention	NN	O
for	IN	O
a	DT	O
variety	NN	O
of	IN	O
reasons	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
alterations	NNS	O
which	WDT	O
modify	VBP	O
the	DT	O
cloning	NN	O
,	,	O
processing	VBG	O
and/or	JJ	O
expression	NN	O
of	IN	O
the	DT	O
gene	NN	O
product	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
alterations	NNS	O
may	MD	O
be	VB	O
introduced	VBN	O
using	VBG	O
techniques	NNS	O
which	WDT	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
e.g.	NN	O
,	,	O
site-directed	JJ	O
mutagenesis	NN	O
,	,	O
to	TO	O
insert	VB	O
new	JJ	O
restriction	NN	O
sites	NNS	O
,	,	O
to	TO	O
alter	VB	O
glycosylation	NN	O
patterns	NNS	O
,	,	O
to	TO	O
introduce	VB	O
or	CC	O
remove	VB	O
attachment	NN	O
groups	NNS	O
(	(	O
e.g.	NN	O
,	,	O
for	IN	O
pegylation	NN	O
or	CC	O
other	JJ	O
conjugation	NN	O
)	)	O
,	,	O
to	TO	O
change	VB	O
codon	JJ	O
preference	NN	O
,	,	O
to	TO	O
introduce	VB	O
splice	NN	O
sites	NNS	O
,	,	O
etc	FW	O
.	.	O
Because	IN	O
of	IN	O
the	DT	O
degeneracy	NN	O
of	IN	O
the	DT	O
genetic	JJ	O
code	NN	O
,	,	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
functionally	RB	O
identical	JJ	O
nucleic	JJ	O
acids	NNS	O
encode	VBP	O
any	DT	O
given	VBN	O
polypeptide	NN	O
.	.	O
For	IN	O
instance	NN	O
codons	NNS	O
AGA	NNP	O
,	,	O
AGG	NNP	O
,	,	O
CGA	NNP	O
,	,	O
CGC	NNP	O
,	,	O
CGG	NNP	O
,	,	O
and	CC	O
CGU	NNP	O
all	DT	O
encode	VBP	O
the	DT	O
amino	NN	O
acid	JJ	O
arginine	NN	O
.	.	O
Thus	RB	O
,	,	O
at	IN	O
every	DT	O
position	NN	O
in	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
where	WRB	O
an	DT	O
arginine	NN	O
is	VBZ	O
specified	VBN	O
by	IN	O
a	DT	O
codon	NN	O
,	,	O
the	DT	O
codon	NN	O
can	MD	O
be	VB	O
altered	VBN	O
to	TO	O
any	DT	O
of	IN	O
the	DT	O
corresponding	JJ	O
codons	NNS	O
described	VBN	O
above	IN	O
without	IN	O
altering	VBG	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
.	.	O
Such	JJ	O
nucleic	JJ	O
acid	NN	O
variations	NNS	O
are	VBP	O
“	JJ	O
silent	JJ	O
variations	NNS	O
”	VBP	O
.	.	O
It	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
understood	JJ	O
that	IN	O
U	NNP	O
in	IN	O
an	DT	O
RNA	NNP	O
sequence	NN	O
corresponds	NNS	O
to	TO	O
T	NNP	O
in	IN	O
a	DT	O
DNA	NN	O
sequence	NN	O
.	.	O
It	PRP	O
will	MD	O
thus	RB	O
be	VB	O
appreciated	VBN	O
by	IN	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
due	JJ	O
to	TO	O
the	DT	O
degeneracy	NN	O
of	IN	O
the	DT	O
genetic	JJ	O
code	NN	O
,	,	O
a	DT	O
multitude	NN	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
sequences	NNS	O
encoding	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
produced	VBN	O
,	,	O
some	DT	O
of	IN	O
which	WDT	O
may	MD	O
bear	VB	O
minimal	JJ	O
sequence	NN	O
identity	NN	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
explicitly	RB	O
disclosed	VBN	O
herein	NN	O
.	.	O
One	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
that	IN	O
each	DT	O
codon	NN	O
in	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
(	(	O
except	IN	O
AUG	NNP	O
and	CC	O
UGC	NNP	O
,	,	O
which	WDT	O
are	VBP	O
ordinarily	RB	O
the	DT	O
only	JJ	O
codon	NN	O
for	IN	O
methionine	NN	O
and	CC	O
tryptophan	NN	O
,	,	O
respectively	RB	O
)	)	O
can	MD	O
be	VB	O
modified	VBN	O
by	IN	O
standard	JJ	O
techniques	NNS	O
to	TO	O
encode	VB	O
a	DT	O
functionally	RB	O
identical	JJ	O
polypeptide	NN	O
.	.	O
Accordingly	RB	O
,	,	O
each	DT	O
silent	JJ	O
variation	NN	O
of	IN	O
a	DT	O
nucleic	NN	O
acid	NN	O
which	WDT	O
encodes	VBZ	O
a	DT	O
polypeptide	NN	O
is	VBZ	O
implicit	JJ	O
in	IN	O
any	DT	O
described	JJ	O
sequence	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
each	DT	O
and	CC	O
every	DT	O
possible	JJ	O
variation	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
that	WDT	O
can	MD	O
be	VB	O
made	VBN	O
by	IN	O
selecting	VBG	O
combinations	NNS	O
based	VBN	O
on	IN	O
possible	JJ	O
codon	NN	O
choices	NNS	O
.	.	O
These	DT	O
combinations	NNS	O
are	VBP	O
made	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
standard	JJ	O
triplet	NN	O
(	(	O
codon	NN	O
)	)	O
genetic	JJ	O
code	NN	O
,	,	O
as	IN	O
applied	VBN	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
All	DT	O
such	JJ	O
variations	NNS	O
of	IN	O
every	DT	O
nucleic	JJ	O
acid	NN	O
herein	NN	O
are	VBP	O
specifically	RB	O
provided	VBN	O
and	CC	O
described	VBN	O
by	IN	O
consideration	NN	O
of	IN	O
the	DT	O
sequence	NN	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
genetic	JJ	O
code	NN	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
is	VBZ	O
fully	RB	O
able	JJ	O
to	TO	O
generate	VB	O
any	DT	O
silent	JJ	O
substitution	NN	O
of	IN	O
the	DT	O
sequences	NNS	O
listed	VBN	O
herein	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
a	DT	O
variety	NN	O
of	IN	O
uses	NNS	O
in	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
recombinant	JJ	O
production	NN	O
(	(	O
i.e.	FW	O
,	,	O
expression	NN	O
)	)	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
typically	RB	O
through	IN	O
expression	NN	O
of	IN	O
a	DT	O
plasmid	JJ	O
expression	NN	O
vector	NN	O
comprising	VBG	O
a	DT	O
sequence	NN	O
encoding	VBG	O
the	DT	O
polypeptide	NN	O
or	CC	O
fragment	JJ	O
thereof	NN	O
;	:	O
as	IN	O
therapeutics	NNS	O
;	:	O
as	IN	O
prophylactics	NNS	O
;	:	O
as	IN	O
diagnostic	JJ	O
tools	NNS	O
;	:	O
as	IN	O
immunogens	NNS	O
;	:	O
as	IN	O
adjuvants	NNS	O
;	:	O
as	IN	O
diagnostic	JJ	O
probes	NNS	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
complementary	JJ	O
or	CC	O
partially	RB	O
complementary	JJ	O
nucleic	JJ	O
acids	NNS	O
(	(	O
including	VBG	O
for	IN	O
detection	NN	O
of	IN	O
a	DT	O
wild-type	JJ	O
oligoadenylate	NN	O
synthetase	NN	O
nucleic	JJ	O
acid	NN	O
)	)	O
,	,	O
as	IN	O
substrates	NNS	O
for	IN	O
further	JJ	O
reactions	NNS	O
,	,	O
e.g.	NN	O
,	,	O
recursive	JJ	O
sequence	NN	O
recombination	NN	O
reactions	NNS	O
or	CC	O
mutation	NN	O
reactions	NNS	O
to	TO	O
produce	VB	O
new	JJ	O
and/or	NNS	O
improved	VBN	O
variants	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Expression	NN	O
Vectors	NNS	O
,	,	O
Methods	NNS	O
of	IN	O
Manufacturing	NNP	O
,	,	O
Gene	NNP	O
Therapy	NNP	O
Recombinant	NNP	O
methods	NNS	O
for	IN	O
producing	VBG	O
and	CC	O
isolating	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
described	VBN	O
herein	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
recombinant	VB	O
production	NN	O
,	,	O
the	DT	O
polypeptides	NNS	O
may	MD	O
be	VB	O
produced	VBN	O
by	IN	O
direct	JJ	O
peptide	NN	O
synthesis	NN	O
using	VBG	O
solid-phase	JJ	O
techniques	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Stewart	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1969	CD	I
)	)	I
Solid-Phase	NNP	I
Peptide	NNP	I
Synthesis	NNP	I
,	,	I
WH	NNP	I
Freeman	NNP	I
Co	NNP	I
,	,	I
San	NNP	I
Francisco	NNP	I
;	:	O
Merrifield	NNP	B
J	NNP	I
.	.	I
(	(	I
1963	CD	I
)	)	I
J	NNP	I
Am	NNP	I
Chem	NNP	I
Soc	NNP	I
85:2149-2154	JJ	I
)	)	O
.	.	O
Peptide	NNP	O
synthesis	NN	O
may	MD	O
be	VB	O
performed	VBN	O
using	VBG	O
manual	JJ	O
techniques	NNS	O
or	CC	O
by	IN	O
automation	NN	O
.	.	O
Automated	VBN	O
synthesis	NN	O
may	MD	O
be	VB	O
achieved	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
using	VBG	O
Applied	NNP	O
Biosystems	NNP	O
431A	CD	O
Peptide	NNP	O
Synthesizer	NNP	O
(	(	O
Perkin	NNP	O
Elmer	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
instructions	NNS	O
provided	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
subsequences	NNS	O
may	MD	O
be	VB	O
chemically	RB	O
synthesized	VBN	O
separately	RB	O
and	CC	O
combined	VBN	O
using	VBG	O
chemical	NN	O
methods	NNS	O
to	TO	O
provide	VB	O
full-length	JJ	O
polypeptides	NNS	O
or	CC	O
fragments	NNS	O
thereof	NN	O
.	.	O
Alternatively	RB	O
,	,	O
such	JJ	O
sequences	NNS	O
may	MD	O
be	VB	O
ordered	VBN	O
from	IN	O
any	DT	O
number	NN	O
of	IN	O
companies	NNS	O
which	WDT	O
specialize	VBP	O
in	IN	O
production	NN	O
of	IN	O
polypeptides	NNS	O
.	.	O
Most	JJS	O
commonly	RB	O
,	,	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
produced	VBN	O
by	IN	O
expressing	VBG	O
coding	VBG	O
nucleic	JJ	O
acids	NNS	O
and	CC	O
recovering	VBG	O
polypeptides	NNS	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
Methods	NNS	O
for	IN	O
producing	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
included	VBN	O
.	.	O
One	CD	O
such	JJ	O
method	NN	O
comprises	NNS	O
introducing	VBG	O
into	IN	O
a	DT	O
population	NN	O
of	IN	O
cells	NNS	O
any	DT	O
nucleic	JJ	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
which	WDT	O
is	VBZ	O
operatively	RB	O
linked	VBN	O
to	TO	O
a	DT	O
regulatory	JJ	O
sequence	NN	O
effective	JJ	O
to	TO	O
produce	VB	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
,	,	O
culturing	VBG	O
the	DT	O
cells	NNS	O
in	IN	O
a	DT	O
culture	NN	O
medium	NN	O
to	TO	O
express	VB	O
the	DT	O
polypeptide	NN	O
,	,	O
and	CC	O
isolating	VBG	O
the	DT	O
polypeptide	NN	O
from	IN	O
the	DT	O
cells	NNS	O
or	CC	O
from	IN	O
the	DT	O
culture	NN	O
medium	NN	O
.	.	O
An	DT	O
amount	NN	O
of	IN	O
nucleic	JJ	O
acid	JJ	O
sufficient	NN	O
to	TO	O
facilitate	VB	O
uptake	NN	O
by	IN	O
the	DT	O
cells	NNS	O
(	(	O
transfection	NN	O
)	)	O
and/or	VBZ	O
expression	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
is	VBZ	O
utilized	JJ	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
such	JJ	O
cells	NNS	O
by	IN	O
any	DT	O
delivery	NN	O
method	NN	O
as	IN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
injection	NN	O
,	,	O
gene	NN	O
gun	NN	O
,	,	O
passive	JJ	O
uptake	NN	O
,	,	O
etc	FW	O
.	.	O
As	IN	O
one	CD	O
skilled	VBD	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
may	MD	O
be	VB	O
part	NN	O
of	IN	O
a	DT	O
vector	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
recombinant	JJ	O
expression	NN	O
vector	NN	O
,	,	O
including	VBG	O
a	DT	O
DNA	NN	O
plasmid	NN	O
vector	NN	O
,	,	O
or	CC	O
any	DT	O
vector	NN	O
as	IN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
vector	NN	O
comprising	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
prepared	VBN	O
and	CC	O
formulated	VBN	O
by	IN	O
standard	JJ	O
recombinant	NN	O
DNA	NNP	O
technologies	NNS	O
and	CC	O
isolation	NN	O
methods	NNS	O
as	IN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
a	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
expression	NN	O
vector	NN	O
may	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
population	NN	O
of	IN	O
cells	NNS	O
of	IN	O
a	DT	O
mammal	NN	O
in	IN	O
vivo	NN	O
,	,	O
or	CC	O
selected	VBN	O
cells	NNS	O
of	IN	O
the	DT	O
mammal	NN	O
(	(	O
e.g.	JJ	O
,	,	O
tumor	JJ	O
cells	NNS	O
)	)	O
may	MD	O
be	VB	O
removed	VBN	O
from	IN	O
the	DT	O
mammal	NN	O
and	CC	O
the	DT	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
vector	NN	O
introduced	VBD	O
ex	JJ	O
vivo	NN	O
into	IN	O
the	DT	O
population	NN	O
of	IN	O
such	JJ	O
cells	NNS	O
in	IN	O
an	DT	O
amount	NN	O
sufficient	NN	O
such	JJ	O
that	IN	O
uptake	JJ	O
and	CC	O
expression	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
results	NNS	O
.	.	O
Or	CC	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
vector	NN	O
comprising	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
produced	VBN	O
using	VBG	O
cultured	JJ	O
cells	NNS	O
in	IN	O
vitro	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
method	NN	O
of	IN	O
producing	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
comprises	VBZ	O
introducing	VBG	O
into	IN	O
a	DT	O
population	NN	O
of	IN	O
cells	NNS	O
a	DT	O
recombinant	JJ	O
expression	NN	O
vector	NN	O
comprising	VBG	O
any	DT	O
nucleic	JJ	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
described	VBD	O
herein	NN	O
in	IN	O
an	DT	O
amount	NN	O
and	CC	O
formula	NN	O
such	JJ	O
that	IN	O
uptake	NN	O
of	IN	O
the	DT	O
vector	NN	O
and	CC	O
expression	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
will	MD	O
result	VB	O
;	:	O
administering	VBG	O
the	DT	O
expression	NN	O
vector	NN	O
into	IN	O
a	DT	O
mammal	JJ	O
by	IN	O
any	DT	O
introduction/delivery	JJ	O
format	NN	O
described	VBD	O
herein	NN	O
;	:	O
and	CC	O
isolating	VBG	O
the	DT	O
polypeptide	NN	O
from	IN	O
the	DT	O
mammal	NN	O
or	CC	O
from	IN	O
a	DT	O
byproduct	NN	O
of	IN	O
the	DT	O
mammal	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
isolated	JJ	O
or	CC	O
recombinant	JJ	O
nucleic	JJ	O
acids	NNS	O
(	(	O
also	RB	O
referred	VBN	O
to	TO	O
herein	VB	O
as	IN	O
polynucleotides	NNS	O
)	)	O
,	,	O
collectively	RB	O
referred	VBD	O
to	TO	O
as	IN	O
“	NNP	O
nucleic	JJ	O
acids	NNS	O
(	(	O
or	CC	O
polynucleotides	NNS	O
)	)	O
of	IN	O
the	DT	O
invention	NN	O
”	NNP	O
,	,	O
which	WDT	O
encode	VBP	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
applications	NNS	O
.	.	O
As	IN	O
discussed	VBN	O
above	IN	O
,	,	O
the	DT	O
polynucleotides	NNS	O
are	VBP	O
useful	JJ	O
in	IN	O
producing	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
useful	JJ	O
for	IN	O
gene	NN	O
therapy	NN	O
,	,	O
DNA	NNP	O
vaccination	NN	O
,	,	O
and	CC	O
immunotherapy	NN	O
,	,	O
as	IN	O
described	VBN	O
elsewhere	RB	O
in	IN	O
this	DT	O
application	NN	O
.	.	O
Any	DT	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
which	WDT	O
includes	VBZ	O
those	DT	O
described	VBN	O
above	IN	O
)	)	O
may	MD	O
encode	VB	O
a	DT	O
fusion	NN	O
protein	NN	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
additional	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
secretion/localization	NN	O
sequence	NN	O
,	,	O
a	DT	O
sequence	NN	O
useful	JJ	O
for	IN	O
solubilization	NN	O
or	CC	O
immobilization	NN	O
(	(	O
e.g.	NN	O
,	,	O
for	IN	O
cell	NN	O
surface	NN	O
display	NN	O
)	)	O
of	IN	O
the	DT	O
polypeptide	NN	O
,	,	O
a	DT	O
sequence	NN	O
useful	JJ	O
for	IN	O
detection	NN	O
and/or	JJ	O
purification	NN	O
of	IN	O
the	DT	O
polypeptide	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
polypeptide	JJ	O
purification	NN	O
subsequence	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
epitope	NN	O
tag	NN	O
,	,	O
a	DT	O
polyhistidine	NN	O
sequence	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
)	)	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
cells	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Such	JJ	O
cells	NNS	O
may	MD	O
express	VB	O
one	CD	O
or	CC	O
more	JJR	O
polypeptides	NNS	O
encoded	VBN	O
by	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
vectors	NNS	O
comprising	VBG	O
any	DT	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Such	JJ	O
vectors	NNS	O
may	MD	O
comprise	VB	O
a	DT	O
plasmid	NN	O
,	,	O
a	DT	O
cosmid	NN	O
,	,	O
a	DT	O
phage	NN	O
,	,	O
a	DT	O
virus	NN	O
,	,	O
or	CC	O
a	DT	O
fragment	NN	O
of	IN	O
a	DT	O
virus	NN	O
.	.	O
Such	JJ	O
vectors	NNS	O
may	MD	O
comprise	VB	O
an	DT	O
expression	NN	O
vector	NN	O
,	,	O
and	CC	O
,	,	O
if	IN	O
desired	VBN	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
operably	RB	O
linked	VBN	O
to	TO	O
a	DT	O
promoter	NN	O
,	,	O
including	VBG	O
those	DT	O
discussed	VBN	O
herein	NN	O
and	CC	O
below	NN	O
.	.	O
Furthermore	RB	O
,	,	O
in	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
compositions	NNS	O
comprising	VBG	O
an	DT	O
excipient	NN	O
or	CC	O
carrier	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
vectors	NNS	O
,	,	O
cells	NNS	O
,	,	O
or	CC	O
host	NN	O
comprising	NN	O
such	JJ	O
nucleic	JJ	O
acids	NNS	O
.	.	O
Such	JJ	O
composition	NN	O
may	MD	O
be	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
and	CC	O
the	DT	O
excipient	NN	O
or	CC	O
carrier	NN	O
may	MD	O
be	VB	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
excipient	NN	O
or	CC	O
carrier	NN	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
includes	VBZ	O
compositions	NNS	O
comprising	VBG	O
two	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
fragments	NNS	O
thereof	VBP	O
(	(	O
e.g.	NN	O
,	,	O
as	IN	O
substrates	NNS	O
for	IN	O
recombination	NN	O
)	)	O
.	.	O
The	DT	O
composition	NN	O
can	MD	O
comprise	VB	O
a	DT	O
library	NN	O
of	IN	O
recombinant	JJ	O
nucleic	JJ	O
acids	NNS	O
,	,	O
where	WRB	O
the	DT	O
library	NN	O
contains	NNS	O
at	IN	O
least	JJS	O
2	CD	O
,	,	O
at	IN	O
least	JJS	O
3	CD	O
,	,	O
at	IN	O
least	JJS	O
5	CD	O
,	,	O
at	IN	O
least	JJS	O
10	CD	O
,	,	O
at	IN	O
least	JJS	O
20	CD	O
,	,	O
at	IN	O
least	JJS	O
50	CD	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
100	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
described	VBN	O
above	IN	O
.	.	O
The	DT	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
optionally	RB	O
cloned	VBN	O
into	IN	O
expression	NN	O
vectors	NNS	O
,	,	O
providing	VBG	O
expression	NN	O
libraries	NNS	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
fragments	NNS	O
thereof	RB	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
vectors	NNS	O
comprising	VBG	O
such	JJ	O
polynucleotides	NNS	O
,	,	O
may	MD	O
be	VB	O
employed	VBN	O
for	IN	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
uses	NNS	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
suitable	JJ	O
carrier	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
pharmaceutical	JJ	O
carrier	NN	O
.	.	O
Such	JJ	O
compositions	NNS	O
comprise	VBP	O
a	DT	O
therapeutically	RB	O
and/or	JJ	O
prophylactically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
the	DT	O
compound	NN	O
,	,	O
and	CC	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
carrier	NN	O
or	CC	O
excipient	NN	O
.	.	O
Such	JJ	O
a	DT	O
carrier	NN	O
or	CC	O
excipient	NN	O
includes	VBZ	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
saline	VB	O
,	,	O
buffered	VBN	O
saline	NN	O
,	,	O
dextrose	VB	O
,	,	O
water	NN	O
,	,	O
glycerol	NN	O
,	,	O
ethanol	NN	O
,	,	O
and	CC	O
combinations	NNS	O
thereof	VBP	O
.	.	O
The	DT	O
formulation	NN	O
should	MD	O
suit	VB	O
the	DT	O
mode	NN	O
of	IN	O
administration	NN	O
.	.	O
Methods	NNS	O
of	IN	O
administering	VBG	O
nucleic	JJ	O
acids	NNS	O
,	,	O
polypeptides	NNS	O
,	,	O
and	CC	O
proteins	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
includes	VBZ	O
recombinant	JJ	O
constructs	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
as	IN	O
broadly	RB	O
described	VBN	O
above	IN	O
.	.	O
The	DT	O
constructs	NNS	O
comprise	VBP	O
a	DT	O
vector	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
a	DT	O
plasmid	NN	O
,	,	O
a	DT	O
cosmid	NN	O
,	,	O
a	DT	O
phage	NN	O
,	,	O
a	DT	O
virus	NN	O
,	,	O
a	DT	O
bacterial	JJ	O
artificial	JJ	O
chromosome	NN	O
(	(	O
BAC	NNP	O
)	)	O
,	,	O
a	DT	O
yeast	JJ	O
artificial	JJ	O
chromosome	NN	O
(	(	O
YAC	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
into	IN	O
which	WDT	O
a	DT	O
nucleic	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
invention	NN	O
has	VBZ	O
been	VBN	O
inserted	VBN	O
,	,	O
in	IN	O
a	DT	O
forward	NN	O
or	CC	O
reverse	NN	O
orientation	NN	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
,	,	O
the	DT	O
construct	NN	O
further	JJ	O
comprises	NNS	O
regulatory	JJ	O
sequences	NNS	O
,	,	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
promoter	NN	O
,	,	O
operably	RB	O
linked	VBN	O
to	TO	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
.	.	O
Large	JJ	O
numbers	NNS	O
of	IN	O
suitable	JJ	O
vectors	NNS	O
and	CC	O
promoters	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
and	CC	O
are	VBP	O
commercially	RB	O
available	JJ	O
.	.	O
General	NNP	O
texts	NN	O
that	WDT	O
describe	VBZ	O
molecular	JJ	O
biological	JJ	O
techniques	NNS	O
useful	JJ	O
herein	NNS	O
,	,	O
including	VBG	O
the	DT	O
use	NN	O
of	IN	O
vectors	NNS	O
,	,	O
promoters	NNS	O
and	CC	O
many	JJ	O
other	JJ	O
relevant	JJ	O
topics	NNS	O
,	,	O
include	VBP	O
Berger	NNP	B
,	,	I
supra	NN	I
;	:	O
Sambrook	NNP	B
(	(	I
1989	CD	I
)	)	I
,	,	I
supra	UH	I
,	,	O
and	CC	O
Ausubel	NNP	B
,	,	I
supra	NN	I
.	.	O
Examples	NNS	O
of	IN	O
techniques	NNS	O
sufficient	JJ	O
to	TO	O
direct	JJ	O
persons	NNS	O
of	IN	O
skill	NN	O
through	IN	O
in	IN	O
vitro	JJ	O
amplification	NN	O
methods	NNS	O
,	,	O
including	VBG	O
the	DT	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
the	DT	O
ligase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
LCR	NNP	O
)	)	O
,	,	O
Q	NNP	O
beta-replicase	NN	O
amplification	NN	O
and	CC	O
other	JJ	O
RNA	NNP	O
polymerase	NN	O
mediated	VBD	O
techniques	NNS	O
(	(	O
e.g.	NN	O
,	,	O
NASBA	NNP	O
)	)	O
,	,	O
e.g.	UH	O
,	,	O
for	IN	O
the	DT	O
production	NN	O
of	IN	O
the	DT	O
homologous	JJ	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
found	VBN	O
in	IN	O
Berger	NNP	B
,	,	O
Sambrook	NNP	B
,	,	O
and	CC	O
Ausubel	NNP	B
,	,	O
all	DT	O
supra	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
Mullis	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,683,202	CD	O
;	:	O
PCR	NNP	B
Protocols	NNP	I
:	:	I
A	DT	I
Guide	NNP	I
to	TO	I
Methods	NNP	I
and	CC	I
Applications	NNP	I
(	(	I
Innis	NNP	I
et	RB	I
al.	RB	I
,	,	I
eds	NNS	I
.	.	I
)	)	I
Academic	NNP	I
Press	NNP	I
Inc.	NNP	I
San	NNP	I
Diego	NNP	I
,	,	I
Calif.	NNP	I
(	(	I
1990	CD	I
)	)	I
(	(	I
“	JJ	I
Innis	NNP	I
”	NNP	I
)	)	I
;	:	O
Arnheim	NNP	B
&	CC	I
Levinson	NNP	I
(	(	I
Oct.	NNP	I
1	CD	I
,	,	I
1990	CD	I
)	)	I
C	NNP	I
&	CC	I
EN	NNP	I
36-47	CD	I
;	:	O
The	DT	B
Journal	NNP	I
Of	IN	I
NIH	NNP	I
Research	NNP	I
(	(	I
1991	CD	I
)	)	I
3:81-94	CD	I
;	:	O
(	(	O
Kwoh	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
86:1173-1177	CD	I
;	:	O
Guatelli	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
87:1874-1878	CD	I
;	:	O
Lomeli	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
J	NNP	I
Clin	NNP	I
Chem	NNP	I
35:1826-1831	CD	I
;	:	O
Landegren	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1988	CD	I
)	)	I
Science	NNP	I
241:1077-1080	CD	I
;	:	O
Van	NNP	B
Brunt	NNP	I
(	(	I
1990	CD	I
)	)	I
Biotechnology	NNP	I
8:291-294	CD	I
;	:	O
Wu	NNP	B
and	CC	I
Wallace	NNP	I
(	(	I
1989	CD	I
)	)	I
Gene	NNP	I
4:560-569	JJ	I
;	:	O
Barringer	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Gene	NNP	I
89:117-122	JJ	I
,	,	O
and	CC	O
Sooknanan	NNP	B
and	CC	I
Malek	NNP	I
(	(	I
1995	CD	I
)	)	I
Biotechnology	NNP	I
13:563-564	CD	I
.	.	O
Improved	VBN	O
methods	NNS	O
of	IN	O
cloning	VBG	O
in	IN	O
vitro	NN	O
amplified	VBN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Wallace	NNP	O
et	CC	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,426,039	CD	O
.	.	O
Improved	VBN	O
methods	NNS	O
of	IN	O
amplifying	VBG	O
large	JJ	O
nucleic	JJ	O
acids	NNS	O
by	IN	O
PCR	NNP	O
are	VBP	O
summarized	VBN	O
in	IN	O
Cheng	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Nature	NN	I
369:684-685	JJ	I
and	CC	O
the	DT	O
references	NNS	O
therein	RB	O
,	,	O
in	IN	O
which	WDT	O
PCR	NNP	O
amplicons	NNS	O
of	IN	O
up	IN	O
to	TO	O
40	CD	O
kilobases	NNS	O
(	(	O
kb	NN	O
)	)	O
are	VBP	O
generated	VBN	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
will	MD	O
appreciate	VB	O
that	DT	O
essentially	RB	O
any	DT	O
RNA	NNP	O
can	MD	O
be	VB	O
converted	VBN	O
into	IN	O
a	DT	O
double	JJ	O
stranded	JJ	O
DNA	NNP	O
suitable	NN	O
for	IN	O
restriction	NN	O
digestion	NN	O
,	,	O
PCR	NNP	O
expansion	NN	O
and	CC	O
sequencing	VBG	O
using	VBG	O
reverse	JJ	O
transcriptase	NN	O
and	CC	O
a	DT	O
polymerase	NN	O
.	.	O
See	VB	O
Ausubel	NNP	O
,	,	O
Sambrook	NNP	O
and	CC	O
Berger	NNP	O
,	,	O
all	DT	O
supra	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
provides	VBZ	O
host	NN	O
cells	NNS	O
that	WDT	O
are	VBP	O
transduced	VBN	O
with	IN	O
vectors	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
and	CC	O
the	DT	O
production	NN	O
of	IN	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
by	IN	O
recombinant	JJ	O
techniques	NNS	O
.	.	O
Host	NNP	O
cells	NNS	O
are	VBP	O
genetically	RB	O
engineered	VBN	O
(	(	O
e.g.	NN	O
,	,	O
transduced	VBD	O
,	,	O
transformed	VBD	O
or	CC	O
transfected	VBN	O
)	)	O
with	IN	O
the	DT	O
vectors	NNS	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
cloning	VBG	O
vector	NN	O
or	CC	O
an	DT	O
expression	NN	O
vector	NN	O
.	.	O
The	DT	O
vector	NN	O
may	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
plasmid	NN	O
,	,	O
a	DT	O
viral	JJ	O
particle	NN	O
,	,	O
a	DT	O
phage	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
engineered	JJ	O
host	NN	O
cells	NNS	O
can	MD	O
be	VB	O
cultured	VBN	O
in	IN	O
conventional	JJ	O
nutrient	JJ	O
media	NNS	O
modified	VBD	O
as	IN	O
appropriate	NN	O
for	IN	O
activating	VBG	O
promoters	NNS	O
,	,	O
selecting	VBG	O
transformants	NNS	O
,	,	O
or	CC	O
amplifying	VBG	O
genes	NNS	O
.	.	O
The	DT	O
culture	NN	O
conditions	NNS	O
,	,	O
such	JJ	O
as	IN	O
temperature	NN	O
,	,	O
pH	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
are	VBP	O
those	DT	O
previously	RB	O
used	VBN	O
with	IN	O
the	DT	O
host	NN	O
cell	NN	O
selected	VBN	O
for	IN	O
expression	NN	O
,	,	O
and	CC	O
will	MD	O
be	VB	O
apparent	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
in	IN	O
the	DT	O
references	NNS	O
cited	VBD	O
herein	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
Freshney	NNP	B
(	(	I
1994	CD	I
)	)	I
Culture	NN	I
of	IN	I
Animal	NNP	I
Cells	NNP	I
,	,	I
a	DT	I
Manual	NNP	I
of	IN	I
Basic	NNP	I
Technique	NNP	I
,	,	I
third	JJ	I
edition	NN	I
,	,	I
Wiley-Liss	NNP	I
,	,	I
New	NNP	I
York	NNP	I
and	CC	O
the	DT	O
references	NNS	O
cited	VBD	O
therein	NN	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
produced	VBN	O
in	IN	O
non-animal	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
plants	NNS	O
,	,	O
yeast	NN	O
,	,	O
fungi	NNS	O
,	,	O
bacteria	NNS	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
Sambrook	NNP	O
,	,	O
Berger	NNP	O
and	CC	O
Ausubel	NNP	O
,	,	O
details	NNS	O
regarding	VBG	O
cell	NN	O
culture	NN	O
are	VBP	O
found	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Payne	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Plant	NNP	I
Cell	NNP	I
and	CC	I
Tissue	NNP	I
Culture	NNP	I
in	IN	I
Liquid	NNP	I
Systems	NNP	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
;	:	O
Gamborg	NNP	B
and	CC	I
Phillips	NNP	I
(	(	I
eds	NNS	I
.	.	I
)	)	I
(	(	I
1995	CD	I
)	)	I
Plant	NNP	I
Cell	NNP	I
,	,	I
Tissue	NNP	I
and	CC	I
Organ	NNP	I
Culture	NNP	I
;	:	O
Fundamental	NNP	B
Methods	NNP	I
Springer	NNP	I
Lab	NNP	I
Manual	NNP	I
,	,	I
Springer-Verlag	NNP	I
(	(	I
Berlin	NNP	I
Heidelberg	NNP	I
New	NNP	I
York	NNP	I
)	)	I
;	:	O
Atlas	NNP	B
&	CC	I
Parks	NNP	I
(	(	I
eds	NNS	I
.	.	I
)	)	I
The	DT	I
Handbook	NNP	I
of	IN	I
Microbiological	NNP	I
Media	NNP	I
(	(	I
1993	CD	I
)	)	I
CRC	NNP	I
Press	NNP	I
,	,	I
Boca	NNP	I
Raton	NNP	I
,	,	I
Fla	NNP	I
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
fragments	NNS	O
thereof	NN	O
may	MD	O
be	VB	O
included	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
expression	NN	O
vectors	NNS	O
for	IN	O
expressing	VBG	O
a	DT	O
polypeptide	NN	O
.	.	O
Such	JJ	O
vectors	NNS	O
include	VBP	O
chromosomal	JJ	O
,	,	O
nonchromosomal	JJ	O
and	CC	O
synthetic	JJ	O
DNA	NNP	O
sequences	NNS	O
,	,	O
e.g.	NN	O
,	,	O
derivatives	NNS	O
of	IN	O
SV40	NNP	O
,	,	O
bacterial	JJ	O
plasmids	NNS	O
,	,	O
phage	NN	O
DNA	NNP	O
,	,	O
baculovirus	NN	O
,	,	O
yeast	NN	O
plasmids	NNS	O
,	,	O
vectors	NNS	O
derived	VBD	O
from	IN	O
combinations	NNS	O
of	IN	O
plasmids	NNS	O
and	CC	O
phage	NN	O
DNA	NN	O
,	,	O
viral	JJ	O
DNA	NNP	O
such	JJ	O
as	IN	O
vaccinia	NN	O
,	,	O
adenovirus	NN	O
,	,	O
fowl	NN	O
pox	NN	O
virus	NN	O
,	,	O
pseudorabies	NNS	O
,	,	O
adeno-associated	JJ	O
virus	NN	O
,	,	O
retroviruses	NNS	O
and	CC	O
many	JJ	O
others	NNS	O
.	.	O
Any	DT	O
vector	NN	O
that	WDT	O
transduces	VBZ	O
genetic	JJ	O
material	NN	O
into	IN	O
a	DT	O
cell	NN	O
,	,	O
and	CC	O
,	,	O
if	IN	O
replication	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
which	WDT	O
is	VBZ	O
replicable	JJ	O
and	CC	O
viable	JJ	O
in	IN	O
the	DT	O
relevant	JJ	O
host	NN	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
in	IN	O
the	DT	O
expression	NN	O
vector	NN	O
is	VBZ	O
operatively	RB	O
linked	VBN	O
to	TO	O
an	DT	O
appropriate	JJ	O
transcription	NN	O
control	NN	O
sequence	NN	O
(	(	O
promoter	NN	O
)	)	O
to	TO	O
direct	VB	O
mRNA	JJ	O
synthesis	NN	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
promoters	NNS	O
include	VBP	O
:	:	O
LTR	NNP	O
or	CC	O
SV40	NNP	O
promoter	NN	O
,	,	O
E.	NNP	O
coli	VBP	O
lac	NN	O
or	CC	O
trp	NN	O
promoter	NN	O
,	,	O
phage	NN	O
lambda	NN	O
PL	NNP	O
promoter	NN	O
,	,	O
CMV	NNP	O
promoter	NN	O
,	,	O
and	CC	O
other	JJ	O
promoters	NNS	O
known	VBN	O
to	TO	O
control	VB	O
expression	NN	O
of	IN	O
genes	NNS	O
in	IN	O
prokaryotic	JJ	O
or	CC	O
eukaryotic	JJ	O
cells	NNS	O
or	CC	O
their	PRP$	O
viruses	NNS	O
.	.	O
The	DT	O
expression	NN	O
vector	NN	O
also	RB	O
contains	VBZ	O
a	DT	O
ribosome	NN	O
binding	NN	O
site	NN	O
for	IN	O
translation	NN	O
initiation	NN	O
,	,	O
and	CC	O
a	DT	O
transcription	NN	O
terminator	NN	O
.	.	O
The	DT	O
vector	NN	O
optionally	RB	O
includes	VBZ	O
appropriate	JJ	O
sequences	NNS	O
for	IN	O
amplifying	VBG	O
expression	NN	O
,	,	O
e.g.	NN	O
,	,	O
an	DT	O
enhancer	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
expression	NN	O
vectors	NNS	O
optionally	RB	O
comprise	VBP	O
one	CD	O
or	CC	O
more	JJR	O
selectable	JJ	O
marker	NN	O
genes	NNS	O
to	TO	O
provide	VB	O
a	DT	O
phenotypic	NN	O
trait	NN	O
for	IN	O
selection	NN	O
of	IN	O
transformed	JJ	O
host	NN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
dihydrofolate	JJ	O
reductase	NN	O
or	CC	O
neomycin	JJ	O
resistance	NN	O
for	IN	O
eukaryotic	JJ	O
cell	NN	O
culture	NN	O
,	,	O
or	CC	O
such	JJ	O
as	IN	O
tetracycline	NN	O
,	,	O
kanamycin	NN	O
or	CC	O
ampicillin	NN	O
resistance	NN	O
in	IN	O
E.	NNP	O
coli	NNS	O
.	.	O
The	DT	O
vector	NN	O
containing	VBG	O
the	DT	O
appropriate	JJ	O
DNA	NNP	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
an	DT	O
appropriate	JJ	O
promoter	NN	O
or	CC	O
control	NN	O
sequence	NN	O
,	,	O
may	MD	O
be	VB	O
employed	VBN	O
to	TO	O
transform	VB	O
an	DT	O
appropriate	JJ	O
host	NN	O
to	TO	O
permit	VB	O
the	DT	O
host	NN	O
to	TO	O
express	VB	O
the	DT	O
polypeptide	NN	O
.	.	O
Examples	NNS	O
of	IN	O
appropriate	JJ	O
expression	NN	O
hosts	NNS	O
include	VBP	O
:	:	O
bacterial	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
Streptomyces	NNS	O
,	,	O
and	CC	O
Salmonella	NNP	O
typhimurium	NN	O
;	:	O
fungal	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
Saccharomyces	NNS	O
cerevisiae	VBP	O
,	,	O
Pichia	NNP	O
pastoris	NN	O
,	,	O
and	CC	O
Neurospora	NNP	O
crassa	NN	O
;	:	O
insect	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
Drosophila	NNP	O
and	CC	O
Spodoptera	NNP	O
frugiperda	NN	O
;	:	O
mammalian	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
CHO	NNP	O
,	,	O
COS	NNP	O
,	,	O
BHK	NNP	O
,	,	O
HEK	NNP	O
293	CD	O
or	CC	O
Bowes	NNP	O
melanoma	NN	O
;	:	O
plant	NN	O
cells	NNS	O
,	,	O
etc	FW	O
.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
that	IN	O
not	RB	O
all	DT	O
cells	NNS	O
or	CC	O
cell	NN	O
lines	NNS	O
need	VBP	O
to	TO	O
be	VB	O
capable	JJ	O
of	IN	O
producing	VBG	O
fully	RB	O
functional	JJ	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
or	CC	O
fragments	NNS	O
thereof	VBP	O
;	:	O
for	IN	O
example	NN	O
,	,	O
antigenic	JJ	O
fragments	NNS	O
of	IN	O
the	DT	O
polypeptide	NN	O
may	MD	O
be	VB	O
produced	VBN	O
in	IN	O
a	DT	O
bacterial	JJ	O
or	CC	O
other	JJ	O
expression	NN	O
system	NN	O
.	.	O
The	DT	O
invention	NN	O
is	VBZ	O
not	RB	O
limited	VBN	O
by	IN	O
the	DT	O
host	NN	O
cells	NNS	O
employed	VBN	O
.	.	O
In	IN	O
bacterial	JJ	O
systems	NNS	O
,	,	O
a	DT	O
number	NN	O
of	IN	O
expression	NN	O
vectors	NNS	O
may	MD	O
be	VB	O
selected	VBN	O
depending	VBG	O
upon	IN	O
the	DT	O
use	NN	O
intended	VBN	O
for	IN	O
the	DT	O
polypeptide	NN	O
or	CC	O
fragment	JJ	O
thereof	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
when	WRB	O
large	JJ	O
quantities	NNS	O
of	IN	O
a	DT	O
polypeptide	NN	O
or	CC	O
fragments	NNS	O
thereof	NNS	O
are	VBP	O
needed	VBN	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
antibodies	NNS	O
,	,	O
vectors	NNS	O
which	WDT	O
direct	VBP	O
high	JJ	O
level	NN	O
expression	NN	O
of	IN	O
fusion	NN	O
proteins	NNS	O
that	WDT	O
are	VBP	O
readily	RB	O
purified	VBN	O
may	MD	O
be	VB	O
desirable	JJ	O
.	.	O
Such	JJ	O
vectors	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
multifunctional	JJ	O
E.	NNP	O
coli	NNS	O
cloning	VBG	O
and	CC	O
expression	NN	O
vectors	NNS	O
such	JJ	O
as	IN	O
BLUESCRIPT	NNP	O
(	(	O
Stratagene	NNP	O
)	)	O
,	,	O
in	IN	O
which	WDT	O
the	DT	O
nucleotide	NN	O
coding	VBG	O
sequence	NN	O
may	MD	O
be	VB	O
ligated	VBN	O
into	IN	O
the	DT	O
vector	NN	O
in-frame	NN	O
with	IN	O
sequences	NNS	O
for	IN	O
the	DT	O
amino-terminal	JJ	O
Met	NNP	O
and	CC	O
the	DT	O
subsequent	JJ	O
7	CD	O
residues	NNS	O
of	IN	O
beta-galactosidase	NN	O
so	IN	O
that	IN	O
a	DT	O
hybrid	JJ	O
protein	NN	O
is	VBZ	O
produced	VBN	O
;	:	O
pIN	JJ	O
vectors	NNS	O
(	(	O
Van	NNP	B
Heeke	NNP	I
&	CC	I
Schuster	NNP	I
(	(	I
1989	CD	I
)	)	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
264:5503-5509	JJ	I
)	)	O
;	:	O
pET	JJ	O
vectors	NNS	O
(	(	O
Novagen	NNP	O
,	,	O
Madison	NNP	O
Wis.	NNP	O
)	)	O
;	:	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Similarly	RB	O
,	,	O
in	IN	O
the	DT	O
yeast	NN	O
Saccharomyces	NNP	O
cerevisiae	VBZ	O
a	DT	O
number	NN	O
of	IN	O
vectors	NNS	O
containing	VBG	O
constitutive	NN	O
or	CC	O
inducible	JJ	O
promoters	NNS	O
such	JJ	O
as	IN	O
alpha	JJ	O
factor	NN	O
,	,	O
alcohol	NN	O
oxidase	NN	O
and	CC	O
PGH	NNP	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
production	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
reviews	NNS	O
,	,	O
see	VBP	O
Ausubel	NNP	B
,	,	I
supra	NN	I
,	,	O
Berger	NNP	B
,	,	I
supra	NN	I
,	,	I
and	CC	I
Grant	NNP	I
et	VBD	I
al	RB	I
.	.	I
(	(	I
1987	CD	I
)	)	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
153:516-544	JJ	I
.	.	O
In	IN	O
mammalian	JJ	O
host	NN	O
cells	NNS	O
,	,	O
a	DT	O
number	NN	O
of	IN	O
expression	NN	O
systems	NNS	O
,	,	O
such	JJ	O
as	IN	O
viral-based	JJ	O
systems	NNS	O
,	,	O
may	MD	O
be	VB	O
utilized	VBN	O
.	.	O
In	IN	O
cases	NNS	O
where	WRB	O
an	DT	O
adenovirus	NN	O
is	VBZ	O
used	VBN	O
as	IN	O
an	DT	O
expression	NN	O
vector	NN	O
,	,	O
a	DT	O
coding	NN	O
sequence	NN	O
is	VBZ	O
optionally	RB	O
ligated	VBN	O
into	IN	O
an	DT	O
adenovirus	JJ	O
transcription/translation	NN	O
complex	JJ	O
consisting	NN	O
of	IN	O
the	DT	O
late	JJ	O
promoter	NN	O
and	CC	O
tripartite	JJ	O
leader	NN	O
sequence	NN	O
.	.	O
Insertion	NN	O
in	IN	O
a	DT	O
nonessential	JJ	O
E1	NNP	O
or	CC	O
E3	NNP	O
region	NN	O
of	IN	O
the	DT	O
viral	JJ	O
genome	NN	O
results	NNS	O
in	IN	O
a	DT	O
viable	JJ	O
virus	NN	O
capable	JJ	O
of	IN	O
expressing	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
infected	JJ	O
host	NN	O
cells	NNS	O
(	(	O
Logan	NNP	B
and	CC	I
Shenk	NNP	I
(	(	I
1984	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
81:3655-3659	JJ	I
)	)	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
transcription	NN	O
enhancers	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
rous	JJ	O
sarcoma	NN	O
virus	NN	O
(	(	O
RSV	NNP	O
)	)	O
enhancer	NN	O
,	,	O
are	VBP	O
used	VBN	O
to	TO	O
increase	VB	O
expression	NN	O
in	IN	O
mammalian	JJ	O
host	NN	O
cells	NNS	O
.	.	O
Host	NNP	O
cells	NNS	O
,	,	O
media	NNS	O
,	,	O
expression	NN	O
systems	NNS	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
production	NN	O
include	VBP	O
those	DT	O
known	VBN	O
for	IN	O
cloning	VBG	O
and	CC	O
expression	NN	O
of	IN	O
various	JJ	O
mammalian	JJ	O
proteins	NNS	O
.	.	O
Specific	JJ	O
initiation	NN	O
signals	NNS	O
can	MD	O
aid	VB	O
in	IN	O
efficient	JJ	O
translation	NN	O
of	IN	O
a	DT	O
polynucleotide	NN	O
coding	VBG	O
sequence	NN	O
of	IN	O
the	DT	O
invention	NN	O
and/or	NN	O
fragments	NNS	O
thereof	NN	O
.	.	O
These	DT	O
signals	NNS	O
can	MD	O
include	VB	O
,	,	O
e.g.	VB	O
,	,	O
the	DT	O
ATG	NNP	O
initiation	NN	O
codon	NN	O
and	CC	O
adjacent	JJ	O
sequences	NNS	O
.	.	O
In	IN	O
cases	NNS	O
where	WRB	O
a	DT	O
coding	NN	O
sequence	NN	O
,	,	O
its	PRP$	O
initiation	NN	O
codon	NN	O
and	CC	O
upstream	JJ	O
sequences	NNS	O
are	VBP	O
inserted	VBN	O
into	IN	O
the	DT	O
appropriate	JJ	O
expression	NN	O
vector	NN	O
,	,	O
no	DT	O
additional	JJ	O
translational	NN	O
control	NN	O
signals	NNS	O
may	MD	O
be	VB	O
needed	VBN	O
.	.	O
However	RB	O
,	,	O
in	IN	O
cases	NNS	O
where	WRB	O
only	RB	O
coding	VBG	O
sequence	NN	O
(	(	O
e.g.	JJ	O
,	,	O
a	DT	O
mature	NN	O
protein	NN	O
coding	VBG	O
sequence	NN	O
)	)	O
,	,	O
or	CC	O
a	DT	O
portion	NN	O
thereof	NN	O
,	,	O
is	VBZ	O
inserted	VBN	O
,	,	O
exogenous	JJ	O
nucleic	JJ	O
acid	JJ	O
transcriptional	JJ	O
control	NN	O
signals	NNS	O
including	VBG	O
the	DT	O
ATG	NNP	O
initiation	NN	O
codon	NN	O
must	MD	O
be	VB	O
provided	VBN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
initiation	NN	O
codon	NN	O
must	MD	O
be	VB	O
in	IN	O
the	DT	O
correct	JJ	O
reading	NN	O
frame	NN	O
to	TO	O
ensure	VB	O
transcription	NN	O
of	IN	O
the	DT	O
entire	JJ	O
insert	NN	O
.	.	O
Exogenous	JJ	O
transcriptional	JJ	O
elements	NNS	O
and	CC	O
initiation	NN	O
codons	NNS	O
can	MD	O
be	VB	O
of	IN	O
various	JJ	O
origins	NNS	O
,	,	O
both	DT	O
natural	JJ	O
and	CC	O
synthetic	JJ	O
.	.	O
The	DT	O
efficiency	NN	O
of	IN	O
expression	NN	O
can	MD	O
be	VB	O
enhanced	VBN	O
by	IN	O
the	DT	O
inclusion	NN	O
of	IN	O
enhancers	NNS	O
appropriate	VBP	O
to	TO	O
the	DT	O
cell	NN	O
system	NN	O
in	IN	O
use	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Scharf	NNP	B
D.	NNP	I
et	FW	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Results	NNP	I
Probl	NNP	I
Cell	NNP	I
Differ	NNP	I
20:125-62	JJ	I
;	:	O
and	CC	O
Bittner	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
Methods	NNS	I
in	IN	I
Enzymol	NNP	I
153:516-544	JJ	I
)	)	O
.	.	O
Polynucleotides	NNS	O
encoding	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
fused	VBN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in-frame	JJ	O
to	TO	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
a	DT	O
secretion/localization	NN	O
sequence	NN	O
,	,	O
to	TO	O
target	VB	O
polypeptide	JJ	O
expression	NN	O
to	TO	O
a	DT	O
desired	VBN	O
cellular	JJ	O
compartment	NN	O
,	,	O
membrane	NN	O
,	,	O
or	CC	O
organelle	RB	O
,	,	O
or	CC	O
to	TO	O
direct	VB	O
polypeptide	JJ	O
secretion	NN	O
to	TO	O
the	DT	O
periplasmic	JJ	O
space	NN	O
or	CC	O
into	IN	O
the	DT	O
cell	NN	O
culture	NN	O
media	NNS	O
.	.	O
Such	JJ	O
sequences	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
those	DT	O
of	IN	O
skill	NN	O
,	,	O
and	CC	O
include	VBP	O
secretion	JJ	O
leader	NN	O
or	CC	O
signal	JJ	O
peptides	NNS	O
,	,	O
organelle	IN	O
targeting	VBG	O
sequences	NNS	O
(	(	O
e.g.	NN	O
,	,	O
nuclear	JJ	O
localization	NN	O
sequences	NNS	O
,	,	O
ER	NNP	O
retention	NN	O
signals	NNS	O
,	,	O
mitochondrial	JJ	O
transit	NN	O
sequences	NNS	O
,	,	O
chloroplast	JJ	O
transit	NN	O
sequences	NNS	O
)	)	O
,	,	O
membrane	FW	O
localization/anchor	NN	O
sequences	NNS	O
(	(	O
e.g.	NN	O
,	,	O
stop	VB	O
transfer	NN	O
sequences	NNS	O
,	,	O
GPI	NNP	O
anchor	NN	O
sequences	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
aspect	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
relates	VBZ	O
to	TO	O
host	VB	O
cells	NNS	O
containing	VBG	O
any	DT	O
of	IN	O
the	DT	O
above-described	JJ	O
nucleic	JJ	O
acids	NNS	O
,	,	O
vectors	NNS	O
,	,	O
or	CC	O
other	JJ	O
constructs	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
host	NN	O
cell	NN	O
can	MD	O
be	VB	O
a	DT	O
eukaryotic	JJ	O
cell	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
,	,	O
a	DT	O
yeast	NN	O
cell	NN	O
,	,	O
or	CC	O
a	DT	O
plant	NN	O
cell	NN	O
,	,	O
or	CC	O
the	DT	O
host	NN	O
cell	NN	O
can	MD	O
be	VB	O
a	DT	O
prokaryotic	JJ	O
cell	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
bacterial	JJ	O
cell	NN	O
.	.	O
Introduction	NN	O
of	IN	O
the	DT	O
construct	NN	O
into	IN	O
the	DT	O
host	NN	O
cell	NN	O
can	MD	O
be	VB	O
effected	VBN	O
by	IN	O
calcium	NN	O
phosphate	NN	O
transfection	NN	O
,	,	O
DEAE-Dextran	NNP	O
mediated	VBD	O
transfection	NN	O
,	,	O
electroporation	NN	O
,	,	O
gene	NN	O
or	CC	O
vaccine	NN	O
gun	NN	O
,	,	O
injection	NN	O
,	,	O
or	CC	O
other	JJ	O
common	JJ	O
techniques	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Davis	NNP	B
,	,	I
L.	NNP	I
,	,	I
Dibner	NNP	I
,	,	I
M.	NNP	I
,	,	I
and	CC	I
Battey	NNP	I
,	,	I
I	PRP	I
.	.	I
(	(	I
1986	CD	I
)	)	I
Basic	NNP	I
Methods	NNP	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
)	)	O
for	IN	O
in	IN	O
vivo	NN	O
,	,	O
ex	FW	O
vivo	FW	O
or	CC	O
in	IN	O
vitro	JJ	O
methods	NNS	O
.	.	O
A	DT	O
host	NN	O
cell	NN	O
strain	NN	O
is	VBZ	O
optionally	RB	O
chosen	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
inserted	JJ	O
sequences	NNS	O
or	CC	O
to	TO	O
process	VB	O
the	DT	O
expressed	VBN	O
protein	NN	O
in	IN	O
the	DT	O
desired	JJ	O
fashion	NN	O
.	.	O
Such	JJ	O
modifications	NNS	O
of	IN	O
the	DT	O
protein	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
acetylation	NN	O
,	,	O
carboxylation	NN	O
,	,	O
glycosylation	NN	O
,	,	O
phosphorylation	NN	O
,	,	O
lipidation	NN	O
and	CC	O
acylation	NN	O
.	.	O
Post-translational	JJ	O
processing	NN	O
which	WDT	O
cleaves	VBZ	O
a	DT	O
“	JJ	O
pre	NN	O
”	NN	O
or	CC	O
a	DT	O
“	JJ	O
prepro	JJ	O
”	FW	O
form	NN	O
of	IN	O
the	DT	O
protein	NN	O
may	MD	O
also	RB	O
be	VB	O
important	JJ	O
for	IN	O
correct	JJ	O
insertion	NN	O
,	,	O
folding	VBG	O
and/or	JJ	O
function	NN	O
.	.	O
Different	NN	O
host	NN	O
cells	NNS	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
Bacillus	NNP	O
sp.	NN	O
,	,	O
yeast	NN	O
or	CC	O
mammalian	JJ	O
cells	NNS	O
such	JJ	O
as	IN	O
CHO	NNP	O
,	,	O
HeLa	NNP	O
,	,	O
BHK	NNP	O
,	,	O
MDCK	NNP	O
,	,	O
HEK	NNP	O
293	CD	O
,	,	O
W138	NNP	O
,	,	O
etc	NN	O
.	.	O
have	VB	O
specific	JJ	O
cellular	JJ	O
machinery	NN	O
and	CC	O
characteristic	JJ	O
mechanisms	NNS	O
for	IN	O
such	JJ	O
post-translational	JJ	O
activities	NNS	O
and	CC	O
may	MD	O
be	VB	O
chosen	VBN	O
to	TO	O
ensure	VB	O
the	DT	O
correct	JJ	O
modification	NN	O
and	CC	O
processing	NN	O
of	IN	O
the	DT	O
introduced	JJ	O
foreign	JJ	O
protein	NN	O
.	.	O
Stable	JJ	O
expression	NN	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
long-term	JJ	O
,	,	O
high-yield	JJ	O
production	NN	O
of	IN	O
recombinant	JJ	O
proteins	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cell	NN	O
lines	NNS	O
which	WDT	O
stably	RB	O
express	VBP	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
transduced	VBN	O
using	VBG	O
expression	NN	O
vectors	NNS	O
which	WDT	O
contain	VBP	O
viral	JJ	O
origins	NNS	O
of	IN	O
replication	NN	O
or	CC	O
endogenous	JJ	O
expression	NN	O
elements	NNS	O
and	CC	O
a	DT	O
selectable	JJ	O
marker	NN	O
gene	NN	O
.	.	O
Following	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
the	DT	O
vector	NN	O
,	,	O
cells	NNS	O
may	MD	O
be	VB	O
allowed	VBN	O
to	TO	O
grow	VB	O
for	IN	O
1-2	JJ	O
days	NNS	O
in	IN	O
an	DT	O
enriched	JJ	O
media	NNS	O
before	IN	O
they	PRP	O
are	VBP	O
switched	VBN	O
to	TO	O
selective	JJ	O
media	NNS	O
.	.	O
The	DT	O
purpose	NN	O
of	IN	O
the	DT	O
selectable	JJ	O
marker	NN	O
is	VBZ	O
to	TO	O
confer	VB	O
resistance	NN	O
to	TO	O
selection	NN	O
,	,	O
and	CC	O
its	PRP$	O
presence	NN	O
allows	VBZ	O
growth	NN	O
and	CC	O
recovery	NN	O
of	IN	O
cells	NNS	O
which	WDT	O
successfully	RB	O
express	VBP	O
the	DT	O
introduced	JJ	O
sequences	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
resistant	JJ	O
clumps	NNS	O
of	IN	O
stably	RB	O
transformed	VBN	O
cells	NNS	O
can	MD	O
be	VB	O
proliferated	VBN	O
using	VBG	O
tissue	JJ	O
culture	NN	O
techniques	NNS	O
appropriate	VBP	O
to	TO	O
the	DT	O
cell	NN	O
type	NN	O
.	.	O
Host	NNP	O
cells	NNS	O
transformed	VBD	O
with	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
optionally	RB	O
cultured	VBN	O
under	IN	O
conditions	NNS	O
suitable	JJ	O
for	IN	O
the	DT	O
expression	NN	O
and	CC	O
recovery	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
protein	NN	O
from	IN	O
cell	JJ	O
culture	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
produced	VBN	O
by	IN	O
a	DT	O
recombinant	JJ	O
cell	NN	O
may	MD	O
be	VB	O
secreted	VBN	O
,	,	O
membrane-bound	JJ	O
,	,	O
or	CC	O
contained	VBD	O
intracellularly	RB	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
sequence	NN	O
and/or	VBD	O
the	DT	O
vector	NN	O
used	VBN	O
.	.	O
As	IN	O
will	MD	O
be	VB	O
understood	VBN	O
by	IN	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
expression	NN	O
vectors	NNS	O
containing	VBG	O
polynucleotides	NNS	O
encoding	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
designed	VBN	O
with	IN	O
signal	NN	O
sequences	NNS	O
which	WDT	O
direct	VBP	O
secretion	NN	O
of	IN	O
the	DT	O
mature	NN	O
polypeptides	VBZ	O
through	IN	O
a	DT	O
prokaryotic	JJ	O
or	CC	O
eukaryotic	JJ	O
cell	NN	O
membrane	NN	O
.	.	O
The	DT	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
optionally	RB	O
comprise	VB	O
a	DT	O
coding	NN	O
sequence	NN	O
fused	VBD	O
in-frame	NN	O
to	TO	O
a	DT	O
marker	NN	O
sequence	NN	O
which	WDT	O
,	,	O
e.g.	NN	O
,	,	O
facilitates	VBZ	O
purification	NN	O
and/or	JJ	O
detection	NN	O
of	IN	O
the	DT	O
encoded	JJ	O
polypeptide	NN	O
.	.	O
Such	JJ	O
purification	NN	O
subsequences	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
metal	NN	O
chelating	VBG	O
peptides	NNS	O
such	JJ	O
as	IN	O
histidine-tryptophan	JJ	O
modules	NNS	O
that	WDT	O
allow	VBP	O
purification	NN	O
on	IN	O
immobilized	JJ	O
metals	NNS	O
,	,	O
a	DT	O
sequence	NN	O
which	WDT	O
binds	VBZ	O
glutathione	NN	O
(	(	O
e.g.	JJ	O
,	,	O
GST	NNP	O
)	)	O
,	,	O
a	DT	O
hemagglutinin	NN	O
(	(	O
HA	NNP	O
)	)	O
tag	NN	O
(	(	O
corresponding	VBG	O
to	TO	O
an	DT	O
epitope	NN	O
derived	VBN	O
from	IN	O
the	DT	O
influenza	NN	O
hemagglutinin	NN	O
protein	NN	O
;	:	O
Wilson	NNP	B
,	,	I
I.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1984	CD	I
)	)	I
Cell	NNP	I
37:767	CD	I
)	)	O
,	,	O
maltose	JJ	O
binding	VBG	O
protein	NN	O
sequences	NNS	O
,	,	O
the	DT	O
FLAG	NNP	O
epitope	NN	O
utilized	VBN	O
in	IN	O
the	DT	O
FLAGS	NNP	O
extension/affinity	NN	O
purification	NN	O
system	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
The	DT	O
inclusion	NN	O
of	IN	O
a	DT	O
protease-cleavable	JJ	O
polypeptide	NN	O
linker	NN	O
sequence	NN	O
between	IN	O
the	DT	O
purification	NN	O
domain	NN	O
and	CC	O
the	DT	O
polypeptide	NN	O
sequence	NN	O
is	VBZ	O
useful	JJ	O
to	TO	O
facilitate	VB	O
purification	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
one	CD	O
expression	NN	O
vector	NN	O
possible	JJ	O
to	TO	O
use	VB	O
in	IN	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
described	VBD	O
herein	JJ	O
provides	VBZ	O
for	IN	O
expression	NN	O
of	IN	O
a	DT	O
fusion	NN	O
protein	NN	O
comprising	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
fused	VBD	O
to	TO	O
a	DT	O
polyhistidine	JJ	O
region	NN	O
separated	VBN	O
by	IN	O
an	DT	O
enterokinase	NN	O
cleavage	NN	O
site	NN	O
.	.	O
The	DT	O
histidine	NN	O
residues	VBZ	O
facilitate	JJ	O
purification	NN	O
on	IN	O
IMIAC	NNP	O
(	(	O
immobilized	VBN	O
metal	NN	O
ion	NN	O
affinity	NN	O
chromatography	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Porath	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Protein	NNP	I
Expression	NNP	I
and	CC	I
Purification	NNP	I
3:263-281	NNP	I
)	)	O
while	IN	O
the	DT	O
enterokinase	NN	O
cleavage	NN	O
site	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
separating	VBG	O
the	DT	O
desired	VBN	O
polypeptide	NN	O
from	IN	O
the	DT	O
polyhistidine	JJ	O
region	NN	O
.	.	O
pGEX	NN	O
vectors	NNS	O
(	(	O
Promega	NNP	O
;	:	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
are	VBP	O
optionally	RB	O
used	VBN	O
to	TO	O
express	VB	O
foreign	JJ	O
polypeptides	NNS	O
as	IN	O
fusion	NN	O
proteins	NNS	O
with	IN	O
glutathione	JJ	O
S-transferase	NNP	O
(	(	O
GST	NNP	O
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
such	JJ	O
fusion	NN	O
proteins	NNS	O
are	VBP	O
soluble	JJ	O
and	CC	O
can	MD	O
easily	RB	O
be	VB	O
purified	VBN	O
from	IN	O
lysed	VBN	O
cells	NNS	O
by	IN	O
adsorption	NN	O
to	TO	O
ligand-agarose	JJ	O
beads	NNS	O
(	(	O
e.g.	NN	O
,	,	O
glutathione-agarose	JJ	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
GST-fusions	NNP	O
)	)	O
followed	VBN	O
by	IN	O
elution	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
free	JJ	O
ligand	NN	O
.	.	O
An	DT	O
additional	JJ	O
construction	NN	O
in	IN	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
described	VBD	O
herein	JJ	O
provides	VBZ	O
for	IN	O
proteins	NNS	O
,	,	O
and	CC	O
their	PRP$	O
encoding	NN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
comprising	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
fragments	NNS	O
thereof	NN	O
)	)	O
,	,	O
e.g.	RB	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
,	,	O
fused	VBD	O
to	TO	O
an	DT	O
Ig	NNP	O
molecule	NN	O
,	,	O
e.g.	NN	O
,	,	O
human	JJ	O
IgG	NNP	O
Fc	NNP	O
(	(	O
“	JJ	O
fragment	NN	O
crystallizable	NN	O
,	,	O
”	''	O
or	CC	O
fragment	JJ	O
complement	NN	O
binding	VBG	O
)	)	O
hinge	NN	O
,	,	O
CH2	NNP	O
domain	NN	O
and	CC	O
CH3	NNP	O
domain	NN	O
(	(	O
and	CC	O
nucleotide	RB	O
sequences	NNS	O
encoding	VBG	O
them	PRP	O
)	)	O
.	.	O
Fc	NNP	O
is	VBZ	O
the	DT	O
portion	NN	O
of	IN	O
the	DT	O
antibody	NN	O
responsible	JJ	O
for	IN	O
binding	VBG	O
to	TO	O
antibody	NN	O
receptors	NNS	O
on	IN	O
cells	NNS	O
and	CC	O
the	DT	O
C1q	NNP	O
component	NN	O
of	IN	O
complement	NN	O
.	.	O
These	DT	O
fusion	NN	O
proteins	VBZ	O
or	CC	O
fragments	NNS	O
thereof	NNS	O
and	CC	O
their	PRP$	O
encoding	NN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
optionally	RB	O
useful	JJ	O
as	IN	O
prophylactic	JJ	O
and/or	NN	O
therapeutic	JJ	O
drugs	NNS	O
or	CC	O
as	IN	O
diagnostic	JJ	O
tools	NNS	O
(	(	O
see	VB	O
also	RB	O
,	,	O
e.g.	RB	O
,	,	O
Challita-Eid	NNP	B
,	,	I
P.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1998	CD	I
)	)	I
J	NNP	I
Immunol	NNP	I
160:3419-3426	CD	I
;	:	O
Sturmhoefel	NNP	B
,	,	I
K.	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
1999	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
59:4964-4972	CD	I
)	)	O
.	.	O
Following	VBG	O
transduction	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
host	NN	O
strain	NN	O
and	CC	O
growth	NN	O
of	IN	O
the	DT	O
host	NN	O
strain	NN	O
to	TO	O
an	DT	O
appropriate	JJ	O
cell	NN	O
density	NN	O
,	,	O
the	DT	O
selected	VBN	O
promoter	NN	O
is	VBZ	O
induced	VBN	O
by	IN	O
appropriate	JJ	O
means	NNS	O
(	(	O
e.g.	NN	O
,	,	O
temperature	NN	O
shift	NN	O
or	CC	O
chemical	JJ	O
induction	NN	O
)	)	O
and	CC	O
cells	NNS	O
are	VBP	O
cultured	VBN	O
for	IN	O
an	DT	O
additional	JJ	O
period	NN	O
.	.	O
Cells	NNS	O
are	VBP	O
typically	RB	O
harvested	VBN	O
by	IN	O
centrifugation	NN	O
,	,	O
disrupted	VBN	O
by	IN	O
physical	JJ	O
or	CC	O
chemical	NN	O
means	NNS	O
,	,	O
and	CC	O
the	DT	O
resulting	VBG	O
crude	JJ	O
extract	NN	O
retained	VBN	O
for	IN	O
further	JJ	O
purification	NN	O
.	.	O
Eukaryotic	JJ	O
or	CC	O
microbial	JJ	O
cells	NNS	O
employed	VBN	O
in	IN	O
expression	NN	O
of	IN	O
the	DT	O
proteins	NNS	O
can	MD	O
be	VB	O
disrupted	VBN	O
by	IN	O
any	DT	O
convenient	JJ	O
method	NN	O
,	,	O
including	VBG	O
freeze-thaw	JJ	O
cycling	NN	O
,	,	O
sonication	NN	O
,	,	O
mechanical	JJ	O
disruption	NN	O
,	,	O
or	CC	O
use	NN	O
of	IN	O
cell	NN	O
lysing	VBG	O
agents	NNS	O
,	,	O
or	CC	O
other	JJ	O
methods	NNS	O
,	,	O
which	WDT	O
are	VBP	O
well	RB	O
know	JJ	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
As	IN	O
noted	VBN	O
,	,	O
many	JJ	O
references	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
culture	NN	O
and	CC	O
production	NN	O
of	IN	O
many	JJ	O
cells	NNS	O
,	,	O
including	VBG	O
cells	NNS	O
of	IN	O
bacterial	JJ	O
,	,	O
plant	NN	O
,	,	O
animal	NN	O
(	(	O
especially	RB	O
mammalian	JJ	O
)	)	O
and	CC	O
archebacterial	JJ	O
origin	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Sambrook	NNP	B
,	,	O
Ausubel	NNP	B
,	,	O
and	CC	O
Berger	NNP	B
(	(	O
all	DT	O
supra	NN	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
Freshney	NNP	B
(	(	I
1994	CD	I
)	)	I
Culture	NN	I
of	IN	I
Animal	NNP	I
Cells	NNP	I
,	,	I
a	DT	I
Manual	NNP	I
of	IN	I
Basic	NNP	I
Technique	NNP	I
,	,	I
third	JJ	I
edition	NN	I
,	,	I
Wiley-Liss	NNP	I
,	,	I
New	NNP	I
York	NNP	I
and	CC	O
the	DT	O
references	NNS	O
cited	VBD	O
therein	RB	O
;	:	O
Doyle	NNP	B
and	CC	I
Griffiths	NNP	I
(	(	I
1997	CD	I
)	)	I
Mammalian	NNP	I
Cell	NNP	I
Culture	NNP	I
:	:	I
Essential	JJ	I
Techniques	NNP	I
John	NNP	I
Wiley	NNP	I
and	CC	I
Sons	NNP	I
,	,	I
New	NNP	I
York	NNP	I
;	:	O
Humason	NNP	B
(	(	I
1979	CD	I
)	)	I
Animal	NNP	I
Tissue	NNP	I
Techniques	NNP	I
,	,	I
fourth	JJ	I
edition	NN	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
and	CC	I
Company	NNP	I
;	:	O
and	CC	O
Ricciardelli	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
In	IN	I
vitro	NN	I
Cell	NNP	I
Dev	NNP	I
Biol	NNP	I
25:1016-1024	JJ	I
.	.	O
For	IN	O
plant	NN	O
cell	NN	O
culture	NN	O
and	CC	O
regeneration	NN	O
see	NN	O
,	,	O
e.g.	VB	O
,	,	O
Payne	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1992	CD	I
)	)	I
Plant	NNP	I
Cell	NNP	I
and	CC	I
Tissue	NNP	I
Culture	NNP	I
in	IN	I
Liquid	NNP	I
Systems	NNP	I
John	NNP	I
Wiley	NNP	I
&	CC	I
Sons	NNP	I
,	,	I
Inc.	NNP	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
;	:	O
Gamborg	NNP	B
and	CC	I
Phillips	NNP	I
(	(	I
eds	NNS	I
.	.	I
)	)	I
(	(	I
1995	CD	I
)	)	I
Plant	NNP	I
Cell	NNP	I
,	,	I
Tissue	NNP	I
and	CC	I
Organ	NNP	I
Culture	NNP	I
;	:	O
Fundamental	NNP	B
Methods	NNP	I
Springer	NNP	I
Lab	NNP	I
Manual	NNP	I
,	,	I
Springer-Verlag	NNP	I
(	(	I
Berlin	NNP	I
Heidelberg	NNP	I
New	NNP	I
York	NNP	I
)	)	I
and	CC	O
Plant	NNP	B
Molecular	NNP	I
Biology	NNP	I
(	(	I
1993	CD	I
)	)	I
R.	NNP	I
R.	NNP	I
D.	NNP	I
Croy	NNP	I
(	(	I
ed	FW	I
.	.	I
)	)	I
Bios	NNP	I
Scientific	NNP	I
Publishers	NNP	I
,	,	I
Oxford	NNP	I
,	,	I
U.K.	NNP	I
ISBN	NNP	I
0	CD	I
12	CD	I
198370	CD	I
6	CD	I
.	.	O
Cell	NNP	O
culture	NN	O
media	NNS	O
in	IN	O
general	JJ	O
are	VBP	O
set	VBN	O
forth	NN	O
in	IN	O
Atlas	NNP	B
and	CC	I
Parks	NNP	I
(	(	I
eds	NNS	I
.	.	I
)	)	I
The	DT	I
Handbook	NNP	I
of	IN	I
Microbiological	NNP	I
Media	NNP	I
(	(	I
1993	CD	I
)	)	I
CRC	NNP	I
Press	NNP	I
,	,	I
Boca	NNP	I
Raton	NNP	I
,	,	I
Fla.	NNP	I
Additional	NNP	O
information	NN	O
for	IN	O
cell	NN	O
culture	NN	O
is	VBZ	O
found	VBN	O
in	IN	O
available	JJ	O
commercial	JJ	O
literature	NN	O
such	JJ	O
as	IN	O
the	DT	O
Life	NNP	O
Science	NNP	O
Research	NNP	O
Cell	NNP	O
Culture	NNP	O
Catalogue	NNP	O
from	IN	O
Sigma-Aldrich	NNP	O
,	,	O
Inc	NNP	O
(	(	O
St	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
(	(	O
“	JJ	O
Sigma-LSRCCC	NNP	O
”	NN	O
)	)	O
and	CC	O
,	,	O
e.g.	RB	O
,	,	O
the	DT	O
Plant	NNP	O
Culture	NNP	O
Catalogue	NNP	O
and	CC	O
supplement	NN	O
also	RB	O
from	IN	O
Sigma-Aldrich	NNP	O
,	,	O
Inc	NNP	O
(	(	O
St	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
(	(	O
“	JJ	O
Sigma-PCCS	NNP	O
”	NN	O
)	)	O
.	.	O
Polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
recovered	VBN	O
and	CC	O
purified	VBN	O
from	IN	O
recombinant	NN	O
cell	NN	O
cultures	NNS	O
by	IN	O
any	DT	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
including	VBG	O
ammonium	NN	O
sulfate	NN	O
or	CC	O
ethanol	JJ	O
precipitation	NN	O
,	,	O
acid	JJ	O
extraction	NN	O
,	,	O
anion	NN	O
or	CC	O
cation	NN	O
exchange	NN	O
chromatography	NN	O
,	,	O
phosphocellulose	JJ	O
chromatography	NN	O
,	,	O
hydrophobic	JJ	O
interaction	NN	O
chromatography	NN	O
,	,	O
affinity	NN	O
chromatography	NN	O
(	(	O
e.g.	NN	O
,	,	O
using	VBG	O
any	DT	O
of	IN	O
the	DT	O
tagging	VBG	O
systems	NNS	O
noted	VBD	O
herein	NN	O
)	)	O
,	,	O
hydroxylapatite	JJ	O
chromatography	NN	O
,	,	O
and	CC	O
lectin	JJ	O
chromatography	NN	O
.	.	O
Protein	NNP	O
refolding	VBG	O
steps	NNS	O
can	MD	O
be	VB	O
used	VBN	O
,	,	O
as	IN	O
desired	VBN	O
,	,	O
in	IN	O
completing	VBG	O
configuration	NN	O
of	IN	O
the	DT	O
mature	NN	O
protein	NN	O
or	CC	O
fragments	NNS	O
thereof	NN	O
.	.	O
Finally	RB	O
,	,	O
high	JJ	O
performance	NN	O
liquid	NN	O
chromatography	NN	O
(	(	O
HPLC	NNP	O
)	)	O
can	MD	O
be	VB	O
employed	VBN	O
in	IN	O
the	DT	O
final	JJ	O
purification	NN	O
steps	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
references	NNS	O
noted	VBD	O
,	,	O
supra	NN	O
,	,	O
a	DT	O
variety	NN	O
of	IN	O
purification	NN	O
methods	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
those	DT	O
set	VBN	O
forth	NN	O
in	IN	O
Sandana	NNP	B
(	(	I
1997	CD	I
)	)	I
Bioseparation	NN	I
of	IN	I
Proteins	NNP	I
,	,	I
Academic	NNP	I
Press	NNP	I
,	,	I
Inc.	NNP	I
;	:	O
Bollag	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Protein	NNP	I
Methods	NNP	I
,	,	I
2.sup.nd	CD	I
Edition	NNP	I
Wiley-Liss	NNP	I
,	,	I
New	NNP	I
York	NNP	I
;	:	O
Walker	NNP	B
(	(	I
1996	CD	I
)	)	I
The	DT	I
Protein	NNP	I
Protocols	NNP	I
Handbook	NNP	I
Humana	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
Jersey	NNP	I
;	:	O
Harris	NNP	B
and	CC	I
Angal	NNP	I
(	(	I
1990	CD	I
)	)	I
Protein	NNP	I
Purification	NNP	I
Applications	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
IRL	NNP	I
Press	NNP	I
at	IN	I
Oxford	NNP	I
,	,	I
Oxford	NNP	I
,	,	I
England	NNP	I
;	:	O
Harris	NNP	B
and	CC	I
Angal	NNP	I
Protein	NNP	I
Purification	NNP	I
Methods	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
IRL	NNP	I
Press	NNP	I
at	IN	I
Oxford	NNP	I
,	,	I
Oxford	NNP	I
,	,	I
England	NNP	I
;	:	O
Scopes	NNP	B
(	(	I
1993	CD	I
)	)	I
Protein	NNP	I
Purification	NNP	I
Principles	NNP	I
and	CC	I
Practice	NNP	I
3.sup.rd	CD	I
Edition	NNP	I
Springer	NNP	I
Verlag	NNP	I
,	,	I
New	NNP	I
York	NNP	I
;	:	O
Janson	NNP	B
and	CC	I
Ryden	NNP	I
(	(	I
1998	CD	I
)	)	I
Protein	NNP	I
Purification	NNP	I
:	:	I
Principles	NNS	I
,	,	I
High	NNP	I
Resolution	NNP	I
Methods	NNP	I
and	CC	I
Applications	NNP	I
,	,	I
Second	NNP	I
Edition	NNP	I
Wiley-VCH	NNP	I
,	,	I
New	NNP	I
York	NNP	I
;	:	O
and	CC	O
Walker	NNP	B
(	(	I
1998	CD	I
)	)	I
Protein	NNP	I
Protocols	NNP	I
on	IN	I
CD-ROM	NNP	I
Humana	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
Jersey	NNP	I
.	.	O
Cell-free	JJ	O
transcription/translation	NN	O
systems	NNS	O
can	MD	O
also	RB	O
be	VB	O
employed	VBN	O
to	TO	O
produce	VB	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
using	VBG	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Several	JJ	O
such	JJ	O
systems	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
.	.	O
A	DT	O
general	JJ	O
guide	NN	O
to	TO	O
in	IN	O
vitro	JJ	O
transcription	NN	O
and	CC	O
translation	NN	O
protocols	NNS	O
is	VBZ	O
found	VBN	O
in	IN	O
Tymms	NNP	B
(	(	I
1995	CD	I
)	)	I
In	IN	I
vitro	JJ	I
Transcription	NNP	I
and	CC	I
Translation	NNP	I
Protocols	NNP	I
:	:	I
Methods	NNS	I
in	IN	I
Molecular	NNP	I
Biology	NNP	I
Volume	NN	I
37	CD	I
,	,	I
Garland	NNP	I
Publishing	NNP	I
,	,	I
New	NNP	I
York	NNP	I
.	.	O
Polynucleotides	NNS	O
that	WDT	O
encode	VBP	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
or	CC	O
complements	NNS	O
of	IN	O
the	DT	O
polynucleotides	NNS	O
(	(	O
including	VBG	O
e.g.	NN	O
,	,	O
antisense	NN	O
or	CC	O
ribozyme	VB	O
molecules	NNS	O
)	)	O
,	,	O
are	VBP	O
optionally	RB	O
administered	VBN	O
to	TO	O
a	DT	O
cell	NN	O
to	TO	O
accomplish	VB	O
a	DT	O
therapeutically	RB	O
useful	JJ	O
process	NN	O
or	CC	O
to	TO	O
express	VB	O
a	DT	O
therapeutically	RB	O
useful	JJ	O
product	NN	O
.	.	O
These	DT	O
in	IN	O
vivo	NN	O
applications	NNS	O
,	,	O
including	VBG	O
gene	NN	O
therapy	NN	O
,	,	O
include	VBP	O
a	DT	O
multitude	NN	O
of	IN	O
techniques	NNS	O
by	IN	O
which	WDT	O
gene	NN	O
expression	NN	O
may	MD	O
be	VB	O
altered	VBN	O
in	IN	O
cells	NNS	O
.	.	O
Such	JJ	O
methods	NNS	O
include	VBP	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
the	DT	O
introduction	NN	O
of	IN	O
genes	NNS	O
for	IN	O
expression	NN	O
of	IN	O
,	,	O
e.g.	UH	O
,	,	O
therapeutically	RB	O
and/or	VBZ	O
prophylactically	RB	O
useful	JJ	O
polypeptides	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Polynucleotides	NNS	O
encoding	VBG	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
particularly	RB	O
useful	JJ	O
for	IN	O
in	IN	O
vivo	JJ	O
therapeutic	JJ	O
applications	NNS	O
,	,	O
using	VBG	O
techniques	NNS	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cultured	VBN	O
cells	NNS	O
are	VBP	O
engineered	VBN	O
ex	JJ	O
vivo	NN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
polynucleotide	NN	O
(	(	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
)	)	O
of	IN	O
the	DT	O
invention	NN	O
and/or	VBZ	O
other	JJ	O
polynucleotide	JJ	O
sequences	NNS	O
encoding	VBG	O
,	,	O
e.g.	NN	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
an	DT	O
antigen	NN	O
,	,	O
cytokine	NN	O
,	,	O
other	JJ	O
co-stimulatory	JJ	O
molecule	NN	O
,	,	O
adjuvant	NN	O
,	,	O
etc.	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
,	,	O
with	IN	O
the	DT	O
engineered	JJ	O
cells	NNS	O
then	RB	O
being	VBG	O
returned	VBN	O
to	TO	O
the	DT	O
patient	NN	O
.	.	O
Cells	NNS	O
may	MD	O
also	RB	O
be	VB	O
engineered	VBN	O
in	IN	O
vivo	NN	O
for	IN	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
polypeptides	NNS	O
in	IN	O
vivo	NN	O
,	,	O
including	VBG	O
polypeptides	NNS	O
and/or	RB	O
antigenic	JJ	O
peptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
viral	JJ	O
vectors	NNS	O
suitable	JJ	O
for	IN	O
organismal	JJ	O
in	IN	O
vivo	JJ	O
transduction	NN	O
and	CC	O
expression	NN	O
are	VBP	O
known	VBN	O
.	.	O
Such	JJ	O
vectors	NNS	O
include	VBP	O
retroviral	JJ	O
vectors	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Miller	NNP	B
,	,	I
Curr	NNP	I
Top	NNP	I
Microbiol	NNP	I
Immunol	NNP	I
(	(	I
1992	CD	I
)	)	I
158:1-24	CD	I
;	:	O
Salmons	NNS	B
and	CC	I
Gunzburg	NNP	I
(	(	I
1993	CD	I
)	)	I
Human	NNP	I
Gene	NNP	I
Therapy	NNP	I
4:129-141	CD	I
;	:	O
Miller	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Methods	NNS	I
in	IN	I
Enzymology	NNP	I
217:581-599	JJ	I
)	)	O
and	CC	O
adeno-associated	JJ	O
vectors	NNS	O
(	(	O
reviewed	VBN	O
in	IN	O
Carter	NNP	B
(	(	I
1992	CD	I
)	)	I
Curr	NNP	I
Opinion	NNP	I
Biotech	NNP	I
3:533-539	CD	I
;	:	O
Muzcyzka	NNP	B
(	(	I
1992	CD	I
)	)	I
Curr	NNP	I
Top	NNP	I
Microbiol	NNP	I
Immunol	NNP	I
.	.	I
158:97-129	JJ	I
)	)	O
.	.	O
Other	JJ	O
viral	JJ	O
vectors	NNS	O
that	WDT	O
are	VBP	O
used	VBN	O
include	JJ	O
adenoviral	JJ	O
vectors	NNS	O
,	,	O
herpes	VBZ	O
viral	JJ	O
vectors	NNS	O
and	CC	O
Sindbis	NNP	O
viral	JJ	O
vectors	NNS	O
,	,	O
as	IN	O
generally	RB	O
described	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Jolly	NNP	B
(	(	I
1994	CD	I
)	)	I
Cancer	NNP	I
Gene	NNP	I
Therapy	NNP	I
1:51-64	CD	I
;	:	O
Latchman	NNP	B
(	(	I
1994	CD	I
)	)	I
Molec	NNP	I
Biotechnol	NNP	I
2:179-195	JJ	I
;	:	O
and	CC	O
Johanning	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Nucl	NNP	I
Acids	NNP	I
Res	NNP	I
23:1495-1501	JJ	I
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
a	DT	O
pox	NN	O
virus	NN	O
vector	NN	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
The	DT	O
pox	JJ	O
viral	JJ	O
vector	NN	O
is	VBZ	O
transfected	VBN	O
with	IN	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
is	VBZ	O
useful	JJ	O
in	IN	O
prophylactic	JJ	O
,	,	O
therapeutic	JJ	O
and	CC	O
diagnostic	JJ	O
applications	NNS	O
where	WRB	O
enhancement	NN	O
of	IN	O
an	DT	O
immune	JJ	O
response	NN	O
,	,	O
such	JJ	O
as	IN	O
e.g.	NN	O
,	,	O
increased	VBD	O
or	CC	O
improved	VBN	O
T	NNP	O
cell	NN	O
proliferation	NN	O
is	VBZ	O
desired	VBN	O
.	.	O
See	VB	O
viral	JJ	O
vectors	NNS	O
discussed	VBN	O
in	IN	O
,	,	O
e.g.	NN	O
,	,	O
Berencsi	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Infect	NNP	I
Dis	NNP	I
(	(	I
2001	CD	I
)	)	I
183	CD	I
(	(	I
8	CD	I
)	)	I
:1171-9	NN	I
;	:	O
Rosenwirth	NNP	B
et	FW	I
al.	NN	I
,	,	I
Vaccine	NNP	I
2001	CD	I
Feb.	NNP	I
8	CD	I
;	:	I
19	CD	I
(	(	I
13-14	CD	I
)	)	I
:1661-70	NN	I
;	:	O
Kittlesen	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
Immunol	NNP	I
(	(	I
2000	CD	I
)	)	I
164	CD	I
(	(	I
8	CD	I
)	)	I
:4204-11	NN	I
;	:	O
Brown	NNP	B
et	FW	I
al	NN	I
.	.	I
Gene	NNP	I
Ther	NNP	I
2000	CD	I
7	CD	I
(	(	I
19	CD	I
)	)	I
:1680-9	NN	I
;	:	O
Kanesa-thasan	NNP	B
et	FW	I
al.	NN	I
,	,	I
Vaccine	NNP	I
(	(	I
2000	CD	I
)	)	I
19	CD	I
(	(	I
4-5	JJ	I
)	)	I
:483-91	NN	I
;	:	O
Sten	NNP	B
(	(	I
2000	CD	I
)	)	I
Drug	VBZ	I
60	CD	I
(	(	I
2	CD	I
)	)	I
:249-71	NN	I
.	.	O
Compositions	NNS	O
comprising	VBG	O
such	JJ	O
vectors	NNS	O
and	CC	O
an	DT	O
acceptable	JJ	O
excipient	NN	O
are	VBP	O
also	RB	O
a	DT	O
feature	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Gene	NNP	O
therapy	NN	O
and	CC	O
genetic	JJ	O
vaccines	NNS	O
provide	VBP	O
methods	NNS	O
for	IN	O
combating	VBG	O
chronic	JJ	O
infectious	JJ	O
diseases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
HIV	NNP	O
infection	NN	O
,	,	O
viral	JJ	O
hepatitis	NN	O
)	)	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
non-infectious	JJ	O
diseases	NNS	O
including	VBG	O
cancer	NN	O
and	CC	O
some	DT	O
forms	NNS	O
of	IN	O
congenital	JJ	O
defects	NNS	O
such	JJ	O
as	IN	O
enzyme	JJ	O
deficiencies	NNS	O
,	,	O
and	CC	O
such	JJ	O
methods	NNS	O
can	MD	O
be	VB	O
employed	VBN	O
with	IN	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
vectors	NNS	O
and	CC	O
cells	NNS	O
comprising	VBG	O
such	JJ	O
polynucleotides	NNS	O
.	.	O
Several	JJ	O
approaches	NNS	O
for	IN	O
introducing	VBG	O
nucleic	JJ	O
acids	NNS	O
and	CC	O
vectors	NNS	O
into	IN	O
cells	NNS	O
in	IN	O
vivo	NN	O
,	,	O
ex	FW	O
vivo	NN	O
and	CC	O
in	IN	O
vitro	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
and	CC	O
can	MD	O
be	VB	O
employed	VBN	O
with	IN	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
and	CC	O
vectors	NNS	O
comprising	VBG	O
such	JJ	O
polynucleotides	NNS	O
.	.	O
These	DT	O
approaches	NNS	O
include	VBP	O
liposome	JJ	O
based	VBN	O
gene	NN	O
delivery	NN	O
(	(	O
Debs	NNP	B
and	CC	I
Zhu	NNP	I
(	(	I
1993	CD	I
)	)	I
WO	VBD	I
93/24640	CD	I
and	CC	O
U.S.	NNP	B
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,641,662	CD	I
;	:	O
Mannino	NNP	B
and	CC	I
Gould-Fogerite	NNP	I
(	(	I
1988	CD	I
)	)	I
BioTechniques	VBZ	I
6	CD	I
(	(	I
7	CD	I
)	)	I
:682-691	NN	I
;	:	O
Rose	NNP	B
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,279,833	CD	I
;	:	O
Brigham	NNP	B
(	(	I
1991	CD	I
)	)	I
WO	VBD	I
91/06309	CD	I
;	:	O
and	CC	O
Feigner	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1987	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
84:7413-7414	CD	I
;	:	O
Brigham	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1989	CD	I
)	)	I
Am	VBP	I
J	NNP	I
Med	NNP	I
Sci	NNP	I
298:278-281	JJ	I
;	:	O
Nabel	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Science	NNP	I
249:1285-1288	CD	I
;	:	O
Hazinski	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Am	VBP	I
J	NNP	I
Resp	NNP	I
Cell	NNP	I
Molec	NNP	I
Biol	NNP	I
4:206-209	JJ	I
;	:	O
and	CC	O
Wang	NNP	B
and	CC	I
Huang	NNP	I
(	(	I
1987	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
84:7851-7855	JJ	I
)	)	O
;	:	O
adenoviral	JJ	O
vector	NN	O
mediated	VBD	O
gene	NN	O
delivery	NN	O
,	,	O
e.g.	NN	O
,	,	O
to	TO	O
treat	VB	O
cancer	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Chen	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1994	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
91:3054-3057	CD	I
;	:	O
Tong	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Gynecol	NNP	I
Oncol	NNP	I
61:175-179	JJ	I
;	:	O
Clayman	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
.	.	I
5:1-6	JJ	I
;	:	O
O'Malley	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Cancer	NNP	I
Res	NNP	I
55:1080-1085	CD	I
;	:	O
Hwang	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Am	VBP	I
J	NNP	I
Respir	NNP	I
Cell	NNP	I
Mol	NNP	I
Biol	NNP	I
13:7-16	CD	I
;	:	O
Haddada	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Curr	NNP	I
Top	NNP	I
Microbiol	NNP	I
Immunol	NNP	I
.	.	I
1995	CD	I
(	(	I
Pt	NNP	I
.	.	I
3	LS	I
)	)	I
:297-306	NN	I
;	:	O
Addison	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
92:8522-8526	CD	I
;	:	O
Colak	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1995	CD	I
)	)	I
Brain	NNP	I
Res	NNP	I
691:76-82	JJ	I
;	:	O
Crystal	NNP	B
(	(	I
1995	CD	I
)	)	I
Science	NNP	I
270:404-410	CD	I
;	:	O
Elshami	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
Human	NNP	I
Gene	NNP	I
Ther	NNP	I
7:141-148	CD	I
;	:	O
Vincent	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1996	CD	I
)	)	I
J	NNP	I
Neurosurg	NNP	I
85:648-654	NN	I
)	)	I
,	,	O
and	CC	O
many	JJ	O
others	NNS	O
.	.	O
Replication-defective	JJ	O
retroviral	JJ	O
vectors	NNS	O
harboring	VBG	O
therapeutic	JJ	O
polynucleotide	NN	O
sequence	NN	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
retroviral	JJ	O
genome	NN	O
have	VBP	O
also	RB	O
been	VBN	O
used	VBN	O
,	,	O
particularly	RB	O
with	IN	O
regard	NN	O
to	TO	O
simple	VB	O
MuLV	NNP	O
vectors	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Miller	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Mol	NNP	I
Cell	NNP	I
Biol	NNP	I
10:4239	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Kolberg	NNP	B
(	(	I
1992	CD	I
)	)	I
J	NNP	I
NIH	NNP	I
Res	NNP	I
4:43	CD	I
,	,	O
and	CC	O
Cornetta	NNP	B
et	VBP	I
al	NN	I
.	.	I
(	(	I
1991	CD	I
)	)	I
Hum	NNP	I
Gene	NNP	I
Ther	NNP	I
2:215	CD	I
)	)	O
.	.	O
Nucleic	NNP	O
acid	NN	O
transport	NN	O
coupled	VBD	O
to	TO	O
ligand-specific	JJ	O
,	,	O
cation-based	JJ	O
transport	NN	O
systems	NNS	O
(	(	O
Wu	NNP	B
and	CC	I
Wu	NNP	I
(	(	I
1988	CD	I
)	)	I
J	NNP	I
Biol	NNP	I
Chem	NNP	I
,	,	I
263:14621-14624	JJ	I
)	)	O
has	VBZ	O
also	RB	O
been	VBN	O
used	VBN	O
.	.	O
Naked	VBN	O
DNA	NNP	O
expression	NN	O
vectors	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
described	VBN	O
(	(	O
Nabel	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
1990	CD	I
)	)	I
,	,	I
supra	NN	I
)	)	O
;	:	O
Wolff	NNP	B
et	FW	I
al	NN	I
.	.	I
(	(	I
1990	CD	I
)	)	I
Science	NN	I
,	,	I
247:1465-1468	JJ	I
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
these	DT	O
approaches	NNS	O
can	MD	O
be	VB	O
adapted	VBN	O
to	TO	O
the	DT	O
invention	NN	O
by	IN	O
incorporating	VBG	O
nucleic	JJ	O
acids	NNS	O
encoding	VBG	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
into	IN	O
the	DT	O
appropriate	JJ	O
vectors	NNS	O
.	.	O
General	NNP	O
texts	NN	O
which	WDT	O
describe	VBZ	O
gene	NN	O
therapy	NN	O
protocols	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
adapted	VBN	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
by	IN	O
introducing	VBG	O
the	DT	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
invention	NN	O
into	IN	O
patients	NNS	O
,	,	O
include	VBP	O
,	,	O
e.g.	JJ	O
,	,	O
Robbins	NNP	B
(	(	I
1996	CD	I
)	)	I
Gene	NNP	I
Therapy	NNP	I
Protocols	NNP	I
,	,	I
Humana	NNP	I
Press	NNP	I
,	,	I
New	NNP	I
Jersey	NNP	I
,	,	O
and	CC	O
Joyner	NNP	B
(	(	I
1993	CD	I
)	)	I
Gene	NNP	I
Targeting	NNP	I
:	:	I
A	DT	I
Practical	NNP	I
Approach	NNP	I
,	,	I
IRL	NNP	I
Press	NNP	I
,	,	I
Oxford	NNP	I
,	,	I
England	NNP	I
.	.	O
Antiviral	JJ	O
Treatments	NNPS	O
The	DT	O
polynucleotides	NNS	O
and	CC	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
used	VBN	O
therapeutically	RB	O
or	CC	O
prophylactically	RB	O
to	TO	O
treat	VB	O
or	CC	O
prevent	VB	O
virus	JJ	O
infection	NN	O
.	.	O
Exemplary	JJ	O
viruses	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
viruses	NNS	O
of	IN	O
the	DT	O
Flaviviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Hepatitis	NNP	O
C	NNP	O
Virus	NNP	O
,	,	O
Yellow	NNP	O
Fever	NNP	O
Virus	NNP	O
,	,	O
West	NNP	O
Nile	NNP	O
Virus	NNP	O
,	,	O
Japanese	JJ	O
Encephalitis	NNP	O
Virus	NNP	O
,	,	O
Dengue	NNP	O
Virus	NNP	O
,	,	O
and	CC	O
Bovine	NNP	O
Viral	NNP	O
Diarrhea	NNP	O
Virus	NNP	O
;	:	O
viruses	NNS	O
of	IN	O
the	DT	O
Hepadnaviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Hepatitis	NNP	O
B	NNP	O
Virus	NNP	O
;	:	O
viruses	NNS	O
of	IN	O
the	DT	O
Picornaviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Encephalomyocarditis	NNP	O
Virus	NNP	O
,	,	O
Human	NNP	O
Rhinovirus	NNP	O
,	,	O
and	CC	O
Hepatitis	NNP	O
A	NNP	O
Virus	NNP	O
;	:	O
viruses	NNS	O
of	IN	O
the	DT	O
Retroviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Human	NNP	O
Immunodeficiency	NNP	O
Virus	NNP	O
,	,	O
Simian	JJ	O
Immunodeficiency	NNP	O
Virus	NNP	O
,	,	O
Human	NNP	O
T-Lymphotrophic	NNP	O
Virus	NNP	O
,	,	O
and	CC	O
Rous	NNP	O
Sarcoma	NNP	O
Virus	NNP	O
;	:	O
viruses	NNS	O
of	IN	O
the	DT	O
Coronaviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
SARS	NNP	O
coronavirus	NN	O
;	:	O
viruses	NNS	O
of	IN	O
the	DT	O
Rhabdoviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Rabies	NNP	O
Virus	NNP	O
and	CC	O
Vesicular	NNP	O
Stomatitis	NNP	O
Virus	NNP	O
,	,	O
viruses	NNS	O
of	IN	O
the	DT	O
Paramyxoviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Respiratory	NNP	O
Syncytial	NNP	O
Virus	NNP	O
and	CC	O
Parainfluenza	NNP	O
Virus	NNP	O
,	,	O
viruses	NNS	O
of	IN	O
the	DT	O
Papillomaviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Human	NNP	O
Papillomavirus	NNP	O
,	,	O
and	CC	O
viruses	NNS	O
of	IN	O
the	DT	O
Herpesviridae	NNP	O
family	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Herpes	NNP	O
Simplex	NNP	O
Virus	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
provide	VB	O
conjugates	NNS	O
,	,	O
such	JJ	O
conjugates	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
non-polypeptide	JJ	O
moiety	NN	O
linked	VBN	O
to	TO	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
which	WDT	O
conjugate	VBP	O
exhibits	NNS	O
an	DT	O
antiviral	JJ	O
property	NN	O
,	,	O
and	CC	O
which	WDT	O
optionally	RB	O
exhibits	VBZ	O
other	JJ	O
desirable	JJ	O
properties	NNS	O
,	,	O
such	JJ	O
as	IN	O
increased	JJ	O
serum	NN	O
half-life	NN	O
and/or	JJ	O
functional	NN	O
in	IN	O
vivo	JJ	O
half-life	NN	O
,	,	O
and/or	NN	O
decreased	VBD	O
antigenicity	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
non-conjugated	JJ	O
polypeptide	NN	O
.	.	O
Some	DT	O
such	JJ	O
conjugates	NNS	O
may	MD	O
exhibit	VB	O
enhanced	JJ	O
efficacy	NN	O
in	IN	O
clearing	VBG	O
a	DT	O
virus	NN	O
from	IN	O
cells	NNS	O
infected	VBN	O
with	IN	O
the	DT	O
virus	NN	O
,	,	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
oligoadenylate	NN	O
synthetase	NN	O
.	.	O
Some	DT	O
such	JJ	O
conjugates	NNS	O
may	MD	O
further	RB	O
have	VB	O
reduced	VBN	O
toxicity	NN	O
compared	VBN	O
to	TO	O
a	DT	O
reference	NN	O
oligoadenylate	NN	O
synthetase	NN	O
.	.	O
It	PRP	O
is	VBZ	O
another	DT	O
object	NN	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
provide	VB	O
a	DT	O
method	NN	O
of	IN	O
inhibiting	VBG	O
viral	JJ	O
replication	NN	O
in	IN	O
virus-infected	JJ	O
cells	NNS	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
administering	VBG	O
to	TO	O
the	DT	O
virus-infected	JJ	O
cells	NNS	O
a	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
an	DT	O
amount	NN	O
effective	JJ	O
to	TO	O
inhibit	VB	O
viral	JJ	O
replication	NN	O
in	IN	O
said	VBD	O
cells	NNS	O
.	.	O
The	DT	O
invention	NN	O
also	RB	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
reducing	VBG	O
the	DT	O
number	NN	O
of	IN	O
copies	NNS	O
of	IN	O
a	DT	O
virus	NN	O
in	IN	O
virus-infected	JJ	O
cells	NNS	O
,	,	O
comprising	VBG	O
administering	VBG	O
to	TO	O
the	DT	O
virus-infected	JJ	O
cells	NNS	O
a	DT	O
polypeptide	NN	O
or	CC	O
conjugate	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
an	DT	O
amount	NN	O
effective	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
number	NN	O
of	IN	O
copies	NNS	O
of	IN	O
the	DT	O
virus	NN	O
in	IN	O
said	VBD	O
cells	NNS	O
.	.	O
The	DT	O
cells	NNS	O
may	MD	O
be	VB	O
in	IN	O
culture	NN	O
or	CC	O
otherwise	RB	O
isolated	VBN	O
from	IN	O
a	DT	O
mammal	NN	O
(	(	O
i.e.	JJ	O
,	,	O
in	IN	O
vitro	NN	O
or	CC	O
ex	VB	O
vivo	NN	O
)	)	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
vivo	NN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
in	IN	O
a	DT	O
mammal	NN	O
,	,	O
in	IN	O
a	DT	O
primate	NN	O
,	,	O
or	CC	O
in	IN	O
man	NN	O
.	.	O
Anticancer	NNP	O
and	CC	O
Inflammation	NNP	O
Treatments	NNP	O
It	PRP	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
that	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
cause	VB	O
certain	JJ	O
cell	NN	O
types	NNS	O
and	CC	O
cell	NN	O
lines	NNS	O
to	TO	O
undergo	VB	O
apoptosis	NN	O
or	CC	O
to	TO	O
affect	VB	O
growth	NN	O
retardation	NN	O
of	IN	O
said	VBD	O
cell	NN	O
lines	NNS	O
or	CC	O
cell	NN	O
types	NNS	O
.	.	O
Such	JJ	O
cell	NN	O
lines	NNS	O
or	CC	O
cell	NN	O
types	NNS	O
include	VBP	O
in	IN	O
an	DT	O
exemplary	JJ	O
embodiment	NN	O
those	DT	O
derived	VBN	O
from	IN	O
the	DT	O
prostate	NN	O
and	CC	O
breast	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
inhibiting	VBG	O
proliferation	NN	O
of	IN	O
a	DT	O
cell	NN	O
population	NN	O
,	,	O
comprising	VBG	O
contacting	VBG	O
the	DT	O
cell	NN	O
population	NN	O
with	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
an	DT	O
amount	NN	O
effective	JJ	O
to	TO	O
decrease	VB	O
proliferation	NN	O
of	IN	O
the	DT	O
cell	NN	O
population	NN	O
.	.	O
The	DT	O
cell	NN	O
population	NN	O
may	MD	O
be	VB	O
in	IN	O
culture	NN	O
or	CC	O
otherwise	RB	O
isolated	VBN	O
from	IN	O
a	DT	O
mammal	NN	O
(	(	O
i.e.	JJ	O
,	,	O
in	IN	O
vitro	NN	O
or	CC	O
ex	VB	O
vivo	NN	O
)	)	O
,	,	O
or	CC	O
may	MD	O
be	VB	O
in	IN	O
vivo	NN	O
,	,	O
e.g.	NN	O
,	,	O
in	IN	O
a	DT	O
subject	NN	O
,	,	O
in	IN	O
a	DT	O
mammal	NN	O
,	,	O
a	DT	O
primate	NN	O
,	,	O
or	CC	O
man	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
treating	VBG	O
cancers	NNS	O
and	CC	O
neoplastic	JJ	O
diseases	NNS	O
using	VBG	O
the	DT	O
polypeptides	NNS	O
and	CC	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Exemplary	JJ	O
cancers	NNS	O
and	CC	O
neoplastic	JJ	O
diseases	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
adrenocortical	JJ	O
carcinoma	NN	O
,	,	O
AIDS	NNP	O
related	VBD	O
cancers	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
Kaposi	NNP	O
's	POS	O
sarcoma	NN	O
,	,	O
AIDS-related	JJ	O
lymphoma	NN	O
,	,	O
anal	JJ	O
cancer	NN	O
,	,	O
astrocytoma	NN	O
,	,	O
basal	NN	O
cell	NN	O
carcinoma	NN	O
,	,	O
bile	JJ	O
duct	NN	O
cancers	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
those	DT	O
of	IN	O
an	DT	O
extrahepatic	JJ	O
nature	NN	O
,	,	O
bladder	NN	O
cancer	NN	O
,	,	O
bone	NN	O
cancers	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
osteosarcomas	NN	O
and	CC	O
malignant	JJ	O
fibrous	JJ	O
histiocytomas	NN	O
,	,	O
brain	NN	O
stem	NN	O
glioma	NN	O
,	,	O
brain	NN	O
tumors	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
gliomas	NN	O
,	,	O
astrocytomas	NN	O
,	,	O
malignant	JJ	O
gliomas	NN	O
,	,	O
ependymomas	NN	O
,	,	O
medulloblastomas	NN	O
,	,	O
and	CC	O
neuroblastomas	RB	O
,	,	O
supratentorial	JJ	O
primitive	JJ	O
neuroectodermal	JJ	O
tumor	NN	O
,	,	O
visual	JJ	O
pathway	NN	O
and	CC	O
hypothalamic	JJ	O
glioma	NN	O
,	,	O
breast	NN	O
cancer	NN	O
,	,	O
bronchial	JJ	O
adenoma	NN	O
,	,	O
Burkitt	NNP	O
's	POS	O
lymphoma	NN	O
,	,	O
carcinoid	JJ	O
tumors	NNS	O
,	,	O
central	JJ	O
nervous	JJ	O
system	NN	O
lymphoma	NN	O
,	,	O
cervical	JJ	O
cancer	NN	O
,	,	O
leukemias	RB	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
hairy	NN	O
cell	NN	O
leukemia	NN	O
,	,	O
acute	JJ	O
lymphoblastic	JJ	O
leukemia	NN	O
,	,	O
acute	JJ	O
myeloid	NN	O
leukemia	NN	O
,	,	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
and	CC	O
chronic	JJ	O
myelogenous	JJ	O
leukemia	NN	O
,	,	O
chronic	JJ	O
myeloproliferative	NN	O
disorders	NNS	O
,	,	O
colorectal	JJ	O
cancer	NN	O
,	,	O
cutaneous	JJ	O
T-cell	NNP	O
lymphoma	NN	O
,	,	O
endometrial	JJ	O
cancer	NN	O
,	,	O
esophageal	JJ	O
cancer	NN	O
,	,	O
Ewing	NNP	O
's	POS	O
family	NN	O
of	IN	O
tumors	NNS	O
,	,	O
extracranial	JJ	O
germ	NN	O
cell	NN	O
tumor	NN	O
,	,	O
extragonadal	JJ	O
germ	NN	O
cell	NN	O
tumor	NN	O
,	,	O
eye	NN	O
cancers	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
intraocular	JJ	O
melanoma	NN	O
and	CC	O
retinoblastoma	NN	O
,	,	O
gallbladder	NN	O
cancer	NN	O
,	,	O
stomach	NN	O
cancer	NN	O
,	,	O
gestational	JJ	O
trophoblastic	JJ	O
tumor	NN	O
,	,	O
head	NN	O
and	CC	O
neck	NN	O
cancer	NN	O
,	,	O
hepatocellular	JJ	O
carcinoma	NN	O
,	,	O
Hodgkin	NNP	O
's	POS	O
lymphoma	NN	O
,	,	O
Non-Hodgkin	NNP	O
's	POS	O
lymphoma	NN	O
,	,	O
primary	JJ	O
CNS	NNP	O
lymphoma	NN	O
,	,	O
nasopharyngeal	JJ	O
cancer	NN	O
,	,	O
islet	NN	O
cell	NN	O
carcinoma	NN	O
,	,	O
kidney	NN	O
(	(	O
renal	JJ	O
cell	NN	O
)	)	O
cancer	NN	O
,	,	O
laryngeal	JJ	O
cancer	NN	O
,	,	O
lip	NN	O
and	CC	O
oral	JJ	O
cancer	NN	O
,	,	O
liver	RB	O
cancer	NN	O
,	,	O
lung	NN	O
cancer	NN	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
non-small	JJ	O
cell	NN	O
and	CC	O
small	JJ	O
cell	NN	O
lung	NN	O
cancers	NNS	O
,	,	O
Waldenstrom	NNP	O
's	POS	O
macroglobulinemia	NN	O
,	,	O
Merkel	NNP	O
cell	NN	O
carcinoma	NN	O
,	,	O
mesothelioma	NN	O
,	,	O
metastatic	JJ	O
squamous	JJ	O
neck	NN	O
cancer	NN	O
,	,	O
multiple	JJ	O
endocrine	NN	O
neoplasia	NN	O
,	,	O
multiple	JJ	O
myeloma	NN	O
,	,	O
plasma	NN	O
cell	NN	O
neoplasm	RB	O
,	,	O
mycosis	NN	O
fungoides	NNS	O
,	,	O
myelodysplastic	JJ	O
syndromes	NNS	O
,	,	O
myeloproliferative	JJ	O
diseases	NNS	O
,	,	O
nasal	JJ	O
cavity	NN	O
and	CC	O
paranasal	NN	O
sinus	NN	O
cancer	NN	O
,	,	O
ovarian	JJ	O
cancer	NN	O
,	,	O
such	JJ	O
as	IN	O
germ	NN	O
cell	NN	O
and	CC	O
epithelial	JJ	O
,	,	O
low-malignant	JJ	O
potential	JJ	O
ovarian	JJ	O
tumor	NN	O
,	,	O
pancreatic	JJ	O
cancer	NN	O
,	,	O
parathyroid	JJ	O
cancer	NN	O
,	,	O
penile	JJ	O
cancer	NN	O
,	,	O
pheochromocytoma	NN	O
,	,	O
pituitary	JJ	O
tumor	NN	O
,	,	O
pleuropulmonary	JJ	O
blastoma	NN	O
,	,	O
prostate	NN	O
cancer	NN	O
,	,	O
rhabdomyosarcoma	NN	O
,	,	O
salivary	JJ	O
gland	NN	O
cancer	NN	O
,	,	O
sarcomas	NN	O
,	,	O
Sezary	NNP	O
syndrome	NN	O
,	,	O
skin	JJ	O
cancer	NN	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
melanoma	NN	O
and	CC	O
squamous	JJ	O
cell	NN	O
carcinoma	NN	O
,	,	O
testicular	JJ	O
cancer	NN	O
,	,	O
thymoma	NN	O
,	,	O
thymic	JJ	O
carcinoma	NN	O
,	,	O
thyroid	JJ	O
cancer	NN	O
,	,	O
transitional	JJ	O
cell	NN	O
cancer	NN	O
,	,	O
trophoblastic	JJ	O
tumor	NN	O
,	,	O
urethral	JJ	O
cancer	NN	O
,	,	O
uterine	JJ	O
cancer	NN	O
,	,	O
vaginal	JJ	O
cancer	NN	O
,	,	O
vulvar	NN	O
cancer	NN	O
,	,	O
and	CC	O
Wilms	NNP	O
'	POS	O
tumor	NN	O
.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
treating	VBG	O
autoimmune	NN	O
diseases	NNS	O
and	CC	O
inflammation	NN	O
using	VBG	O
the	DT	O
polypeptides	NNS	O
and	CC	O
polynucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
said	VBD	O
autoimmune	NN	O
and	CC	O
inflammatory	JJ	O
diseases	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
asthma	NN	O
,	,	O
Crohn	NNP	O
's	POS	O
disease	NN	O
,	,	O
Guillain-Barre	NNP	O
syndrome	NN	O
,	,	O
multiple	JJ	O
sclerosis	NN	O
,	,	O
myasthenia	NN	O
gravis	NN	O
,	,	O
optic	JJ	O
neuritis	NN	O
,	,	O
psoriasis	NN	O
,	,	O
rheumatoid	JJ	O
arthritis	NN	O
,	,	O
Grave	NNP	O
's	POS	O
disease	NN	O
,	,	O
Hashimoto	NNP	O
's	POS	O
(	(	O
thyroiditis	NN	O
)	)	O
disease	NN	O
,	,	O
Ord	NNP	O
's	POS	O
thyroiditis	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
diabetes	VBZ	O
mellitus	NN	O
,	,	O
Reiter	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
autoimmune	JJ	O
hepatitis	NN	O
,	,	O
primary	JJ	O
biliary	JJ	O
cirrhosis	NN	O
,	,	O
liver	JJ	O
cirrhosis	NN	O
,	,	O
liver	JJ	O
fibrosis	NN	O
,	,	O
antiphospholipid	JJ	O
antibody	NN	O
syndrome	NN	O
,	,	O
opsoclonus	JJ	O
myoclonus	NN	O
syndrome	NN	O
,	,	O
temporal	JJ	O
arteritis	NN	O
,	,	O
acute	NN	O
disseminated	VBD	O
encephalomyelitis	NN	O
,	,	O
Goodpasture	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
Wegener	NNP	O
's	POS	O
granulomatosis	NN	O
,	,	O
coeliac	JJ	O
disease	NN	O
,	,	O
pemphigus	NN	O
,	,	O
polyarthritis	NN	O
,	,	O
warm	JJ	O
autoimmune	NN	O
hemolytic	JJ	O
anemia	NN	O
,	,	O
Takayasu	NNP	O
's	POS	O
arteritis	NN	O
,	,	O
coronary	JJ	O
artery	NN	O
disease	NN	O
,	,	O
endometriosis	NN	O
,	,	O
interstitial	JJ	O
cystitis	NN	O
,	,	O
neuromyotonia	NN	O
,	,	O
scleroderma	NN	O
,	,	O
vitiligo	NN	O
,	,	O
vulvodynia	NN	O
,	,	O
Chagas	NNP	O
'	POS	O
disease	NN	O
,	,	O
sarcoidosis	NN	O
,	,	O
chronic	JJ	O
fatigue	NN	O
syndrome	NN	O
,	,	O
acute	JJ	O
respiratory	NN	O
distress	NN	O
syndrome	NN	O
,	,	O
tendonitis	NN	O
,	,	O
bursitis	NN	O
,	,	O
polymyalgia	NN	O
rheumatica	NN	O
,	,	O
inflammatory	JJ	O
bowel	NN	O
disease	NN	O
,	,	O
chronic	JJ	O
obstructive	JJ	O
pulmonary	JJ	O
disease	NN	O
,	,	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
cardiovascular	JJ	O
disease	NN	O
,	,	O
chronic	JJ	O
cholecystitis	NN	O
,	,	O
bronchiectasis	NN	O
,	,	O
pneumoconiosis	NN	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
silicosis	NN	O
,	,	O
osteoarthritis	NN	O
,	,	O
atherosclerosis	NN	O
,	,	O
dysautonomia	NN	O
,	,	O
ankylosing	VBG	O
spondylitis	NN	O
,	,	O
acute	JJ	O
anterior	JJ	O
uvelitis	NN	O
,	,	O
systemic	JJ	O
lupus	NN	O
erythematosus	NN	O
,	,	O
insulin-dependent	JJ	O
diabetes	NNS	O
mellitus	NN	O
,	,	O
pemphigus	JJ	O
vulgaris	NN	O
,	,	O
experimental	JJ	O
allergic	NN	O
encephalomyelitis	NN	O
,	,	O
experimental	JJ	O
autoimmune	NN	O
uveorenitis	NN	O
,	,	O
mixed	JJ	O
connective	JJ	O
tissue	NN	O
disease	NN	O
,	,	O
Sjorgen	NNP	O
's	POS	O
syndrome	NN	O
,	,	O
autoimmune	JJ	O
hemolytic	JJ	O
anemia	NN	O
,	,	O
autoimmune	JJ	O
thrombocytopenic	JJ	O
purpura	NN	O
,	,	O
acute	JJ	O
rheumatic	JJ	O
fever	NN	O
,	,	O
mixed	JJ	O
essential	JJ	O
cryoglobulinemia	NN	O
,	,	O
juvenile	NN	O
rheumatoid	NN	O
arthritis	NN	O
,	,	O
degenerative	JJ	O
joint	NN	O
disease	NN	O
,	,	O
ankylosing	VBG	O
spondylitis	NN	O
,	,	O
psoriatic	JJ	O
arthritis	NN	O
,	,	O
neuralgia	RB	O
,	,	O
synoviitis	NN	O
,	,	O
glomerulonephritis	NN	O
,	,	O
vasculitis	NN	O
,	,	O
inflammations	NNS	O
that	WDT	O
occur	VBP	O
as	IN	O
sequellae	NN	O
to	TO	O
influenza	VB	O
,	,	O
the	DT	O
common	JJ	O
cold	NN	O
and	CC	O
other	JJ	O
viral	JJ	O
infections	NNS	O
,	,	O
gout	NN	O
,	,	O
contact	NN	O
dermatitis	NN	O
,	,	O
low	JJ	O
back	RB	O
and	CC	O
neck	NN	O
pain	NN	O
,	,	O
dysmenorrhea	NN	O
,	,	O
headache	NN	O
,	,	O
toothache	NN	O
,	,	O
sprains	NNS	O
,	,	O
strains	NNS	O
,	,	O
myositis	NN	O
,	,	O
burns	NNS	O
,	,	O
injuries	NNS	O
,	,	O
and	CC	O
pain	NN	O
and	CC	O
inflammation	NN	O
that	IN	O
follow	JJ	O
surgical	JJ	O
and	CC	O
dental	JJ	O
procedures	NNS	O
in	IN	O
a	DT	O
subject	NN	O
.	.	O
Cell	NNP	O
Growth	NNP	O
and	CC	O
Tissue	NNP	O
Regeneration	NNP	O
Treatments	VBZ	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
stimulate	VB	O
a	DT	O
mitogenic	NN	O
,	,	O
cell	VBP	O
growth-promoting	JJ	O
program	NN	O
in	IN	O
specific	JJ	O
cell	NN	O
types	NNS	O
and	CC	O
cell	NN	O
lines	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
Huh7	NNP	O
hepatoma	NN	O
cells	NNS	O
and	CC	O
MRC5	NNP	O
fetal	JJ	O
lung	NN	O
fibroblast	NN	O
cells	NNS	O
.	.	O
This	DT	O
mitogenic	JJ	O
program	NN	O
is	VBZ	O
identified	VBN	O
using	VBG	O
expression	NN	O
microarray	NN	O
analysis	NN	O
and	CC	O
cell	NN	O
viability	NN	O
assays	NNS	O
of	IN	O
cells	NNS	O
and	CC	O
cell	NN	O
lines	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
uses	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
stimulate	VB	O
cell	NN	O
growth	NN	O
and	CC	O
tissue	NN	O
regeneration	NN	O
in	IN	O
vitro	NN	O
,	,	O
in	IN	O
vivo	NN	O
,	,	O
and	CC	O
ex	FW	O
vivo	FW	O
using	VBG	O
tissues	NNS	O
and	CC	O
cells	NNS	O
derived	VBN	O
from	IN	O
subjects	NNS	O
or	CC	O
mammals	NNS	O
.	.	O
Derivatives	NNS	O
of	IN	O
the	DT	O
Polypeptides	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
for	IN	O
polypeptides	NNS	O
that	WDT	O
differ	VBP	O
from	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
by	IN	O
1	CD	O
to	TO	O
34	CD	O
amino	NN	O
acids	NNS	O
,	,	O
such	JJ	O
differences	NNS	O
may	MD	O
include	VB	O
substitutions	NNS	O
,	,	O
insertions	NNS	O
,	,	O
deletions	NNS	O
,	,	O
the	DT	O
incorporation	NN	O
of	IN	O
modified	VBN	O
amino	NN	O
acids	NNS	O
or	CC	O
amino	NN	O
acid	JJ	O
derivatives	NNS	O
,	,	O
and	CC	O
the	DT	O
addition	NN	O
or	CC	O
deletion	NN	O
of	IN	O
amino	JJ	O
acids	NNS	O
from	IN	O
the	DT	O
C-terminus	NNP	O
or	CC	O
N-terminus	NNP	O
of	IN	O
the	DT	O
polypeptides	NNS	O
.	.	O
One	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	JJ	O
substitutions	NNS	O
may	MD	O
be	VB	O
made	VBN	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
according	VBG	O
to	TO	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
substitution	NN	O
group	NN	O
(	(	O
such	JJ	O
as	IN	O
,	,	O
a	DT	O
conservative	JJ	O
substitution	NN	O
group	NN	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
one	CD	O
set	NN	O
forth	NN	O
below	IN	O
.	.	O
Alternatively	RB	O
,	,	O
or	CC	O
in	IN	O
addition	NN	O
,	,	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	JJ	O
substitutions	NNS	O
may	MD	O
made	VB	O
in	IN	O
the	DT	O
polypeptides	NNS	O
which	WDT	O
introduces	NNS	O
or	CC	O
removes	VBZ	O
an	DT	O
amino	NN	O
acid	NN	O
residue	JJ	O
comprising	VBG	O
an	DT	O
attachment	NN	O
group	NN	O
for	IN	O
a	DT	O
non-polypeptide	JJ	O
moiety	NN	O
.	.	O
Examples	NNS	O
include	VBP	O
introduction	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
N-glycosylation	JJ	O
site	NN	O
(	(	O
s	PRP	O
)	)	O
,	,	O
introduction	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
cysteine	JJ	O
residue	NN	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
lysine	JJ	O
residue	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
removal	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
N-glycosylation	JJ	O
site	NN	O
(	(	O
s	PRP	O
)	)	O
,	,	O
and/or	''	O
or	CC	O
removal	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
lysine	NN	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
histidine	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Some	DT	O
such	JJ	O
polypeptides	NNS	O
exhibit	VBP	O
an	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
.	.	O
Conservative	JJ	O
substitutions	NNS	O
groups	NNS	O
include	VBP	O
:	:	O
Group	NNP	O
1	CD	O
,	,	O
Alanine	NNP	O
(	(	O
A	NNP	O
)	)	O
Glycine	NNP	O
(	(	O
G	NNP	O
)	)	O
Serine	NNP	O
(	(	O
S	NNP	O
)	)	O
Threonine	NNP	O
(	(	O
T	NNP	O
)	)	O
,	,	O
Group	NNP	O
2	CD	O
,	,	O
Aspartic	NNP	O
acid	NN	O
(	(	O
D	NNP	O
)	)	O
Glutamic	NNP	O
acid	NN	O
(	(	O
E	NNP	O
)	)	O
,	,	O
Group	NNP	O
3	CD	O
,	,	O
Asparagine	NNP	O
(	(	O
N	NNP	O
)	)	O
Glutamine	NNP	O
(	(	O
Q	NNP	O
)	)	O
,	,	O
Group	NNP	O
4	CD	O
,	,	O
Arginine	NNP	O
(	(	O
R	NNP	O
)	)	O
Lysine	NNP	O
(	(	O
K	NNP	O
)	)	O
Histidine	NNP	O
(	(	O
H	NNP	O
)	)	O
,	,	O
Group	NNP	O
5	CD	O
,	,	O
Isoleucine	NNP	O
(	(	O
I	PRP	O
)	)	O
Leucine	NNP	O
(	(	O
L	NNP	O
)	)	O
Methionine	NNP	O
(	(	O
M	NNP	O
)	)	O
Valine	NNP	O
(	(	O
V	NNP	O
)	)	O
,	,	O
and	CC	O
Group	NNP	O
6	CD	O
,	,	O
Phenylalanine	NNP	O
(	(	O
F	NNP	O
)	)	O
Tyrosine	NNP	O
(	(	O
Y	NNP	O
)	)	O
Tryptophan	NNP	O
(	(	O
W	NNP	O
)	)	O
.	.	O
Other	JJ	O
substitution	NN	O
groups	NNS	O
of	IN	O
amino	JJ	O
acids	NNS	O
can	MD	O
be	VB	O
envisioned	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
amino	JJ	O
acids	NNS	O
can	MD	O
be	VB	O
grouped	VBN	O
by	IN	O
similar	JJ	O
function	NN	O
or	CC	O
chemical	NN	O
structure	NN	O
or	CC	O
composition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
acidic	JJ	O
,	,	O
basic	JJ	O
,	,	O
aliphatic	JJ	O
,	,	O
aromatic	JJ	O
,	,	O
sulfur-containing	JJ	O
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
Aliphatic	JJ	O
grouping	NN	O
may	MD	O
comprise	VB	O
:	:	O
Glycine	NNP	O
(	(	O
G	NNP	O
)	)	O
,	,	O
Alanine	NNP	O
(	(	O
A	NNP	O
)	)	O
,	,	O
Valine	NNP	O
(	(	O
V	NNP	O
)	)	O
,	,	O
Leucine	NNP	O
(	(	O
L	NNP	O
)	)	O
,	,	O
Isoleucine	NNP	O
(	(	O
I	PRP	O
)	)	O
.	.	O
Other	JJ	O
groups	NNS	O
containing	VBG	O
amino	NN	O
acids	NNS	O
that	WDT	O
are	VBP	O
considered	VBN	O
conservative	JJ	O
substitutions	NNS	O
for	IN	O
one	CD	O
another	DT	O
include	NN	O
:	:	O
Aromatic	JJ	O
:	:	O
Phenylalanine	NN	O
(	(	O
F	NNP	O
)	)	O
,	,	O
Tyrosine	NNP	O
(	(	O
Y	NNP	O
)	)	O
,	,	O
Tryptophan	NNP	O
(	(	O
W	NNP	O
)	)	O
;	:	O
Sulfur-containing	JJ	O
:	:	O
Methionine	NNP	O
(	(	O
M	NNP	O
)	)	O
,	,	O
Cysteine	NNP	O
(	(	O
C	NNP	O
)	)	O
;	:	O
Basic	JJ	O
:	:	O
Arginine	NN	O
(	(	O
R	NNP	O
)	)	O
,	,	O
Lysine	NNP	O
(	(	O
K	NNP	O
)	)	O
,	,	O
Histidine	NNP	O
(	(	O
H	NNP	O
)	)	O
;	:	O
Acidic	$	O
:	:	O
Aspartic	JJ	O
acid	NN	O
(	(	O
D	NNP	O
)	)	O
,	,	O
Glutamic	NNP	O
acid	NN	O
(	(	O
E	NNP	O
)	)	O
,	,	O
Asparagine	NNP	O
(	(	O
N	NNP	O
)	)	O
,	,	O
Glutamine	NNP	O
(	(	O
Q	NNP	O
)	)	O
.	.	O
See	NNP	O
also	RB	O
Creighton	NNP	B
(	(	I
1984	CD	I
)	)	I
Proteins	VBZ	I
,	,	I
W.H	NNP	I
.	.	I
Freeman	NNP	I
and	CC	I
Company	NNP	I
,	,	O
for	IN	O
additional	JJ	O
groupings	NNS	O
of	IN	O
amino	JJ	O
acids	NNS	O
.	.	O
Listing	NN	O
of	IN	O
a	DT	O
polypeptide	JJ	O
sequence	NN	O
herein	NN	O
,	,	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
above	JJ	O
substitution	NN	O
groups	NNS	O
,	,	O
provides	VBZ	O
an	DT	O
express	JJ	O
listing	NN	O
of	IN	O
all	DT	O
conservatively	RB	O
substituted	VBN	O
polypeptide	NN	O
sequences	NNS	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
isolated	JJ	O
or	CC	O
recombinant	JJ	O
polypeptides	NNS	O
each	DT	O
comprising	VBG	O
a	DT	O
sequence	NN	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
(	(	O
e.g.	JJ	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
91	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
92	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
93	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
94	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
96	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
97	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
98	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
sequence	NN	O
identity	NN	O
)	)	O
to	TO	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
FIG	NNP	O
.	.	O
1	CD	O
.	.	O
In	IN	O
some	DT	O
instances	NNS	O
the	DT	O
polypeptide	NN	O
exhibits	VBZ	O
oligoadenylate	JJ	O
synthetase	NN	O
activity	NN	O
.	.	O
The	DT	O
degree	NN	O
to	TO	O
which	WDT	O
a	DT	O
sequence	NN	O
(	(	O
polypeptide	JJ	O
or	CC	O
nucleic	JJ	O
acid	NN	O
)	)	O
is	VBZ	O
similar	JJ	O
to	TO	O
another	DT	O
provides	VBZ	O
an	DT	O
indication	NN	O
of	IN	O
similar	JJ	O
structural	JJ	O
and	CC	O
functional	JJ	O
properties	NNS	O
for	IN	O
the	DT	O
two	CD	O
sequences	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
sequences	NNS	O
which	WDT	O
have	VBP	O
a	DT	O
similar	JJ	O
sequence	NN	O
to	TO	O
any	DT	O
given	VBN	O
exemplar	JJ	O
sequence	NN	O
are	VBP	O
a	DT	O
feature	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
sequences	NNS	O
that	WDT	O
have	VBP	O
percent	VBN	O
sequence	NN	O
identities	NNS	O
as	IN	O
defined	VBN	O
below	IN	O
are	VBP	O
a	DT	O
feature	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
methods	NNS	O
of	IN	O
determining	VBG	O
sequence	NN	O
relationships	NNS	O
can	MD	O
be	VB	O
used	VBN	O
,	,	O
including	VBG	O
manual	JJ	O
alignment	NN	O
and	CC	O
computer	NN	O
assisted	VBD	O
sequence	NN	O
alignment	NN	O
and	CC	O
analysis	NN	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
computer	NN	O
programs	NNS	O
for	IN	O
performing	VBG	O
sequence	NN	O
alignments	NNS	O
are	VBP	O
available	JJ	O
,	,	O
or	CC	O
an	DT	O
alignment	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
manually	RB	O
by	IN	O
one	CD	O
of	IN	O
skill	NN	O
.	.	O
As	IN	O
noted	VBN	O
above	IN	O
,	,	O
the	DT	O
sequences	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
and	CC	O
nucleic	JJ	O
acids	NNS	O
employed	VBN	O
in	IN	O
the	DT	O
subject	JJ	O
invention	NN	O
need	MD	O
not	RB	O
be	VB	O
identical	JJ	O
,	,	O
but	CC	O
can	MD	O
be	VB	O
substantially	RB	O
identical	JJ	O
to	TO	O
the	DT	O
corresponding	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
or	CC	O
nucleic	JJ	O
acid	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
subject	JJ	O
to	TO	O
various	JJ	O
changes	NNS	O
,	,	O
such	JJ	O
as	IN	O
one	CD	O
or	CC	O
more	JJR	O
amino	JJ	O
acid	NN	O
insertions	NNS	O
,	,	O
deletions	NNS	O
,	,	O
and/or	JJ	O
substitutions	NNS	O
,	,	O
either	RB	O
conservative	JJ	O
or	CC	O
non-conservative	JJ	O
,	,	O
including	VBG	O
where	WRB	O
,	,	O
e.g.	VB	O
,	,	O
such	JJ	O
changes	NNS	O
might	MD	O
provide	VB	O
for	IN	O
certain	JJ	O
advantages	NNS	O
in	IN	O
their	PRP$	O
use	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
in	IN	O
their	PRP$	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
use	NN	O
or	CC	O
administration	NN	O
or	CC	O
diagnostic	JJ	O
application	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
subject	JJ	O
to	TO	O
various	JJ	O
changes	NNS	O
,	,	O
such	JJ	O
as	IN	O
one	CD	O
or	CC	O
more	JJR	O
substitutions	NNS	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
codons	NNS	O
such	JJ	O
that	IN	O
a	DT	O
particular	JJ	O
codon	NN	O
encodes	VBZ	O
the	DT	O
same	JJ	O
or	CC	O
a	DT	O
different	JJ	O
amino	NN	O
acid	NN	O
,	,	O
resulting	VBG	O
in	IN	O
either	CC	O
a	DT	O
silent	JJ	O
variation	NN	O
(	(	O
as	IN	O
defined	VBN	O
herein	NN	O
)	)	O
or	CC	O
non-silent	JJ	O
variation	NN	O
,	,	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
deletions	NNS	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
(	(	O
or	CC	O
codons	NNS	O
)	)	O
in	IN	O
the	DT	O
sequence	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acids	NNS	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
include	VB	O
one	CD	O
or	CC	O
more	JJR	O
codons	NNS	O
that	WDT	O
provide	VBP	O
for	IN	O
optimum	JJ	O
expression	NN	O
in	IN	O
an	DT	O
expression	NN	O
system	NN	O
(	(	O
e.g.	UH	O
,	,	O
bacterial	JJ	O
or	CC	O
mammalian	JJ	O
)	)	O
,	,	O
while	IN	O
,	,	O
if	IN	O
desired	VBN	O
,	,	O
said	VBD	O
one	CD	O
or	CC	O
more	JJR	O
codons	NNS	O
still	RB	O
encode	VBP	O
the	DT	O
same	JJ	O
amino	NN	O
acid	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Such	JJ	O
nucleic	JJ	O
acid	NNS	O
changes	NNS	O
might	MD	O
provide	VB	O
for	IN	O
certain	JJ	O
advantages	NNS	O
in	IN	O
their	PRP$	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
use	NN	O
or	CC	O
administration	NN	O
,	,	O
or	CC	O
diagnostic	JJ	O
application	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acids	NNS	O
and	CC	O
polypeptides	NNS	O
can	MD	O
be	VB	O
modified	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
ways	NNS	O
so	RB	O
long	RB	O
as	IN	O
they	PRP	O
comprise	VBP	O
a	DT	O
sequence	NN	O
substantially	RB	O
identical	JJ	O
(	(	O
as	IN	O
defined	VBN	O
below	IN	O
)	)	O
to	TO	O
a	DT	O
sequence	NN	O
in	IN	O
a	DT	O
respective	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
identical	JJ	O
”	NN	O
or	CC	O
“	NN	O
identity	NN	O
,	,	O
”	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
sequences	NNS	O
,	,	O
refers	NNS	O
to	TO	O
two	CD	O
or	CC	O
more	JJR	O
sequences	NNS	O
that	WDT	O
are	VBP	O
the	DT	O
same	JJ	O
or	CC	O
have	VBP	O
a	DT	O
specified	VBN	O
percentage	NN	O
of	IN	O
amino	NN	O
acid	NN	O
residues	NNS	O
or	CC	O
nucleotides	NNS	O
that	WDT	O
are	VBP	O
the	DT	O
same	JJ	O
,	,	O
when	WRB	O
compared	VBN	O
and	CC	O
aligned	VBN	O
for	IN	O
maximum	JJ	O
similarity	NN	O
,	,	O
as	IN	O
determined	VBN	O
using	VBG	O
a	DT	O
sequence	NN	O
comparison	NN	O
algorithm	NN	O
or	CC	O
by	IN	O
visual	JJ	O
inspection	NN	O
.	.	O
The	DT	O
“	JJ	O
percent	NN	O
sequence	NN	O
identity	NN	O
”	NNP	O
(	(	O
“	CD	O
%	NN	O
identity	NN	O
”	NNP	O
)	)	O
of	IN	O
a	DT	O
subject	JJ	O
sequence	NN	O
to	TO	O
a	DT	O
reference	NN	O
(	(	O
i.e	NN	O
.	.	O
query	NN	O
)	)	O
sequence	NN	O
means	VBZ	O
that	IN	O
the	DT	O
subject	JJ	O
sequence	NN	O
is	VBZ	O
identical	JJ	O
(	(	O
i.e.	FW	O
,	,	O
on	IN	O
an	DT	O
amino	JJ	O
acid-by-amino	JJ	O
acid	JJ	O
basis	NN	O
for	IN	O
a	DT	O
polypeptide	JJ	O
sequence	NN	O
,	,	O
or	CC	O
a	DT	O
nucleotide-by-nucleotide	JJ	O
basis	NN	O
for	IN	O
a	DT	O
polynucleotide	JJ	O
sequence	NN	O
)	)	O
by	IN	O
a	DT	O
specified	JJ	O
percentage	NN	O
to	TO	O
the	DT	O
query	NN	O
sequence	NN	O
over	IN	O
a	DT	O
comparison	NN	O
length	NN	O
.	.	O
Site	NNP	O
Directed	VBD	O
Mutagenesis	NNP	O
to	TO	O
Create	VB	O
the	DT	O
Polypeptides	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
engineered	VBN	O
using	VBG	O
any	DT	O
standard	JJ	O
method	NN	O
of	IN	O
site-directed	JJ	O
mutagenesis	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
synthetized	VBN	O
using	VBG	O
specific	JJ	O
oligonucleotide	JJ	O
primers	NNS	O
and	CC	O
a	DT	O
high	JJ	O
fidelity	NN	O
DNA	NNP	O
polymerase	NN	O
.	.	O
The	DT	O
target	NN	O
sequence	NN	O
is	VBZ	O
contained	VBN	O
on	IN	O
a	DT	O
double	JJ	O
stranded	VBN	O
plasmid	NN	O
isolated	VBN	O
from	IN	O
a	DT	O
methylation-competent	JJ	O
E.	NNP	O
coli	NNS	O
strain	NN	O
.	.	O
Complimentary	NNP	O
oligonucleotides	NNS	O
containing	VBG	O
the	DT	O
desired	VBN	O
mutation	NN	O
are	VBP	O
synthesized	VBN	O
and	CC	O
purified	VBN	O
using	VBG	O
polyacrylamide	JJ	O
gel	JJ	O
electrophoresis	NN	O
.	.	O
A	DT	O
thermal	JJ	O
cycler	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
control	VB	O
the	DT	O
temperature	NN	O
for	IN	O
alternating	VBG	O
cycles	NNS	O
of	IN	O
denaturation	NN	O
of	IN	O
the	DT	O
double	NN	O
stranded	VBD	O
plasmid	JJ	O
template	NN	O
(	(	O
94°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
seconds	NNS	O
)	)	O
,	,	O
annealing	VBG	O
of	IN	O
the	DT	O
oligonucleotide	JJ	O
primers	NNS	O
(	(	O
55°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
minute	NN	O
)	)	O
,	,	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
primers	NNS	O
with	IN	O
a	DT	O
high	JJ	O
fidelity	NN	O
polymerase	NN	O
(	(	O
68°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
minute/kb	NN	O
of	IN	O
plasmid	JJ	O
length	NN	O
)	)	O
.	.	O
After	IN	O
approximately	RB	O
15	CD	O
cycles	NNS	O
,	,	O
the	DT	O
mixture	NN	O
of	IN	O
newly	RB	O
synthetized	VBN	O
and	CC	O
input	VBN	O
DNA	NNP	O
are	VBP	O
treated	VBN	O
with	IN	O
a	DT	O
restriction	NN	O
enzyme	NN	O
specific	NN	O
for	IN	O
methylated	JJ	O
residues	NNS	O
(	(	O
Dpn	NNP	O
I	PRP	O
)	)	O
to	TO	O
digest	VB	O
the	DT	O
parental	JJ	O
plasmid	NN	O
.	.	O
The	DT	O
resulting	VBG	O
DNA	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
chemically	RB	O
or	CC	O
electrically	RB	O
competent	JJ	O
bacterial	JJ	O
strains	NNS	O
for	IN	O
screening	VBG	O
and	CC	O
isolation	NN	O
of	IN	O
plasmids	NNS	O
containing	VBG	O
the	DT	O
desired	JJ	O
mutation	NN	O
.	.	O
Plasmid	NNP	O
DNA	NNP	O
is	VBZ	O
isolated	VBN	O
from	IN	O
the	DT	O
transformants	NNS	O
and	CC	O
screened	VBD	O
via	IN	O
fluorescent	JJ	O
dye-terminator	NN	O
sequencing	VBG	O
to	TO	O
confirm	VB	O
the	DT	O
mutant	JJ	O
sequence	NN	O
.	.	O
Bulk	JJ	O
Drug	NNP	O
Product	NNP	O
Expression	NNP	O
,	,	O
Fermentation	NNP	O
,	,	O
and	CC	O
Purification	NNP	O
An	DT	O
E.	NNP	O
coli	NNS	O
strain	VBP	O
containing	VBG	O
a	DT	O
lysogen	NN	O
of	IN	O
ADE3	NNP	O
,	,	O
and	CC	O
therefore	RB	O
carrying	VBG	O
a	DT	O
chromosomal	JJ	O
copy	NN	O
of	IN	O
the	DT	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
gene	NN	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
the	DT	O
lacUV5	NN	O
promoter	NN	O
,	,	O
is	VBZ	O
transformed	VBN	O
with	IN	O
a	DT	O
bacterial	JJ	O
expression	NN	O
vector	NN	O
containing	VBG	O
an	DT	O
IPTG-inducible	JJ	O
promoter	NN	O
encoding	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
corresponding	VBG	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Cultures	NNS	O
are	VBP	O
grown	VBN	O
in	IN	O
luria	JJ	O
broth	DT	O
medium	NN	O
supplemented	VBD	O
with	IN	O
34	CD	O
μg/mL	NNS	O
chloroamphenicol	NN	O
and	CC	O
15	CD	O
μg/mL	JJ	O
kanamycin	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
When	WRB	O
the	DT	O
OD600	NNP	O
reaches	VBZ	O
>	RB	O
0.4	CD	O
,	,	O
the	DT	O
temperature	NN	O
is	VBZ	O
reduced	VBN	O
to	TO	O
18°	CD	O
C.	NNP	O
and	CC	O
the	DT	O
cells	NNS	O
are	VBP	O
induced	VBN	O
with	IN	O
0.5	CD	O
mM	NNS	O
IPTG	NNP	O
for	IN	O
17	CD	O
hours	NNS	O
.	.	O
The	DT	O
bacterial	JJ	O
cells	NNS	O
are	VBP	O
then	RB	O
resuspended	VBN	O
in	IN	O
buffer	NN	O
containing	VBG	O
50	CD	O
mM	JJ	O
NaH2PO4	NNP	O
,	,	O
pH	NN	O
8	CD	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
20	CD	O
mM	NN	O
imidazole	NN	O
,	,	O
10	CD	O
%	NN	O
glycerol	NN	O
,	,	O
0.1	CD	O
%	NN	O
NP40	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
and	CC	O
protease	NN	O
inhibitors	NNS	O
(	(	O
VWR	NNP	O
)	)	O
,	,	O
lysed	VBN	O
in	IN	O
a	DT	O
Gaulin	NNP	O
homogenizer	NN	O
,	,	O
and	CC	O
centrifuged	VBD	O
to	TO	O
remove	VB	O
cell	NN	O
debris	NN	O
before	IN	O
protein	JJ	O
purification	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
purification	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
using	VBG	O
a	DT	O
polyhistidine	NN	O
tag	NN	O
at	IN	O
the	DT	O
amino-terminus	NN	O
.	.	O
A	DT	O
nickel	JJ	O
column	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
affinity	NN	O
purifications	NNS	O
of	IN	O
polyhistidine	NN	O
tags	NNS	O
,	,	O
with	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
5	CD	O
mL	NN	O
column	NN	O
being	VBG	O
utilized	VBN	O
for	IN	O
lysate	NN	O
generated	VBN	O
by	IN	O
4	CD	O
L	NNP	O
of	IN	O
E.	NNP	O
coli	NNS	O
.	.	O
The	DT	O
lysate	NN	O
is	VBZ	O
loaded	VBN	O
onto	IN	O
the	DT	O
column	NN	O
and	CC	O
then	RB	O
washed	VBD	O
with	IN	O
Buffer	NNP	O
A	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
20	CD	O
mM	NN	O
imidazole	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
7.5	CD	O
)	)	O
.	.	O
A	DT	O
step	NN	O
elution	NN	O
to	TO	O
7	CD	O
%	NN	O
Buffer	NNP	O
B	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
M	NNP	O
imidazole	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
,	,	O
for	IN	O
3.2	CD	O
column	NN	O
volumes	NNS	O
is	VBZ	O
then	RB	O
carried	VBN	O
out	RP	O
.	.	O
A	DT	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
Buffer	NNP	O
B	NNP	O
over	IN	O
3	CD	O
column	NN	O
volumes	NNS	O
is	VBZ	O
then	RB	O
carried	VBN	O
out	RP	O
.	.	O
The	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
then	RB	O
be	VB	O
gel-filtered	JJ	O
into	IN	O
Buffer	NNP	O
C	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
150	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
and	CC	O
loaded	VBN	O
onto	IN	O
a	DT	O
cation	NN	O
exchange	NN	O
column	NN	O
for	IN	O
further	JJ	O
purification	NN	O
.	.	O
After	IN	O
the	DT	O
protein	NN	O
is	VBZ	O
loaded	VBN	O
,	,	O
the	DT	O
column	NN	O
is	VBZ	O
washed	VBN	O
with	IN	O
Buffer	NNP	O
C	NNP	O
followed	VBN	O
by	IN	O
a	DT	O
step	NN	O
elution	NN	O
to	TO	O
75	CD	O
%	NN	O
of	IN	O
Buffer	NNP	O
D	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
1	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
,	,	O
then	RB	O
a	DT	O
5	CD	O
column	NN	O
volume	NN	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
Buffer	NNP	O
D.	NNP	O
The	DT	O
protein	NN	O
is	VBZ	O
then	RB	O
gel	JJ	O
filtered	VBN	O
into	IN	O
Buffer	NNP	O
E	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
and	CC	O
stored	VBN	O
at	IN	O
−20°	NNP	O
C.	NNP	O
Different	NNP	O
embodiments	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
:	:	O
those	DT	O
lacking	VBG	O
a	DT	O
polyhistidine	NN	O
tag	NN	O
,	,	O
those	DT	O
possessing	VBG	O
a	DT	O
polyarginine	NN	O
tag	NN	O
,	,	O
those	DT	O
with	IN	O
reduced	JJ	O
cysteine	NN	O
content	NN	O
,	,	O
those	DT	O
with	IN	O
amino	JJ	O
acid	JJ	O
sequence	NN	O
variations	NNS	O
designed	VBN	O
to	TO	O
make	VB	O
the	DT	O
drug	NN	O
candidate	NN	O
more	RBR	O
thermally	RB	O
stable	JJ	O
,	,	O
those	DT	O
with	IN	O
modifications	NNS	O
to	TO	O
enhance	VB	O
or	CC	O
reduce	VB	O
a	DT	O
particular	JJ	O
activity	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidate	NN	O
,	,	O
may	MD	O
require	VB	O
alternative	JJ	O
purification	NN	O
strategies	NNS	O
.	.	O
Embodiments	NNS	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
candidate	NN	O
lacking	VBG	O
a	DT	O
polyhistidine	NN	O
tag	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
may	MD	O
be	VB	O
directly	RB	O
applied	VBN	O
to	TO	O
a	DT	O
cation	NN	O
exchange	NN	O
column	NN	O
.	.	O
Additional	JJ	O
steps	NNS	O
,	,	O
for	IN	O
example	NN	O
the	DT	O
use	NN	O
of	IN	O
hydrophobic	JJ	O
interaction	NN	O
chromatography	NN	O
,	,	O
may	MD	O
be	VB	O
utilized	VBN	O
by	IN	O
taking	VBG	O
the	DT	O
protein	NN	O
in	IN	O
Buffer	NNP	O
F	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
1	CD	O
M	NNP	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
and	CC	O
running	VBG	O
a	DT	O
10	CD	O
column	NN	O
volume	NN	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
Buffer	NNP	O
E.	NNP	O
Other	JJ	O
affinity	NN	O
columns	NNS	O
or	CC	O
sizing	VBG	O
columns	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
purify	VB	O
different	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
polypeptide	JJ	O
drug	NN	O
candidates	NNS	O
.	.	O
Alternative	NNP	O
techniques	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
exchange	NN	O
of	IN	O
buffers	NNS	O
,	,	O
concentration	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidates	NNS	O
and	CC	O
purification	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidates	NNS	O
.	.	O
These	DT	O
could	MD	O
include	VB	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
ultrafiltration	NN	O
,	,	O
tangential	JJ	O
flow	NN	O
filtration	NN	O
and	CC	O
diafiltration	NN	O
for	IN	O
the	DT	O
concentration	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidate	NN	O
and	CC	O
for	IN	O
exchange	NN	O
of	IN	O
buffers	NNS	O
.	.	O
Techniques	NNS	O
such	PDT	O
a	DT	O
precipitation	NN	O
of	IN	O
the	DT	O
drug	NN	O
candidates	NNS	O
by	IN	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
or	CC	O
some	DT	O
other	JJ	O
chemical	JJ	O
agent	NN	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
.	.	O
Denaturing	VBG	O
the	DT	O
drug	NN	O
candidate	NN	O
in	IN	O
urea	NN	O
or	CC	O
some	DT	O
other	JJ	O
denaturant	NN	O
and	CC	O
refolding	VBG	O
it	PRP	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
.	.	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
stabilized	VBN	O
by	IN	O
excipients	NNS	O
containing	VBG	O
salts	NNS	O
;	:	O
solutions	NNS	O
stable	VBP	O
at	IN	O
300	CD	O
mM	NNS	O
NaCl	NNP	O
can	MD	O
begin	VB	O
to	TO	O
precipitate	VB	O
at	IN	O
150	CD	O
mM	NN	O
NaCl	NNP	O
.	.	O
For	IN	O
this	DT	O
reason	NN	O
excipient	NN	O
mixtures	NNS	O
will	MD	O
favor	VB	O
these	DT	O
stabilizing	VBG	O
salt	NN	O
concentrations	NNS	O
,	,	O
which	WDT	O
could	MD	O
include	VB	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
sodium	VB	O
phosphate	NN	O
,	,	O
sodium	NN	O
chloride	NN	O
,	,	O
calcium	NN	O
chloride	NN	O
,	,	O
and	CC	O
magnesium	NN	O
chloride	NN	O
.	.	O
The	DT	O
addition	NN	O
of	IN	O
amino	JJ	O
acid-based	JJ	O
excipients	NNS	O
such	JJ	O
as	IN	O
arginine	NN	O
have	VBP	O
proven	VBN	O
to	TO	O
be	VB	O
stabilizing	VBG	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
A	DT	O
10	CD	O
%	NN	O
solution	NN	O
of	IN	O
sucrose	JJ	O
allows	VBZ	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
be	VB	O
stable	JJ	O
at	IN	O
1	CD	O
mg/mL	NN	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
2	CD	O
%	NN	O
w/v	JJ	O
arginine	NN	O
allows	VBZ	O
some	DT	O
embodiments	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
to	TO	O
be	VB	O
stable	JJ	O
at	IN	O
3	CD	O
mg/mL	NN	O
.	.	O
For	IN	O
this	DT	O
reason	NN	O
,	,	O
other	JJ	O
amino	NN	O
acid	NNS	O
based	VBN	O
compounds	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
histidine	VB	O
,	,	O
glutamine	NN	O
,	,	O
glycine	NN	O
and	CC	O
human	JJ	O
albumin	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
excipients	NNS	O
.	.	O
The	DT	O
addition	NN	O
of	IN	O
excipients	NNS	O
such	JJ	O
as	IN	O
glycerol	NN	O
is	VBZ	O
stabilizing	VBG	O
to	TO	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
polypeptide	NN	O
has	VBZ	O
a	DT	O
maximum	JJ	O
concentration	NN	O
with	IN	O
10	CD	O
%	NN	O
glycerol	NN	O
(	(	O
v/v	NN	O
)	)	O
of	IN	O
1	CD	O
mg/mL	NNS	O
;	:	O
while	IN	O
at	IN	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
the	DT	O
drug	NN	O
candidates	NNS	O
are	VBP	O
stable	JJ	O
up	IN	O
to	TO	O
12	CD	O
mg/mL	NNS	O
.	.	O
Excipient	JJ	O
mixtures	NNS	O
containing	VBG	O
compounds	NNS	O
with	IN	O
similar	JJ	O
chemical	NN	O
properties	NNS	O
are	VBP	O
envisioned	VBN	O
that	IN	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
polyols	NNS	O
such	JJ	O
as	IN	O
mannitol	NN	O
,	,	O
xylitol	NNP	O
and	CC	O
sorbitol	NN	O
.	.	O
Disaccharides	NNS	O
such	JJ	O
as	IN	O
sucrose	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
to	TO	O
be	VB	O
stabilizing	VBG	O
at	IN	O
10	CD	O
%	NN	O
w/v	NN	O
;	:	O
other	JJ	O
disaccharides	NNS	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
maltose	VB	O
and	CC	O
trehalose	VB	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
.	.	O
Monosaccharides	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Polysorbates	NNS	O
,	,	O
polyethyleneglycols	NNS	O
and	CC	O
similar	JJ	O
compounds	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
practice	NN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
As	IN	O
one	CD	O
skilled	VBD	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
antioxidants	NNS	O
and	CC	O
preservatives	NNS	O
may	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
ensure	VB	O
stability	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
during	IN	O
storage	NN	O
.	.	O
Antioxidants	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
sodium	VB	O
citrate	NN	O
,	,	O
may	MD	O
be	VB	O
stabilizing	VBG	O
for	IN	O
long	JJ	O
term	NN	O
storage	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Preservatives	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
benzyl	VB	O
alcohol	NN	O
may	MD	O
also	RB	O
be	VB	O
stabilizing	VBG	O
to	TO	O
the	DT	O
polypeptides	NNS	O
during	IN	O
storage	NN	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
final	JJ	O
excipient	NN	O
mixtures	NNS	O
.	.	O
Measurement	NN	O
of	IN	O
Oligoadenylate	NNP	O
Synthetase	NNP	O
Activity	NNP	O
of	IN	O
Polypeptides	NNP	O
The	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
activities	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
measured	VBN	O
according	VBG	O
to	TO	O
previously	RB	O
published	VBN	O
methods	NNS	O
(	(	O
Justesen	NNP	B
,	,	I
J.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
Nuc	NNP	I
Acids	NNP	I
Res	NNP	I
.	.	I
8:3073-3085	CD	I
,	,	I
1980	CD	I
)	)	O
.	.	O
Briefly	NNP	O
,	,	O
protein	NN	O
is	VBZ	O
activated	VBN	O
with	IN	O
200	CD	O
μg/ml	JJ	O
polyinosinic	NN	O
:	:	O
polycytidylic	JJ	O
acid	NN	O
in	IN	O
buffer	NN	O
containing	VBG	O
20	CD	O
mM	JJ	O
Tris-HCl	NNP	O
,	,	O
pH	NN	O
7.8	CD	O
,	,	O
50	CD	O
mM	NN	O
Mg	NNP	O
(	(	O
OAc	NNP	O
)	)	O
2	CD	O
,	,	O
1	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
0.2	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2.5	CD	O
mM	NN	O
ATP	NNP	O
,	,	O
α	NNP	O
[	VBZ	O
32P	CD	O
]	NN	O
ATP	NNP	O
,	,	O
0.5	CD	O
mg/ml	NN	O
BSA	NNP	O
,	,	O
and	CC	O
10	CD	O
%	NN	O
glycerol	NN	O
.	.	O
The	DT	O
reaction	NN	O
proceeds	NNS	O
at	IN	O
37°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
minutes	NNS	O
to	TO	O
24	CD	O
hours	NNS	O
and	CC	O
is	VBZ	O
terminated	VBN	O
by	IN	O
heating	VBG	O
to	TO	O
90°	CD	O
C.	NNP	O
for	IN	O
3	CD	O
minutes	NNS	O
.	.	O
2-4	JJ	O
μl	NN	O
of	IN	O
the	DT	O
reaction	NN	O
mixture	NN	O
is	VBZ	O
spotted	VBN	O
onto	IN	O
a	DT	O
PEI-cellulose	JJ	O
thin	JJ	O
layer	NN	O
plate	NN	O
.	.	O
After	IN	O
drying	VBG	O
,	,	O
the	DT	O
plate	NN	O
is	VBZ	O
developed	VBN	O
with	IN	O
0.4	CD	O
M	NNP	O
Tris-HCl	NNP	O
,	,	O
30	CD	O
mM	NN	O
MgCl2	NNP	O
,	,	O
pH	VBD	O
8.7	CD	O
.	.	O
The	DT	O
plate	NN	O
is	VBZ	O
dried	VBN	O
and	CC	O
visualized	VBN	O
by	IN	O
phosphorimager	NN	O
analysis	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
reaction	NN	O
mixture	NN	O
can	MD	O
be	VB	O
further	RB	O
incubated	VBN	O
with	IN	O
0.05	CD	O
U/μl	NNP	O
calf	NN	O
intestinal	JJ	O
phosphatase	NN	O
to	TO	O
remove	VB	O
the	DT	O
terminal	JJ	O
phosphate	NN	O
.	.	O
Thin	NNP	O
layer	NN	O
chromatographic	JJ	O
separation	NN	O
is	VBZ	O
achieved	VBN	O
using	VBG	O
a	DT	O
0.76	CD	O
M	NNP	O
KH2PO4	NNP	O
,	,	O
pH	VBZ	O
3.6	CD	O
developing	VBG	O
buffer	NN	O
system	NN	O
.	.	O
The	DT	O
plate	NN	O
is	VBZ	O
then	RB	O
dried	VBN	O
and	CC	O
visualized	VBN	O
by	IN	O
phosphorimager	NN	O
analysis	NN	O
.	.	O
Measurement	NN	O
of	IN	O
Antiviral	NNP	O
Activity	NNP	O
of	IN	O
Polypeptides	NNP	O
The	DT	O
ability	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
protect	VB	O
cultured	JJ	O
cells	NNS	O
from	IN	O
cytotoxic	NN	O
viruses	NNS	O
is	VBZ	O
demonstrated	VBN	O
using	VBG	O
a	DT	O
murine	NN	O
encephalomyocarditis	NN	O
virus	NN	O
(	(	O
EMCV	NNP	O
,	,	O
ATCC	NNP	O
strain	VBP	O
VR-129B	NNP	O
)	)	O
infection	NN	O
model	NN	O
.	.	O
Other	JJ	O
in	IN	O
vitro	JJ	O
virus	NN	O
infection	NN	O
models	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
flaviviruses	NNS	O
such	JJ	O
as	IN	O
bovine	JJ	O
diarrheal	NN	O
virus	NN	O
,	,	O
West	NNP	O
Nile	NNP	O
Virus	NNP	O
,	,	O
and	CC	O
GBV-C	NNP	O
virus	NN	O
,	,	O
other	JJ	O
RNA	NNP	O
viruses	NNS	O
such	JJ	O
as	IN	O
respiratory	JJ	O
syncytial	JJ	O
virus	NN	O
,	,	O
and	CC	O
the	DT	O
HCV	NNP	O
replicon	NN	O
systems	NNS	O
(	(	O
e.g	NN	O
.	.	O
Blight	NNP	B
,	,	I
K.	NNP	I
J.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
2002	CD	I
.	.	I
J.	NNP	I
Virology	NNP	I
,	,	I
76:13001-13014	NNP	I
)	)	O
.	.	O
Any	DT	O
appropriate	JJ	O
cultured	VBN	O
cell	NN	O
competent	NN	O
for	IN	O
viral	JJ	O
replication	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
in	IN	O
the	DT	O
antiviral	JJ	O
assays	NNS	O
.	.	O
Human	NNP	O
Huh7	NNP	O
hepatoma	NN	O
cells	NNS	O
are	VBP	O
seeded	VBN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
1×104	CD	O
cells/well	NN	O
in	IN	O
96	CD	O
well	RB	O
culture	NN	O
plates	NNS	O
and	CC	O
incubated	JJ	O
overnight	NN	O
in	IN	O
complete	JJ	O
medium	NN	O
(	(	O
DMEM	NNP	O
containing	VBG	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
)	)	O
.	.	O
The	DT	O
following	JJ	O
morning	NN	O
,	,	O
the	DT	O
media	NNS	O
is	VBZ	O
replaced	VBN	O
with	IN	O
complete	JJ	O
medium	NN	O
containing	VBG	O
0-10	JJ	O
μM	JJ	O
protein	NN	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
protein	NN	O
dilution	NN	O
buffer	NN	O
.	.	O
When	WRB	O
desired	VBN	O
,	,	O
alpha-interferon	NN	O
is	VBZ	O
added	VBN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
100	CD	O
IU/ml	NNP	O
.	.	O
Cells	NNS	O
are	VBP	O
pretreated	VBN	O
for	IN	O
2-8	JJ	O
hours	NNS	O
preceding	VBG	O
viral	JJ	O
infection	NN	O
.	.	O
After	IN	O
pretreatment	NN	O
,	,	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
medium	NN	O
containing	VBG	O
dilutions	NNS	O
of	IN	O
EMC	NNP	O
virus	NN	O
in	IN	O
complete	JJ	O
medium	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
wells	NNS	O
.	.	O
In	IN	O
the	DT	O
experiments	NNS	O
described	VBD	O
herein	RB	O
,	,	O
a	DT	O
range	NN	O
of	IN	O
50-500	JJ	O
plaque	NN	O
forming	VBG	O
units	NNS	O
(	(	O
pfu	NN	O
)	)	O
is	VBZ	O
added	VBN	O
per	IN	O
well	RB	O
.	.	O
Viral	JJ	O
infection	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
proceed	VB	O
overnight	JJ	O
(	(	O
approximately	RB	O
18	CD	O
hours	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
proportion	NN	O
of	IN	O
viable	JJ	O
cells	NNS	O
is	VBZ	O
calculated	VBN	O
using	VBG	O
any	DT	O
available	JJ	O
cell	NN	O
viability	NN	O
or	CC	O
cytotoxicity	NN	O
reagents	NNS	O
.	.	O
The	DT	O
results	NNS	O
described	VBD	O
herein	NNS	O
are	VBP	O
obtained	VBN	O
using	VBG	O
a	DT	O
cell	NN	O
viability	NN	O
assay	VBP	O
that	IN	O
measures	VBZ	O
conversion	NN	O
of	IN	O
a	DT	O
tetrazolium	NN	O
compound	NN	O
[	IN	O
3-	JJ	O
(	(	O
4,5-dimethyl-2-yl	JJ	O
)	)	O
-5-	NN	O
(	(	O
3-carboxymethoxyphenyl	JJ	O
)	)	O
-2-	NN	O
(	(	O
4-sulfophenyl	JJ	O
)	)	O
-2H-tetrazolium	NN	O
,	,	O
inner	JJ	O
salt	NN	O
;	:	O
MTS	NNP	O
]	NNP	O
to	TO	O
a	DT	O
colored	VBN	O
formazan	NN	O
compound	NN	O
in	IN	O
viable	JJ	O
cells	NNS	O
.	.	O
The	DT	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan	VB	O
is	VBZ	O
detected	VBN	O
in	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
reader	NN	O
at	IN	O
an	DT	O
absorbance	NN	O
of	IN	O
492	CD	O
nm	NNS	O
.	.	O
The	DT	O
resulting	VBG	O
optical	JJ	O
densities	NNS	O
either	CC	O
are	VBP	O
plotted	VBN	O
directly	RB	O
to	TO	O
estimate	VB	O
cell	NN	O
viability	NN	O
or	CC	O
are	VBP	O
normalized	VBN	O
by	IN	O
control-treated	JJ	O
samples	NNS	O
to	TO	O
calculate	VB	O
a	DT	O
percentage	NN	O
of	IN	O
viable	JJ	O
cells	NNS	O
after	IN	O
treatment	NN	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
shows	NNS	O
representative	JJ	O
data	NNS	O
from	IN	O
experiments	NNS	O
comparing	VBG	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
a	DT	O
Class	NN	O
I	PRP	O
enzymatically	RB	O
inactive	JJ	O
mutant	NN	O
to	TO	O
a	DT	O
reference	NN	O
polypeptide	NN	O
which	WDT	O
is	VBZ	O
identical	JJ	O
except	IN	O
for	IN	O
the	DT	O
Class	NN	O
I	PRP	O
modification	VBP	O
.	.	O
In	IN	O
this	DT	O
particular	JJ	O
case	NN	O
,	,	O
the	DT	O
reference	NN	O
is	VBZ	O
itself	PRP	O
a	DT	O
Class	NN	O
III	NNP	O
mutant	JJ	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Treatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
protein	NN	O
or	CC	O
vehicle	NN	O
containing	VBG	O
medium	NN	O
alone	RB	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
significant	JJ	O
decreases	NNS	O
in	IN	O
cell	NN	O
viability	NN	O
.	.	O
Conversely	RB	O
,	,	O
pretreatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
vehicle	NN	O
containing	VBG	O
medium	NN	O
did	VBD	O
not	RB	O
protect	VB	O
against	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
when	WRB	O
infected	VBN	O
with	IN	O
either	DT	O
50	CD	O
or	CC	O
250	CD	O
pfu	JJ	O
EMCV	NNP	O
.	.	O
Pretreatment	NN	O
with	IN	O
either	CC	O
the	DT	O
reference	NN	O
polypeptide	NN	O
or	CC	O
a	DT	O
Class	NN	O
I	PRP	O
mutant	VBP	O
polypeptide	RB	O
resulted	VBN	O
in	IN	O
very	RB	O
similar	JJ	O
dose-dependent	NN	O
increases	NNS	O
in	IN	O
cell	NN	O
viability	NN	O
of	IN	O
Huh7	NNP	O
cells	NNS	O
,	,	O
with	IN	O
half-maximal	JJ	O
inhibitory	NN	O
doses	NNS	O
of	IN	O
approximately	RB	O
1	CD	O
μM	NNS	O
and	CC	O
2.5-3	JJ	O
μM	NN	O
at	IN	O
viral	JJ	O
doses	NNS	O
of	IN	O
50	CD	O
and	CC	O
250	CD	O
pfu	NN	O
,	,	O
respectively	RB	O
.	.	O
Polypeptide	NNP	O
Pegylation	NNP	O
;	:	O
Sulfhydryl	NNP	O
Conjugation	NNP	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
was	VBD	O
achieved	VBN	O
by	IN	O
mixing	VBG	O
diothiothreitol	NN	O
(	(	O
DTT	NNP	O
)	)	O
-free	VBP	O
purified	VBN	O
polypeptide	IN	O
with	IN	O
activated	JJ	O
mPEG-MAL	NN	O
(	(	O
Nektar	NNP	O
Therapeutics	NNP	O
)	)	O
at	IN	O
a	DT	O
0.5-10:1	JJ	O
molar	NN	O
ratio	NN	O
.	.	O
The	DT	O
reaction	NN	O
proceeded	VBD	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
5	CD	O
min-2	JJ	O
hours	NNS	O
and	CC	O
was	VBD	O
quenched	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
2	CD	O
mM	NN	O
DTT	NNP	O
.	.	O
Conjugation	NN	O
occurred	VBD	O
at	IN	O
multiple	JJ	O
cysteine	NN	O
sites	NNS	O
using	VBG	O
linear	JJ	O
20	CD	O
kDa	NN	O
and	CC	O
branched	VBD	O
40	CD	O
kDa	NN	O
PEGs	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
6A	CD	O
and	CC	O
6B	CD	O
)	)	O
.	.	O
Non-pegylated	JJ	O
forms	NNS	O
and	CC	O
forms	NNS	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
PEG	NNS	O
can	MD	O
be	VB	O
separated	VBN	O
from	IN	O
each	DT	O
other	JJ	O
using	VBG	O
a	DT	O
variety	NN	O
of	IN	O
chromatographic	JJ	O
methodologies	NNS	O
as	IN	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
In	IN	O
exemplary	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
ion	NN	O
exchange	NN	O
columns	NN	O
,	,	O
hydrophobic	JJ	O
interactions	NNS	O
columns	VBP	O
,	,	O
gel	JJ	O
filtration	NN	O
and	CC	O
size	NN	O
exclusion	NN	O
chromatography	NN	O
,	,	O
each	DT	O
alone	CD	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
another	DT	O
,	,	O
can	MD	O
be	VB	O
utilized	VBN	O
for	IN	O
isolation	NN	O
of	IN	O
the	DT	O
different	JJ	O
PEG	NNP	O
forms	NNS	O
.	.	O
Polypeptide	NNP	O
Pegylation	NNP	O
;	:	O
N-Terminal	JJ	O
Polypeptides	NNP	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
pegylated	VBN	O
at	IN	O
the	DT	O
N-terminal	JJ	O
amine	NN	O
.	.	O
To	TO	O
polypeptides	NNS	O
in	IN	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	NN	O
5	CD	O
containing	VBG	O
20	CD	O
mM	JJ	O
sodium	NN	O
cyanobororohydride	NN	O
and	CC	O
stirring	NN	O
in	IN	O
an	DT	O
ice	NN	O
bath	NN	O
are	VBP	O
added	VBN	O
a	DT	O
5-fold	JJ	O
excess	NN	O
of	IN	O
mPEG	JJ	O
butyrALD-40K	NN	O
.	.	O
The	DT	O
reaction	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
proceed	VB	O
for	IN	O
up	RB	O
to	TO	O
ten	VB	O
hours	NNS	O
and	CC	O
then	RB	O
quenched	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
a	DT	O
50-fold	JJ	O
excess	NN	O
of	IN	O
glycine	NN	O
.	.	O
Reaction	NN	O
products	NNS	O
are	VBP	O
analyzed	VBN	O
by	IN	O
SDS-PAGE	NNP	O
.	.	O
The	DT	O
following	JJ	O
examples	NNS	O
are	VBP	O
offered	VBN	O
by	IN	O
way	NN	O
of	IN	O
illustration	NN	O
and	CC	O
not	RB	O
by	IN	O
way	NN	O
of	IN	O
limitation	NN	O
.	.	O
EXAMPLES	NNP	O
Example	NNP	O
1	CD	O
Site	NNP	O
Directed	NNP	O
Mutagenesis	NNP	O
The	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
engineered	VBN	O
using	VBG	O
any	DT	O
standard	JJ	O
method	NN	O
of	IN	O
site-directed	JJ	O
mutagenesis	NN	O
.	.	O
The	DT	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
corresponding	VBG	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
were	VBD	O
synthesized	VBN	O
using	VBG	O
specific	JJ	O
oligonucleotide	JJ	O
primers	NNS	O
and	CC	O
a	DT	O
high	JJ	O
fidelity	NN	O
DNA	NNP	O
polymerase	NN	O
.	.	O
The	DT	O
target	NN	O
sequence	NN	O
was	VBD	O
contained	VBN	O
on	IN	O
a	DT	O
double	JJ	O
stranded	VBN	O
plasmid	NN	O
isolated	VBN	O
from	IN	O
a	DT	O
methylation-competent	JJ	O
E.	NNP	O
coli	NNS	O
strain	NN	O
.	.	O
Complimentary	NNP	O
oligonucleotides	NNS	O
containing	VBG	O
the	DT	O
desired	VBN	O
mutation	NN	O
were	VBD	O
synthesized	VBN	O
and	CC	O
purified	VBN	O
using	VBG	O
polyacrylamide	JJ	O
gel	JJ	O
electrophoresis	NN	O
.	.	O
A	DT	O
thermal	JJ	O
cycler	NN	O
was	VBD	O
used	VBN	O
to	TO	O
control	VB	O
the	DT	O
temperature	NN	O
for	IN	O
alternating	VBG	O
cycles	NNS	O
of	IN	O
denaturation	NN	O
of	IN	O
the	DT	O
double	NN	O
stranded	VBD	O
plasmid	JJ	O
template	NN	O
(	(	O
94°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
seconds	NNS	O
)	)	O
,	,	O
annealing	VBG	O
of	IN	O
the	DT	O
oligonucleotide	JJ	O
primers	NNS	O
(	(	O
55°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
minute	NN	O
)	)	O
,	,	O
and	CC	O
extension	NN	O
of	IN	O
the	DT	O
primers	NNS	O
with	IN	O
a	DT	O
high	JJ	O
fidelity	NN	O
polymerase	NN	O
(	(	O
68°	CD	O
C.	NNP	O
for	IN	O
1	CD	O
minute/kb	NN	O
of	IN	O
plasmid	JJ	O
length	NN	O
)	)	O
.	.	O
After	IN	O
approximately	RB	O
15	CD	O
cycles	NNS	O
,	,	O
the	DT	O
mixture	NN	O
of	IN	O
newly	RB	O
synthetized	VBN	O
and	CC	O
input	VBN	O
DNA	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
restriction	NN	O
enzyme	NN	O
specific	NN	O
for	IN	O
methylated	JJ	O
residues	NNS	O
(	(	O
Dpn	NNP	O
I	PRP	O
)	)	O
to	TO	O
digest	VB	O
the	DT	O
parental	JJ	O
plasmid	NN	O
.	.	O
The	DT	O
resulting	VBG	O
DNA	NN	O
was	VBD	O
introduced	VBN	O
into	IN	O
chemically	RB	O
or	CC	O
electrically	RB	O
competent	JJ	O
bacterial	JJ	O
strains	NNS	O
for	IN	O
screening	VBG	O
and	CC	O
isolation	NN	O
of	IN	O
plasmids	NNS	O
containing	VBG	O
the	DT	O
desired	JJ	O
mutation	NN	O
.	.	O
Plasmid	NNP	O
DNA	NNP	O
was	VBD	O
isolated	VBN	O
from	IN	O
the	DT	O
transformants	NNS	O
and	CC	O
screened	VBD	O
via	IN	O
fluorescent	JJ	O
dye-terminator	NN	O
sequencing	VBG	O
to	TO	O
confirm	VB	O
the	DT	O
mutant	JJ	O
sequence	NN	O
.	.	O
Example	RB	O
2	CD	O
Bulk	NNP	O
Drug	NNP	O
Product	NNP	O
Expression	NNP	O
,	,	O
Fermentation	NNP	O
,	,	O
and	CC	O
Purification	NNP	O
An	DT	O
E.	NNP	O
coli	NNS	O
strain	VBP	O
containing	VBG	O
a	DT	O
lysogen	NN	O
of	IN	O
λDE3	NNP	O
,	,	O
and	CC	O
therefore	RB	O
carrying	VBG	O
a	DT	O
chromosomal	JJ	O
copy	NN	O
of	IN	O
the	DT	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
gene	NN	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
the	DT	O
lacUV5	NN	O
promoter	NN	O
,	,	O
was	VBD	O
transformed	VBN	O
with	IN	O
a	DT	O
bacterial	JJ	O
expression	NN	O
vector	NN	O
containing	VBG	O
an	DT	O
IPTG-inducible	JJ	O
promoter	NN	O
encoding	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
corresponding	VBG	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Cultures	NNS	O
were	VBD	O
grown	VBN	O
in	IN	O
luria	JJ	O
broth	DT	O
medium	NN	O
supplemented	VBD	O
with	IN	O
34	CD	O
μg/mL	NNS	O
chloroamphenicol	NN	O
and	CC	O
15	CD	O
μg/mL	JJ	O
kanamycin	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
When	WRB	O
the	DT	O
OD600	NNP	O
reaches	VBZ	O
>	RB	O
0.4	CD	O
,	,	O
the	DT	O
temperature	NN	O
was	VBD	O
reduced	VBN	O
to	TO	O
18°	CD	O
C.	NNP	O
and	CC	O
the	DT	O
cells	NNS	O
were	VBD	O
induced	VBN	O
with	IN	O
0.5	CD	O
mM	NNS	O
IPTG	NNP	O
for	IN	O
17	CD	O
hours	NNS	O
.	.	O
The	DT	O
bacterial	JJ	O
cells	NNS	O
were	VBD	O
then	RB	O
resuspended	VBN	O
in	IN	O
buffer	NN	O
containing	VBG	O
50	CD	O
mM	JJ	O
NaH2PO4	NNP	O
,	,	O
pH	NN	O
8	CD	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
20	CD	O
mM	NN	O
imidazole	NN	O
,	,	O
10	CD	O
%	NN	O
glycerol	NN	O
,	,	O
0.1	CD	O
%	NN	O
NP40	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
and	CC	O
protease	NN	O
inhibitors	NNS	O
(	(	O
VWR	NNP	O
)	)	O
,	,	O
lysed	VBN	O
in	IN	O
a	DT	O
Gaulin	NNP	O
homogenizer	NN	O
,	,	O
and	CC	O
centrifuged	VBD	O
to	TO	O
remove	VB	O
cell	NN	O
debris	NN	O
before	IN	O
protein	JJ	O
purification	NN	O
.	.	O
Purification	NN	O
of	IN	O
histidine	NN	O
tagged	VBN	O
polypeptides	NNS	O
:	:	O
Purification	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
was	VBD	O
achieved	VBN	O
using	VBG	O
a	DT	O
polyhistidine	NN	O
tag	NN	O
at	IN	O
the	DT	O
amino-terminus	NN	O
.	.	O
A	DT	O
nickel	JJ	O
column	NN	O
,	,	O
specifically	RB	O
a	DT	O
GE	NNP	O
Healthcare	NNP	O
5	CD	O
mL	NN	O
HisTrap	NNP	O
FF	NNP	O
column	NN	O
(	(	O
17-5255-01	JJ	O
)	)	O
,	,	O
was	VBD	O
used	VBN	O
with	IN	O
two	CD	O
stacked	VBD	O
5	CD	O
mL	NN	O
columns	NN	O
.	.	O
The	DT	O
lysate	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
the	DT	O
column	NN	O
with	IN	O
a	DT	O
1.5	CD	O
mL/min	NN	O
flowrate	NN	O
.	.	O
The	DT	O
column	NN	O
was	VBD	O
then	RB	O
washed	VBN	O
with	IN	O
15	CD	O
column	NN	O
volumes	NNS	O
(	(	O
CV	NNP	O
)	)	O
of	IN	O
Buffer	NNP	O
A	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
20	CD	O
mM	NN	O
imidazole	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
7.5	CD	O
)	)	O
.	.	O
A	DT	O
step	NN	O
elution	NN	O
to	TO	O
7	CD	O
%	NN	O
Buffer	NNP	O
B	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
M	NNP	O
imidazole	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
7.5	CD	O
)	)	O
was	VBD	O
run	VBN	O
for	IN	O
2.5	CD	O
CV	NNP	O
.	.	O
A	DT	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
B	NNP	O
over	IN	O
2.5	CD	O
CV	NNP	O
was	VBD	O
then	RB	O
carried	VBN	O
out	RP	O
.	.	O
All	DT	O
purification	NN	O
steps	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
from	IN	O
the	DT	O
nickel	JJ	O
column	NN	O
containing	VBG	O
the	DT	O
polypeptide	NN	O
were	VBD	O
mixed	JJ	O
and	CC	O
diluted	VBD	O
1:1	CD	O
with	IN	O
Buffer	NNP	O
A.	NN	O
CaCl2	NNP	O
(	(	O
from	IN	O
sterile	NN	O
filtered	VBD	O
1	CD	O
M	NNP	O
stock	NN	O
solution	NN	O
)	)	O
was	VBD	O
added	VBN	O
to	TO	O
a	DT	O
2	CD	O
mM	NN	O
final	JJ	O
concentration	NN	O
.	.	O
Filtration	NN	O
was	VBD	O
done	VBN	O
to	TO	O
clarify	VB	O
.	.	O
The	DT	O
filtrate	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
an	DT	O
octyl	JJ	O
FF	NNP	O
column	NN	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-1359-01	JJ	O
)	)	O
equilibrated	VBN	O
in	IN	O
buffer	NN	O
A	NN	O
at	IN	O
a	DT	O
0.5	CD	O
mL/min	NN	O
flowrate	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
was	VBD	O
in	IN	O
the	DT	O
flowthrough	JJ	O
fractions	NNS	O
.	.	O
The	DT	O
octyl	JJ	O
column	NN	O
flowthrough	NN	O
was	VBD	O
added	VBN	O
to	TO	O
5	CD	O
volumes	NNS	O
of	IN	O
Buffer	NNP	O
C	NNP	O
(	(	O
10	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
pH	RB	O
8.8	CD	O
)	)	O
.	.	O
The	DT	O
polypeptide	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
DEAE	NNP	O
FF	NNP	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-5154-01	JJ	O
)	)	O
5	CD	O
mL	JJ	O
column	NN	O
for	IN	O
endotoxin	NN	O
removal	NN	O
,	,	O
at	IN	O
a	DT	O
1.5	CD	O
mL/min	NN	O
flowrate	NN	O
.	.	O
This	DT	O
was	VBD	O
followed	VBN	O
by	IN	O
a	DT	O
5	CD	O
CV	NNP	O
Buffer	NNP	O
C	NNP	O
wash	NN	O
,	,	O
1.5	CD	O
mL/min	NN	O
flowrate	NN	O
,	,	O
then	RB	O
a	DT	O
10	CD	O
CV	NNP	O
gradient	NN	O
from	IN	O
10	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
pH	VBZ	O
8.8	CD	O
to	TO	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
1	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
pH	VBD	O
8.0	CD	O
was	VBD	O
run	VBN	O
.	.	O
The	DT	O
flowthrough	JJ	O
fractions	NNS	O
were	VBD	O
pooled	VBN	O
and	CC	O
diluted	VBN	O
1:1	CD	O
with	IN	O
Buffer	NNP	O
C	NNP	O
while	IN	O
gently	RB	O
mixing	VBG	O
,	,	O
and	CC	O
the	DT	O
pH	NN	O
was	VBD	O
adjusted	VBN	O
to	TO	O
6.8	CD	O
with	IN	O
2	CD	O
N	NNP	O
HCl	NNP	O
.	.	O
Then	RB	O
the	DT	O
polypeptide	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
5	CD	O
mL	NN	O
HiTrap	NNP	O
SP	NNP	O
FF	NNP	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-5157-01	JJ	O
)	)	O
column	NN	O
at	IN	O
a	DT	O
1.5	CD	O
mL/min	NN	O
flowrate	NN	O
.	.	O
After	IN	O
the	DT	O
polypeptide	NN	O
was	VBD	O
loaded	VBN	O
,	,	O
the	DT	O
column	NN	O
was	VBD	O
washed	VBN	O
with	IN	O
5	CD	O
CV	NNP	O
of	IN	O
Buffer	NNP	O
C	NNP	O
(	(	O
adjusted	VBN	O
to	TO	O
pH	VB	O
6.8	CD	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
step	NN	O
elution	NN	O
to	TO	O
75	CD	O
%	NN	O
of	IN	O
Buffer	NNP	O
D	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
1	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
,	,	O
then	RB	O
a	DT	O
5	CD	O
CV	NNP	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
Buffer	NNP	O
D.	NNP	O
The	DT	O
polypeptide	NN	O
was	VBD	O
then	RB	O
gel	JJ	O
filtered	VBN	O
into	IN	O
Buffer	NNP	O
E	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
and	CC	O
stored	VBN	O
at	IN	O
−20°	NNP	O
C.	NNP	O
Purification	NNP	O
of	IN	O
non-tagged	JJ	O
or	CC	O
native	JJ	O
polypeptides	NNS	O
:	:	O
Purification	NN	O
of	IN	O
polypeptides	NNS	O
lacking	VBG	O
an	DT	O
affinity	NN	O
tag	NN	O
was	VBD	O
also	RB	O
achieved	VBN	O
.	.	O
Growth	NNP	O
and	CC	O
preparation	NN	O
of	IN	O
clarified	JJ	O
lysate	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
previously	RB	O
described	VBN	O
.	.	O
Alternatively	RB	O
,	,	O
to	TO	O
clarify	VB	O
extracts	NNS	O
and	CC	O
remove	VB	O
endotoxin	NN	O
,	,	O
tangential	JJ	O
flow	NN	O
filtration	NN	O
through	IN	O
a	DT	O
hollow	JJ	O
fiber	NN	O
filtration	NN	O
device	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O
Lysate	NNP	O
was	VBD	O
mixed	JJ	O
with	IN	O
CaCl2	NNP	O
to	TO	O
a	DT	O
final	JJ	O
CaCl2	NNP	O
concentration	NN	O
of	IN	O
2	CD	O
mM	NN	O
.	.	O
Tangential	JJ	O
flow	NN	O
filtration	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
a	DT	O
GE	NNP	O
Healthcare	NNP	O
Midgee—UFP-500-E-MM01A	NNP	O
(	(	O
56-4100-56	CD	O
)	)	O
which	WDT	O
has	VBZ	O
a	DT	O
500	CD	O
kDa	NN	O
cutoff	NN	O
.	.	O
The	DT	O
flowrate	NN	O
was	VBD	O
190	CD	O
mL/min	NN	O
and	CC	O
the	DT	O
filtrate	NN	O
was	VBD	O
collected	VBN	O
and	CC	O
taken	VBN	O
to	TO	O
the	DT	O
next	JJ	O
step	NN	O
.	.	O
The	DT	O
protocol	NN	O
utilized	JJ	O
GE	NNP	O
Healthcare	NNP	O
HITRAP	NNP	O
SP	NNP	O
FF	NNP	O
5	CD	O
ml	NN	O
columns	NN	O
(	(	O
17-5157-01	JJ	O
)	)	O
,	,	O
for	IN	O
the	DT	O
initial	JJ	O
capture	NN	O
step	NN	O
,	,	O
with	IN	O
a	DT	O
5	CD	O
mL	JJ	O
column	NN	O
volume	NN	O
utilized	VBN	O
for	IN	O
the	DT	O
amount	NN	O
of	IN	O
lysate	NN	O
generated	VBN	O
by	IN	O
a	DT	O
4	CD	O
L	NNP	O
growth/induction	NN	O
.	.	O
The	DT	O
lysate	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
the	DT	O
column	NN	O
with	IN	O
a	DT	O
1.5	CD	O
mL/min	NN	O
flowrate	NN	O
.	.	O
The	DT	O
column	NN	O
was	VBD	O
then	RB	O
washed	VBN	O
with	IN	O
5	CD	O
column	NN	O
volumes	NNS	O
of	IN	O
Buffer	NNP	O
A	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
25	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.4	CD	O
)	)	O
.	.	O
The	DT	O
polypeptide	NN	O
was	VBD	O
eluted	VBN	O
via	IN	O
a	DT	O
step	NN	O
gradient	NN	O
to	TO	O
33	CD	O
%	NN	O
Buffer	NNP	O
B	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
1	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
which	WDT	O
was	VBD	O
run	VBN	O
for	IN	O
3	CD	O
CV	NNP	O
.	.	O
All	DT	O
subsequent	JJ	O
steps	NNS	O
subsequent	JJ	O
were	VBD	O
carried	VBN	O
out	RP	O
under	IN	O
endotoxin	JJ	O
free	JJ	O
conditions	NNS	O
.	.	O
Peak	JJ	O
fractions	NNS	O
from	IN	O
the	DT	O
cation	NN	O
exchange	NN	O
step	NN	O
were	VBD	O
pooled	VBN	O
and	CC	O
diluted	VBN	O
1:1	CD	O
v/v	NN	O
with	IN	O
Buffer	NNP	O
C	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
1	CD	O
M	NNP	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
,	,	O
pH	RB	O
6.8	CD	O
)	)	O
and	CC	O
adjusted	VBN	O
to	TO	O
1	CD	O
M	NNP	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
by	IN	O
adding	VBG	O
the	DT	O
appropriate	JJ	O
volume	NN	O
of	IN	O
4	CD	O
M	NNP	O
(	(	O
NH4	NNP	O
)	)	O
2SO4	CD	O
at	IN	O
pH	NN	O
6.8	CD	O
.	.	O
CaCl2	NNP	O
was	VBD	O
added	VBN	O
to	TO	O
a	DT	O
2	CD	O
mM	NN	O
final	JJ	O
concentration	NN	O
in	IN	O
the	DT	O
gently	RB	O
stirring	VBG	O
solution	NN	O
then	RB	O
filtered	VBD	O
to	TO	O
clarify	VB	O
.	.	O
The	DT	O
polypeptide	NN	O
was	VBD	O
then	RB	O
loaded	VBN	O
onto	IN	O
a	DT	O
5	CD	O
mL	NN	O
HiTrap	NNP	O
Phenyl	NNP	O
HP	NNP	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-5195-01	JJ	O
)	)	O
column	NN	O
at	IN	O
a	DT	O
0.5	CD	O
mL/min	NN	O
flowrate	NN	O
,	,	O
and	CC	O
the	DT	O
column	NN	O
was	VBD	O
washed	VBN	O
with	IN	O
5	CD	O
CV	NNP	O
of	IN	O
Buffer	NNP	O
C	NNP	O
,	,	O
then	RB	O
a	DT	O
0.25	CD	O
CV	NNP	O
gradient	NN	O
to	TO	O
33	CD	O
%	NN	O
Buffer	NNP	O
D	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
at	IN	O
pH	JJ	O
6.8	CD	O
)	)	O
was	VBD	O
performed	VBN	O
.	.	O
33	CD	O
%	NN	O
Buffer	NNP	O
D	NNP	O
was	VBD	O
run	VBN	O
for	IN	O
2	CD	O
CV	NNP	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
1	CD	O
CV	NNP	O
gradient	NN	O
to	TO	O
55	CD	O
%	NN	O
D.	NNP	O
The	DT	O
polypeptide	NN	O
was	VBD	O
then	RB	O
eluted	VBN	O
with	IN	O
a	DT	O
5	CD	O
CV	NNP	O
elution	NN	O
at	IN	O
55	CD	O
%	NN	O
Buffer	NNP	O
D.	NNP	O
The	DT	O
polypeptide	NN	O
then	RB	O
went	VBD	O
through	IN	O
a	DT	O
flowthrough	JJ	O
anion	NN	O
exchange	NN	O
step	NN	O
to	TO	O
remove	VB	O
impurities	NNS	O
and	CC	O
any	DT	O
remaining	VBG	O
endotoxin	NN	O
.	.	O
It	PRP	O
was	VBD	O
diluted	VBN	O
5:1	CD	O
with	IN	O
Buffer	NNP	O
E	NNP	O
(	(	O
10	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
20	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
at	IN	O
pH	JJ	O
8	CD	O
)	)	O
and	CC	O
adjusted	VBN	O
to	TO	O
a	DT	O
final	JJ	O
pH	NN	O
of	IN	O
7.2	CD	O
by	IN	O
slow	JJ	O
addition	NN	O
of	IN	O
2	CD	O
N	NNP	O
HCl	NNP	O
to	TO	O
a	DT	O
gently	RB	O
stirred	VBN	O
solution	NN	O
.	.	O
The	DT	O
polypeptide	NN	O
was	VBD	O
loaded	VBN	O
on	IN	O
a	DT	O
5	CD	O
mL	NN	O
HiTrap	NNP	O
DEAE	NNP	O
FF	NNP	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-5154-01	JJ	O
)	)	O
column	NN	O
at	IN	O
1.5	CD	O
mL/min	NN	O
and	CC	O
washed	VBD	O
with	IN	O
5	CD	O
CV	NNP	O
of	IN	O
Buffer	NNP	O
E.	NNP	O
The	DT	O
polypeptide	NN	O
was	VBD	O
in	IN	O
the	DT	O
flowthrough	JJ	O
fractions	NNS	O
.	.	O
The	DT	O
flowthrough	JJ	O
fractions	NNS	O
were	VBD	O
pooled	VBN	O
and	CC	O
diluted	VBN	O
1:1	CD	O
with	IN	O
Buffer	NNP	O
E	NNP	O
and	CC	O
adjusted	VBN	O
to	TO	O
pH	VB	O
6.4	CD	O
.	.	O
The	DT	O
protein	NN	O
was	VBD	O
loaded	VBN	O
onto	IN	O
a	DT	O
HITRAP	NNP	O
SP	NNP	O
FF	NNP	O
5	CD	O
ml	NN	O
column	NN	O
(	(	O
GE	NNP	O
Healthcare	NNP	O
17-5157-01	JJ	O
)	)	O
at	IN	O
a	DT	O
1.0	CD	O
mL/min	NN	O
flowrate	NN	O
and	CC	O
washed	VBD	O
with	IN	O
2	CD	O
CV	NNP	O
of	IN	O
Buffer	NNP	O
E.	NNP	O
The	DT	O
polypeptide	NN	O
was	VBD	O
eluted	VBN	O
with	IN	O
a	DT	O
10	CD	O
CV	NNP	O
gradient	NN	O
to	TO	O
100	CD	O
%	NN	O
Buffer	NNP	O
F	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
500	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
30	CD	O
%	NN	O
glycerol	NN	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
at	IN	O
pH	RB	O
6.4	CD	O
)	)	O
at	IN	O
a	DT	O
0.5	CD	O
mL/min	NN	O
flowrate	NN	O
.	.	O
The	DT	O
peak	JJ	O
fractions	NNS	O
were	VBD	O
pooled	VBN	O
and	CC	O
gel-filtered	VBN	O
at	IN	O
a	DT	O
2	CD	O
mL/min	NN	O
flowrate	NN	O
,	,	O
using	VBG	O
a	DT	O
GE	NNP	O
Healthcare	NNP	O
HiTrap	NNP	O
Desalting	NNP	O
column	NN	O
(	(	O
17-1408-01	JJ	O
)	)	O
into	IN	O
Buffer	NNP	O
G	NNP	O
(	(	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
25	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.4	CD	O
)	)	O
and	CC	O
stored	VBN	O
at	IN	O
−80°	NNP	O
C.	NNP	O
Alternatively	RB	O
,	,	O
the	DT	O
cation	NN	O
exchange	NN	O
fractions	NNS	O
were	VBD	O
pooled	VBN	O
and	CC	O
uniformly	RB	O
concentrated	JJ	O
via	IN	O
ultrafiltration	NN	O
using	VBG	O
an	DT	O
Amicon	NNP	O
polyethersulfone	NN	O
10,000	CD	O
NMWL	NNP	O
membrane	NN	O
(	(	O
PBGC02510	NNP	O
)	)	O
.	.	O
Buffer	NNP	O
exchange	NN	O
into	IN	O
Buffer	NNP	O
G	NNP	O
was	VBD	O
carried	VBN	O
out	RP	O
via	IN	O
diafiltration	NN	O
or	CC	O
gel-filtration	NN	O
.	.	O
The	DT	O
addition	NN	O
of	IN	O
excipients	NNS	O
such	JJ	O
as	IN	O
glycerol	NN	O
was	VBD	O
stabilizing	VBG	O
to	TO	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
polypeptide	NN	O
with	IN	O
a	DT	O
polyhistidine	JJ	O
affinity	NN	O
tag	NN	O
had	VBD	O
a	DT	O
maximum	JJ	O
concentration	NN	O
with	IN	O
10	CD	O
%	NN	O
glycerol	NN	O
(	(	O
v/v	NN	O
)	)	O
of	IN	O
1	CD	O
mg/mL	NNS	O
;	:	O
while	IN	O
at	IN	O
40	CD	O
%	NN	O
glycerol	NN	O
,	,	O
the	DT	O
polypeptide	NN	O
was	VBD	O
stable	JJ	O
up	RB	O
to	TO	O
12	CD	O
mg/mL	NNS	O
.	.	O
Amino	NNP	O
acid-based	JJ	O
excipients	NNS	O
such	JJ	O
as	IN	O
arginine	NN	O
have	VBP	O
proven	VBN	O
to	TO	O
be	VB	O
stabilizing	VBG	O
to	TO	O
this	DT	O
polypeptide	NN	O
.	.	O
A	DT	O
10	CD	O
%	NN	O
solution	NN	O
of	IN	O
sucrose	JJ	O
allows	VBZ	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
be	VB	O
stable	JJ	O
at	IN	O
1	CD	O
mg/mL	NN	O
,	,	O
the	DT	O
addition	NN	O
of	IN	O
2	CD	O
%	NN	O
w/v	JJ	O
arginine	NN	O
allowed	VBD	O
an	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
to	TO	O
be	VB	O
stable	JJ	O
at	IN	O
3	CD	O
mg/mL	NN	O
.	.	O
An	DT	O
embodiment	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
lacking	VBG	O
an	DT	O
affinity	NN	O
tag	NN	O
for	IN	O
purification	NN	O
was	VBD	O
also	RB	O
stabilized	VBN	O
by	IN	O
particular	JJ	O
excipients	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
25	CD	O
%	NN	O
glycerol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2	CD	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	NN	O
6.4	CD	O
was	VBD	O
found	VBN	O
to	TO	O
stabilize	VB	O
the	DT	O
polypeptide	NN	O
at	IN	O
6	CD	O
mg/mL	NN	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
10	CD	O
%	NN	O
mannitol	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.5	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
2	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
arginine	NN	O
at	IN	O
pH	NN	O
6.4	CD	O
was	VBD	O
found	VBN	O
to	TO	O
stabilize	VB	O
the	DT	O
polypeptide	NN	O
at	IN	O
4	CD	O
mg/mL	NN	O
.	.	O
Example	RB	O
3	CD	O
Measurement	NNP	O
of	IN	O
Oligoadenylate	NNP	O
Synthetase	NNP	O
Activity	NNP	O
of	IN	O
Polypeptides	NNP	O
The	DT	O
oligoadenylate	JJ	O
synthetase	NN	O
activities	NNS	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
were	VBD	O
measured	VBN	O
according	VBG	O
to	TO	O
previously	RB	O
published	VBN	O
methods	NNS	O
(	(	O
Justesen	NNP	B
,	,	I
J.	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
Nuc	NNP	I
Acids	NNP	I
Res	NNP	I
.	.	I
8:3073-3085	CD	I
,	,	I
1980	CD	I
)	)	O
.	.	O
Briefly	NNP	O
,	,	O
protein	NN	O
was	VBD	O
activated	VBN	O
with	IN	O
200	CD	O
μg/ml	JJ	O
polyinosinic	NN	O
:	:	O
polycytidylic	JJ	O
acid	NN	O
in	IN	O
buffer	NN	O
containing	VBG	O
20	CD	O
mM	JJ	O
Tris-HCl	NNP	O
,	,	O
pH	NN	O
7.8	CD	O
,	,	O
50	CD	O
mM	NN	O
Mg	NNP	O
(	(	O
OAc	NNP	O
)	)	O
2	CD	O
,	,	O
1	CD	O
mM	NN	O
DTT	NNP	O
,	,	O
0.2	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
2.5	CD	O
mM	NN	O
ATP	NNP	O
,	,	O
α	NNP	O
[	VBZ	O
32P	CD	O
]	NN	O
ATP	NNP	O
,	,	O
0.5	CD	O
mg/ml	NN	O
BSA	NNP	O
,	,	O
and	CC	O
10	CD	O
%	NN	O
glycerol	NN	O
.	.	O
The	DT	O
reaction	NN	O
proceeded	VBD	O
at	IN	O
37°	CD	O
C.	NNP	O
for	IN	O
30	CD	O
minutes	NNS	O
to	TO	O
24	CD	O
hours	NNS	O
and	CC	O
was	VBD	O
terminated	VBN	O
by	IN	O
heating	VBG	O
to	TO	O
90°	CD	O
C.	NNP	O
for	IN	O
3	CD	O
minutes	NNS	O
.	.	O
2-4	JJ	O
μl	NN	O
of	IN	O
the	DT	O
reaction	NN	O
mixture	NN	O
was	VBD	O
spotted	VBN	O
onto	IN	O
a	DT	O
PEI-cellulose	JJ	O
thin	JJ	O
layer	NN	O
plate	NN	O
.	.	O
After	IN	O
drying	VBG	O
,	,	O
the	DT	O
plate	NN	O
was	VBD	O
developed	VBN	O
with	IN	O
0.4	CD	O
M	NNP	O
Tris-HCl	NNP	O
,	,	O
30	CD	O
mM	NN	O
MgCl2	NNP	O
,	,	O
pH	VBD	O
8.7	CD	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
dried	VBN	O
and	CC	O
visualized	VBN	O
by	IN	O
phosphorimager	NN	O
analysis	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
reaction	NN	O
mixture	NN	O
was	VBD	O
further	RBR	O
incubated	VBN	O
with	IN	O
0.05	CD	O
U/μl	NNP	O
calf	NN	O
intestinal	JJ	O
phosphatase	NN	O
to	TO	O
remove	VB	O
the	DT	O
terminal	JJ	O
phosphate	NN	O
.	.	O
Thin	NNP	O
layer	NN	O
chromatographic	JJ	O
separation	NN	O
was	VBD	O
achieved	VBN	O
using	VBG	O
a	DT	O
0.76	CD	O
M	NNP	O
KH2PO4	NNP	O
,	,	O
pH	VBZ	O
3.6	CD	O
developing	VBG	O
buffer	NN	O
system	NN	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
then	RB	O
dried	VBN	O
and	CC	O
visualized	VBN	O
by	IN	O
phosphorimager	NN	O
analysis	NN	O
.	.	O
Example	RB	O
4	CD	O
Measurement	NNP	O
of	IN	O
Antiviral	NNP	O
Activity	NNP	O
of	IN	O
Polypeptides	NNP	O
The	DT	O
ability	NN	O
of	IN	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
protect	VB	O
cultured	JJ	O
cells	NNS	O
from	IN	O
cytotoxic	NN	O
viruses	NNS	O
was	VBD	O
demonstrated	VBN	O
using	VBG	O
a	DT	O
murine	NN	O
encephalomyocarditis	NN	O
virus	NN	O
(	(	O
EMCV	NNP	O
,	,	O
ATCC	NNP	O
strain	VBP	O
VR-129B	NNP	O
)	)	O
infection	NN	O
model	NN	O
.	.	O
Human	NNP	O
Huh7	NNP	O
hepatoma	NN	O
cells	NNS	O
were	VBD	O
seeded	VBN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
1×104	CD	O
cells/well	NN	O
in	IN	O
96	CD	O
well	RB	O
culture	NN	O
plates	NNS	O
and	CC	O
incubated	JJ	O
overnight	NN	O
in	IN	O
complete	JJ	O
medium	NN	O
(	(	O
DMEM	NNP	O
containing	VBG	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
)	)	O
.	.	O
The	DT	O
following	JJ	O
morning	NN	O
,	,	O
the	DT	O
media	NNS	O
was	VBD	O
replaced	VBN	O
with	IN	O
complete	JJ	O
medium	NN	O
containing	VBG	O
0-10	JJ	O
μM	JJ	O
protein	NN	O
or	CC	O
equivalent	JJ	O
amounts	NNS	O
of	IN	O
protein	NN	O
dilution	NN	O
buffer	NN	O
.	.	O
When	WRB	O
appropriate	JJ	O
,	,	O
alpha-interferon	NN	O
was	VBD	O
added	VBN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
100	CD	O
IU/ml	NNP	O
.	.	O
Cells	NNS	O
were	VBD	O
pretreated	VBN	O
for	IN	O
2-8	JJ	O
hours	NNS	O
preceding	VBG	O
viral	JJ	O
infection	NN	O
.	.	O
After	IN	O
pretreatment	NN	O
,	,	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
medium	NN	O
containing	VBG	O
dilutions	NNS	O
of	IN	O
EMC	NNP	O
virus	NN	O
in	IN	O
complete	JJ	O
medium	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
wells	NNS	O
.	.	O
In	IN	O
the	DT	O
experiments	NNS	O
described	VBD	O
herein	RB	O
,	,	O
a	DT	O
range	NN	O
of	IN	O
50-500	JJ	O
plaque	NN	O
forming	VBG	O
units	NNS	O
(	(	O
pfu	NN	O
)	)	O
was	VBD	O
added	VBN	O
per	IN	O
well	RB	O
.	.	O
Viral	JJ	O
infections	NNS	O
were	VBD	O
allowed	VBN	O
to	TO	O
proceed	VB	O
overnight	JJ	O
(	(	O
approximately	RB	O
18	CD	O
hours	NNS	O
)	)	O
,	,	O
and	CC	O
the	DT	O
proportion	NN	O
of	IN	O
viable	JJ	O
cells	NNS	O
was	VBD	O
calculated	VBN	O
using	VBG	O
a	DT	O
cell	NN	O
viability	NN	O
assay	VBP	O
that	IN	O
measures	NNS	O
compound	VBP	O
[	IN	O
3-	JJ	O
(	(	O
4,5-dimethyl-2-yl	JJ	O
)	)	O
-5-	NN	O
(	(	O
3-carboxymethoxyphenyl	JJ	O
)	)	O
-2-	NN	O
(	(	O
4-sulfophenyl	JJ	O
)	)	O
-2H-tetrazolium	NN	O
,	,	O
inner	JJ	O
salt	NN	O
;	:	O
MTS	NNP	O
]	NNP	O
to	TO	O
a	DT	O
colored	VBN	O
formazan	NN	O
compound	NN	O
in	IN	O
viable	JJ	O
cells	NNS	O
.	.	O
The	DT	O
conversion	NN	O
of	IN	O
MTS	NNP	O
to	TO	O
formazan	VB	O
was	VBD	O
detected	VBN	O
in	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
reader	NN	O
at	IN	O
an	DT	O
absorbance	NN	O
of	IN	O
492	CD	O
nm	NNS	O
.	.	O
The	DT	O
resulting	VBG	O
optical	JJ	O
densities	NNS	O
either	CC	O
were	VBD	O
plotted	VBN	O
directly	RB	O
to	TO	O
estimate	VB	O
cell	NN	O
viability	NN	O
or	CC	O
were	VBD	O
normalized	VBN	O
by	IN	O
control-treated	JJ	O
samples	NNS	O
to	TO	O
calculate	VB	O
a	DT	O
percentage	NN	O
of	IN	O
viable	JJ	O
cells	NNS	O
after	IN	O
treatment	NN	O
.	.	O
FIG	NNP	O
.	.	O
3	CD	O
shows	NNS	O
representative	JJ	O
data	NNS	O
from	IN	O
experiments	NNS	O
comparing	VBG	O
the	DT	O
antiviral	JJ	O
activity	NN	O
of	IN	O
a	DT	O
Class	NN	O
I	PRP	O
enzymatically	RB	O
inactive	JJ	O
mutant	NN	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
expression	NN	O
of	IN	O
SEQUENCE:4	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:4	NNP	O
)	)	O
of	IN	O
the	DT	O
invention	NN	O
by	IN	O
cloning	VBG	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
and	CC	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
,	,	O
followed	VBN	O
by	IN	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
to	TO	O
a	DT	O
reference	NN	O
polypeptide	NN	O
which	WDT	O
is	VBZ	O
identical	JJ	O
except	IN	O
for	IN	O
the	DT	O
Class	NN	O
I	PRP	O
modification	VBP	O
(	(	O
the	DT	O
result	NN	O
of	IN	O
expression	NN	O
of	IN	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
the	DT	O
invention	NN	O
by	IN	O
cloning	VBG	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	NN	O
vector	NN	O
and	CC	O
transformation	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
,	,	O
followed	VBN	O
by	IN	O
expression	NN	O
and	CC	O
purification	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
)	)	O
.	.	O
In	IN	O
this	DT	O
particular	JJ	O
case	NN	O
,	,	O
the	DT	O
reference	NN	O
is	VBZ	O
itself	PRP	O
a	DT	O
Class	NN	O
III	NNP	O
mutant	JJ	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Treatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
protein	NN	O
or	CC	O
vehicle-containing	JJ	O
medium	NN	O
alone	RB	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
significant	JJ	O
decreases	NNS	O
in	IN	O
cell	NN	O
viability	NN	O
.	.	O
Conversely	RB	O
,	,	O
pretreatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
increasing	VBG	O
concentrations	NNS	O
of	IN	O
vehicle-containing	JJ	O
medium	NN	O
did	VBD	O
not	RB	O
protect	VB	O
against	IN	O
EMCV-induced	NNP	O
cell	NN	O
death	NN	O
when	WRB	O
infected	VBN	O
with	IN	O
either	DT	O
50	CD	O
or	CC	O
250	CD	O
pfu	JJ	O
EMCV	NNP	O
.	.	O
Pretreatment	NN	O
with	IN	O
either	CC	O
the	DT	O
reference	NN	O
polypeptide	NN	O
or	CC	O
a	DT	O
Class	NN	O
I	PRP	O
mutant	VBP	O
polypeptide	RB	O
resulted	VBN	O
in	IN	O
very	RB	O
similar	JJ	O
dose-dependent	NN	O
increases	NNS	O
in	IN	O
cell	NN	O
viability	NN	O
of	IN	O
Huh7	NNP	O
cells	NNS	O
,	,	O
with	IN	O
half-maximal	JJ	O
inhibitory	NN	O
doses	NNS	O
of	IN	O
approximately	RB	O
1	CD	O
μM	NNS	O
and	CC	O
2.5-3	JJ	O
μM	NN	O
at	IN	O
viral	JJ	O
doses	NNS	O
of	IN	O
50	CD	O
and	CC	O
250	CD	O
pfu	NN	O
,	,	O
respectively	RB	O
.	.	O
Example	RB	O
5	CD	O
Polypeptide	NNP	O
Pegylation	NNP	O
;	:	O
Sulfhydryl	NNP	O
Conjugation	NNP	O
of	IN	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
to	TO	O
the	DT	O
polypeptides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
was	VBD	O
achieved	VBN	O
by	IN	O
mixing	VBG	O
diothiothreitol	NN	O
(	(	O
DTT	NNP	O
)	)	O
-free	VBP	O
purified	VBN	O
polypeptide	IN	O
with	IN	O
activated	JJ	O
mPEG-MAL	NN	O
(	(	O
Nektar	NNP	O
Therapeutics	NNP	O
)	)	O
at	IN	O
a	DT	O
0.5-10:1	JJ	O
molar	NN	O
ratio	NN	O
.	.	O
The	DT	O
reaction	NN	O
proceeded	VBD	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
5	CD	O
min-2	JJ	O
hours	NNS	O
and	CC	O
was	VBD	O
quenched	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
2	CD	O
mM	NN	O
dithiothreitol	NN	O
.	.	O
Conjugation	NN	O
occurred	VBD	O
at	IN	O
multiple	JJ	O
cysteine	NN	O
sites	NNS	O
using	VBG	O
linear	JJ	O
20	CD	O
kDa	NN	O
and	CC	O
branched	VBD	O
40	CD	O
kDa	NN	O
PEGs	NNP	O
(	(	O
FIGS	NNP	O
.	.	O
6A	CD	O
and	CC	O
6B	CD	O
)	)	O
.	.	O
Non-pegylated	JJ	O
forms	NNS	O
and	CC	O
forms	NNS	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
PEG	JJ	O
groups	NNS	O
were	VBD	O
separated	VBN	O
from	IN	O
each	DT	O
other	JJ	O
using	VBG	O
SDS-PAGE	NNP	O
.	.	O
Example	RB	O
6	CD	O
Toxicology	NNP	O
Analysis	NNP	O
The	DT	O
objective	NN	O
of	IN	O
this	DT	O
study	NN	O
was	VBD	O
to	TO	O
assess	VB	O
the	DT	O
7-day	JJ	O
acute	JJ	O
toxicity	NN	O
of	IN	O
a	DT	O
protein-based	JJ	O
drug	NN	O
(	(	O
“	JJ	O
test	NN	O
article	NN	O
”	NN	O
or	CC	O
“	VB	O
TA1	NNP	O
”	NNP	O
)	)	O
in	IN	O
out-bred	JJ	O
mice	NN	O
.	.	O
“	JJ	O
TA1	NNP	O
”	NN	O
or	CC	O
“	JJ	O
test	NN	O
article	NN	O
”	VBZ	O
refers	NNS	O
to	TO	O
a	DT	O
Class	NN	O
III	NNP	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
expressed	VBN	O
and	CC	O
purified	VBN	O
by	IN	O
cloning	VBG	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
of	IN	O
the	DT	O
invention	NN	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
pET9d	NN	O
,	,	O
followed	VBN	O
by	IN	O
transformation	NN	O
of	IN	O
the	DT	O
recombinant	JJ	O
clone	NN	O
into	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
strain	NN	O
.	.	O
Protein	NNP	O
expression	NN	O
and	CC	O
purification	NN	O
was	VBD	O
effected	VBN	O
as	IN	O
described	NN	O
elsewhere	RB	O
in	IN	O
the	DT	O
specification	NN	O
.	.	O
The	DT	O
study	NN	O
was	VBD	O
comprised	VBN	O
of	IN	O
three	CD	O
groups	NNS	O
(	(	O
N=10	NNP	O
,	,	O
5	CD	O
male	NN	O
and	CC	O
5	CD	O
female	NN	O
)	)	O
of	IN	O
CD-1	NNP	O
mice	NN	O
(	(	O
6-7	JJ	O
weeks	NNS	O
,	,	O
Simonsen	NNP	O
Laboratories	NNPS	O
,	,	O
Gilroy	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
On	IN	O
Day	NNP	O
0	CD	O
,	,	O
the	DT	O
animals	NNS	O
were	VBD	O
weighed	VBN	O
and	CC	O
given	VBN	O
permanent	JJ	O
study	NN	O
numbers	NNS	O
.	.	O
Their	PRP$	O
dosages	NNS	O
were	VBD	O
calculated	VBN	O
based	VBN	O
on	IN	O
group	NN	O
's	POS	O
average	JJ	O
body	NN	O
weights	NNS	O
.	.	O
The	DT	O
mice	NN	O
were	VBD	O
dosed	VBN	O
once	RB	O
daily	JJ	O
by	IN	O
the	DT	O
intraperitoneal	JJ	O
route	NN	O
(	(	O
IP	NNP	O
)	)	O
for	IN	O
seven	CD	O
days	NNS	O
with	IN	O
vehicle	NN	O
,	,	O
TA1	NNP	O
at	IN	O
5	CD	O
mg/kg	NN	O
,	,	O
or	CC	O
TA1	NNP	O
at	IN	O
25	CD	O
mg/kg	NN	O
.	.	O
The	DT	O
animals	NNS	O
were	VBD	O
monitored	VBN	O
for	IN	O
clinical	JJ	O
signs	NNS	O
and	CC	O
mortality	NN	O
following	VBG	O
each	DT	O
dose	NN	O
.	.	O
On	IN	O
day	NN	O
7	CD	O
,	,	O
all	DT	O
mice	NNS	O
were	VBD	O
weighed	VBN	O
,	,	O
sacrificed	VBN	O
and	CC	O
underwent	JJ	O
necropsy	NN	O
.	.	O
Target	NN	O
organs	NNS	O
were	VBD	O
collected	VBN	O
and	CC	O
fixed	VBN	O
in	IN	O
10	CD	O
%	NN	O
formalin	NN	O
for	IN	O
histology	NN	O
processing	NN	O
,	,	O
which	WDT	O
included	VBD	O
brain	NN	O
,	,	O
lungs	NNS	O
,	,	O
heart	NN	O
,	,	O
thymus	NN	O
,	,	O
liver	RB	O
,	,	O
spleen	JJ	O
,	,	O
kidneys	NNS	O
,	,	O
stomach	NN	O
,	,	O
testes	NNS	O
(	(	O
male	NN	O
)	)	O
/ovaries	NNS	O
(	(	O
female	NN	O
)	)	O
.	.	O
The	DT	O
vehicle	NN	O
for	IN	O
this	DT	O
study	NN	O
was	VBD	O
a	DT	O
clear	JJ	O
solution	NN	O
composed	VBN	O
of	IN	O
:	:	O
50	CD	O
mM	NN	O
NaH2PO4	NNP	O
,	,	O
300	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
10	CD	O
%	NN	O
Sucrose	NNP	O
,	,	O
2	CD	O
%	NN	O
glutamine	NN	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.5	CD	O
mM	NN	O
DTT	NNP	O
in	IN	O
deionized	JJ	O
H2O	NNP	O
.	.	O
TA1	NNP	O
was	VBD	O
provided	VBN	O
in	IN	O
7	CD	O
tubes	NNS	O
of	IN	O
4.5	CD	O
ml	JJ	O
solution	NN	O
each	DT	O
.	.	O
TA1	NNP	O
was	VBD	O
dissolved	VBN	O
into	IN	O
the	DT	O
vehicle	NN	O
at	IN	O
the	DT	O
concentration	NN	O
of	IN	O
2.5	CD	O
mg/ml	NN	O
.	.	O
Upon	IN	O
delivery	NN	O
it	PRP	O
was	VBD	O
stored	VBN	O
in	IN	O
the	DT	O
non-GLP	JJ	O
compartment	NN	O
of	IN	O
the	DT	O
−80°	NNP	O
C.	NNP	O
freezer	NN	O
until	IN	O
needed	VBN	O
for	IN	O
the	DT	O
study	NN	O
.	.	O
Thirty	NNP	O
(	(	O
30	CD	O
)	)	O
CD-1	NNP	O
mice	NN	O
(	(	O
15	CD	O
male	NN	O
and	CC	O
15	CD	O
female	NN	O
)	)	O
(	(	O
Mus	NNP	O
musculus	NN	O
)	)	O
were	VBD	O
used	VBN	O
in	IN	O
the	DT	O
study	NN	O
.	.	O
Mice	NNP	O
were	VBD	O
selected	VBN	O
for	IN	O
the	DT	O
study	NN	O
since	IN	O
mice	NNS	O
are	VBP	O
an	DT	O
accepted	JJ	O
species	NNS	O
frequently	RB	O
used	VBN	O
in	IN	O
the	DT	O
pre-clinical	JJ	O
evaluation	NN	O
of	IN	O
drugs	NNS	O
intended	VBN	O
for	IN	O
human	JJ	O
use	NN	O
.	.	O
All	DT	O
animals	NNS	O
were	VBD	O
weighed	VBN	O
on	IN	O
Day	NNP	O
0	CD	O
,	,	O
Day	NNP	O
3	CD	O
and	CC	O
Day	NNP	O
7	CD	O
.	.	O
Each	DT	O
animal	NN	O
received	VBD	O
a	DT	O
single	JJ	O
IP	NNP	O
dose	NN	O
of	IN	O
test	NN	O
article	NN	O
daily	RB	O
for	IN	O
seven	CD	O
days	NNS	O
.	.	O
Dose	NNP	O
volumes	NNS	O
were	VBD	O
calculated	VBN	O
based	VBN	O
on	IN	O
the	DT	O
average	JJ	O
body	NN	O
weights	NNS	O
for	IN	O
each	DT	O
group	NN	O
.	.	O
Clinical	JJ	O
observations	NNS	O
,	,	O
including	VBG	O
morbidity	NN	O
,	,	O
mortality	NN	O
,	,	O
and	CC	O
overt	JJ	O
signs	NNS	O
of	IN	O
toxic	NN	O
or	CC	O
pharmacologic	JJ	O
effect	NN	O
(	(	O
s	NN	O
)	)	O
were	VBD	O
recorded	VBN	O
for	IN	O
animals	NNS	O
periodically	RB	O
throughout	IN	O
the	DT	O
in-life	JJ	O
portion	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O
Body	NNP	O
weights	NNS	O
ranged	VBD	O
from	IN	O
24.3	CD	O
to	TO	O
38.0	CD	O
g.	NN	O
There	EX	O
were	VBD	O
no	DT	O
drug	NN	O
related	VBN	O
effects	NNS	O
on	IN	O
body	NN	O
weights	NNS	O
.	.	O
There	EX	O
was	VBD	O
no	DT	O
mortality	NN	O
observed	VBD	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
this	DT	O
study	NN	O
.	.	O
All	DT	O
animals	NNS	O
appeared	VBD	O
bright	JJ	O
,	,	O
alert	JJ	O
,	,	O
active	JJ	O
and	CC	O
responsive	JJ	O
,	,	O
no	DT	O
significant	JJ	O
observations	NNS	O
were	VBD	O
recorded	VBN	O
during	IN	O
the	DT	O
in-life	JJ	O
phase	NN	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
body	NN	O
weights	NNS	O
and	CC	O
clinical	JJ	O
observations	NNS	O
,	,	O
no	DT	O
observable	JJ	O
toxic	JJ	O
effect	NN	O
of	IN	O
compound	NN	O
TA1	NNP	O
was	VBD	O
detected	VBN	O
at	IN	O
the	DT	O
dose	NN	O
levels	NNS	O
evaluated	VBN	O
.	.	O
Histopathology	NNP	O
examination	NN	O
of	IN	O
major	JJ	O
organs	NNS	O
by	IN	O
a	DT	O
certified	JJ	O
pathologist	NN	O
also	RB	O
determined	VBD	O
that	IN	O
no	DT	O
detectable	JJ	O
toxicity	NN	O
on	IN	O
histologic	JJ	O
level	NN	O
was	VBD	O
present	JJ	O
.	.	O
Briefly	NNP	O
,	,	O
brain	NN	O
,	,	O
heart	NN	O
,	,	O
stomach	NN	O
,	,	O
kidney	NN	O
,	,	O
liver	NN	O
,	,	O
spleen	NN	O
,	,	O
and	CC	O
gonads	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
hematoxylin-eosin	NN	O
stained	VBD	O
glass	NN	O
slides	NNS	O
and	CC	O
evaluated	VBN	O
histopathologically	RB	O
.	.	O
All	DT	O
protocol-specified	JJ	O
tissues	NNS	O
from	IN	O
all	DT	O
animals	NNS	O
were	VBD	O
examined	VBN	O
.	.	O
There	EX	O
were	VBD	O
no	DT	O
toxicologically	RB	O
relevant	JJ	O
lesions	NNS	O
seen	VBN	O
in	IN	O
the	DT	O
tissues	NNS	O
examined	VBN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
groups	NNS	O
.	.	O
The	DT	O
test	NN	O
article	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
well-tolerated	JJ	O
at	IN	O
the	DT	O
doses	NNS	O
given	VBN	O
under	IN	O
the	DT	O
conditions	NNS	O
of	IN	O
this	DT	O
study	NN	O
.	.	O
Example	RB	O
7	CD	O
Antibody	NNP	O
Development	NNP	O
Monoclonal	NNP	O
antibodies	NNS	O
were	VBD	O
developed	VBN	O
against	IN	O
a	DT	O
polypeptide	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
With	IN	O
respect	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
antibodies	NNS	O
,	,	O
“	JJ	O
HIS-OAS1	NNP	O
”	NN	O
and	CC	O
“	JJ	O
his-tagged	JJ	O
OAS1	NNP	O
”	NNP	O
refer	NN	O
to	TO	O
the	DT	O
polypeptide	JJ	O
product	NN	O
resulting	VBG	O
from	IN	O
expression	NN	O
of	IN	O
SEQUENCE:2	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
)	)	O
as	IN	O
cloned	VBN	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	JJ	O
expression	NN	O
vector	NN	O
and	CC	O
expressed	VBN	O
in	IN	O
and	CC	O
purified	VBD	O
from	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
(	(	O
Novagen	NNP	O
,	,	O
La	NNP	O
Jolla	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
specification	NN	O
.	.	O
“	JJ	O
Non-HIS-OAS1	NNP	O
”	NN	O
and	CC	O
“	JJ	O
non-his	JJ	O
tagged	VBN	O
OAS1	NNP	O
”	NNP	O
refer	NN	O
to	TO	O
the	DT	O
polypeptide	JJ	O
product	NN	O
resulting	VBG	O
from	IN	O
expression	NN	O
of	IN	O
SEQUENCE:3	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:3	NNP	O
)	)	O
as	IN	O
cloned	VBN	O
into	IN	O
the	DT	O
NcoI	NNP	O
and	CC	O
BamHI	NNP	O
sites	NNS	O
of	IN	O
the	DT	O
pET9d	JJ	O
expression	NN	O
vector	NN	O
and	CC	O
expressed	VBN	O
in	IN	O
and	CC	O
purified	VBD	O
from	IN	O
the	DT	O
Rosetta	NNP	O
DE3	NNP	O
bacterial	JJ	O
host	NN	O
(	(	O
Novagen	NNP	O
,	,	O
La	NNP	O
Jolla	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
specification	NN	O
.	.	O
Materials	NNS	O
:	:	O
Criteria	NNP	O
for	IN	O
acceptability	NN	O
for	IN	O
hybridoma	NN	O
development	NN	O
components	NNS	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O
received	VBN	O
from	IN	O
companies	NNS	O
certified	VBN	O
according	VBG	O
to	TO	O
DIN	NNP	O
EN	NNP	O
ISO	NNP	O
9001	CD	O
;	:	O
delivered	VBN	O
at	IN	O
the	DT	O
correct	JJ	O
storage	NN	O
temperature	NN	O
;	:	O
received	VBN	O
with	IN	O
a	DT	O
certificate	NN	O
of	IN	O
analysis	NN	O
;	:	O
AND	CC	O
passing	VBG	O
in-house	JJ	O
testing	NN	O
in	IN	O
cell	NN	O
culture	NN	O
and	CC	O
test	NN	O
fusions	NNS	O
.	.	O
Chemicals	NNS	O
:	:	O
Not	RB	O
listed	VBN	O
chemicals	NNS	O
are	VBP	O
pro	JJ	O
analysi	FW	O
(	(	O
p.a	FW	O
.	.	O
)	)	O
quality	NN	O
and	CC	O
were	VBD	O
received	VBN	O
from	IN	O
Fluka	NNP	O
,	,	O
Merck	NNP	O
,	,	O
Sigma	NNP	O
and	CC	O
Riedel-de	NNP	O
Haen	NNP	O
.	.	O
Aminopterin	NNP	O
Hybri-Max	NNP	O
2×10−5	CD	O
M	NNP	O
(	(	O
50×	CD	O
)	)	O
,	,	O
SIGMA	NNP	O
;	:	O
Antibiotic/Antimycotic	NNP	O
:	:	O
10000	CD	O
I.E	NNP	O
.	.	O
Penicillin	NNP	O
,	,	O
10000	CD	O
μg/ml	NN	O
Streptomycin	NNP	O
,	,	O
25	CD	O
μg/ml	NN	O
Amphotericin	NNP	O
(	(	O
100×	CD	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
;	:	O
BSA	NNP	O
(	(	O
Bovine	NNP	O
Serum	NNP	O
Albumin	NNP	O
)	)	O
,	,	O
SIGMA	NNP	O
;	:	O
DMEM	NNP	O
(	(	O
Dulbecco	NNP	O
's	POS	O
Modified	NNP	O
Eagle	NNP	O
Medium	NNP	O
)	)	O
,	,	O
SIGMA	NNP	O
;	:	O
DMSO	NNP	O
Hybri-Max	NNP	O
,	,	O
SIGMA	NNP	O
;	:	O
FCS	NNP	O
(	(	O
Fetal	NNP	O
Calf	NNP	O
Serum	NNP	O
)	)	O
,	,	O
PAA	NNP	O
;	:	O
Freund	NNP	O
's	POS	O
Complete	NNP	O
,	,	O
Incomplete	NNP	O
Adjuvant	NNP	O
,	,	O
SIGMA	NNP	O
;	:	O
GlutaMAX-I	NNP	O
Supplement	NNP	O
2×10−1	CD	O
M	NNP	O
(	(	O
100×	CD	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
;	:	O
L-Glutamine	JJ	O
2×10−1	CD	O
M	NNP	O
(	(	O
100×	CD	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
;	:	O
Goat	NNP	O
anti-Mouse	NN	O
IgG	NNP	O
(	(	O
mouse	NN	O
Fc	NNP	O
specific	NN	O
)	)	O
-AP	NN	O
(	(	O
alkaline	JJ	O
phosphatase	NN	O
)	)	O
,	,	O
SIGMA	NNP	O
;	:	O
HT	NNP	O
Supplement	NNP	O
(	(	O
50×	CD	O
)	)	O
:	:	O
Hypoxanthine	NNP	O
(	(	O
5×10−3	CD	O
M	NNP	O
)	)	O
,	,	O
Thymidine	NNP	O
(	(	O
0.8×10−3	CD	O
M	NNP	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
MEM	NNP	O
Non-essential	NNP	O
Amino	NNP	O
acid	JJ	O
Solution	NNP	O
(	(	O
100×	CD	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
;	:	O
2-Mercaptoethanol	JJ	O
,	,	O
SIGMA	NNP	O
;	:	O
Sodium	NNP	O
pyruvate	VBP	O
MEM	NNP	O
10−1	CD	O
M	NNP	O
mM	NN	O
(	(	O
100×	CD	O
)	)	O
,	,	O
GIBCO/BRL	NNP	O
;	:	O
4-Nitrophenyl	JJ	O
Phosphate	NNP	O
,	,	O
SIGMA	NNP	O
;	:	O
Polyethylene	NNP	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
Hybri-Max	NNP	O
(	(	O
3550	CD	O
)	)	O
,	,	O
SIGMA	NNP	O
Mice	NNP	O
:	:	O
For	IN	O
generation	NN	O
of	IN	O
hybridomas	NN	O
,	,	O
BALB/C	NNP	O
mice	NNP	O
(	(	O
female	JJ	O
,	,	O
about	RB	O
8	CD	O
weeks	NNS	O
old	JJ	O
)	)	O
from	IN	O
Charles	NNP	O
River	NNP	O
Laboratories	NNP	O
(	(	O
Germany	NNP	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O
Myeloma	NNP	O
cell	NN	O
line	NN	O
:	:	O
For	IN	O
fusion	NN	O
the	DT	O
myeloma	NN	O
cell	NN	O
line	NN	O
SP2/0-Ag14	NNP	O
from	IN	O
German	JJ	O
Collection	NNP	O
of	IN	O
Microorganisms	NNP	O
and	CC	O
Cell	NNP	O
Cultures	NNP	O
(	(	O
DSMZ	NNP	O
GmbH	NNP	O
,	,	O
Braunschweig	NNP	O
)	)	O
was	VBD	O
used	VBN	O
.	.	O
This	DT	O
cell	NN	O
line	NN	O
is	VBZ	O
a	DT	O
hybrid	NN	O
between	IN	O
BALB/c	NNP	O
spleen	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
myeloma	NN	O
cell	NN	O
line	NN	O
P3×63Ag8	NNP	O
.	.	O
The	DT	O
cells	NNS	O
were	VBD	O
described	VBN	O
as	IN	O
not	RB	O
synthesizing	VBG	O
or	CC	O
secreting	VBG	O
immunoglobulin	NN	O
chains	NNS	O
,	,	O
being	VBG	O
resistant	JJ	O
to	TO	O
8-azaguanine	JJ	O
at	IN	O
20	CD	O
μg/ml	NN	O
,	,	O
and	CC	O
not	RB	O
growing	VBG	O
in	IN	O
HAT	NNP	O
(	(	O
Hypoxanthine	NNP	O
,	,	O
Aminopterin	NNP	O
,	,	O
Thymidine	NNP	O
)	)	O
medium	NN	O
.	.	O
The	DT	O
SP2/0	NNP	O
cells	NNS	O
are	VBP	O
routinely	RB	O
maintained	VBN	O
in	IN	O
tissue	NN	O
culture	NN	O
flasks	NNS	O
in	IN	O
standard	JJ	O
growth	NN	O
medium	NN	O
(	(	O
with	IN	O
10	CD	O
%	NN	O
FCS	NNP	O
)	)	O
.	.	O
Regularly	RB	O
a	DT	O
new	JJ	O
aliquot	NN	O
of	IN	O
frozen	JJ	O
SP2/0	NNP	O
cells	NNS	O
was	VBD	O
used	VBN	O
in	IN	O
order	NN	O
to	TO	O
avoid	VB	O
the	DT	O
development	NN	O
of	IN	O
HGPRT-positive	JJ	O
revertants	NNS	O
.	.	O
Myeloma	NNP	O
cells	NNS	O
are	VBP	O
negative	JJ	O
in	IN	O
all	DT	O
mycoplasma	NN	O
tests	NNS	O
performed	VBN	O
by	IN	O
DSMZ	NNP	O
GmbH	NNP	O
.	.	O
Antigen	NN	O
:	:	O
A	DT	O
preparation	NN	O
of	IN	O
his-tagged	JJ	O
OAS1	NNP	O
(	(	O
concentration	NN	O
3	CD	O
mg/ml	NN	O
in	IN	O
50	CD	O
mM	NNS	O
NaH2PO4/300	NNP	O
mM	VBP	O
NaCl/40	NNP	O
%	NN	O
glycerol/1	NN	O
mM	NN	O
EDTA/2	NNP	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
was	VBD	O
used	VBN	O
for	IN	O
immunization	NN	O
and	CC	O
screening	NN	O
.	.	O
For	IN	O
negative	JJ	O
selection	NN	O
of	IN	O
clones	NNS	O
reacting	VBG	O
to	TO	O
his-tag	JJ	O
,	,	O
his-beta	JJ	O
galactosidase	NN	O
(	(	O
concentration	NN	O
2.36	CD	O
mg/ml	NN	O
in	IN	O
25	CD	O
mM	NNS	O
HEPES/200	NNP	O
mM	NN	O
NaCl/1	NNP	O
Mm	NNP	O
EDTA/5	NNP	O
%	NN	O
glycerol	NN	O
,	,	O
pH	RB	O
6.8	CD	O
)	)	O
,	,	O
and	CC	O
for	IN	O
positive	JJ	O
selection	NN	O
non-his-tagged	JJ	O
human	JJ	O
OAS1	NNP	O
(	(	O
concentration	NN	O
4.3	CD	O
mg/ml	NN	O
in	IN	O
50	CD	O
mM	NNS	O
NaH2PO4/300	NNP	O
mM	VBP	O
NaCl/40	NNP	O
%	NN	O
glycerol/1	NN	O
mM	NN	O
EDTA/2	NNP	O
mM	NN	O
DTT	NNP	O
at	IN	O
pH	RB	O
6.8	CD	O
)	)	O
,	,	O
were	VBD	O
used	VBN	O
.	.	O
Immunization	NN	O
:	:	O
Six	JJ	O
mice	NNS	O
were	VBD	O
immunized	VBN	O
intraperitoneal	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
39	CD	O
days	NNS	O
.	.	O
For	IN	O
immunization	NN	O
a	DT	O
water-in-oil	JJ	O
emulsion	NN	O
of	IN	O
equal	JJ	O
volumes	NNS	O
of	IN	O
antigen	NN	O
and	CC	O
Freund	NNP	O
's	POS	O
complete	JJ	O
or	CC	O
incomplete	JJ	O
adjuvant	NN	O
was	VBD	O
prepared	VBN	O
.	.	O
The	DT	O
mice	NN	O
with	IN	O
the	DT	O
highest	JJS	O
antiserum	NN	O
titer	NN	O
were	VBD	O
chosen	VBN	O
for	IN	O
fusion	NN	O
and	CC	O
stimulated	VBD	O
over	IN	O
4	CD	O
days	NNS	O
.	.	O
Preparation	NN	O
of	IN	O
the	DT	O
antiserum	NN	O
:	:	O
The	DT	O
blood	NN	O
from	IN	O
the	DT	O
immunized	JJ	O
mice	NN	O
was	VBD	O
allowed	VBN	O
to	TO	O
stay	VB	O
for	IN	O
1	CD	O
h	NN	O
at	IN	O
RT	NNP	O
.	.	O
After	IN	O
incubation	NN	O
overnight	VBD	O
at	IN	O
4°	CD	O
C.	NNP	O
,	,	O
the	DT	O
blood	NN	O
was	VBD	O
centrifuged	VBN	O
for	IN	O
10	CD	O
min	NN	O
at	IN	O
10000	CD	O
g.	NN	O
The	DT	O
supernatant	NN	O
(	(	O
antiserum	NN	O
)	)	O
was	VBD	O
collected	VBN	O
and	CC	O
tested	VBN	O
in	IN	O
ELISA	NNP	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
General	NNP	O
handling	NN	O
of	IN	O
cells	NNS	O
and	CC	O
cell	NN	O
culture	NN	O
supernatants	NNS	O
:	:	O
Cells	NNS	O
were	VBD	O
handled	VBN	O
under	IN	O
sterile	JJ	O
conditions	NNS	O
using	VBG	O
laminar	JJ	O
air	NN	O
flow	NN	O
system	NN	O
,	,	O
sterile	JJ	O
materials	NNS	O
and	CC	O
sterile	JJ	O
solutions	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
in	IN	O
a	DT	O
humid	NN	O
atmosphere	RB	O
containing	VBG	O
5	CD	O
%	NN	O
carbon	NN	O
dioxide	NN	O
.	.	O
For	IN	O
cultivation	NN	O
of	IN	O
the	DT	O
hybridoma	NN	O
cells	NNS	O
,	,	O
a	DT	O
complete	JJ	O
growth	NN	O
medium	NN	O
(	(	O
CGM	NNP	O
)	)	O
containing	VBG	O
DMEM	NNP	O
with	IN	O
supplements	NNS	O
2-mercaptoethanol	JJ	O
,	,	O
L-Glutamin	NNP	O
,	,	O
GlutaMax	NNP	O
,	,	O
HT	NNP	O
,	,	O
non	RB	O
essential	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
sodium	NN	O
pyruvate	NN	O
,	,	O
antibiotics/antimycotic	JJ	O
solution	NN	O
(	(	O
in	IN	O
concentrations	NNS	O
recommended	VBN	O
by	IN	O
the	DT	O
supplier	NN	O
)	)	O
and	CC	O
FCS	NNP	O
at	IN	O
different	JJ	O
concentrations	NNS	O
(	(	O
10	CD	O
%	NN	O
,	,	O
15	CD	O
%	NN	O
or	CC	O
20	CD	O
%	NN	O
)	)	O
were	VBD	O
used	VBN	O
.	.	O
The	DT	O
cell	NN	O
culture	NN	O
supernatants	NNS	O
from	IN	O
hybridoma	NN	O
cells	NNS	O
contained	VBN	O
usually	RB	O
12	CD	O
to	TO	O
20	CD	O
μg/ml	NNS	O
antibody	NN	O
.	.	O
Determination	NN	O
of	IN	O
the	DT	O
suitable	JJ	O
cell	NN	O
culture	NN	O
supernatant	JJ	O
dilution	NN	O
was	VBD	O
recommended	VBN	O
for	IN	O
every	DT	O
experiment	NN	O
(	(	O
dilution	NN	O
range	NN	O
:	:	O
from	IN	O
undiluted	VBN	O
to	TO	O
1:1000	CD	O
)	)	O
.	.	O
Preparation	NN	O
of	IN	O
spleen	JJ	O
cells	NNS	O
and	CC	O
cell	NN	O
fusion	NN	O
:	:	O
A	DT	O
single	JJ	O
cell	NN	O
suspension	NN	O
of	IN	O
pooled	JJ	O
spleens	NNS	O
was	VBD	O
prepared	VBN	O
.	.	O
The	DT	O
spleen	JJ	O
cells	NNS	O
and	CC	O
the	DT	O
myeloma	NN	O
cells	NNS	O
were	VBD	O
washed	VBN	O
several	JJ	O
times	NNS	O
with	IN	O
DMEM	NNP	O
and	CC	O
fused	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
1	CD	O
ml	NNS	O
50	CD	O
%	NN	O
(	(	O
w/v	NN	O
)	)	O
PEG	NN	O
3550	CD	O
(	(	O
ratio	NN	O
spleen	NN	O
cells	NNS	O
to	TO	O
SP2/0	NNP	O
3:1	CD	O
)	)	O
.	.	O
The	DT	O
resulting	VBG	O
hybridomas	NN	O
were	VBD	O
resuspended	VBN	O
in	IN	O
CGM	NNP	O
containing	VBG	O
20	CD	O
%	NN	O
FCS	NNP	O
and	CC	O
aminopterin	NN	O
(	(	O
HAT	NNP	O
medium	NN	O
)	)	O
.	.	O
The	DT	O
cell	NN	O
suspension	NN	O
(	(	O
140	CD	O
μl/well	NN	O
)	)	O
was	VBD	O
plated	VBN	O
out	RP	O
into	IN	O
eight	CD	O
96-well	JJ	O
tissue	NN	O
culture	NN	O
flat-bottom	JJ	O
plates	NNS	O
(	(	O
Corning-Costar	NNP	O
)	)	O
containing	VBG	O
140	CD	O
μl/well	NNP	O
CGM	NNP	O
(	(	O
20	CD	O
%	NN	O
FCS	NNP	O
)	)	O
with	IN	O
peritoneal	JJ	O
exudate	NN	O
cells	NNS	O
as	IN	O
feeder	NN	O
cells	NNS	O
.	.	O
The	DT	O
plates	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
10	CD	O
days	NNS	O
.	.	O
During	IN	O
this	DT	O
period	NN	O
,	,	O
cells	NNS	O
were	VBD	O
fed	VBN	O
two	CD	O
times	NNS	O
with	IN	O
HAT	NNP	O
medium	NN	O
.	.	O
An	DT	O
aliquot	NN	O
of	IN	O
the	DT	O
spleen	NN	O
cell	NN	O
preparation	NN	O
was	VBD	O
cultivated	VBN	O
10	CD	O
days	NNS	O
in	IN	O
a	DT	O
T-flask	NNP	O
,	,	O
and	CC	O
the	DT	O
cell	NN	O
culture	NN	O
supernatant	NN	O
served	VBD	O
as	IN	O
a	DT	O
positive	JJ	O
control	NN	O
in	IN	O
ELISA	NNP	O
.	.	O
Another	DT	O
aliquot	NN	O
of	IN	O
the	DT	O
spleen	NN	O
cell	NN	O
preparation	NN	O
was	VBD	O
frozen	VBN	O
in	IN	O
freezing	VBG	O
medium	NN	O
(	(	O
FCS+10	NNP	O
%	NN	O
dimethyl	NN	O
sulfoxide	NN	O
)	)	O
and	CC	O
stored	VBN	O
in	IN	O
liquid	NN	O
nitrogen	NN	O
.	.	O
Screening	VBG	O
assay	NN	O
:	:	O
An	DT	O
ELISA	NNP	O
was	VBD	O
used	VBN	O
for	IN	O
screening	NN	O
of	IN	O
IgG	NNP	O
in	IN	O
cell	NN	O
culture	NN	O
supernatants	NNS	O
.	.	O
96	CD	O
well	RB	O
flat-bottom	JJ	O
polystyrene	NN	O
microtiter	NN	O
plates	NNS	O
(	(	O
Greiner	NNP	O
,	,	O
Cat	NNP	O
.	.	O
No	DT	O
655061	CD	O
)	)	O
were	VBD	O
coated	VBN	O
with	IN	O
50	CD	O
μl/well	NN	O
antigen	NN	O
(	(	O
2	CD	O
μg/ml	NN	O
)	)	O
in	IN	O
0.5	CD	O
M	NNP	O
carbonate/bicarbonate	NN	O
buffer	NN	O
,	,	O
pH	JJ	O
9.6	CD	O
.	.	O
After	IN	O
incubation	NN	O
overnight	NN	O
(	(	O
o/n	NN	O
)	)	O
in	IN	O
a	DT	O
moist	JJ	O
chamber	NN	O
at	IN	O
4°	CD	O
C.	NNP	O
the	DT	O
plates	NNS	O
were	VBD	O
washed	VBN	O
with	IN	O
tris-buffered	JJ	O
saline	NN	O
(	(	O
TBS	NNP	O
,	,	O
50	CD	O
mM	NN	O
Tris	NNP	O
,	,	O
pH	NN	O
7.8	CD	O
,	,	O
500	CD	O
mM	NN	O
sodium	NN	O
chloride	NN	O
)	)	O
containing	VBG	O
0.01	CD	O
%	NN	O
Triton	NNP	O
X-100	NNP	O
(	(	O
washing	VBG	O
buffer	NN	O
)	)	O
and	CC	O
blocked	VBN	O
with	IN	O
200	CD	O
μl/well	RB	O
2	CD	O
%	NN	O
FCS	NNP	O
in	IN	O
TBS	NNP	O
(	(	O
blocking	VBG	O
buffer	NN	O
)	)	O
for	IN	O
1	CD	O
hour	NN	O
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
RT	NNP	O
)	)	O
on	IN	O
a	DT	O
shaker	NN	O
.	.	O
The	DT	O
wells	NNS	O
were	VBD	O
washed	VBN	O
with	IN	O
washing	VBG	O
buffer	NN	O
and	CC	O
100	CD	O
μl	NN	O
cell	NN	O
culture	NN	O
supernatant	JJ	O
antisera	NN	O
(	(	O
a	DT	O
2-fold	JJ	O
dilution	NN	O
series	NN	O
in	IN	O
blocking	VBG	O
buffer	NN	O
,	,	O
starting	VBG	O
with	IN	O
1:100	CD	O
)	)	O
were	VBD	O
added	VBN	O
in	IN	O
the	DT	O
appropriate	JJ	O
well	NN	O
.	.	O
Cell	NNP	O
culture	NN	O
supernatant	NN	O
from	IN	O
SP	NNP	O
2/0	CD	O
myeloma	NN	O
cells	NNS	O
was	VBD	O
used	VBN	O
as	IN	O
negative	JJ	O
control	NN	O
.	.	O
As	IN	O
positive	JJ	O
control	NN	O
cell	NN	O
culture	NN	O
supernatant	NN	O
from	IN	O
spleen	JJ	O
cells	NNS	O
culture	NN	O
was	VBD	O
used	VBN	O
.	.	O
The	DT	O
plates	NNS	O
were	VBD	O
incubated	VBN	O
on	IN	O
a	DT	O
shaker	NN	O
for	IN	O
1	CD	O
h	NN	O
at	IN	O
RT	NNP	O
,	,	O
followed	VBN	O
by	IN	O
several	JJ	O
washes	NNS	O
.	.	O
For	IN	O
detection	NN	O
of	IN	O
bound	NN	O
antibodies	NNS	O
plates	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
50	CD	O
μl/well	NNS	O
goat	RB	O
anti-mouse	VBP	O
IgG	NNP	O
conjugated	VBD	O
to	TO	O
alkaline	VB	O
phosphatase	NN	O
(	(	O
1:5000	CD	O
)	)	O
in	IN	O
blocking	VBG	O
buffer	NN	O
for	IN	O
1	CD	O
h	NN	O
at	IN	O
RT	NNP	O
on	IN	O
a	DT	O
shaker	NN	O
,	,	O
followed	VBN	O
by	IN	O
several	JJ	O
washes	NNS	O
and	CC	O
addition	NN	O
of	IN	O
150	CD	O
μl/well	NNP	O
substrate	NN	O
buffer	NN	O
(	(	O
2	CD	O
mM	RB	O
4-nitrophenyl	JJ	O
phosphate	NN	O
in	IN	O
5	CD	O
%	NN	O
diethanolamine+0.5	NN	O
mM	NN	O
MgCl2	NNP	O
,	,	O
pH	RB	O
9.8	CD	O
)	)	O
.	.	O
The	DT	O
optical	JJ	O
density	NN	O
(	(	O
OD	NNP	O
)	)	O
was	VBD	O
estimated	VBN	O
in	IN	O
a	DT	O
12-channel	JJ	O
Dynex	NNP	O
Opsys	NNP	O
MR	NNP	O
microplate	NN	O
reader	NN	O
at	IN	O
405	CD	O
nm	NNS	O
.	.	O
Wells	NNP	O
with	IN	O
OD405	NNP	O
nm	RB	O
two-fold	VBD	O
higher	JJR	O
than	IN	O
the	DT	O
OD405	NNP	O
nm	NN	O
of	IN	O
the	DT	O
average	JJ	O
plate	NN	O
value	NN	O
were	VBD	O
selected	VBN	O
as	IN	O
positive	JJ	O
.	.	O
Selection	NN	O
of	IN	O
stable	JJ	O
antibody	NN	O
producers	NNS	O
:	:	O
Cells	NNS	O
from	IN	O
positive	JJ	O
wells	NNS	O
were	VBD	O
transferred	VBN	O
into	IN	O
wells	NNS	O
of	IN	O
24	CD	O
well	NN	O
plates	NNS	O
and	CC	O
cultivated	VBN	O
for	IN	O
a	DT	O
few	JJ	O
days	NNS	O
.	.	O
An	DT	O
ELISA	NNP	O
on	IN	O
his-tagged	JJ	O
OAS1	NNP	O
,	,	O
non-his-tagged	JJ	O
OAS1	NNP	O
and	CC	O
his-beta	JJ	O
galactosidase	NN	O
in	IN	O
order	NN	O
to	TO	O
select	VB	O
the	DT	O
specific	JJ	O
binders	NNS	O
was	VBD	O
carried	VBN	O
out	RP	O
.	.	O
Because	IN	O
of	IN	O
the	DT	O
high	JJ	O
probability	NN	O
of	IN	O
chromosome	NN	O
loss	NN	O
in	IN	O
the	DT	O
hybrids	NNS	O
this	DT	O
phase	NN	O
was	VBD	O
kept	VBN	O
as	RB	O
short	JJ	O
as	IN	O
possible	JJ	O
.	.	O
Limiting	VBG	O
dilution	NN	O
cloning	NN	O
:	:	O
As	RB	O
soon	RB	O
as	IN	O
positive	JJ	O
wells	NNS	O
were	VBD	O
identified	VBN	O
,	,	O
hybridoma	JJ	O
cells	NNS	O
were	VBD	O
cloned	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
overgrowth	NN	O
by	IN	O
non-producing	JJ	O
cells	NNS	O
(	(	O
first	JJ	O
cloning	NN	O
)	)	O
.	.	O
To	TO	O
ensure	VB	O
that	IN	O
the	DT	O
antibodies	NNS	O
are	VBP	O
truly	RB	O
monoclonal	JJ	O
,	,	O
the	DT	O
hybridomas	NN	O
were	VBD	O
cloned	VBN	O
again	RB	O
(	(	O
second	JJ	O
cloning	NN	O
)	)	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
limiting	VBG	O
dilution	NN	O
was	VBD	O
used	VBN	O
for	IN	O
both	DT	O
cloning	NN	O
procedures	NNS	O
.	.	O
IgG	NNP	O
producing	VBG	O
cells	NNS	O
were	VBD	O
distributed	VBN	O
into	IN	O
one	CD	O
96	CD	O
well	RB	O
plate	VB	O
containing	VBG	O
feeder	NN	O
cells	NNS	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
1-3	JJ	O
cells	NNS	O
per	IN	O
well	RB	O
.	.	O
After	IN	O
8-10	JJ	O
days	NNS	O
(	(	O
depending	VBG	O
on	IN	O
growths	NNS	O
characteristics	NNS	O
)	)	O
,	,	O
all	DT	O
plates	NNS	O
were	VBD	O
visually	RB	O
inspected	VBN	O
under	IN	O
the	DT	O
microscope	NN	O
for	IN	O
detection	NN	O
of	IN	O
monoclonal	JJ	O
growth	NN	O
.	.	O
Culture	NN	O
supernatants	NNS	O
from	IN	O
such	JJ	O
wells	NNS	O
were	VBD	O
screened	VBN	O
for	IN	O
specific	JJ	O
immunoglobulin	NN	O
content	NN	O
by	IN	O
the	DT	O
above	JJ	O
described	NN	O
screening	VBG	O
assay	NN	O
.	.	O
The	DT	O
appropriate	JJ	O
clones	NNS	O
concerning	VBG	O
growth	NN	O
characteristic	JJ	O
and	CC	O
ELISA	NNP	O
signal	NN	O
were	VBD	O
selected	VBN	O
,	,	O
transferred	VBN	O
into	IN	O
wells	NNS	O
of	IN	O
a	DT	O
24	CD	O
well	RB	O
plate	NN	O
and	CC	O
cultivated	VBN	O
for	IN	O
some	DT	O
days	NNS	O
.	.	O
A	DT	O
screening	NN	O
assay	NN	O
was	VBD	O
performed	VBN	O
.	.	O
This	DT	O
procedure	NN	O
was	VBD	O
repeated	VBN	O
two	CD	O
to	TO	O
three	CD	O
times	NNS	O
.	.	O
The	DT	O
appropriate	JJ	O
subclone	NN	O
was	VBD	O
selected	VBN	O
respectively	RB	O
for	IN	O
the	DT	O
second	JJ	O
cloning	NN	O
procedure	NN	O
and	CC	O
cryopreservation/production	NN	O
.	.	O
Antiserum	JJ	O
results	NNS	O
:	:	O
The	DT	O
ELISA	NNP	O
results	NNS	O
of	IN	O
the	DT	O
antisera	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
,	,	O
which	WDT	O
provides	VBZ	O
ELISA	NNP	O
results	NNS	O
(	(	O
OD405	NNP	O
nm	RB	O
)	)	O
of	IN	O
antisera	NN	O
against	IN	O
OAS1	NNP	O
after	IN	O
15	CD	O
min	JJ	O
incubation	NN	O
with	IN	O
substrate	NN	O
.	.	O
The	DT	O
mice	NN	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
were	VBD	O
chosen	VBN	O
for	IN	O
fusion	NN	O
.	.	O
Results	NNS	O
after	IN	O
fusion	NN	O
and	CC	O
selection	NN	O
of	IN	O
stable	JJ	O
antibody	NN	O
producers	NNS	O
:	:	O
The	DT	O
fusion	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
good	JJ	O
growing	VBG	O
hybridomas	NN	O
.	.	O
After	IN	O
the	DT	O
selection	NN	O
of	IN	O
stable	JJ	O
antibody	NN	O
producers	NNS	O
,	,	O
three	CD	O
primary	JJ	O
cultures	NNS	O
were	VBD	O
identified	VBN	O
as	IN	O
positive	JJ	O
.	.	O
These	DT	O
primary	JJ	O
cultures	NNS	O
were	VBD	O
screened	VBN	O
on	IN	O
his-tagged	JJ	O
and	CC	O
non-his-tagged	JJ	O
OAS1	NNP	O
,	,	O
and	CC	O
his-tagged	JJ	O
beta	NN	O
galactosidase	NN	O
.	.	O
The	DT	O
OD405	NNP	O
values	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	NNP	O
2.	CD	O
which	WDT	O
shows	VBZ	O
the	DT	O
ELISA	NNP	O
signals	NNS	O
of	IN	O
primary	JJ	O
cultures	NNS	O
OD405	NNP	O
nm	RB	O
after	IN	O
1	CD	O
h	JJ	O
incubation	NN	O
with	IN	O
substrate	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
primary	JJ	O
cultures	NNS	O
1	CD	O
and	CC	O
2	CD	O
bind	NN	O
specifically	RB	O
to	TO	O
OAS1	NNP	O
protein	NN	O
;	:	O
therefore	IN	O
these	DT	O
cells	NNS	O
were	VBD	O
taken	VBN	O
into	IN	O
1st	CD	O
cloning	NN	O
.	.	O
The	DT	O
antibodies	NNS	O
of	IN	O
primary	JJ	O
culture	NN	O
11	CD	O
bind	NN	O
his-tag	NN	O
and	CC	O
were	VBD	O
excluded	VBN	O
.	.	O
From	IN	O
the	DT	O
foregoing	NN	O
,	,	O
although	IN	O
specific	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
have	VBP	O
been	VBN	O
described	VBN	O
herein	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
illustration	NN	O
,	,	O
various	JJ	O
modifications	NNS	O
may	MD	O
be	VB	O
made	VBN	O
without	IN	O
departing	VBG	O
from	IN	O
the	DT	O
spirit	NN	O
and	CC	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
invention	NN	O
is	VBZ	O
not	RB	O
limited	JJ	O
except	IN	O
as	IN	O
by	IN	O
the	DT	O
appended	JJ	O
claims	NNS	O
.	.	O
All	DT	O
publications	NNS	O
,	,	O
published	VBN	O
patent	NN	O
applications	NNS	O
,	,	O
and	CC	O
patent	NN	O
documents	NNS	O
disclosed	VBN	O
herein	NNS	O
are	VBP	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Claims	NNS	O
(	(	O
1	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
4	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=38067726	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
5	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
1	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
3	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
3	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
2	CD	O
)	)	O
Citations	NNPS	O
(	(	O
3	CD	O
)	)	O
Family	RB	O
Cites	VBZ	O
Families	NNS	O
(	(	O
1	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
3	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
15	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Owner	NNP	O
name	NN	O
:	:	O
ILLUMIGEN	NNP	O
BIOSCIENCES	NNP	O
INC.	NNP	O
,	,	O
WASHINGTON	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNORS	NNP	O
:	:	O
IADONATO	NNP	O
,	,	O
SHAWN	NNP	O
P	NNP	O
;	:	O
MAGNESS	NNP	O
,	,	O
CHARLES	NNP	O
L	NNP	O
;	:	O
BRANUM	NNP	O
,	,	O
MARK	NNP	O
;	:	O
AND	CC	O
OTHERS	NNPS	O
;	:	O
REEL/FRAME:025799/0667	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20070213	CD	O
Owner	NNP	O
name	NN	O
:	:	O
IB	NNP	O
SECURITYHOLDERS	NNP	O
,	,	O
LLC	NNP	O
,	,	O
WASHINGTON	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
ASSIGNMENT	NNP	O
OF	IN	O
ASSIGNORS	NNP	O
INTEREST	NNP	O
;	:	O
ASSIGNORS	NNP	O
:	:	O
CUBIST	NNP	O
PHARMACEUTICALS	NNP	O
,	,	O
INC.	NNP	O
;	:	O
ILLUMIGEN	NNP	O
BIOSCIENCES	NNP	O
,	,	O
INC.	NNP	O
;	:	O
REEL/FRAME:026182/0758	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20101110	CD	O
Owner	NNP	O
name	NN	O
:	:	O
KINETA	NNP	O
TWO	NNP	O
,	,	O
LLC	NNP	O
,	,	O
WASHINGTON	NNP	O
Free	NNP	O
format	NN	O
text	NN	O
:	:	O
MERGER	NN	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
IB	NNP	O
SECURITYHOLDER	NNP	O
,	,	O
LLC	NNP	O
;	:	O
REEL/FRAME:033122/0802	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20110620	CD	O
Year	NN	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
